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Abstract 
 
Urgent action is required to combat the ongoing threat of antimicrobial 
resistance.  Trojan horse conjugates, where antimicrobials are linked to a 
nutrient carrier, can evade permeability-related resistance through active 
transport of drugs into bacterial cells.  The work presented herein explores 
modification of the linker moiety between a citrate siderophore and 
ciprofloxacin, as well as the addition of glycosyl groups to catecholate 
siderophore moieties to mimic the salmochelins; stealth siderophores 
which can evade the mammalian defence protein siderocalin. 
 
Two linkers were investigated, one containing a carbamate and the other a 
disulfide bond neighbouring a carbamate group.  These were chosen to 
give intracellular release of the antimicrobial, either by the action of 
carboxylesterases or through reduction of the disulfide bond by thiolate 
anions in the cytoplasm, respectively.  A carbamate-linked conjugate was 
synthesised and screened against wild type E. coli, and demonstrated lower 
antimicrobial activity than that for the parent drug.  Screening against a 
bacterial strain lacking the outer membrane ferric citrate receptor FecA 
demonstrated that FecA is not essential for uptake of the synthesised 
conjugate.  The synthesis of a disulfide linked conjugate was unsuccessful, 
due to release of free ciprofloxacin during the final deprotection step. 
 
A salmochelin-inspired conjugate was synthesised.  Whilst it demonstrated 
reduced antimicrobial activity against wild type E. coli in iron rich media, 
compared to the parent drug, higher antimicrobial activity was observed in 
iron-limited media, suggesting active uptake.  A DNA gyrase assay showed 
that the inhibitory activity of this conjugate was lower than the free drug, 
suggesting that the antimicrobial activity observed under iron deficiency 
may be due extracellular iron sequestration by the siderophore.
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1.1 Overview 
 
With the ever growing emergence of antibiotic resistance, new strategies 
are required to overcome the crisis.  This thesis details one strategy in the 
development against the threat of resistance, the Trojan horse strategy.  
This strategy employs siderophore-antimicrobial conjugates which are 
designed to exploit bacterial iron uptake mechanisms to aid drug 
effectiveness.  In turn this thesis discusses the synthesis, characterisation 
and investigation of siderophore-fluoroquinolone Trojan horse 
antimicrobial conjugates, with a view to provide further insight into the 
design features required.  Therefore this introduction provides an overview 
of the literature to set the context for the work presented in this thesis.  
Most examples discussed herein relate predominantly to the 
fluoroquinolone class of antimicrobial agents, the focus of the work 
presented.  However, it should be highlighted that many examples relate to 
other classes of antibiotics, which are highlighted where relevant. 
 
1.2 Antibiotics 
 
The discovery of antibiotics proved a turning point in modern medicine, 
allowing the treatment of a number of infectious diseases.
1, 2
  The first class 
of antibiotics discovered were the sulfonamides in 1935, and were quickly 
followed by the β-lactams in 1941.1, 2  A quick succession of other new 
antimicrobial classes were produced until 1968, though this age of 
antibiotic discovery was eventually succeeded by a development void.
1, 2
  
Subsequently, the next two classes of antibiotics were only discovered in 
2000 and 2003, respectively.
1, 2
  With the continued rise in bacterial 
resistance, novel antibiotics and strategies are required.
3-8
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Fluoroquinolone antimicrobials 
 
During the synthesis of the antimalarial agent chloroquine (1-1) it was 
discovered in 1962 that an impurity (1-2) demonstrated activity against 
Gram-negative bacteria, which subsequently lead to the development of 
synthetic nalidixic acid (1-3) as the first commercial quinolone (Figure 
1).
9-11
  However, nalidixic acid 1-3 demonstrates activity primarily against 
the Enterobacteriaceae family of bacterial species, which coupled with 
poor pharmacokinetics, limited clinical use.
9, 12
 
 
 
Figure 1 - Development of nalidixic acid (1-3) from impurity 1-2 
discovered during the synthesis of chloroquine (1-1). 
 
Later developments of the quinolone class saw the introduction of the 
fluoroquinolones in the early 1980s.  Norfloxacin 1-4 (1980) and 
ciprofloxacin 1-5 (1983) are fully synthetic second-generation 
antimicrobials belonging to this class.
13, 14
  The enhancement of their 
activity and their broader spectrum against both Gram-negative and Gram-
positive bacteria, compared to the original quinolones, lead to their 
widespread use.
10, 15
  Indeed, ciprofloxacin 1-5 remains one of the most 
commonly prescribed antimicrobials worldwide.
10, 16, 17
  More recent 
developments include the introduction of the third and fourth generation 
fluoroquinolones, characterised as such due to their improved activity 
against Gram-positive strains and general enchantment in their spectrum of 
activity, with examples such as sparfloxacin 1-6 and moxifloxacin 1-7.
16, 18
 
 
Chapter 1 
30 
 
Currently, a new fluoroquinolone, delafloxacin 1-8, is in phase III clinical 
trials, with its anionic charge contrasting with the typical zwitterionic 
character of other fluoroquinolones.
19-22
  Using moxifloxacin 1-7 as a 
comparison, delafloxacin 1-8 was shown to have enhanced uptake in 
bacteria under acidic conditions (pH 5.4), with increased activity against 
Staphylococcus aureus.
20
  This enhancement in activity for delafloxacin 1-
8 over moxifloxacin 1-7 under acidic conditions was proposed to be due to 
the transmembrane diffusion model.
20
  Accounting for this, the authors 
suggest that under neutral conditions inside the bacterial cell, delafloxacin 
1-8 will be deprotonated and thus will be less likely to diffuse from the cell 
than moxifloxacin 1-7, thus explaining the increased accumulation of 
delafloxacin observed.
20
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Mechanism of fluoroquinolone action 
 
The antimicrobial activity of the fluoroquinolones arises from their ability 
to disrupt two enzymes within bacterial species that are part of the 
deoxyribonucleic acid (DNA) replication pathway: DNA gyrase (Gram-
negative strains) and topoisomerase IV (Gram-positive strains).
23-26
  These 
two enzymes are critical as they stabilise supercoiled bacterial DNA by 
creating negative supercoils to relieve topological stress during DNA 
replication.
26, 27
  Both DNA gyrase and topoisomerase IV comprise four 
subunits, though they differ in how DNA is allowed to pass through, with 
DNA gyrase wrapping DNA around itself while topoisomerase IV does 
not.
26, 27
  However, both use a double-strand passage mode of action and 
thus the mechanism of action of fluoroquinolones is similar for each 
enzyme.
26, 27
 
 
One early proposed mechanism of fluoroquinolone activity suggested that 
four fluoroquinolones were required to inhibit the enzymes by stacking into 
a binding pocket.
28
  However, Laponogov et al. later co-crystallised 
moxifloxacin 1-7 with DNA and topoisomerase IV from Streptococcus 
pneumoniae, showing only two fluoroquinolones are required.
23
  In 
addition, Bax et al. co-crystallised ciprofloxacin 1-5 with DNA and DNA 
gyrase from S. aureus, agreeing with Laponogov et al. that two 
fluoroquinolones interchelate DNA between the DNA base pairs, 
stabilising a ternary complex in the GyrB/ParC subunits of the enzyme 
(Figure 2).
24
  As can be seen in A, B and C of Figure 2, the three 
viewpoints of the structure demonstrate where DNA sits within the 
subunits of DNA gyrase, as well as where ciprofloxacin interchelates 
(highlighted in A).  View D in turn shows the specific binding of 
ciprofloxacin within the DNA base pairs (Figure 2).  Whilst Bax et al. 
used MnCl2 as part of their crystallisation conditions,
24
 the presence of 
Mn
2+
 in their structure agrees with previous work demonstrating metal ions 
must be present for cleavage of the DNA backbone, though this was shown 
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in human topoisomerase IIα.29  It had been previously suggested that 
magnesium ions play a role in stabilising the ternary complex by 
encouraging tighter binding.
30
  As such, the presence of metal ions in the 
structure reported by Bax et al. lends support to the role of metal ions in 
fluoroquinolone action. 
 
 
Figure 2 - Ciprofloxacin co-crystallised with both DNA and DNA gyrase 
of S. aureus, where two fluoroquinolones stabilise the ternary complex by 
interchelating between the DNA base pairs: A - side view; B - front view; 
C - angled view; D - zoom of one binding site.  PDB code: 2xct.
24
  Gold = 
DNA backbone/carbon; grey = carbon; blue = nitrogen; red = oxygen; 
green = fluorine; Mn = grey sphere.  Translucent surface - negative charge 
shown in red and positive charge shown in blue. 
 
More recently, Osheroff et al. demonstrated that topoisomerase IV-
fluoroquinolone interactions are mediated through a water-metal ion bridge 
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through serine and glutamic acid residues, furthering support for the role of 
metal ions in fluoroquinolone binding.
31
  However, Drlica et al. have also 
recently proposed that that there are two modes of drug binding for 
modified fluoroquinolones in gyrase-DNA complexes.
25
  Drlica et al. 
found that attachment of a chloroacetyl moiety to the piperazinyl moiety of 
ciprofloxacin 1-5 can lead to an interaction with a different subunit of both 
DNA gyrase and topoisomerase IV.  This new interaction occurred through 
nucleophilic attack of a cysteine unit at the chloroacetyl moiety of the 
modified drug, which resulted in the GyrA and GyrB subunits being cross-
linked, despite being 17Å apart (Figure 3).
25
  Furthermore Drlica et al. also 
reportedly identified a second potential binding pocket bridging the GyrA-
GyrA interface.
25
  However, it should be highlighted that the addition of a 
chloroacetyl moiety is not suitable within drug design given that it would 
be too reactive within untargeted cells.  As such, the concept of a second 
mode of action must be considered with caution given that Drlica et al. did 
not use a standard fluoroquinolone, instead adding a reactive species which 
allowed for this observed interaction. 
 
 
Figure 3 - Simplified representation of secondary binding mode for 
modified fluoroquinolones in DNA gyrase, proposed by Drlica et al.
25
 
 
Given that fluoroquinolone activity results in the inhibition of both DNA 
gyrase and topoisomerase IV, these antimicrobials ultimately lead to 
bacterial apoptosis.  Furthermore, with ongoing discussion regarding the 
mechanism of fluoroquinolone activity, it is still important that this 
antimicrobial class continues to be developed, as alluded to earlier with 
delafloxacin 1-8. 
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Understanding the fluoroquinolone pharmacophore 
 
With the continued development of fluoroquinolones, it is important to 
consider the pharmacophore of fluoroquinolones to understand what 
functional groups are tolerated, and those which are essential for their 
activity (Figure 4).
12, 32
  As Figure 4 shows, there are a number of 
positions where substitutions can be made on the fluoroquinolones.  The β-
keto acid, labelled 3, is essential for target site binding (purple - Figure 
4),
26
 and thus no changes should be made.
12, 32
  The R group at point 1 
(gold - Figure 4) has been shown to control potency, with some effect on 
the pharmacokinetics, with small non polar groups the best tolerated.
12, 32
  
Modification at point 2 (orange - Figure 4) is possible, with small rings 
tolerated, but given it is close to the gyrase binding unit, small hydrophobic 
groups are best, and this position is often left unfunctionalised.  Addition of 
small polar groups at point 4 (pink - Figure 4), such as amino or hydroxyl 
groups, can aid potency, as well as improve Gram-positive activity.
12, 32
  
The addition of the fluoride group at point 5 (green - Figure 4) to the 
original quinolones helped improve gyrase and antimicrobial potency by up 
to 100-fold more than other groups in the same position, and thus was the 
most important addition into the pharmacophore.
12, 32
  Perhaps the next 
most important substitution point on the pharmacophore is the R group at 
point 6 (blue - Figure 4), controlling pharmacokinetics, potency and 
spectrum activity.  Generally, 5- and 6- membered rings are the most 
active, with an incorporated secondary or tertiary amino group being the 
most effective for oral efficacy.
12, 32
  Finally, the X group at point 7 (red - 
Figure 4) also helps control the pharmacokinetics as well as anaerobic 
activity, with small polar groups best tolerated.
12, 32
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Figure 4 - Basic pharmacophore for fluoroquinolones with substitution 
positions numbered. 
 
Despite the success of the fluoroquinolones, they, like most classes of 
antimicrobials, face the growing problem of antibiotic resistance.  Bacterial 
resistance to fluoroquinolones results from a number of mechanisms, 
which are outlined below. 
 
1.3 Bacterial Resistance to Antibiotics 
 
The emergence of antibiotic resistance was reported almost as quickly as 
the introduction of the first antibiotics.  In 1940 an enzyme able to 
decompose penicillin (later known as a β-lactamase) was discovered,33 
before even the widespread use of the drug.  With an ever increasing 
number of drug resistant bacterial strains discovered, the problem has 
become a global threat, with the World Health Organisation concluding in 
their 2014 report that bacterial resistance is a “major public health 
concern”.34  As such, there are warnings that unless the problem is tackled, 
the concept of returning to a pre-antibiotic era, where common infections 
cannot be effectively treated, will become a reality.
35
 
 
The increasing pace of resistance has been attributed to a number of 
factors, primarily through the misuse and overuse of antibiotics in both 
human and veterinary medicine.
4, 36
  Furthermore, some species of fungi 
and bacteria produce their own antibiotics in order to compete with other 
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organisms, and these, in turn, carry genes encoding resistance to the 
antibiotic they produced.
36
  Coupled with the intrinsic resistance of some 
bacterial species to certain antimicrobial agents, these forms of resistance 
can lead to acquired resistance through the ability of microorganisms to 
trade DNA through horizontal transfer (Figure 5).
3, 36
  The rise in multi-
drug resistant (MDR) strains of bacteria has therefore occurred through the 
ability of organisms to share resistance genes, with resistance arising 
through several mechanisms. 
 
 
Figure 5 - Horizontal transfer of antibiotic resistance genes between 
bacterial cells.
3, 36
  Transduction = Viral transfer / Transformation = 
Foreign absorption / Conjugation = Intra- or Interspecies transfer. 
 
Mechanisms of resistance 
 
There are a number mechanisms by which bacteria exhibit antimicrobial 
resistance, with some combining several of these mechanisms, leading to 
MDR bacterial strains.
4, 36-40
  Such mechanisms include reduced 
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permeability (A - Figure 6), upregulation of efflux pumps (B - Figure 6), 
alterations or mutations to the intracellular drug binding sites (C - Figure 
6), enzymes that inactivate the antibiotic through modification (D - Figure 
6) and enzymes which can degrade the drug (E - Figure 6).
4, 36-40
 
 
 
Figure 6 - Schematic diagram demonstrating the mechanisms of bacterial 
resistance.
4, 36-40
  A - Reduced permeability; B - Efflux pumps (orange 
rectangle); C - Alterations of binding sites, e.g. gyrase (purple), RNA 
polymerase subunits (maroon) or other target proteins (white); D - 
Modification by enzymes (light purple); E - Degradation by enzymes (light 
blue). 
 
With regards to the fluoroquinolones, resistance has been shown to occur 
through each of the mechanisms highlighted above (Figure 6).
16, 38-40
  For 
example, it has been shown that a variant of an aminoglycoside acetyl 
transferase could modify fluoroquinolones through N-acetylation of the 
piperazinyl moiety of norfloxacin 1-4 and ciprofloxacin 1-5 (Figure 7), 
resulting in reduction of the antimicrobial activity.
41
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Figure 7 – Enzymatic deactivation of ciprofloxacin 1-5 by N-acetylation.41 
 
As mentioned previously, Osheroff et al. have demonstrated that a water-
metal ion bridge facilitates fluoroquinolone-topoisomerase IV binding 
through a serine and glutamic acid residue.
31
  Interestingly, this observation 
provides a likely mechanism for a previously known form of 
fluoroquinolone resistance resulting from mutations of these residues.
31, 40
  
Indeed, mutations and alterations to binding sites are common forms of 
fluoroquinolone resistance and include proteins known as quinolone 
resistance proteins (Qnr), which shield the DNA-gyrase complex, 
preventing drug access.
40
 
 
In order to reduce intracellular drug concentration, expression of efflux 
pumps can cause resistance to fluoroquinolones by removing the 
antimicrobial agent from the bacterial cell.
37
  Furthermore, a reduction in 
cell permeability can also result in a decrease in intracellular drug 
concentration.  One form of reduced permeability results from the 
formation of bacterial biofilms, making it difficult for the antibiotic to 
penetrate the polymer matrix formed, ensuing resistance.
42
  In addition, the 
routes by which fluoroquinolones enter bacterial cells are through either 
passive diffusion or through non-specific porin channels, such as OmpF 
and OmpC, in the outer cell membrane.
40, 43
  As such, downregulation of 
these outer membrane porins can lead to a reduction in the intracellular 
concentration of the drug through reduced uptake into the cell.
40
  It is 
resistance associated to a reduction in cell permeability that the Trojan 
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horse strategy aims to overcome, by increasing the intracellular 
concentration of the drug, discussed in greater detail later in this Chapter.
5-8
 
 
Combating antimicrobial resistance 
 
With the prevalence of antibiotic resistance, a number of strategies have 
been developed to counter the growing problem.  However, as a recent 
study found, spending in the United Kingdom on antibiotic resistance 
research amounted to just £102 million between 1997 and 2010, accounting 
for only 3.9% of the total spend on infectious diseases,
44
 presenting a 
significant hurdle in the development of new strategies against resistance. 
 
Typical strategies employed against bacterial resistance include the 
development of new antibiotics, discovery of natural products with 
antibacterial activity, combination therapy, development of analogues of 
existing drugs, and new methodologies of drug delivery.
3-8
  All these 
strategies are important in the struggle against antimicrobial resistance.  
This thesis is concerned with the development of siderophore-antimicrobial 
conjugates, the so called ‘Trojan horse’ strategy, introduced as a means to 
overcome permeability-related resistance through the delivery of the drug 
via the iron uptake systems.
5-8, 45
  As such, the remainder of this Chapter 
focuses on this strategy as one approach against antimicrobial resistance. 
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1.4 Siderophores 
 
Iron bioavailability 
 
Iron is an essential nutrient for cells, being a cofactor in a number of 
enzymes as a result of its redox chemistry.
46
  As a result almost all bacteria, 
like most other living organisms, require iron as a nutrient for survival.
46
  
Despite the abundance of iron in the environment, its bioavailability is 
severely limited as it exists mainly as insoluble ferric iron (Fe(III)), due to 
the aerobic conditions of our atmosphere limiting the presence of soluble 
ferrous iron (Fe(II)).
47
  Consequently, the concentration of free Fe(III) is 
limited to ~ 10
-18
-10
-24
 M under physiological conditions (for Fe(OH)3).
47, 
48
  With the scarce availability of Fe(II) in aerobic environments, bacteria 
have had to evolve mechanisms for the sequestration of Fe(III), producing 
chelating ligands known as siderophores.  These chelators can solubilise 
Fe(III) and mediate its uptake into the cell, allowing bacteria to maintain 
adequate cellular iron concentrations for their survival within the 
mammalian host.
45, 49-51
 
 
Types of siderophores 
 
The first siderophores were identified in the early 1950s and recognised as 
growth factors for the organisms from which they were acquired.
52
  Since 
then over 500 unique siderophores have been discovered, obtained from 
bacterial, fungal and plant species.
45, 49-51
 
 
Siderophores are generally grouped by their chelating units, with the most 
common siderophore classes being catecholate (e.g. enterobactin 1-9), 
hydroxamate (e.g. desferrioxamine B 1-11) or α-hydroxycarboxylate (e.g. 
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citric acid 1-12) (Figure 8).  As Figure 8 shows, these iron binding units 
contain oxygen moieties as hard Lewis base donors, which can meet the 
binding requirements of the hard Lewis acid Fe(III), given its d
5
 high-spin 
electronic configuration.
45, 50
  However, it is also possible for nitrogen and 
sulfur donating moieties to bind iron, though they have a lower affinity for 
iron(III).  Enterobactin 1-9, produced by a number of species including 
Escherichia coli, is one of the strongest iron chelators known, given that it 
is a hexadentate ligand capable of forming an octahedral 1:1 complex with 
Fe(III).
53
  However, a number of hydrolysis products of enterobactin exist, 
such as the tetradentate linear dimer 1-10, which are known to support 
bacterial growth.
54
  Furthermore, citric acid 1-12 acts an exogenous 
siderophore, not produced by bacteria but uptaken due to its abundance in 
nature and iron binding capability.
55, 56
 
 
 
Figure 8 - Common siderophore binding units, with representative 
examples enterobacin 1-9, enterobactin linear dimer 1-10, desferrioxamine 
B 1-11 and citric acid 1-12. 
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As mentioned above, the ability of siderophores to scavenge Fe(III) from 
the environment allows them to provide the required nutrient to the 
bacterial cell.  Thus it is important to understand the iron-binding strength 
of siderophores, generally reported as a pFe(III) value, which is defined as 
the negative logarithm of free [Fe(III)] under fixed conditions 
([siderophore] = 10 µM and [Fe(III)] = 1 µM at pH 7.4).  Based on this, the 
pFe(III) values of enterobactin 1-9 have been determined as 35.5, 
desferrioxamine B 1-11 as 26.5 and citric acid 1-12 as 17.7.
57
  As such, 
these pFe(III) values help demonstrate that hexadentate ligands are the 
strongest at Fe(III) binding, given their capacity to form octahedral 
complexes and thus complete the coordination sphere of Fe(III).  However, 
a range of tetradentate, tridentate and bidentate siderophores have been 
shown to support bacterial growth, such as the aforementioned citric acid 
1-12.
45, 50, 55, 56
  Considering the abundance of siderophores available, and 
their variations in ligand geometry and structure, the siderophore uptake 
mechanisms are relatively general.
45, 50
 
 
Ferric-siderophore uptake mechanisms 
 
Gram-negative bacteria have two membranes, with a periplasm in between.  
Whilst the outer membrane is freely permeable towards small hydrophobic 
molecules, due to the lipid bilayer which contains porins such as OmpF,
40, 
43
 most ferric-siderophore complexes are too large for these porins and thus 
require specific uptake mechanisms.
58
  These uptake mechanisms have 
developed so the ferric-siderophore complex can be transported through 
both cell membranes into the cytoplasm (Figure 9). 
 
Ferric-siderophore uptake occurs whereby the complex is transported 
through an outer membrane receptor, generally specific to each ferric-
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siderophore complex, into the periplasm (Figure 9).
58
  Examples of these 
specific outer receptors include FecA for the uptake of ferric-citrate,
59-62
 
and FepA for the uptake of ferric-enterobactin.
58, 63
  Reported crystal 
structures of these two proteins, and those solved for other outer membrane 
receptors, demonstrate barrel structures spanning the membrane through 
which the complex is transported.
62, 63
  The process of transport through the 
outer membrane receptor is dependent on the TonB complex, consisting of 
three inner membrane proteins: TonB, ExbB and ExbD.  The TonB 
complex is an energy transducer, aiding in the transfer of energy between 
the cytoplasmic membrane to the outer membrane.
64, 65
 
 
 
Figure 9 - Schematic representation of ferric-siderophore complexes into a 
Gram-negative bacteria cell.  Blue circle/half-circle = Siderophore / Red 
circle = Fe(III). 
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Once inside the periplasm, the complexes are shuttled through to the ABC 
transporters by periplasmic-binding proteins (Figure 9).
58
  Like the outer 
membrane receptors, there are generally specific periplasmic binding 
proteins for each ferric-siderophore complexes, such as FecB for citrate 
and FepB for catecholate siderophores, though they are accommodating for 
other related structures.
58
  Finally, access into the cytoplasm occurs 
through ABC transporters, which consist of four structural domains: two 
transmembrane domains forming a channel and two ATP binding domains 
(Figure 9).
58
  On entry into the cytoplasm, release of the iron from the 
complex can occur via two routes, either through reduction of Fe(III) to 
Fe(II), or through degradation of the siderophore itself.
45
 
 
Compared to Gram-negative bacteria, less is known about the Fe(III) 
uptake mechanisms into Gram-positive bacteria, with research centered on 
Bacillus subtilis and S. aureus.
45, 66
  Given that Gram-positive bacteria do 
not have an outer membrane, the uptake mechanism is analogous to the 
inner membrane transport system of Gram-negative bacteria.  Instead of a 
periplasmic-binding protein, there is a lipoprotein anchored to the 
membrane, which is assumed to interact with an ABC transporter to shuttle 
the complex into the cell.
66
 
 
Fortunately, the binding units of the siderophore are the only components 
essential for recognition for the uptake proteins, which allows for 
attachment of other moieties to the siderophore backbone without 
disrupting siderophore uptake.
5
  Such a feature can be exploited to deliver 
antimicrobials via the Trojan horse strategy through the uptake 
mechanisms, as a means to by-pass permeability-related resistance 
pathways,
5-8
 discussed later in this Chapter. 
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Mammalian response to siderophores and the fight-back by bacteria 
 
Given the success of bacteria in scavenging iron within their host to 
survive, mammals have evolved several defence mechanisms to limit free 
iron concentration.  Whilst not produced directly as a defence against 
pathogens, mammalian hosts do generate iron storage and transport 
proteins, ferritin and transferrin.
67, 68
  These proteins are produced 
predominantly to protect the host from free iron, which can otherwise be 
involved in Fenton chemistry that leads to cell damage, though these 
proteins are capable of competing for free iron.
67, 68
 
 
Further to production of iron storage and transport proteins, many 
mammalian hosts generate proteins known as siderocalins, a subset of the 
lipocalin family.
69-73
  These proteins are able to bind ferric-catecholate 
siderophores using three positively charged residues at the top of a 
hydrophobic pocket, which interact with the negative charge of the ferric-
catecholate complexes.
69-73
  This was demonstrated by the crystal structure 
of siderocalin bound to fluvibactin (1-13), produced by Vibrio fluvials 
(Figure 10).
73
  A combination of cation-π and ionic interactions stabilise 
the protein-siderophore complex.
69-73
  Furthermore, a number of 
catecholate siderophores have been found to bind to siderocalin, including 
enterobactin 1-9,
70
 and the mixed ligand catecholate siderophore 
carboxymycobactin 1-14 (from Mycobacterium).
74
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Figure 10 - Crystal structure of siderocalin bound to ferric-fluvibactin.  
PDB code: 4K19.
73
  Grey = carbon; blue = nitrogen; red = oxygen; Fe = 
coral sphere.  Surface - negative charge shown in red and positive charge 
shown in blue. 
 
However, with the continuous struggle between the mammalian host and 
microorganisms in the competition for iron, bacteria have evolved to evade 
the siderocalin protein.  By taking advantage of the strict binding 
requirements of siderocalin, some bacterial species now produce and 
secrete so called ‘stealth siderophores’.  Petrobactin 1-15, produced by 
both Bacillus antracis and Bacillus cereus, contains an unusual 3,4-
catecholate arrangement, and is thus able to avoid siderocalin binding by 
virtue of this change in configuration.
75, 76
  In addition, the bacterial species 
E. coli, Salmonella sp. and Klebsiella sp. have each been found to produce 
a glucosylated analogue of enterobactin known as salmochelin S4 1-16.
77, 
78
  Furthermore, hydrolysis products of salmochelin S4, such as 
salmochelin S1 1-17, are known to support bacterial growth, though less is 
currently known about the production and uptake of these salmochelins.
77-
79
  The glucosyl moieties introduce sufficient steric hindrance to disrupt the 
ability of siderocalin to scavenge the salmochelins.
70
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With the knowledge that siderocalin can sequester catecholate 
siderophores, it is important to consider the siderocalin protein when 
designing siderophore-antimicrobial Trojan horse conjugates, as a means to 
avoid potential catecholate-antimicrobial conjugates also being scavenged 
by this protein.  Such an approach is targeted with a salmochelin-inspired 
conjugate, discussed in detail in Chapter 4. 
 
1.5 Trojan Horse Strategy 
 
Overview of the concept 
 
Inspired by Greek mythology, the concept of the Trojan horse strategy 
involves disguising an antimicrobial as an essential nutrient to a bacterial 
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species.  The strategy aims to exploit bacterial iron uptake so as to actively 
transport a siderophore-antimicrobial conjugate into the cell, as a means to 
evade resistance associated with a reduction of cell membrane permeability 
or efflux pumps.
5-8, 80
  The requirement for iron enables these conjugates to 
be uptaken into microbial cells to avoid iron starvation, where the 
conjugate as a whole, or the released drug, can lead to antimicrobial 
activity (Figure 11).
80
  The use of this strategy is of particular interest to 
the work presented in this thesis, with the approach having been widely 
studied previously.  Moreover, it should be noted that the strategy was first 
developed in nature, with naturally occurring Trojan horse conjugates, 
known as the sideromycins. 
 
 
Figure 11 - Simple representation of the Trojan horse strategy.  Green 
diamond = antibiotic drug; blue rectangle = linker; dark blue half circle = 
siderophore; red = Fe(III). 
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Natural Trojan Horse Conjugates – The Sideromycins 
 
In the competition for iron between bacterial species, some bacterial strains 
have evolved to produce their own natural Trojan horse conjugates, the 
sideromycins, as a means to gain a survival advantage.  For example 
Actinomyces subtropicus produces the albomycins (e.g. albomycin δ2 1-18) 
which consists of a hydroxamate siderophore, analogous to ferrichrome 1-
19, linked through a serine spacer to a thioribosyl-pyrimidine antibiotic.
80, 
81
  It was shown that albomycin is taken up through the ferrichrome outer 
membrane receptor protein FhuA.  Once inside the cell the antibiotic is 
released by enzymatic action, leading to cell death.
80, 82
  Further examples 
include ferrimycin (1-20) and the salmycins (1-21 - 1-24), each containing 
the siderophore desferrioxamine B 1-11 linked to antimicrobial moieties 
which can act against a variety of bacterial species.
6, 80
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Unsurprisingly, the discovery of the sideromycins has inspired the targeted 
approach of developing synthetic Trojan horse conjugates, with extensive 
research in the design of these compounds.
5-7, 80
 
 
Synthetic Trojan Horse Conjugates 
 
Among the first synthetic Trojan horse conjugates, Zähner et al. reported in 
1977 two conjugates based on ferrichrome 1-19 and desferrioxamine B 1-
11, conjugated to a sulfonamide antimicrobial agent, compounds 1-25 and 
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1-26 respectively.
83
  Impressively, they found that compound 1-25 was 
active against S. aureus, at similar levels to the parent drug, though 
compound 1-26 had no activity.
83
  Not only did this early study 
demonstrate the viability of the Trojan horse approach, but it was also the 
first to pose the questions of siderophore and linker choice, and whether 
drug release was required to retain antibiotic activity.
83
  Further to the use 
of sulfonamides, conjugates have been designed using other antibiotics 
such as vancomycin, β-lactams and fluoroquinolones.5-8, 84 
 
 
 
Siderophore-β-lactam Trojan horse conjugates 
 
Since the original work of Zähner et al. a significant proportion of reported 
examples have focused on the use of β-lactam antibiotics in Trojan horse 
conjugates.
5-8
  The advantage of such an approach is that this antibiotic 
class targets proteins involved in the cell wall synthesis, which are located 
in the bacterial periplasm.  As such, the siderophore-β-lactam conjugates 
only have to pass through the outer cell membrane to reach their target.
85
  
As a result, siderophore-β-lactam conjugates have generally had the most 
success. 
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Early studies of siderophore-β-lactam conjugates established the approach 
can lead to a significant improvement in antibiotic activity.
86-91
  Two such 
early examples, reported by Ohi et al. in 1986, demonstrated that a single 
catechol moiety attached to ureidopenicillins, could lead to a 60-fold 
increase in activity against Pseudomonas aeruginosa strains compared to 
the parent drug (1-27 and 1-28).
86, 87
  Furthermore the authors postulated 
that the siderophore component was aiding conjugate uptake.
86, 87
  Soon 
after, Mochizuki et al. demonstrated the activity of their mono-catechol 
conjugate of cephalosporin (1-29) was significantly enhanced in low-iron 
environments in E. coli, by up to 20000-fold compared to when iron was 
not limited, suggesting their compound utilised the iron uptake systems.
88
  
As Miller later discussed, the fact these conjugates did not possess 
traditional hexadentate ligands suggests that a ligand:iron stoichiometry of 
1:1 is not crucial for transport.
92
 
 
 
 
Subsequent studies of siderophore-β-lactam Trojan horse conjugates have 
investigated mixed ligand siderophores, such as that by Miller et al.
93
  A 
conjugate containing both catechol and hydroxamate moieties, linked to the 
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antimicrobial Lorabid, conjugate 1-30, showed a 2000-fold increase in 
activity against a strain of Acinetobacter compared to the parent drug.
93
  
Other promising siderophore-β-lactam conjugates followed,94, 95 including 
1-31, an acylated triscatecholate siderophore-β-lactam conjugate.96  As a 
simple mimic of enterobactin 1-9, conjugate 1-31 was designed to maintain 
the hexadentate ligand geometry without incorporating the synthetic 
challenge of the triserine backbone of enterobactin.
96
  The use of acylated 
catechol moieties proved an interesting addition, designed to act as a 
prodrug to releasing the required iron binding hydroxylate moieties whilst 
allowing the conjugate to avoid potential methylation by catechol O-methyl 
transferase (COMT), which would prevent iron binding.
96
  Such an 
approach was based on an earlier study by Ohi et al. who demonstrated 
improved stability of an acylated conjugate against COMT.
96, 97
  Further to 
this, conjugate 1-31 showed an eightfold increase in antimicrobial activity 
against E. coli, compared to ampicillin.
96
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More recently, Nolan et al. employed enterobactin as the choice of 
siderophore in a β-lactam conjugate of ampicillin (1-32).98  It was found 
that that antimicrobial activity was enhanced by up to 1000-fold compared 
to the parent drug against certain E. coli strains.
98
  It was also demonstrated 
that attachment at the C-5 position of one of the catechol moieties did not 
disrupt conjugate uptake, assumed to be as a result of the long and flexible 
linker used between the antimicrobial and enterobactin siderophore.
98
  
However, as discussed earlier, the conjugate was scavenged by the 
mammalian response protein siderocalin, preventing its activity.
98
  To 
avoid this unwanted outcome, Nolan et al. subsequently produced 
salmochelin-inspired conjugates, which were shown to avoid siderocalin 
binding and are discussed in greater detail in Chapter 4.
99
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With the successes demonstrated by improved activity of siderophore-β-
lactam conjugates compared to their parent drugs, it is important to 
highlight that comparative results have been achieved with monosulfactam 
and monocarbam siderophore-antimicrobial conjugates,
100-103
 including 
recent interest and development by AstraZeneca.
104-106
 
 
Siderophore-β-lactam conjugates undergoing clinical trials 
 
Of significance, it should be highlighted that two siderophore-antibiotic 
conjugates are currently undergoing clinical trials, demonstrating the 
progress in the Trojan horse strategy.  Of these two conjugates one contains 
a monosulfactam antimicrobial 1-33,
107-109
 and the other a β-lactam 1-
34.
110-112
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Conjugate 1-33, known as BAL30072, is currently being developed by 
Basilea Pharmaceutica.  The conjugate utilises a dihydropyridone moiety 
as the chelating unit,
107-109
 analogous in structure to the hydroxypridinone 
group of siderophores.
113
  This group of siderophores have a higher binding 
interaction with metal ions than hydroxamates.
113
  Moreover, conjugate 1-
33 is undergoing phase I trials, having shown potent activity against 
numerous Gram-negative species, including MDR Acinetobacter spp. and 
MDR P. aeruginosa, with MIC90 (MIC where 90% inhibition occurs) 
values of 4 and 8 µg/mL for each strain respectively.
107-109
 
 
Making better progress, conjugate 1-34 (S-649266), in development 
through Shionogi & Co., is actively recruiting for phase III trials at the time 
of writing.
110-112, 114
  S-649266 1-34 was shown to demonstrate activity 
against a number of MDR Enterobacteriaceae, and additionally it was 
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established that it maintains high stability against hydrolysis and 
degradation by β-lactamases.110-112 
 
It should be noted that both conjugates 1-33 and 1-34 share a similar design 
feature, with the iron chelating moieties being in the 3,4-arrangement.  This 
arrangement within these conjugates are similar in nature to the stealth 
siderophore petrobactin 1-15, and therefore provides an attractive 
consideration for the future of conjugate design.  Therefore, with these two 
compounds in clinical trials, it will be interesting to see their continued 
development, as well as their influence on the design of future siderophore-
β-lactam Trojan horse conjugates. 
 
Siderophore-fluoroquinolone Trojan horse conjugates 
 
With the success demonstrated by siderophore-β-lactam conjugates, a 
number of studies have targeted siderophore-fluoroquinolone Trojan horse 
conjugates, given the widespread use of fluoroquinolone antimicrobials.  
However, the drug target within Gram-negative bacteria for the 
fluoroquinolones is located in the cytoplasm, providing an added 
challenged to conjugate design as they are required to cross both the outer 
and inner cell membranes.  As such, there are fewer reported examples of 
fluoroquinolone conjugates.  Whilst evidence has been demonstrated that 
siderophore-fluoroquinolone conjugates are taken up through the iron 
uptake mechanisms, it should be noted that no current siderophore-
fluoroquinolone conjugates have demonstrated increased antimicrobial 
activity against either Gram-positive or Gram-negative bacteria.
115-128
  
Indeed, these studies have led to concerns that the siderophore/linker 
moieties of the conjugates may be reducing antimicrobial binding through 
steric hindrance within the target site.  Nevertheless, these investigations 
provide understanding towards the key features required in siderophore-
fluoroquinolone conjugate design. 
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One early example was a siderophore-quinolone conjugate, reported by 
Miller et al. producing a conjugate between nalidixic acid 1-3 and 
desferrioxamine B 1-11, to give compound 1-35.
129
  Interestingly, the 
conjugate was connected through an amide bond at the β-keto acid, which, 
as highlighted earlier, is essential for gyrase binding.  However, Miller et 
al. accounted for this as part of their design, hoping for the naldixic acid 
moiety to intercalate into DNA, allowing the iron-siderophore complex to 
induce redox damage to the DNA through the Fenton reaction.
129
  
However, despite being found that the conjugate could perform DNA 
cleavage in vitro, it was only when Fe(II), hydrogen peroxide and ascorbate 
were present.
129
 
 
 
 
Later studies using fluoroquinolone antimicrobials investigated not only 
the choice of siderophore, but also linker design.  For example, Hennard et 
al. reported a conjugate of norfloxacin 1-4 to the siderophore pyoverdin (1-
36), finding it to be approximately 50 times less active against DNA 
gyrase, with a corresponding reduction in antimicrobial activity, 
postulating this reduction in activity was due to steric hindrance.
115
  
However, of importance in the Trojan horse strategy, Hennard et al. 
demonstrated that the conjugate was transported into the cells of P. 
aeruginosa, passing through FpvA, the outer membrane receptor for 
pyoverdin.
115
  To investigate linker design, Hennard et al. also designed a 
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comparative siderophore-norfloxacin conjugate incorporating an 
(acyloxy)alkyl carbamate based linker, (discussed later in Chapter 2, 2-7), 
designed to allow for intracellular release of the drug.
115
  It should be 
highlighted that Hennard et al. were among the first to discuss using a bio-
labile linker as an essential requirement in siderophore-fluoroquinolone 
conjugates.  Subsequent investigations also explored the differences 
between non-labile linkers and (acyloxy)alkyl carbamate based linkers, 
such as those by Rivault et al. (1-37/2-8),
116
 Noël et al. (1-38/2-9),
117
 and 
Nolan et al. (1-39/2-10),
120, 123
 with each showing that their non-labile 
linked siderophore-fluoroquinolone conjugates had reduced antimicrobial 
activity compared to the parent drug.  With regards to these studies, it 
should be noted that Rivault et al. linked norfloxacin to pyochelin (1-37), a 
siderophore of P. aeruginosa.
116
  The authors reasoned that the reduced 
activity of 1-37 compared to the parent drug resulted from either a lack of 
active transport or from steric hindrance of the DNA gyrase site by the 
siderophore moiety.
116
  Similarly Noël et al. built on the work of Rivault et 
al. by also producing pyochelin based conjugates, such as 1-38, though 
functionalised through the N3” position.117  Like the investigation before 
theirs, Noël et al. found that the stable linker between the siderophore and 
antimicrobial led to reduced antimicrobial activity.  However, Noël et al. 
did demonstrate active transport of 1-38,
117
 once again showing the 
viability of using siderophores for active transport of fluoroquinolones via 
the iron uptake mechanisms.  Furthermore, Nolan et al. also demonstrated 
that 1-39, a conjugate between enterobactin and ciprofloxacin, was actively 
transported into P. aeruginosa.
123
  It should be highlighted that each of 
these studies indicates the importance of linker choice.  The use of 
(acyloxy)alkyl carbamates as bio-labile linkers will be discussed later in 
Chapter 2. 
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With the indication that linker choice is a key factor in the design of 
siderophore-fluoroquinolone conjugates, Ji and Miller have also explored 
the use of bio-labile linkers.
118, 119
  Based on the concept of a trimethyl lock 
as the linker moiety, they envisaged that drug release would occur through 
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the route outlined in Scheme 1.
118, 119
  The notion of a trimethyl lock arises 
from three interlocking methyl groups with unfavourable steric 
interactions.
130
  In turn, the steric clash between these methyl groups 
encourage lactonization on action by an enzyme, to give a 
hydrocoumarin.
130
 
 
 
Scheme 1- Proposed mechanism of drug release from the trimethyl lock 
derived conjugates.
118, 119
 
 
Ji and Miller designed conjugates 1-40 and 1-41 using desferrioxamine B 
1-11 and ciprofloxacin 1-5 as the siderophore and antimicrobial moieties, 
respectively.
118
  Both conjugates incorporated a trimethyl lock-based 
linker, with 1-40 designed to undergo esterase cleavage of the linker, whilst 
1-41 was expected to respond to phosphatase.  It was found that the 
antimicrobial activity of 1-40 was lower than that for free ciprofloxacin 1-
5, and the authors postulated that either extracellular esterases could have 
led to early release of the drug or that the conjugate was a poor substrate 
for these esterases.
118
  In addition, it was found that conjugate 1-41 was 
inactive, suggesting that the linker did not cleave as planned or that it did 
not go through the active uptake systems.
118
  Subsequently, Ji and Miller 
produced conjugate 1-42, designed to undergo drug release as a result of 
ferric reductases, allowing for release via an analogous mechanism to  that 
outlined in Scheme 1.
119
  This alteration to the linker design was to exploit 
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the fact that ferric reductases, responsible for release of iron from ferric-
siderophore complexes, are found inside the bacterial cell.
119, 131
  
Unfortunately, Ji and Miller found that the activity of 1-42 was lower than 
that of free ciprofloxacin, with the authors suggesting that both the 
siderophore choice/recognition, as well as the linker activation efficiency 
require optimisation to allow for drug release.
119
 
 
 
 
As a means to understand further the effects of linker choice, the Duhme-
Klair/Routledge research group investigated citric acid 1-12 based 
siderophore-ciprofloxacin conjugates, performing DNA gyrase inhibition 
assays to determine the correlation between linker design and antimicrobial 
activity.
121, 124, 128
  The linker length was systematically increased through 
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conjugates 1-43, 1-44 and 1-45.  Furthermore, conjugate 1-46 was 
produced, using staphyloferrin A (secreted by S. aureus) as the 
siderophore, to increase the number of iron binding moieties.  Interestingly, 
a correlation was established between an increase in the linker 
length/siderophore size and a decrease in DNA gyrase inhibition, which 
also matched a decrease in antimicrobial activity compared to the free 
antimicrobial ciprofloxacin 1-5.
121, 124, 128
  These results indicate that 
choosing a suitable linker is fundamental in allowing for optimum activity 
of the fluoroquinolones inside the bacterial cell, and go to highlight further 
the requirement for bio-labile linkers. 
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Fardeau et al. recently introduced an ester linkage, designed to allow 
release of the antimicrobial from conjugate 1-47.
127
  Whilst 1-47 
demonstrated reduced activity against P. aeruginosa (DSM 1117), it was 
found that the hydrolysis product 1-48 matched the activity of free 
ciprofloxacin.
127
  This indication that small functional groups can remain 
attached to the fluoroquinolones without an apparent loss of activity is 
encouraging, and can influence the design of future conjugates.  However, 
as highlighted earlier, one form of resistance to fluoroquinolones results 
from N-acetylation,
41
 and so it should be noted that in some bacterial 
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species small groups attached to fluoroquinolones will be less tolerated 
than in others.  The ultimate goal still remains to design siderophore-
fluoroquinolone conjugates which incorporate a bio-labile linker which 
only allows for intracellular drug release after uptake. 
 
 
 
1.6 Project Aims 
 
The work presented in this thesis outlines the development of novel 
siderophore-fluoroquinolone Trojan horse conjugates, focusing on 
ciprofloxacin 1-5 as the antimicrobial.  Two avenues of conjugate design 
were explored.  The first involves the concept of linker design as a means 
of potentially allowing for intracellular drug release, with the synthesis and 
characterisation of a carbamate-linked citrate-ciprofloxacin conjugate 
(Chapter 2), and attempted synthesis of a disulfide-linked citrate-
ciprofloxacin conjugate (Chapter 3).  The second design concept involved 
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investigating the next generation of siderophore choice for Trojan horse 
conjugates, with the synthesis and characterisation of a salmochelin-
inspired ciprofloxacin conjugate (Chapter 4).  The isolated conjugates were 
evaluated for their antimicrobial activity and compared to the parent 
antimicrobial.  Given that the aim of the Trojan horse strategy is to 
overcome resistance due to a reduction in intracellular drug concentration, 
resulting from reduced permeability and the expression of efflux pumps, it 
was anticipated that these conjugates will bypass these resistance 
mechanisms by their active uptake.  It is thus aimed that the conjugates 
presented in this thesis will provide further understanding to the design 
concepts required in siderophore-fluoroquinolone conjugates. 
  
Chapter 2: Synthesis and 
antimicrobial activity 
testing of a carbamate-
linked citrate-
ciprofloxacin conjugate 
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2.1 Aims and overview 
 
In siderophore-fluoroquinolone Trojan horse conjugates, the linker is a key 
component in conjugate design, with it now understood that the linker 
requires bio-labile groups for drug release.  This Chapter discusses the 
incorporation of a carbamate linker between a citrate siderophore and 
ciprofloxacin as the drug.  The aim of the research presented in this 
Chapter was to investigate the function of a carbamate group as a bio-labile 
linker to release free ciprofloxacin after delivery of the conjugate into the 
cell. 
 
2.2 Introduction 
 
Prodrugs: Carbamates 
 
Prodrugs have become an ever more important strategy in drug 
development.
132
  Most prodrugs are designed to include minor alterations 
to the physical properties of an existing drug, with the ability to undergo 
chemical or enzymatic transformation in vivo, releasing the active 
pharmacophore component as a means to improve properties, such as poor 
solubility.
132
  Further to this, the prodrug approach can also be applied to 
newly designed siderophore-fluoroquinolone conjugates, as a means of 
releasing the antimicrobial in vivo upon uptake. 
 
As discussed in Chapter 1, a number of studies have investigated 
siderophore-fluoroquinolone conjugates.
115-128
  However, at the time of 
writing, every reported siderophore-fluoroquinolone conjugate has seen a 
reduction of activity compared to the parent antimicrobial.
115-128
  It is 
therefore necessary to consider bio-labile linker design as a means to 
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release the antimicrobial, following a prodrug approach.  A number of 
studies have investigated using potentially bio-labile carbamate linkers 
between the siderophore and fluoroquinolone in prodrug Trojan horse 
conjugates.
115-120
  Whilst these studies incorporated carbamate linkers into 
their conjugates, they all unfortunately found that their conjugates had 
reduced activity compared to the parent drug, as discussed later in this 
Chapter.
115-120
  It is however clear that optimisation is required to find a 
suitable carbamate linker between the siderophore and fluoroquinolone 
moieties to allow for adequate drug release in vivo. 
 
The importance of the quinolone moiety for target binding of the 
fluoroquinolones (discussed in Chapter 1) has thus far limited the diversity 
of possible Trojan horse conjugation (Red - Figure 12).  The only 
siderophore-fluoroquinolone conjugates documented in the literature are 
bonded through the secondary amine of the piperazinyl moiety (Green - 
Figure 12).
115-128
   
 
 
Figure 12 - Structure of ciprofloxacin demonstrating where conjugation is 
feasible. 
 
For a prodrug approach in siderophore-fluoroquinolone Trojan horse 
conjugates, there are a number of bio-labile functionalisations available for 
the amino group, such as enamines, N-Mannich bases and carbamates, 
which can allow drug release via pH or enzymatic action, depending on 
which cleavage mechanism is used.
132, 133
  The carbamate functional group 
(Figure 13), utilised as a potential bio-labile group in siderophore-
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fluoroquinolone conjugates,
115-120
 is derived from an amine and carboxylic 
acid.  The carbamate group has been of interest as it is often more 
enzymatically stable than its corresponding ester, yet more prone to 
hydrolysis than amides.
132
  As such, the bioconversion of carbamates 
requires esterases, classes of which are present in bacteria, to release the 
parent drug.
134, 135
 
 
 
Figure 13 - Generic structure of a carbamate, and common carbamates 
used as protecting groups for amines, the Fmoc, Boc and CBz groups. 
 
Chemical stability of carbamates 
 
The ability to tune the stability of the carbamates can allow for the 
selective removal of individual carbamate moieties.  Such a strategy can be 
exploited in the design of Trojan horse conjugates by incorporating a 
carbamate.  The chemical stability of the carbamate group is influenced by 
its neighbouring groups, with there being two proposed mechanisms for 
carbamate decomposition by the hydroxide ion.
136-138
  The first results from 
nucleophilic substitution, with hydroxide attack at the carbonyl, followed 
by the loss of the alcohol from the ester end (Scheme 2).
136-138
  This in turn 
leaves the carbamic acid, which readily decomposes to the amine and 
carbon dioxide (Scheme 2).
136-138
  The second follows an E1cB 
mechanism, whereby deprotonation of a proton from the amide component 
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of the carbamate group allows for a cascade through to an isocyanate 
intermediate (Scheme 3).
136-138
  Addition of water to the quaternary carbon 
reforms carbamic acid, which can decompose to give the amine and carbon 
dioxide (Scheme 3).
136-138
 
 
 
Scheme 2 - Carbamate cleavage via nucleophilic substitution. 
 
 
Scheme 3 - Carbamate cleavage via an E1cB mechanism. 
 
The differences between the two mechanisms relates to the availability of 
an amide proton, though the E1cB mechanism (Scheme 3) has only been 
demonstrated with a phenolic moiety, and is related to the pKa of the 
phenol.
136-138
  On the other hand, nucleophilic substitution can occur with 
either aromatic or aliphatic based alcohols (Scheme 2), as well as in cases 
where there are two functional groups on the amide moiety.  Steric effects 
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of the -OR group and the –NR1R2 groups were shown to have an effect on 
carbamates by slowing or even preventing hydroxide attack at the carbonyl, 
and thus improving their stability against hydroxides.
137
  With regard to 
carbamate stability in acids, it has been shown that carbamates can be first 
protonated by strong acids such as hydrogen bromide, with the bromide ion 
next acting as a good nucleophile to attack the methylene group in a SN2-
type manner to give carbon dioxide, the amine and an alkyl halide (Scheme 
4),
139
 though in general carbamates are otherwise considered stable in 
acids.
138
 
 
 
Scheme 4 - Acid based cleavage of carbamates. 
 
Depending on their relative stabilities, carbamates are frequently used as 
protecting groups for amines, such as the tert-butyloxycarbonyl (Boc), 
fluorenylmethyloxycrbonyl (Fmoc) and carboxybenzyl (CBz) groups 
(Figure 13), as they can tuned to be acid or base labile.  Conditions for the 
removal of the Boc group, for example, require acidic conditions, such as 
hydrochloric or trifluoroacetic acid, due to the formation of isobutylene.
140
  
Additionally, the Boc group is stable under basic conditions, as a result of 
the steric hindrance of the -
t
Bu group preventing hydroxide attack.  On the 
other hand, the CBz group is stable under dilute acidic, basic and neutral 
conditions, with cleavage carried out predominantly by hydrogenolysis.
140
  
However, the CBz group can be removed with strong acids such as 
hydrogen bromide, through the mechanism shown in Scheme 4.  In 
contrast, the Fmoc group cannot be cleaved by acids or hydrogenolysis, as 
neither SN1 or SN2 mechanisms can work at the methylene group due to 
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steric hindrance.  However, the Fmoc group can be cleaved using mild 
bases, such as piperidine, as the presence of the electron withdrawing 
fluorene ring system makes the proton on the β-carbon mildly acidic, with 
a pKa of ~25, compared to other alkyl groups.  Deprotonation with a base 
in turn gives an aromatic anion intermediate, which obeys Hückel’s rule of 
4n+2 π-electrons, before the elimination of dibenzofulvene, carbon dioxide 
and an amine.
140, 141
 
 
Whilst the chemical stability of carbamates can allow for the introduction 
of carbamates that are stable to a range of conditions used during synthesis, 
their enzymatic cleavage through carboxylesterases is determined generally 
by the access of the substrate to the active site.
134, 142
  As such, it can be 
hypothesised that the use of a carbamate linker in the Trojan horse strategy 
should allow for intracellular release of an antimicrobial, given that 
carboxylesterases are present in bacteria,
134, 135
 and that carbamates have 
been used as prodrugs in a range of substrates, demonstrating the versatility 
of such enzymes. 
 
Carbamate containing prodrugs 
 
Several examples are reported in the literature where carbamates are used 
as prodrugs in medicinal chemistry.  One interesting approach, developed 
by Devarakonda et al., saw a carbamate prodrug of doxorubicin which 
cleaved using an electron cascade that resulted from enzymatic attack on a 
β-galactoside.143  The activity of β-galactosidase causes the self-
immolative destruction of the spacer, releasing the drug (Scheme 5).  
Furthermore, this approach was later applied by Tòth et al. to allow for the 
enzymatic release of an imaging agent for PARACEST MRI.
144
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Scheme 5 - β-galactosidase enzymatic cleavage of a linker incorporating a 
carbamate demonstrated by Devarakonda et al. as a prodrug for 
doxorubicin
143
 and by Tòth et al. for an imaging agent.
144
 
 
Other examples of carbamate prodrugs have been developed, such as a 
carbamate derivative of gabapentin, used for the treatment of epilepsy.
145
  
Gabapentin, 2-1, has a limited ability to pass through cellular membranes 
by passive diffusion, as a result of its zwitterionic form at physiological 
pH.  The carbamate prodrug XP13512, 2-2, was therefore designed to 
overcome the pharmacokinetic limitations of gabapentin by removing the 
zwitterionic character, allowing for better passive absorption.  
Significantly, XP13512 2-2 was found to be chemically stable at 
physiological pH yet was rapidly hydrolysed to gabapentin 2-1 by 
nonspecific carboxylesterases.
145
 
 
 
 
The carbamate prodrug approach has also been applied to colon cancer 
therapy, with the design of irinotecan 2-3.  Irinotecan acts as a prodrug, 
with the carbamate cleaved by carboxylesterases to release its active form, 
SN-38 2-4 (Scheme 6), which can then inhibit topoisomerase I inside the 
cancer cell to prevent DNA replication and transcription.
146, 147
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Scheme 6 - Irinotecan is hydrolysed by carboxylesterases to its active form 
SN-38, 2-4.
146, 147
 
 
The use of carbamates as bio-labile linkers for fluoroquinolone 
antimicrobials was first introduced by Alexander et al., who designed 
carbamate prodrugs of norfloxcin 1-4.
148
  They designed prodrugs 2-5 and 
2-6, using (acyloxy)alkyl carbamates as the bio-labile attachment on the 
antimicrobial, designed to undergo esterase-catalysed hydrolysis.  These 
prodrugs were not designed to improve their uptake into bacteria, as per the 
Trojan horse strategy, but were instead designed to improve the oral 
absorption of the parent drug, by removing its zwitterionic character.
148
  
Nevertheless, their use of a carbamate group as the attachment provided an 
early insight into the potential of this functionalisation as a bio-labile 
linker.  As Alexander et al. highlight, the success of using a carbamate is 
based on its ability to hydrolyse to a carbamic acid and an alcohol.
148
  Their 
choice of using (acyloxy)alkyl carbamates was based on their earlier work, 
where they demonstrated esterase induced cleavage of the ester, producing 
a carboxylic acid and an intermediate that triggered spontaneous cleavage 
to give an aldehyde and the unstable carbamic acid (Scheme 7).
149
  In turn 
the carbamic acid would breakdown to release the free amine and carbon 
dioxide. 
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Scheme 7 - Cleavage of (acyloxy)alkyl carbamates following esterase 
cleavage of the ester group.
149
 
 
While Alexander et al. found that carbamate prodrugs 2-5 and 2-6 had 
good chemical stability at physiological pH, the prodrugs had lower 
solubility than norfloxacin in aqueous media.
148
  However, while they 
found that 2-6 was active against S. aureus, the compound was not active 
in Gram-negative species, suggesting that the linker was either not 
hydrolysed, or was slow to hydrolyse.
148
  Furthermore, by administering 
compound 2-6 to rhesus monkeys, they found that their compound was not 
efficiently absorbed and/or hydrolysed, indicating their compound had a 
lower bioavailability than the parent drug.
148
  As such, Alexander et al. 
discussed that improving the aqueous solubility would improve the 
absorption rate, which in turn could potentially increase the rate of linker 
hydrolysis.
148
  Despite the reduction in aqeuous solubility, and subsequent 
reduction in antimicrobial activity of these compounds, their choice of 
carbamate linker, demonstrating its cleavage, inspired a number of other 
investigations into the use of (acyloxy)alkyl carbamates within the Trojan 
horse strategy. 
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Carbamates used as bio-labile linkers in Trojan Horse conjugates 
 
Following the work by Alexander et al., later developments saw a number 
of attempts to introduce (acyloxy)alkyl carbamate based linkers in 
siderophore-fluoroquinolone conjugates.
115-117, 120
 
 
In 2001, Hennard et al. developed a conjugate of norfloxacin to the 
siderophore pyoverdin, with a methylenedioxy group, linked to the drug 
through a carbamate (compound 2-7).
115
  The activity of 2-7 was higher 
than that of a comparable non-labile linked conjugate, yet was lower than 
that for the free drug norfloxacin.  The authors also postulated premature 
hydrolysis by esterase of 2-7 prior to uptake, analogous to that 
demonstrated in Scheme 7, contributed to the lowered activity of their 
conjugate.
115
 
 
Similar studies reported in 2007 by Rivault et al. (2-8),
116
 in 2011 by Noël 
et al. (2-9),
117
 and in 2015 by Zheng and Nolan (2-10),
120
 each also using 
methylenedioxy linkers through a carbamate between the siderophore and 
fluoroquinolone in Trojan horse conjugates, showed similar limitations, 
with premature release of the antimicrobials from the linkers, and a 
reduction in activity of the conjugates compared to the parent drug.  
Furthermore, highlighting the premature cleavage of their conjugate, Noël 
et al. demonstrated their conjugate was active against P. aeruginosa 
PAD14, a TonB deficient strain.
7, 117
  Expecting their conjugate to display 
no activity against this strain, and having anticipated it would require the 
iron uptake systems, they proposed that extracellular hydrolases secreted 
by the bacteria into the media had led to the premature cleavage of their 
linker.
7, 117
  With premature cleavage, leading to the release of the free drug 
from their conjugates,
115-117, 120
 the reduction in antimicrobial activity is 
therefore likely due to incomplete cleavage of the drug from the conjugate, 
though none of the investigations report such findings. 
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With the use of (acyloxy)alkyl carbamate based linkers having 
demonstrated premature cleavage, likely through the mechanism outlined 
in Scheme 7, it is clear the carbamate linkage between fluoroquinolones 
and the siderophore requires further optimisation, to allow controlled 
release of the parent drug. 
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Conjugate Design 
 
As previous investigations have demonstrated that stable, permanent 
linkers between the siderophore and fluoroquinolone antimicrobial 
components lead to reduced activity, and that those who introduced bio-
labile linkers encountered premature drug release,
115-128
 it is necessary to 
design new Trojan horse conjugates with bio-labile linkers that will release 
the drug inside the cell.  Taking inspiration from other carbamate prodrugs 
and linkers, and knowing that a number of bacterial species produce 
carboxylesterases,
135
 two regioisomeric conjugates, 2-11 and 2-12 were 
designed by incorporating citrate as the siderophore moiety and 
ciprofloxacin 1-5 as the antimicrobial component, linked through a 
carbamate.  As can be seen, the carbamate linker does not incorporate a 
neighbouring methylenedioxy group like that used for conjugates with a 
(acyloxy)alkyl carbamate linker.
115-117, 120
  This potential design 
improvement  was made to increase the stability of the carbamate group, by 
removing one cleavable site (the ester) that leads to the breakdown of the 
carbamate (Scheme 7).  However, determination of the conjugates 
increased stability would only be confirmed on their isolation.  
Furthermore, these two designed conjugates 2-11 and 2-12 would allow for 
direct comparison to previous citrate based siderophore-fluoroquinolone 
conjugates, compounds 1-43, 1-44 and 1-45 (Chapter 1), which had 
incorporated stable, permanent linkers.
121, 128
  Such a comparison could 
therefore help indicate the stability of the carbamate linker. 
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Synthesis of carbamates 
 
A number of syntheses are available to introduce carbamates.
150, 151
  For 
example, the common amino protecting carbamates, such as the Fmoc, and 
CBz groups, are introduced by reaction of their corresponding 
chloroformates or anhydrides with the necessary amine.
140
  On the other 
hand, the Boc group is traditionally added using di-tert-butyl 
dicarbonate.
140
 
 
However, the use of a chloroformate or an anhydride may not always be 
optimal.  The synthesis of a chloroformate generally requires the use of 
phosgene (Scheme 8).
150, 151
  Similarly, anhydrides can also require the use 
of phosgene for their synthesis.  However, alkyl carbonates are common 
by-products, resulting from reaction of alcohols with the chloroformate, 
which can reduce the yields of carbamate formation.
152
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Scheme 8 - Synthesis of carbamates using phosgene, with a chloroformate 
as the intermediate. 
 
Despite the ability of phosgene to form chloroformates and anhydrides, 
phosgene is an extremely toxic gas, proving a significant hazard in its 
handling and use.
150-152
  As such, structurally related substitutes for 
phosgene were developed, diphosgene and triphosgene (2-13 and 2-14 
respectively), which are safer and easier to handle.
150, 151, 153
  
Demonstrating this, Pasquato et al. reacted both triphosgene and 
diphosgene separately with methanol, finding that phosgene is produced as 
an intermediate in each reaction.
153
  Furthermore, they were also able to 
show that reactivity of phosgene is two orders of magnitude faster than 
triphosgene, and therefore does not accumulate during the reaction, 
meaning the concentration of phosgene was always very low.
153
  In turn, 
they concluded that triphosgene is a safer alternative to phosgene. 
 
 
 
Given the risks associated with phosgene related agents, despite the 
development of the comparatively safer triphosgene reagent, alternative 
activating agents have been investigated.  Analogous to the use of 
phosgene type reagents to activate alcohols are examples such as the use of 
benzotriazole carbonates,
154
 carbonyldiimidazole,
155
 and N,N’- 
disuccinimidyl carbonate,
156, 157
 as well as a number of other carbonate 
activating agents.
150, 151, 158
  The use of a benzotriazole carbonate first 
required the synthesis of 1,1-bis[6-(trifluoro-
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methyl)benzotriazolyl]carbonate (though through the use of diphosgene), 
which in turn could be used to activate an alcohol before the addition of an 
amine to form the required carbamate (Scheme 9).
154
  As indicated above, 
dimethyl or diphenyl carbonates,
158
 and carbonyldiimidazole can activate 
alcohols in a similar manner.
155
 
 
 
Scheme 9 - General scheme for the synthesis of carbamates using 
BTBC.
154
 
 
Analogous to the use of the examples described above is the use of N,N’-
disuccinimidyl carbonate, also requiring the activation of an alcohol, 
followed by the addition of an amine (Scheme 10).
156, 157
  Interestingly, 
N,N’-disuccinimidyl carbonate had been previously used to activate an 
amine to form a carbamate intermediate, for the synthesis of ureas 
(Scheme 11).
159
  However, the route outlined in Scheme 11, where the 
amine is activated, has not been applied in the synthesis of carbamates, 
presumably as a result of subsequent studies where the alcohol is activated 
first. 
  
Chapter 2 
83 
 
 
Scheme 10 - General scheme for the synthesis of carbamates using N,N’-
disuccinimidyl carbonate.
156, 157
 
 
 
Scheme 11 - Formation of ureas using N,N’-disuccinimidyl carbonate to 
produce a carbamate intermediate.
159
 
 
Further to the use of activating agents, carbamates have also been accessed 
through other means that introduce the necessary carbonyl.
150, 151
  Early 
examples used carbon monoxide and oxygen in the presence of metal 
catalysts.
150, 151
  However, later studies moved away from using carbon 
monoxide in favour of safer alternatives, such as the use of metal 
carbonates and hydrogen carbonates.
160
  Butcher investigated the use of 
potassium carbonate and its ability to synthesise carbamates obtaining them 
in 40% yield, though also observing an alkylated side product (Scheme 
12).
160
  It was hypothesised that carbon dioxide was generated in situ, 
limiting the potential yield of the carbamate to 50%.  Therefore Butcher 
bubbled carbon dioxide gas into the reaction mixture, increasing the yield 
of carbamate to 60%.
160
  Subsequent consideration of the metal carbonate 
lead to the use of caesium carbonate, giving a significant improvement in 
the carbamate yield at 96%.
160
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Scheme 12 - Use of metal carbonates in the synthesis of a carbamate and 
alkylated side product.
160
 
 
Subsequent studies based on Butcher’s work saw different uses of carbon 
dioxide gas to aid in carbamate formation.  For example, Rossi et al. used 
carbon dioxide with tetraethylammonium hydroxide to give 
tetraethylammonium hydrogen carbonate.
161
  Subsequent reaction of the 
tetraethylammonium hydrogen carbonate with an amine and alkylating 
agent gave a carbamate product.
161
  Later, Jung et al.  reported the use of a 
three-component coupling of an amine with an alkyl halide and carbon 
dioxide gas in the presence of caesium carbonate and tetrabutylammonium 
iodide, producing carbamates in good yields (Scheme 13).
162
  In addition, 
they found that tetrabutylammonium iodide prevented direct N-alkylation 
by undergoing halide exchange to yield the more reactive iodide species.
162
 
 
 
Scheme 13 - Reported synthesis of carbamates by Jung et al. using carbon 
dioxide.
162
 
 
Beyond using activating agents, or introducing the carbonyl functionality 
through the use of gaseous carbon dioxide/monoxide, a number of 
rearrangement reactions also exist for the synthesis of carbamates.
150, 151
  
For example the Hoffmann (Scheme 14),
163
 and Curtius rearrangements.
150, 
151
  However, the Hoffmann rearrangement requires a primary 
carboxamide, whilst the Curtius rearrangement requires the pyrolysis of an 
acyl azide to produce an isocyanate, which can then react with an alcohol 
to produce a carbamate.
150, 151
  As such these rearrangements are not 
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always suitable in circumstances where the precursor functionality is either 
not available, or not possible to synthesise. 
 
 
Scheme 14 - Example Hoffmann rearrangement to synthesise methyl 
carbamates.
163
 
 
Synthetic considerations for the target compounds 2-11 and 2-12 
 
With a number of synthetic methodologies available to produce 
carbamates, it is important to consider the target compounds of this 
Chapter, compounds 2-11 and 2-12.  The disconnection of compound 2-11 
provides insight into the options available to introduce the carbamate 
group, by identifying the individual components (Figure 14).  As can be 
seen, the target compound 2-11 consists of four key components that can 
be obtained as four individual starting materials: citric acid 1-12, 2-
bromoethylamine or ethanolamine, carbon dioxide and ciprofloxacin 1-5.  
The disconnection of 2-12 provides the same individual components 
(Figure 14). 
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Figure 14 - Disconnection of compounds 2-11 and 2-12 to their key 
components. 
 
As such the individual components of compound 2-11 suggest that suitable 
methodologies to introduce the carbonyl functionality would be via 
reaction with carbon dioxide gas, or by direct activation of an alcohol 
group.  This Chapter discusses the introduction of a carbamate group into a 
Trojan horse conjugate by using these methodologies. 
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2.3 Synthesis 
 
Initial synthetic route targeting a 1,5-citrate-ciprofloxacin conjugate 
incorporating a carbamate linker 
 
The first carbamate-linked conjugate targeted for synthesis was compound 
2-11.  Having previously considered the synthesis and disconnection of the 
carbamate group in compound 2-11 (Figure 14), it was decided to 
introduce the carbamate group using carbon dioxide.
162
  As such the 
synthetic route for compound 2-11 was initially planned as shown in 
Scheme 15. 
 
Chapter 2 
88 
 
 
Scheme 15 - Initial synthetic route towards compound 2-11.  (a) MeOH, 
SOCl2, reflux, 65%; (b) CO2, Cs2CO3, TBAI, DMF, 2-18 = 9% / 2-19 = 
22%; (c) Deprotection; (d) DCC, 1,4-dioxane; (e) (i) 0.1 M TBAH, (ii) 0.1 
M HCl. 
 
In addition, the isolation of compound 2-20 would allow for the synthesis 
of the other regioisomer target, compound 2-12, through the use of a 
different dimethylcitrate moiety.  Thus the planned synthesis of compound 
2-12, from 2-20, is shown in Scheme 16.  The syntheses to obtain two 
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regioisomeric dimethylcitrate moieties, which were planned for use in the 
synthesis of both 2-11 and 2-12, are discussed later. 
 
 
Scheme 16 - Planned synthesis of 2-12 from intermediate compound 2-20.  
(a) DCC, 1,4-dioxane; (b) (i) 0.1 M TBAH, (ii) 0.1 M HCl. 
 
Protection of ciprofloxacin 1-5 by methyl esterification 
 
The first step in the synthesis was the protection of the carboxylic acid 
moiety of ciprofloxacin 1-5.  This protection was necessary to prevent 
unwanted side reactions later in the synthetic route, such as potential amide 
coupling to the β-keto acid, which is essential for antimicrobial activity 
(Chapter 1).
10, 26
  Furthermore, protection of the acid would remove the 
zwitterionic character of ciprofloxacin at neutral pH, which limits its 
solubility in both aqueous and organic solvents.  This would allow easier 
Chapter 2 
90 
 
handling of the drug component during subsequent synthetic steps.  It was 
decided to protect ciprofloxacin 1-5 with the methyl ester group to produce 
2-15 in order to allow for global deprotection of the methyl ester groups of 
2-22 later in the synthetic route.
121
 
 
To protect the carboxylic acid, ciprofloxacin 1-5 was heated under reflux in 
methanol with thionyl chloride (Scheme 17).
121
  Compound 2-15 was 
isolated in 65% yield after work up and characterised using 
1
H and 
13
C 
NMR spectroscopy, infra-red spectroscopy and ESI mass spectrometry.  
The formation of 2-15 was supported by 
1
H NMR spectroscopy, with the 
appearance of a singlet resonance at 3.89 ppm of relative integration three, 
corresponding to the methyl ester group.  The 
13
C NMR spectrum also 
showed a new resonance at 51.9 ppm, also corresponding to the methyl 
ester group.  In addition, ESI-MS analysis gave a molecular ion peak 
[M+H]
+
 for 2-15 at m/z 346.1557, consistent with a compound of formula 
C18H20FN3O3. 
 
 
Scheme 17 - Esterification of ciprofloxacin 1-5 to produce 2-15.  (a) 
MeOH, SOCl2, reflux, 65%. 
 
Protection of citric acid 1-12 
 
Citric acid 1-12 has three carboxylic acid groups, yet in the target 
compound 2-11 only the central acid moiety is required for the amide 
connection to the remainder of the molecule.  It was therefore necessary to 
Chapter 2 
91 
 
protect the primary carboxylic acid groups, yet leave the central tertiary 
carboxylic acid unprotected, to give 1,5-dimethyl citrate 2-21.  To achieve 
this, citric acid 1-12 was heated under reflux in methanol with concentrated 
sulfuric acid for one hour to produce 2-21 in 16% yield (Scheme 18).
121, 164, 
165
 
 
 
Scheme 18 - Synthesis of 1,5-dimethyl citrate 2-21 from citric acid 1-12, 
with 1,3,5-trimethyl citrate 2-25 as a by-product.  (a) MeOH, H2SO4, reflux 
1 h, 16% (2-21) / 3% (2-25). 
 
However, during the synthesis of 1,5-dimethyl citrate 2-21 the 
esterification process is non-specific, and so the by-product 1,3,5-trimethyl 
citrate 2-25 is also produced.  The purification processes of two published 
procedures were combined to isolate each product separately.  Firstly, the 
method of Hirota et al. was employed, whereby the reaction solution was 
neutralised using calcium hydroxide, the precipitate filtered, and the filtrate 
concentrated in vacuo.
164
  Next the purification process followed that of 
Guo et al.
165
  The resulting solid was sonicated in water and the insoluble 
material filtered off.  The filtrate was acidified using concentrated 
hydrochloric acid, resulting in a precipitate that was then isolated by 
filtration.  This precipitate was dissolved in aqueous sodium hydrogen 
carbonate and washed with chloroform.  The aqueous phase was reacidified 
with concentrated hydrochloric acid to yield 1,5-dimethyl citrate 2-21 in 
16% yield, characterised using 
1
H and 
13
C NMR spectroscopy, infra-red 
spectroscopy and ESI mass spectrometry.  The formation of 1,5-dimethyl 
citrate 2-21 was supported by 
1
H NMR spectroscopy, with the appearance 
of a singlet resonance at 3.56 ppm of relative integration six, corresponding 
to the two methyl ester groups.  Furthermore, ESI-MS analysis gave a 
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molecular ion peak [M+Na]
+
 for 2-21 at m/z 243.0475, consistent with a 
molecule of formula C8H12NaO7. 
 
To isolate the by-product, the chloroform washes were concentrated in 
vacuo, affording 1,3,5-trimethyl citrate 2-25 in 3% yield, characterised 
using 
1
H and 
13
C NMR spectroscopy, infra-red spectroscopy and ESI mass 
spectrometry.  The formation of 1,3,5-trimethyl citrate 2-25 was supported 
by 
1
H NMR spectroscopy, with the appearance of a singlet resonance at 
3.56 ppm of relative integration six, corresponding to two methyl ester 
groups.  In addition, a singlet at 3.65 ppm of relative integration three, 
corresponding to the central methyl ester group, was also evident in the 
spectra.  ESI-MS analysis showed a molecular ion peak [M+Na]
+
 for 2-25 
at m/z 257.0632, consistent with a molecule of formula C9H14NaO7.  The 
isolation of 1,3,5-trimethyl citrate 2-25 therefore allows for the synthesis of 
1,3-dimethyl citrate 2-23 (Scheme 19).  Whilst 2-23 was not required in 
the synthesis of 2-11, it is useful for the synthesis of the other regioisomer 
target, 2-12, demonstrated by the planned synthesis outlined earlier in 
Scheme 16. 
 
Therefore, 1,3-dimethyl citrate 2-23 was synthesised from 1,3,5-trimethyl 
citrate 2-25 via reaction with 0.1 M sodium hydroxide solution in a 1:1 
mixture of methanol and water for 2 hours (Scheme 19).  The reaction 
mixture was extracted with ethyl acetate to recover unreacted 1,3,5-
trimethyl citrate 2-25.  The aqueous fraction was then acidified with 1 M 
hydrochloric acid, followed by extraction with ethyl acetate to afford 1,3-
dimethyl citrate 2-23.  Recrystallisation from toluene gave 2-23 in 27% 
yield, based on conversion from 1,3,5-trimethyl citrate 2-25, and 
characterised using 
1
H and 
13
C NMR spectroscopy, infra-red spectroscopy 
and ESI mass spectrometry.  Successful formation of 2-23 was supported 
by 
1
H NMR spectroscopy, with the observation of two singlets, both of 
relative integration of three, at 3.76 ppm and 3.66 ppm, corresponding to 
the α-methyl and β-methyl esters respectively.  In addition, ESI-MS 
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analysis gave a molecular ion peak [M-H]
-
 for 2-23 at m/z 219.0514, 
consistent with a molecule of formula C8H11O7. 
 
 
Scheme 19 - Synthesis of 1,3-dimethyl citrate 2-23 from 1,3,5-trimethyl 
citrate 2-25.  (a) 0.1 M NaOH, MeOH:H2O 1:1, 2 h, 27%. 
 
Formation of the carbamate utilising carbon dioxide 
 
As highlighted in Scheme 15, the proposed synthesis of the carbamate 
group involved the use of carbon dioxide.  This involved the use of the 
ciprofloxacin amine, carbon dioxide, an alkyl halide, caesium carbonate 
and tetrabutylammonium iodide, following the methodology of Jung et al. 
(Scheme 13).
162
 
 
It was decided to employ N-Fmoc-2-bromoethylamine 2-16 in order to 
synthesise 2-18, as the Fmoc protecting group requires mild basic 
conditions for deprotection. Such deprotection conditions would be 
unlikely to cleave the required carbamate linker in 2-5. 
 
Compound 2-18 was synthesised using commercially available N-Fmoc-2-
bromoethylamine 2-16, and ciprofloxacin methyl ester 2-15 (Scheme 20).  
Firstly, ciprofloxacin methyl ester 2-15 was mixed with caesium carbonate 
and tetrabutylammonium iodide in anhydrous N,N-dimethylformamide, 
and then bubbled with carbon dioxide gas for 2 hours.  N-Fmoc-2-
bromoethylamine 2-16 was dissolved in anhydrous N,N-
dimethylformamide and added dropwise with continued gas bubbling.  
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After work-up and purification compound 2-18 was isolated in 9% yield.  
Successful formation of 2-18 was supported by ESI-MS analysis, which 
gave a molecular ion peak [M+H]
+
 for 2-18 at m/z 655.2566, consistent 
with a compound of formula C36H36FN4O7. 
 
 
Scheme 20 - Formation of the Fmoc protected carbamate target 2-18.  (a) 
CO2, Cs2CO3, TBAI, DMF, 9%. 
 
Despite repetitions, the best yield obtained for compound 2-18 remained at 
9%.  In each attempt, Fmoc deprotection occurred, with dibenzofulvene (2-
26) formation observed, identified by a singlet resonance at 6.10 ppm in 
the 
1
H NMR spectrum, of relative integration two, characteristic of the two 
alkene protons.  Furthermore, no evidence was found for the formation of 
2-20 as a by-product, suggesting that Fmoc deprotection occurred from the 
starting material 2-16 prior to its reaction with ciprofloxacin methyl ester 
2-15.  The potential cause for Fmoc deprotection could be due to either the 
piperazinyl moiety of the antimicrobial acting as a base, or due to the 
caesium carbonate base in the reaction mixture.  However, the piperazinyl 
nitrogen of ciprofloxacin (pKa = 8.74) is less basic than that of caesium 
carbonate (pKa = 10.25 for carbonic acid), and also less than that of 
piperidine (pKa = 11.22), which is generally used for Fmoc 
deprotection.
166-168
  Given the pKa of the acidic proton in the Fmoc group is 
~25,
140, 141
 it is likely that caesium carbonate is the reason for the Fmoc 
deprotection, given it is the stronger base.  However, as reported pKa 
values are based on aqueous media, these values can only indicate their 
reactivity in organic solvents, especially when a number of amines have 
been shown to have increased pKa values in solvents such as acetronitrile 
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and tetrahydrofuran.
169
  Based on this, the exact cause of Fmoc 
deprotection is not clear.  Despite not knowing the cause of the 
deprotection, any early deprotection of the starting material 2-16 could lead 
to the formation of 2-27, from the reaction of the released free amine to 
form the cyclic carbamate, though it should be noted that no evidence of 2-
27 was observed.  Given the low yields obtained for 2-18, it was therefore 
decided to change the protecting group of the amine on the starting alkyl 
bromide, as a means to overcome the observed deprotection of the Fmoc 
group. 
 
 
 
It was decided that the CBz protecting group was to be utilised as an 
alternative protecting group.  As such, an analogous carbamate, 2-19, was 
targeted (Scheme 15 and Scheme 21). 
 
Benzyl (2-bromoethyl)carbamate 2-17 was synthesised from 2-
bromoethylamine and benzyl chloroformate, according to a literature 
procedure,
170
 in 90% yield, and was characterised using 
1
H and 
13
C NMR 
spectroscopy, infra-red spectroscopy and ESI mass spectrometry.  The 
successful formation of 2-17 was supported by identical data to the 
literature, including a characteristic resonance at 156.5 ppm for the 
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carbamate functional group in the 
13
C NMR spectrum.  Furthermore, ESI-
MS analysis gave a molecular ion peak [M+H]
+
 for 2-17 at m/z 258.0127, 
consistent with a molecule of formula C10H13BrNO2.  On reacting 2-17 
with ciprofloxacin methyl ester 2-15, under the previously described 
conditions, 2-19 was isolated in 22% yield (Scheme 21).  Successful 
formation of 2-19 was supported by 
13
C NMR spectroscopy, with a 
characteristic resonance at 155.4 ppm for the carbamate functional group.  
ESI-MS analysis gave a molecular ion peak [M+H]
+
 for 2-19 at m/z 
567.2241, consistent with a molecule of formula C29H32FN4O7. 
 
 
Scheme 21 - Formation of the CBz protected carbamate target 2-19.  (a) 
CO2, Cs2CO3, TBAI, DMF, 22%. 
 
Despite the successful synthesis of compound 2-19 and the improvement in 
the yield of the carbamate formation, it was apparent that the use of 
gaseous carbon dioxide as a reagent was not as effective as desired.  Thus it 
was determined that an alternative methodology be explored for the 
introduction of the carbamate group, so as to obtain higher yields. 
 
Activation of N-CBz-ethanolamine 2-28 using N,N’-disuccinimidyl 
carbonate 
 
It was decided to investigate the application of N,N’-disuccinimidyl 
carbonate to activate an alcohol, before the addition of ciprofloxacin 
methyl ester 2-15, to produce the required carbamate.
156, 157
  Ethanolamine 
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was protected using benzyl chloroformate, according to a literature 
procedure,
171
 to afford 2-28 (Scheme 22) in 87% yield, characterised by 
1
H 
and 
13
C NMR spectroscopy, infra-red spectroscopy and ESI mass 
spectrometry.  The successful formation of 2-28 was supported by identical 
data to the literature, including a characteristic resonance at 157.5 ppm in 
the 
13
C NMR spectrum for the carbamate functional group.  Furthermore, 
ESI-MS analysis gave a molecular ion peak [M+H]
+
 for 2-28 at m/z 
196.0965, consistent with a compound of formula C10H14NO3. 
 
In order to form the carbamate bond, the alcohol of 2-28 was activated 
using N,N’-disuccinimidyl carbonate, in the presence of pyridine and 
potassium phosphate tribasic, followed by the addition of ciprofloxacin 
methyl ester 2-15.  After work up and purification, compound 2-19 was 
obtained in 65% yield (Scheme 22).  Successful formation of the product 
was confirmed by comparative spectroscopic data from the previous 
reaction using carbon dioxide (Scheme 15), with the same characteristic 
resonance at 155.4 ppm for the carbamate functional group in the 
13
C NMR 
spectrum, as well as a matching ESI-MS peak. 
 
 
Scheme 22 - Activation of N-CBz-ethanolamine 2-28 using N,N’-
disuccinimidyl carbonate to form the required carbamate bond.  (a) DSC, 
pyridine, DMF, K3PO4, 65%. 
 
The successful synthesis of 2-19 would have allowed the continuation of 
the initial synthetic route outline in Scheme 15.  Nevertheless a new 
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shorter synthetic route was planned as outlined in Scheme 23.  This new 
route was aimed to provide a more efficient route to the target compound 
2-11 as it is shorter, and could therefore potentially have a greater overall 
yield. 
 
Second synthetic route targeting a 1,5-citrate-ciprofloxacin conjugate 
incorporating a carbamate linker 
 
With the initial synthetic route determined to be unviable in terms of the 
low yields obtained at an early stage in the synthesis (Scheme 15), and the 
subsequent successful application of N,N’-disuccinimidyl carbonate to 
activate an alcohol and give a carbamate, a shorter route was considered. 
 
Thus a new synthetic route was designed (Scheme 23), first involving the 
coupling of 1,5-dimethyl citrate 2-21 and ethanolamine to produce the 
intermediate 2-29.  Subsequent activation of 2-29, using N,N’-
disuccinimidyl carbonate, followed by the addition of ciprofloxacin methyl 
ester 2-15, would introduce the carbamate group to give 2-22.
157
  Finally, it 
was planned that base hydrolysis would furnish the required target 2-11 
(Scheme 23). 
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Scheme 23 - Second synthetic route towards compound 2-11.  (a) 
ethanolamine, coupling reagent; (b) DSC, DMF, DIPEA, 45%; (c) (i) 0.1 
M TBAH, (ii) 0.1 M HCl. 
 
Coupling 1,5-dimethyl citrate 2-21 and ethanolamine 
 
In order to proceed with the second synthetic route (Scheme 23), various 
reaction conditions were investigated in order to couple 1,5-dimethyl 
citrate 2-21 and ethanolamine utilising a range of coupling agents to 
produce 2-29 (Scheme 24 and Scheme 25).  The coupling agents 
investigated for the amide coupling were DCC, DCC/DMAP, ethyl 
chloroformate, CDI and HATU.   
 
The use of DCC proved unsuccessful (Scheme 24), with a complex 
mixture observed in the 
1
H NMR spectrum.  Furthermore a [M-H2O]
+
 peak 
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was observed in the ESI-MS spectrum at 409.2327, suggesting the reaction 
stopped at the N-acyl urea by-product, compound 2-30. 
 
 
 
The use of ethyl chloroformate also proved unsuccessful (Scheme 24), 
with side reactions occurring that indicated issues with chemoselectivity of 
the reaction.  The crude 
1
H NMR once again proved complex, and the ESI-
MS spectrum indicated a number of intermediates which suggested the 
reaction did not proceed as desired, such as compounds 2-31, 2-32, and 2-
33 either/or 2-34, with [M+Na]
+
 peaks for each intermediate compound at 
387.0898, 358.1113 and 315.0687 respectively.  Furthermore the by-
product 2-35 was isolated, supported by ESI-MS analysis, with a [M+Na]
+
 
peak at 156.0632, consistent with a molecule of formula C5H11NNaO3. 
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On using CDI, amide coupling was observed, yet not at as desired, instead 
giving by-products (Scheme 24).  On the first attempt, whereby CDI was 
used in 1.3-fold excess, and ethanolamine in 15-fold excess, compound 2-
36 was isolated in 69% yield, supported by ESI-MS analysis, with a 
[M+Na]
+
 peak at 344.1412, consistent with a molecule of formula 
C12H23N3NaO7.  Dropping the excess amount of ethanolamine to 1.3-fold 
resulted in the formation of 2-37 in 24% yield, supported by ESI-MS 
analysis, with a [M-H]
-
 peak at 248.0781, consistent with a molecule of 
formula C9H14NO7.  Furthermore, the citrate region in the 
1
H NMR 
indicated an unsymmetrical set of methylene CH2 protons, with four sets of 
roofed doublets at 2.68, 2.93, 3.02 and 3.06 ppm, indicative of two pairs of 
diastereotopic protons for 2-37. 
 
 
 
 
Scheme 24 - Attempted synthesis of 2-29.  (a) ethanolamine, DCC, 1,4-
dioxane.  (b) ethanolamine, ethyl chloroformate, THF, N-
methylmorpholine.  (c) ethanolamine, CDI, THF. 
 
It was thus found that HATU mediated coupling proved successful in 
giving 2-29, in 92% yield (Scheme 25).  The successful formation of 2-29 
was supported by 
13
C NMR spectroscopy, with a characteristic resonance 
at 176.3 ppm for the amide functional group.  In addition, ESI-MS analysis 
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gave a molecular ion peak [M+Na]
+
 for 2-29 at m/z 286.0904, consistent 
with a compound of formula C10H17NNaO7.  Additionally, a pair of roofed 
doublets, characteristic of a symmetrical citrate moiety, was present in the 
1
H NMR spectrum (Figure 15).  These resonances can be assigned to the 
diastereotopic methylene protons (Ha, Hb), and hence couple to each other, 
arising as the pair of doublets with a coupling constant of 15.2 Hz, 
characteristic of geminal 
2
J coupling between protons on an sp
3 
carbon.
172
  
Their close chemical shifts mean they exhibit a roof effect, seen in their 
signal profile. 
 
 
Scheme 25 - Synthesis of 2-29.  (a) HATU, DMF, DIPEA, ethanolamine, 
92%. 
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Figure 15 - 
1
H NMR spectrum of 2-29 in CD3OD, shown in the region 
between 2.00-2.35 ppm.  The J-coupling splitting pattern is shown below, 
explaining the splitting for each of the resonances.  *The assignment of H
a
 
and H
b
 can be interchanged. 
 
Formation of the carbamate functional group via N,N’-disuccinimidyl 
carbonate activation 
 
The conditions used for the formation of 2-19 (Scheme 22) were employed 
towards the synthesis of 2-22, from 2-29 and ciprofloxacin methyl ester 2-
15.  However, on the first attempt using N,N’-disuccinimidyl carbonate, 
pyridine and potassium phosphate tribasic in DMF, 2-22 was not formed.  
The reaction conditions were therefore altered, substituting potassium 
phosphate and pyridine with DIPEA (Scheme 26).  The crude reaction 
mixture was monitored by ESI-MS analysis, giving a molecular ion peak 
for 2-38 (Scheme 26).  It was on confirmation of the presence of the 
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activated intermediate that the ciprofloxacin methyl ester 2-15 was added.  
After workup and purification, 2-22 was isolated in 45% yield, 
characterised using 
1
H and 
13
C NMR spectroscopy, infra-red spectroscopy 
and ESI mass spectrometry.  The successful formation of 2-22 was 
supported by 
13
C NMR spectroscopy, with a characteristic resonance at 
155.5 ppm for the carbamate functional group.  Furthermore, ESI-MS 
analysis gave a molecular ion peak [M+Na]
+
 for 2-22 at m/z 657.2194, 
consistent with a molecule of formula C29H35FN4NaO11.  Additionally, 
there was a pair of roofed doublets present in the 
1
H NMR spectrum, 
characteristic of a symmetrical citrate moiety, similar to those already 
described for 2-29, highlighting the retained symmetry of the methylene 
protons. 
 
 
Scheme 26 - Reaction utilising N,N’-disuccinimidyl carbonate to form the 
required carbamate bond to produce compound 2-22.  (a) DSC, DMF, 
DIPEA; (b) 2-15, DMF, 45%. 
 
Base hydrolysis of compound 2-22 to target compound 2-11 
 
With compound 2-22 synthesised, deprotection to give 2-11 was explored 
(Scheme 23).  Compound 2-22 was treated with 0.1 M 
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tetrabutylammonium hydroxide in methanol, followed by the addition of 
0.1 M hydrochloric acid until the solution was at pH 1.4 and precipitate had 
formed (Scheme 23).  The chemical structure of the isolated precipitate 
was investigated.  The loss of the characteristic methyl ester signals in the 
1
H NMR spectrum was observed, and also ESI-MS gave a molecular ion 
peak [M-H]
-
 at m/z 591.1749, consistent with a molecule of formula 
C26H28FN4O11.  However, it was not compound 2-11 that was isolated, but 
instead it was the regioisomer 2-12, in 64% yield (Scheme 27). 
 
 
Scheme 27 - Isomerisation of compound 2-22 on base hydrolysis, giving 
the regioisomeric target, 2-12.  (a) (i) 0.1 M TBAH, (ii) 0.1 M HCl, 64%. 
 
The characterisation data that supported the formation of 2-12 rather than 
the expected 2-11 was investigated.  The 
1
H NMR spectrum was recorded 
in both CD3OD (Figure 16) and in d6-DMSO (Figure 17).  The resonances 
due to the citrate moiety consist of two sets of roofed doublets, which are 
assigned to the methylene protons (Ha, Hb, Hc and Hd - Figure 16).  As 
each pair of these methylene protons, Ha / Hb and Hc / Hd, respectively, are 
diastereotopic, they demonstrate geminal coupling, with two sets of 
doublets observed.  Given the close chemical shifts for these signals, they 
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also exhibit a roof effect, seen in their signal profiles.  The citrate region of 
the 
1
H NMR spectrum in d6-DMSO (Figure 17) shows a similar signal 
profile, with one of the resonance peaks overlapping with the residual d5-
DMSO solvent peak. 
 
 
Figure 16 - 
1
H NMR spectrum of 2-12 in CD3OD, shown in the region 
between 2.55-3.05 ppm.  The J-coupling splitting pattern is shown below, 
explaining the splitting for each of the resonances.  *The assignment of H
a
 
and H
b
 can be interchanged.  **The assignment of H
c
 and H
d
 can be 
interchanged. 
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Figure 17 - 
1
H NMR spectrum of the citrate moiety in 2-12 in d6-DMSO, 
shown in the region between 2.40-2.85 ppm. 
 
While the 
1
H NMR spectrum supported the formation of an unsymmetrical 
citrate, indicative of the citrate moiety of compound 2-12, further 
supporting data was required.  Firstly, the citrate region of the 
13
C NMR 
spectrum showed two resonances corresponding to the methylene carbons, 
at 43.3 and 42.9 ppm, respectively, as opposed to one that would be 
expected for the symmetrical compound 2-11 (Figure 18). 
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Figure 18 - 
13
C NMR spectrum of 2-12 in d6-DMSO, shown in the region 
between 40.5-45.0 ppm. 
 
The Heteronuclear Multiple Bond Correlation (HMBC) NMR spectrum 
was investigated, with a focus on the citrate region in the 
1
H NMR 
spectrum (Figure 19).  As the HMBC NMR spectrum shows, there are 
three carbonyl resonance signals at 175.7, 172.1 and 170.5 ppm around the 
two methylene proton environments 1 and 2.  This is indicative of an 
unsymmetrical citrate moiety, supporting the formation of 2-12.  The 
Heteronuclear Single Quantum Correlation (HSQC) NMR spectrum was 
also investigated (Figure 20).  With a focus on the citrate region in the 
1
H 
NMR spectrum, the HSQC NMR spectrum also suggests the formation of 
2-12, with two carbon environments corresponding to the citrate protons.  
This supports the 
13
C NMR spectrum (Figure 18), and was reinforced 
further by negative signals in the DEPT spectrum. 
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Figure 19 - HMBC spectrum of 2-12 in d6-DMSO, shown in the region 
between 169.5-175.5 ppm in the 
13
C NMR and 2.45-2.80 ppm in the 
1
H 
NMR spectrum.  The resonance signals at 175.7, 172.1 and 170.5 ppm in 
the 
13
C NMR spectrum show there are three different carbonyl 
environments around the two methylene proton environments (labelled 1 
and 2). 
 
 
Figure 20 - HSQC spectrum of 2-12 in d6-DMSO, shown in the region 
between 41.45-44.5 ppm in the 
13
C NMR and 2.45-2.85 ppm in the 
1
H 
NMR spectrum.  There are two resonance signals in the 
13
C NMR 
spectrum, at 43.3 and 42.9 ppm corresponding to the methylene carbons of 
the citrate moiety (labelled 1 and 2). 
 
The resonances observed in the 
13
C NMR spectrum are essential for 
assignment of the carbonyl moieties (Figure 21).  There are six carbonyl 
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environments for 2-12, including a doublet with a coupling constant of 2.3 
Hz at 177.1 ppm, characteristic of a 
4
JC-F coupling,
173
 corresponding to the 
carbonyl in the fluoroquinolone moiety (C-2).  The carbonyl environments 
of 2-12 were thus fully assigned (Figure 21).  In a 
13
C spectrum of 
compound 2-11 only five carbonyl environments would have been 
observed.  The extra signal observed for the isolated product confirms that 
it was compound 2-12. 
 
 
Figure 21 - 
13
C NMR spectrum 2-12 in d6-DMSO, shown in the region 
between 177.2-155.0 ppm.  The full assignment of the carbonyl 
environments of 2-12 was made using all the available NMR data. 
 
Determination of the mechanism of isomerisation of the citrate 
siderophore component 
 
As base hydrolysis of compound 2-2 led to the formation of 2-12, rather 
than the expected product 2-11, it was important to understand the 
mechanism by which isomerisation occurred.  It was found during the 
purification of 2-22, by silica gel column chromatography, that succinimide 
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2-39 was also isolated.  Formation of succinimide 2-39 was supported by 
the loss of the signal for one methyl group in the 
1
H NMR spectrum and 
also by ESI-MS analysis, with a molecular ion peak [M+H]
+
 at m/z 
603.2112, consistent with a molecule of formula C28H32FN4O10.  
Furthermore, the citrate region between 2.75-3.10 ppm of the 
1
H NMR 
displayed a profile different to that of 2-22 (Figure 22). 
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Figure 22 - 
1
H NMR spectrum of 2-39 in CDCl3, shown in the region 
between 2.75-3.10 ppm.  The J-coupling splitting pattern is shown below, 
explaining the splitting for each of the resonances.  *The assignment of H
a
 
and H
b
 can be interchanged.  **The assignment of H
c
 and H
d
 can be 
interchanged. 
 
As can be seen in Figure 22, the resonances due to the succinimide moiety 
consist of two sets of doublets, which are assigned to the methylene 
protons as before.  Furthermore, Correlation Spectroscopy (COSY) NMR 
and HSQC NMR supported the formation of 2-39.  Final confirmation of 
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the formation of 2-39 was by single crystal X-ray diffraction analysis 
(Figure 23).  The single crystals of 2-39 grew from a methanolic solution 
of 2-22, suggesting that 2-39 could be an intermediate in the isolation of 2-
12 from 2-22, discussed later (Scheme 29). 
 
 
Figure 23 - ORTEP diagram (50% probability ellipsoids) of 2-39, shown 
as one chiral form of a racemate.  Space group: P-1.  Crystal contains both 
enantiomers that are related, with the S enantiomer shown and R omitted 
for clarity. 
 
The isolation of compound 2-39 allowed for the investigation of the route 
of succinimide cleavage.  The cleavage of 2-39 can proceed via two 
possible routes, giving either compound 2-11 or 2-12.  Compound 2-11 
would require the succinimide to cleave via route 1 (Green - Scheme 28), 
whereas compound 2-12 would see cleavage via route 2 (Red - Scheme 
28).  On treating 2-39 with 0.1 M tetrabutylammonium hydroxide in 
methanol, followed by the addition of 0.1 M HCl to acidfy the solution, it 
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was found that the only product was 2-12 (Scheme 28), with the 
characterisation data identical to that already discussed. 
 
 
Scheme 28 - Base hydrolysis of succinimide 2-39 to give either 2-11 or 2-
12, or a mixture of both, through either Route 1 (Green) or Route 2 (Red).  
(a) (i) 0.1 M TBAH, (ii) 0.1 M HCl. 
 
It can therefore be summarised that the formation of 2-12 proceeded 
through the intermediate 2-39 with the loss of methanol, before ring 
opening of the succinimide to give the target compound (Scheme 29).  As 
such it was also concluded that isolating compound 2-11 was not possible 
via the synthetic route carried out.  The isolation of 2-12 did however allow 
for antimicrobial screening to determine the viability of the carbamate 
group as a bio-labile linker. 
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Scheme 29 - Summary of the formation of 2-12 from 2-22.  (a) (i) 0.1 M 
TBAH, (ii) 0.1 M HCl. 
 
2.4 Antimicrobial Activity Testing of the 1,3-Citrate-
Ciproxfloxacin Conjugate, 2-12 
 
Stability Testing 
 
With compound 2-12 isolated, it was essential to determine its stability 
prior to biological screening.  It was observed during the synthesis that the 
carbamate group was chemically stable between pH 1.4-12 in aqueous 
solution.  However, it was still important to determine the stability of 2-12 
over time at biologically relevant pH in aqueous media.  The stability of 2-
12 was monitored by 
1
H NMR in D2O with 0.042 M Na2HPO4, 0.008 M 
NaCl and DCl (HCl in D2O), at pD 7.01 as a mimic of the M9 minimal 
media to be used during the biological screening.  As can be seen in Figure 
24 there was no change in the 
1
H NMR spectrum after 74 h.  It was 
therefore determined that 2-12 was stable for a suitable period of time for 
biological screening. 
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Figure 24 - 
1
H NMR spectrum of 2-12 in D2O with 0.042 M Na2HPO4, 
0.008 M NaCl and DCl (HCl in D2O), at pD 7.01, as a mimic of M9 
Minimal Media.  The blue spectrum shows the sample at t = 0 h.  The red 
spectrum shows the sample at t = 74 h. 
 
Bacterial Growth Assay 
 
Having isolated and determined the stability of the 1,3-citrate-carbamate 
ciprofloxacin conjugate 2-12, it was necessary to test for its antimicrobial 
activity, with ciprofloxacin 1-5 as a positive control.  The antimicrobial 
activity of 2-12 was first assessed by carrying out a growth assay of the 
bacterial strain E. coli BW25113 wild type in two media, Lysogeny broth 
(LB) nutrient and M9 minimal.  LB media is a nutritionally rich medium 
containing tryptone and yeast, providing amino acids, organic compounds 
and Fe(III) essential for bacterial growth.  With nutrient deficient 
conditions, M9 minimal media allows the nutrient composition to be 
controlled for a more direct comparison to in vivo conditions, where Fe(III) 
concentrations are extremely low.  It is known that under iron deficiency, 
siderophore production and uptake would be upregulated in bacterial cells, 
and so screening a Trojan horse conjugate under such conditions should 
facilitate its uptake.  Therefore screening in both media will allow for the 
direct comparison of the ability of the conjugate to compete for uptake 
under nutrient rich conditions, as well as under iron deficiency. 
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Using a plate reader the growth of the wild type E. coli cells was 
determined by the optical density (OD650) values at drug concentrations of 
0.01 µM, 0.1 µM, 0.5 µM, 1 µM and 10 µM, with a negative control of 0 
µM (DMSO).  The OD650 values correspond to the absorbance of a sample 
against the length of the cuvette at 650 nm.  This in turn allows for the 
quantification of the bacterial cell concentration.  Readings were taken 
every 30 minutes over 16 hours, with the plate shaken at 37 °C in between 
each reading (Chapter 7).  Although time points were taken over 16 hours, 
the data presented is at the time point at 10 hours, where bacterial growth 
has plateaux (Figure 25 - Figure 28 - see Appendix II for individual 
graphs). 
 
The assay indicates that conjugate 2-12 is active against wild type E. coli, 
with growth suppressed at 10 µM of the drug in both media (Figure 25 and 
Figure 26).  The assay carried out in LB demonstrates that at lower drug 
concentrations of 0.01 µM, 0.1 µM and 0.5 µM for 2-12, cell growth is 
relatively unaffected, comparable to when no drug is present (Figure 25).  
This is likely to be due to the readily available nutrients within the media. 
Activity was observed at a lower concentration of 0.1 µM for free 
ciprofloxacin.  However, at a much higher concentration of 10 µM (Figure 
25) there is near complete suppression of growth for the free ciprofloxacin 
drug, yet unfortunately some growth was still seen for the conjugate 2-12.  
Therefore the growth assay in LB indicates that 2-12 is less active than the 
parent drug. 
 
Chapter 2 
118 
 
 
Figure 25 - E. coli BW25113WT growth in LB media across 
concentrations at t = 10 h for both ciprofloxacin 1-5 (blue) and conjugate 2-
12 (red).  The experiment was run in quadruplicate and the error bars show 
one standard deviation from the mean. 
 
The trend of activity for the growth assay of wild type E. coli in M9 
minimal media is comparable to that in LB media (Figure 26).  Under 
these conditions E. coli growth was clearly diminished, with lower OD650 
values compared to when using LB media, due to the lower nutrient 
availability.  From both assays the difference in activity between 
ciprofloxacin and conjugate 2-12 can be clearly seen at lower drug 
concentrations of 0.1 µM.  Furthermore, an estimate of a minimum 
inhibitory concentration (MIC) value can be made. For ciprofloxacin 1-5, 
the assays suggest an estimate of the MIC of between 0.01 µM and 0.1 µM 
(Figure 26), whereas for conjugate 2-12 an estimate of the MIC would be 
between 0.5 µM and 1 µM, suggesting the conjugate is approximately 50-
100 times less active than the parent drug.  Across all concentrations, the 
ciprofloxacin assay had less wild type E. coli growth in M9 minimal media 
than that observed for conjugate 2-12, demonstrating again that the 
conjugate is less active than ciprofloxacin. 
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Figure 26 - E. coli BW25113WT growth in M9 minimal media across 
concentrations at t = 10 h for both ciprofloxacin 1-5 (blue) and conjugate 2-
12 (red).  The experiment was run in quadruplicate and the error bars show 
one standard deviation from the mean.  For 0.01 µM ciprofloxacin the 
experiment was run in triplicate. 
 
With the wild type E. coli strain demonstrating that conjugate 2-12 had 
antimicrobial activity, it was decided to investigate how the conjugate 
enters the bacterial cell.  The Trojan horse strategy aims to exploit the iron 
uptake system, to actively uptake, and thus increase the intracellular 
concentration of the antimicrobial.  Therefore, to test this hypothesis, 
conjugate 2-12 was next screened against E. coli BW25113 FecA::kan, a 
strain whereby the outer membrane receptor FecA is knocked-out.
60
  As 
discussed in Chapter 1, FecA is the outer membrane receptor which 
recognises and transports citrate siderophores across the outer membrane.
60
  
Given that conjugate 2-12 incorporates citrate as its siderophore moiety, it 
would be advantageous to determine if it utilises the iron uptake 
mechanism to transport the antimicrobial into the cell. 
 
Using the same methodology as that used for the growth assays against E. 
coli BW25113WT, conjugate 2-12 was screened against E. coli BW25113 
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FecA::kan in both LB and M9 minimal media (Figure 27 and Figure 28 - 
see Appendix II for individual graphs).  As can be seen, both assays 
demonstrate that conjugate 2-12 retains activity at the highest concentration 
of 10 µM, and that this activity is reduced compared to the parent 
ciprofloxacin antimicrobial.  As such, it was determined that the outer 
membrane receptor FecA is not essential for the uptake of conjugate 2-12.  
However, it can be seen that at 1 µM, the approximate concentration at 
which conjugate 2-12 has an MIC value in wild type E. coli (Figure 25 and 
Figure 26), the rate of growth for E. coli BW25113 FecA::kan matches 
that for lower concentrations of the drug, and even the growth control of 0 
µM (Figure 27 and Figure 28).  Speculatively, this could indicate that 
whilst FecA is not essential for the uptake of conjugate 2-12 into E. coli, it 
may still have a role in aiding the active uptake of the conjugate at higher 
concentrations.  It must be stated that this data does not allow for the 
potential role of FecA as an active transporter to be confirmed, and as such 
more assays are needed at intermittent concentrations between 1 µM and 
10 µM to see if there is a more obvious correlation.  Furthermore, with the 
highest concentration at 10 µM indicating activity of conjugate 2-12 in E. 
coli BW25113 FecA::kan, confirming that FecA is not essential, it would 
therefore suggest that conjugate 2-12 enters the bacterial cell via another 
mechanism, likely to be through passive diffusion. 
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Figure 27 - E. coli BW25113 FecA::kan growth in LB media across 
concentrations at t = 10 h for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
 
 
Figure 28 - E. coli BW25113 FecA::kan growth in M9 minimal media 
across concentrations at t = 10 h for both ciprofloxacin 1-5 and conjugate 
2-12.  The experiment was run in quadruplicate and the error bars show 
one standard deviation from the mean.  For 0 µM ciprofloxacin the 
experiment was run in triplicate. 
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The growth assays for both wild type and and BW25113 FecA::kan strains 
indicate that conjugate 2-12 is active against E. coli, yet also that its ability 
to prevent bacterial growth was less than that for ciprofloxacin 1-5.  These 
results are consistent with other reported fluoroquinolone-siderophore 
conjugates, which show reduced activity of the drug.
115-128
  It has been 
proposed that non-labile substituent groups conjugated via the piperazinyl 
ring of ciprofloxacin 1-5 prevent the conjugates from forming the dimer in 
the DNA replication complex.
128
  To test this theory a DNA gyrase assay 
was performed to test the activity of 2-12 in its ability to inhibit DNA 
replication. 
 
DNA Gyrase Assay 
 
To establish if the ciprofloxacin moiety of conjugate 2-12 inhibited the 
supercoiling of DNA by the gyrase protein (Chapter 1), a DNA gyrase 
assay was performed.  Relaxed and supercoiled DNA run at different rates 
on an agarose gel, allowing for the two forms to be separated and then 
visualised.  Compounds that inhibit DNA gyrase will show higher levels of 
relaxed DNA, with limited supercoiling, especially at higher drug 
concentrations.  Alternatively, compounds with lower or no activity will 
still demonstrate higher levels of supercoiled DNA at higher drug 
concentrations. 
 
The assay consisted of the conjugate 2-12 being mixed with the DNA and 
gyrase over a range of concentrations from 0 µM to 20 µM.  Negative and 
positive controls were used whereby either the drug or gyrase were omitted 
from the mixtures, respectively.  The DNA gyrase assay was also 
performed using ciprofloxacin 1-5 to allow for comparison.  Relaxed DNA 
with gyrase was incubated with the drugs at 37 °C for 30 minutes and then 
separated using electrophoresis on an agarose gel (Chapter 7).  After 
electrophoresis, the stained gel showed an increase in the inhibition of 
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DNA gyrase with an increase in drug concentration for both compounds, 
shown by the increased amounts of relaxed DNA.  However, it was clear 
that 2-12 has lower inhibitory activity at higher concentrations with the 
presence of some supercoiled DNA at 20 µM, whereas the band assigned 
to the supercoiled form is not apparent at 5 µM for ciprofloxacin 1-5 
(Figure 29).  This indicates that ciprofloxacin 1-5 is more effective than 
conjugate 2-12 at inhibiting DNA gyrase, as a lower concentration is 
required for full inhibition. 
 
 
Figure 29 - DNA gyrase assay of A) ciprofloxacin 1-5 and B) conjugate 2-
12 at concentrations ranging from 20-0 µM.  0 µM = DMSO control.  + = 
positive control, with DNA gyrase present without the antimicrobial.  - = 
negative control, no DNA gyrase or antimicrobial. 
 
Interestingly, the DNA gyrase assay showed the presence of supercoiled 
DNA at both 10 µM and 20 µM for conjugate 2-12 (Figure 29).  This in 
turn supports the fact there was growth at 10 µM, albeit limited, in both 
wild type and BW25113 fecA::kan E. coli strains in the presence of 2-12 
(Figure 25 - Figure 28).  Given that it has been determined that FecA is 
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not essential for the uptake of 2-12, the presence of supercoiled DNA at 20 
µM in the gyrase assay can help support the suggestion that FecA may play 
some role in the active transport of conjugate 2-12 at higher concentrations.  
This is because at 10 µM concentration of 2-12 in the growth assays 
(Figure 25 - Figure 28), there is still near complete suppression of the 
growth of the E. coli strains.  As the DNA gyrase assay directly delivers 
the compound to the gyrase target in vitro, the assay only gives an 
indication of the efficacy of the conjugate.  However, the in vivo growth 
assays can potentially involve the active transport of conjugate 2-12 
through the FecA system, and so potentially increase the intracellular 
concentration of the conjugate drug, leading to an observed improvement 
in activity at 10 µM concentration, compared to the DNA gyrase assay.  
Despite this speculative suggestion, more growth assay data is required to 
support this hypothesis, as stated previously.  It should also be noted that 
for the in vivo growth assays, the conjugate has to pass through both the 
outer and cytoplasmic membranes to reach the target site. 
 
Both the growth and gyrase assays indicated that conjugate 2-12 is an 
active antimicrobial, yet that its activity is reduced compared to the parent 
antimicrobial ciprofloxacin 1-5.  Whilst there is some suggestion that FecA 
is involved in the uptake of 2-12, more data is required to confirm this, 
though it has been determined that FecA is not essential for the uptake and 
activity of the conjugate.  Furthermore, it is unclear whether the lower 
activity of conjugate 2-12 is due to a lack of cleavage of the carbamate 
group to release the parent antimicrobial, or due to a lack of active 
transport, or a combination of both.  Further growth assays at 
concentrations between 1 µM and 10 µM against E. coli BW25113 
FecA::kan would allow for a greater understanding of the role of FecA, if 
any, in the uptake of conjugate 2-12. 
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2.5 Summary, conclusions and future work for Chapter 2 
 
The target compound 2-12, a conjugate incorporating citrate as the 
siderophore, a carbamate as a potentially bio-labile linker, and 
ciprofloxacin as the antimicrobial, was synthesised and characterised.  In 
addition, the isolation of 2-12 indicates that isomerisation occurred during 
base hydrolysis.  Therefore, the synthetic route followed to obtain 2-12 
only allows for the isolation of the one regioisomer.  To target 2-11, a new 
synthetic route would have to be established involving different protecting 
groups on both the antimicrobial and siderophore moieties, to avoid the 
base hydrolysis step where isomerisation occurred. 
 
Furthermore, the antimicrobial screening of 2-12 was conducted, in both 
wild type and BW25113 fecA::kan E. coli strains.  Additionally, a DNA 
gyrase assay was performed.  These biological assays determined that 
conjugate 2-12 is an active antimicrobial, though less so than the parent 
ciprofloxacin.  It was determined that the conjugate does not require the 
outer membrane receptor FecA for uptake into the cell, though it remains 
unclear whether FecA plays a role in aiding the uptake of the citrate 
containing conjugate 2-12.  Thus future work would require more assays to 
be undertaken at intermittent concentrations to determine any potential role 
of FecA.  Furthermore, it is also unclear if there is a lack of cleavage the 
carbamate linker to release the parent drug.  As such determination of 
whether the linker can cleave inside the cell must be examined.  In addition 
to this, other potential bio-labile linkers must continue to be explored, to 
further the understanding of the requirements of linker design in 
siderophore-fluoroquinolone Trojan horse conjugates.  The synthesis 
towards another such conjugate is discussed in Chapter 3. 
  
Chapter 3: Towards the 
synthesis of a disulfide-
linked citrate-
ciprofloxacin conjugate 
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3.1 Aims and overview 
 
Having confirmed the importance of bio-labile linkers in siderophore-
fluoroquinolone conjugate design, it was necessary to consider other 
available linkers which can allow intracellular drug release, building upon 
the previous investigation of a carbamate linker discussed in Chapter 2.  
This Chapter therefore discusses the design and synthesis towards a Trojan 
horse conjugate incorporating a disulfide linker at the β-position to a 
carbamate between the siderophore and fluoroquinolone moieties.  The aim 
of the research presented in this Chapter was to examine whether the 
combination of a disulfide and carbamate group is suitable for intracellular 
release of free ciprofloxacin in the cytoplasm. 
 
3.2 Introduction 
 
In order to identify a suitable bio-labile linker for use in siderophore-
fluoroquinolone Trojan horse conjugates, it was necessary to consider other 
functional groups that can allow for intracellular release of the 
antimicrobial.  As Chapter 2 highlighted, the requirement for bio-labile 
linkers between the siderophore and fluoroquinolone antimicrobial 
components is essential, given the reduction in antimicrobial activity for all 
reported siderophore-fluoroquinolone Trojan horse conjugates.
115-128
 
 
A potentially bio-labile linker incorporating a carbamate group with 
compound 2-12 was investigated in Chapter 2.  One hypothesis for the 
reduction in activity for 2-12 is a lack of cleavage of the carbamate group.  
It was therefore necessary to consider alternative functional groups which 
can facilitate cleavage of a carbamate, to release the free drug, under 
conditions present in the cytoplasm of a bacterial cell.  As studies into 
(acyloxy)alkyl carbamate based linkers of Trojan horse conjugates have 
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demonstrated premature cleavage, attributed to esterase action (Chapter 
2),
115-117, 120
 other functional groups that can induce intramolecular 
cleavage of carbamates were considered. 
 
Bio-labile linkers: Disulfides 
 
Stability of disulfides under physiologically relevant conditions 
 
It was recently highlighted that a disulfide-containing linker can lead to 
intramolecular cleavage of a carbamate group, to release a drug or probe 
within a range of cell types.
174
  Indeed, two mechanisms for drug release 
from such linkers have been proposed (Scheme 30).
175
  Pathway A (blue - 
Scheme 30) occurs through cleavage of the disulfide linker by a thiolate 
anion.  The resulting linker-derived thiolate group in turn undergoes 
intramolecular attack at the carbamate carbonyl, releasing the free drug and 
cyclopentyl thiocarbonate.
175
  Conversely, Pathway B (red - Scheme 30) 
occurs where the free thiolate can attack the carbon adjacent to the 
carbamate in an SN2 reaction, leading to intramolecular decomposition, 
releasing carbon dioxide, thioepoxide and the free drug.
175
 
 
 
Scheme 30 - Proposed mechanism of drug release from a disulfide 
containing conjugate via two potential pathways as a result of attack from a 
thiolate species (A - blue / B - red).
175
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These mechanisms rely on the basis that most cell types contain free thiols 
which can reduce disulfide bonds, especially given that thioredoxin, an 
enzyme catalyst for thiol-disulfide exchange reactions, is ubiquitous in all 
organisms.
175-182
  The ability of a thiol to attack the disulfide linker depends 
on its ability to deprotonate at physiological pH to give the reactive 
species, the thiolate anion.
181, 183
  This is clearly dependent on the pKa of 
the thiol group.  For example, if the pKa was 6.4, there would be 90% of 
the thiolate anion present at a physiological pH of 7.4.  Conversely, with a 
pKa of 8.4 there would be only 10% thiolate.
183
  Given that the pKa values 
of the thiol groups of the common disulfide reducing agents dithiothreitol, 
glutathione and dithioerythritol are 9.20, 9.42 and 9.50, respectively, the 
presence of their respective thiolate anions at pH 7.4 are low.
184-186
  Despite 
this, thiolate anions are the reactive species required to reduce disulfide 
bonds, even if they are only present as a small fraction.
184
 
 
The fact that thioredoxin is present within bacterial species would indicate 
that use of a disulfide linker can be exploited for siderophore-
fluoroquinolone Trojan horse conjugates.  Furthermore, it should also be 
noted that in a number of Gram-negative bacteria species, the cytoplasm is 
kept under reducing conditions, due to the presence of free thiols such as 
glutathione and thioredoxin, whilst the periplasm is maintained under 
oxidising conditions by the disulfide-forming enzyme DsbA.
181, 187
  As 
such, cleavage of a disulfide bond would occur selectively in the 
cytoplasm.  Additionally, it should also be highlighted that the redox 
environment in human blood is oxidative, ensuring that future developed 
disulfide containing drugs would be stable in transport to their intended 
targets.
174
 
 
By considering the mechanisms of drug release (Scheme 30) it is possible 
to take advantage of the reducing conditions of the bacterial cell cytoplasm 
to target bio-labile linkers containing a disulfide bond in siderophore-
fluoroquinolone Trojan horse conjugates. 
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Disulfides used in prodrugs and fluorescent probes 
 
To exploit the ability of cells to reduce disulfide bonds, a number of studies 
have demonstrated the use of a disulfide at the β-position relative to a 
carbamate or carbonate.
175-180
  In turn, these studies planned for the 
disulfide to cleave the carbamate or carbonate groups, releasing either a 
drug or a probe, through the mechanisms outlined in Scheme 30.
175-180
  
Wender et al. first introduced such a disulfide-based linker in 2006, 
designing a luciferin-transporter conjugate 3-1, for the monitoring of 
uptake and release of luciferin within prostate cancer cells.
176
  Luciferin is 
a general term used for light-emitting compounds,
188
 which can be used as 
luminescent probes for studying cellular uptake.
176
  Interestingly, Wender 
et al. also designed conjugates 3-2 and 3-3, demonstrating increased 
stability of the conjugate as the neighbouring alkyl linker length 
increased.
176
  On incubation of the conjugates in HEPES  buffered saline 
(pH 7.4) at 37 °C they found the conjugates had half-lives of 3 hours, 11 
hours and 33 hours for 3-1 to 3-2 to 3-3 respectively.
176
  However, on 
addition of 10 mM dithiothreitol all three conjugates were cleaved within 
minutes, releasing luciferin, demonstrating that the bio-labile linker cleaves 
and releases the probe as planned.
176
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Later, Low et al. introduced prodrugs of camptothecin, conjugated through 
a disulfide to a folate peptide, using both a carbonate and a comparative 
ester linkage (3-4 and 3-5).
177
  Interestingly, Low et al. found that drug 
release for the ester linker (3-5) was much lower than that of the carbonate 
(3-4),
177
 indicating the necessity of a carbonate for drug release. 
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The use of carbamates with neighbouring disulfide linkages was later 
developed by Satyam, who developed folate-drug conjugates.
175
  The 
conjugates, using anti-cancer drugs such as daunomycin (conjugate 3-6) 
and paclitaxel, were linked through a carbamate with a disulfide linker at 
the β-position.175  In turn, Satyam also demonstrated that these conjugates 
released the free drugs in the presence of sulfhydryl species such as 
dithiothreitol, dithioerythritol and glutathione at pH 7.4, proposing the 
mechanism discussed in Scheme 30.
175
  Subsequent studies by Satyam et 
al. applied the use of the same linker in a range of other prodrugs.
178, 179
 
 
 
 
Significantly, Kim et al. recently demonstrated a fluorescent probe which 
gained cytoplasmic entry into bacterial cells through the use of the 
siderophore desferrioxamine B 1-11, before cleavage of a disulfide bond to 
release the probe.
180
  The conjugate, compound 3-7, has a disulfide linkage 
at the β-position to two carbamates, one attached to a fluorescent probe, 
and another to the siderophore.
180
  This study was reported whilst the work 
conducted and presented herein was already underway. 
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The linker of Kim et al. was designed to be reactive on entry into the 
cytoplasm, given the reducing capability of the cytoplasm, whereby 
cleavage of the disulfide bond releases the free amine of the fluorophore, 
which in turn altered the photochemical property of the probe (Figure 30).  
To assess  3-7, Pseudomonas putida ATCC and E. coli BW25113 were 
selected as the bacterial strains, as neither produce desferrioxamine B, yet 
both are able to use it as a xenosiderophore.
180
  Kim et al. were thus able to 
follow the conjugate into the cell, monitoring a range of fluorescent states 
that allowed the determination of the siderophore-fluorophore conjugate 
uptake and fluorophore release (Figure 30).
180
  However, it was found that 
while conjugate 3-7 was able to access the cytoplasm of P. putida, it was 
not able to enter into E. coli, though it should be noted that this strain of E. 
coli lacks a high affinity outer membrane receptor for desferrioxamine 
B.
180
  In turn, it could be hypothesised that a specific choice of siderophore 
would allow for improved uptake into various bacterial strains. 
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Figure 30 - Schematic overview for monitoring a fluorescent probe 
released from 3-7.
180
  Taken from H. S. Kim, W. Y. Song and H. K. Kim, 
Org. Biomol. Chem., 2015, 37, 73-76, with permission from The Royal 
Society of Chemistry. 
 
Given the demonstration of siderophore uptake and subsequent 
cytoplasmic cleavage of a disulfide linkage by Kim et al.,
180
 a rationale of  
the approach outlined within this Chapter for choosing a disulfide-linked 
carbamate linker for siderophore-fluoroquinolone Trojan horse conjugates  
was provided. 
 
Conjugate Design 
 
To further develop the carbamate-linked conjugate 2-12 (Chapter 2), it was 
decided to incorporate a disulfide linkage at the β-position to the 
carbamate.  This approach, which was inspired by the previous 
investigations described above, was also chosen by Kim et al. whose work 
was reported in parallel to the study presented herein.
175-180
  The conjugate 
presented in this Chapter, compound 3-8, was based on 2-12, with a focus 
on decreasing the stability of the carbamate linker within the cytoplasm of 
bacterial cells, through the use of a neighbouring disulfide.  Conjugate 3-8 
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allowed a direct comparison with conjugate 2-12 (Chapter 2), with the 
disulfide linkage expected to allow for selective cleavage within the 
cytoplasm.  In addition, based upon the observed isomerisation of the 
citrate moiety on treatment with hydroxide, discussed in Chapter 2, a single 
regioisomer of the citrate moiety was incorporated in the design of 
compound 3-8. 
 
 
 
In targeting compound 3-8, it was planned to exploit the reducing 
conditions in the cytoplasm to allow for release of ciprofloxacin,
180
 via the 
mechanism proposed by Satyam (Scheme 31).
175
 
 
 
Scheme 31 - Proposed mechanism of ciprofloxacin 1-5 release from 
compound 3-8 via two potential pathways as a result of attack from a 
thiolate species (A - blue / B - red). 
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Designing the synthesis of compound 3-8 
 
In order to plan the synthetic route to compound 3-8, its disconnection was 
considered to give the key components (Figure 31).  Given the similarities 
between compound 3-8 and compound 2-12, the two compounds have the 
same four key components: citric acid 1-12, a linker unit consisting of a 
free alcohol and amine, carbon dioxide and ciprofloxacin 1-5. 
 
 
Figure 31 - The key structural components of conjugate 3-8. 
 
The individual components of compound 3-8 indicate that as for compound 
2-12 previously, the carbonyl functionality of the carbamate can be 
introduced via activation of an alcohol.  However, it was the introduction 
of the disulfide linker which required further consideration. 
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Synthesis of unsymmetrical disulfides 
 
A number of synthetic routes are available to form disulfide bonds, such as 
oxidation of thiols and exchange reactions.
189, 190
  However, whilst many 
examples exist for the synthesis of symmetrical disulfides, most are not 
suitable for the synthesis of unsymmetrical disulfides due to the possibility 
of side reactions.  Side reactions can include thiol-disulfide exchange 
resulting in symmetrical disulfides, or competitive formation of 
symmetrical disulfides, each reducing the yield of the desired 
unsymmetrical product.
190
 
 
One of the most common methods for the synthesis of disulfides involves 
oxidation of thiols, typically using oxidizing agents such as iodine, 
hydrogen peroxide and dichlorodicyanoquinone.
189, 190
  Unsymmetrical 
disulfides can be prepared through the oxidation route, though mixtures of 
three disulfides are often formed.
189, 190
  Nevertheless, examples have been 
reported with high yields of unsymmetrical disulfide products obtained 
through oxidation reactions.
191, 192
  For example, Suzuki et al. mixed two 
thiols in a 9:10 ratio with sodium tellurite to produce unsymmetrical 
disulfides in high yields (Scheme 32).
191
  However the authors proposed 
that the coupling of the two different thiols proceeds through the initial 
conversion of the more reactive thiol to form a symmetrical disulfide, 
followed by gradual thiol-disulfide exchange with the less reactive thiol.
191
 
 
 
Scheme 32 - Synthesis of disulfides using sodium tellurite, reported by 
Suzuki et al.
191
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Another such example was more recently reported by Wang et al., who 
employed dichlorodicyanoquinone (DDQ) to selectively form 
unsymmetrical disulfides from equimolar ratios of two different thiols 
(Scheme 33).
192
  It was found the reaction proceeds quickly as a ‘one pot’ 
method, using a range of different thiols, in high yields.
192
  However, 
Wang et al. found that whilst secondary thiols could also successfully form 
the required products, tertiary thiols could not, reasoning this was due to 
steric hindrance.
192
  In addition it was also found that the reactions were 
not successful when free amino groups were present on one thiol moiety.
192
  
Given that one component required towards the synthesis of compound 3-8 
incorporates a free amine (Figure 31), such a limitation of the 
methodology of Wang et al. would prove problematic. 
 
 
Scheme 33 - Synthesis of disulfides using dichlorodicyanoquinone, 
reported by Wang et al.
192
 
 
The use of thiol-disulfide exchange reactions can lead to a mixture of 
disulfide products, though this can be controlled by using an excess of the 
symmetrical disulfide.
189, 190
  However, this method of unsymmetrical 
disulfide preparation typically requires purification of the required product 
from the mixture, usually by column chromatography.  Furthermore, whilst 
the exchange method is generally less efficient, it does allow for a 
potentially greater scope of use, as a wide range of functional groups are 
tolerated under the mild conditions used.
190
  Perhaps the most widely 
applied thiol-disulfide exchange reactions involve exchanges with a 2-
pyridyl disulfanyl species, prepared from reaction of a thiol with 2,2’-
dipyridyl disulfide (Scheme 34).
193, 194
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Scheme 34 - General scheme for the synthesis of unsymmetrical disulfides 
by thiol-disulfide exchange with a 2-pyridyl disulfanyl species.
193, 194
 
 
Brzezinska and Ternay developed an efficient method to produce 
unsymmetrical disulfides, containing a benzothiazole fragement, on mixing 
2,2’-dithiobis(benzothiazole) (3-9) with a number of thiols (Scheme 35).195  
The by-product, 2-mercaptobenzothiazole (3-11), could be removed via 
aqueous extraction, allowing the isolation of product 3-10 in high yield, 
without the requirement for column chromatography.
195
  In addition, it was 
then possible to mix the product 3-10 with other thiols, producing an 
unsymmetrical disulfide in high yield and another 2-mercaptobenzothiazole 
(3-11).
195
 
 
 
Scheme 35 - Synthesis of disulfides using 2,2’-dithiobis(benzothiazole) as 
reported by Brzezinska and Ternay.
195
 
 
However, whilst both viable approaches, the use of either a 2-pyridyl 
disulfanyl species or 2,2’-dithiobis(benzothiazole) each require the initial 
formation of an unsymmetrical disulfide bond, before subsequent 
exchange.  Fortunately, the intermediate component required for the 
synthesis of compound 3-8 (Figure 31), has been reported in the literature 
(Scheme 36).
178
  An advantage of this approach is that while non-selective 
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exchange can occur, producing a mixture of disulfides, the use of the tert-
butyloxycarbonyl protecting group allows simple purification by column 
chromatography.  A combination of easy purification, inexpensive starting 
materials, and avoiding precursor disulfide formation from 2-
mercaptoethanol, makes this approach highly attractive to apply towards 
the synthesis of 3-8.  The use of the symmetrical 2-hydroxyethyl disulfide 
3-12 demonstrates the versatility of thiol-disulfide exchange reactions, as it 
does not require the use of a sacrificial component like those when using a 
2-pyridyl disulfanyl species or 2,2’-dithiobis(benzothiazole). 
 
 
Scheme 36 - Synthesis of compound 3-13 by thiol-disulfide exchange.
178
  
(a) Cysteamine.HCl, MeOH, Et3N; (b) Boc2O, MeOH. 
 
3.3 Synthesis 
 
Taking inspiration from the synthesis of compound 2-12, and having 
considered the disconnection of compound 3-8 (Figure 31), the synthesis 
of compound 3-8 was attempted via the route planned in Scheme 37.  
Following a literature procedure, compound 3-13 was targeted through a 
thiol-disulfide exchange with cysteamine from 2-hydroxyethyl disulfide 3-
12 (Scheme 37), followed by immediate Boc protection for ease of 
purification.
178
  Deprotection of the Boc group to give 3-14, also based on 
the literature,
178
 followed by amide coupling with 1,5-dimethyl citrate 2-21 
would provide intermediate 3-15.  Next the carbamate group would be 
introduced in the same manner as discussed in Chapter 2, via activation of 
a free alcohol utilising N,N’-disuccinimidyl carbonate, to produce 
compound 3-16.  Finally, it was planned that base hydrolysis of the ester 
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groups would isomerise the citrate moiety to give 3-8, as established in 
Chapter 2 (Scheme 37).  However, the attempts to produce compound 3-8 
were not successful, as discussed in greater detail later. 
 
 
Scheme 37 - Synthetic route towards compound 3-8.  (a) Cysteamine.HCl, 
MeOH, Et3N; (b) Boc2O, MeOH, 48%; (c) TFA, CH2Cl2; (d) HATU, 
DMF, DIPEA, 46%; (e) DSC, DIPEA, DMF, 37%; (f) (i) 0.1 M NaOH, 
H2O, (ii) HCl. 
 
Synthesis of the methyl ester protected disulfide conjugate 3-16 
 
Thiol-disulfide exchange of 2-hydroxyethyl disulfide 3-12 to produce 3-13 
 
The first step in the synthesis was a thiol-disulfide exchange of 2-
hydroxyethyl disulfide 3-12 with cysteamine hydrochloride in the presence 
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of triethylamine (Scheme 38), in line with a literature procedure.
178
  This 
was followed by the addition of di-tert-butyl dicarbonate, to allow easier 
purification and isolation of compound 3-13.
178
  Compound 3-13 was 
isolated in 48% yield, and characterised using 
1
H and 
13
C NMR 
spectroscopy, infra-red spectroscopy and ESI mass spectrometry.  
Formation of 3-13 was supported by a characteristic resonance at 156.0 
ppm for the carbamate group in the 
13
C NMR spectrum, as well as a singlet 
in the 
1
H NMR spectrum at 1.44 ppm, of relative integration nine, for the 
tert-butyl group.  In addition, ESI-MS analysis gave a molecular ion peak 
[M+Na]
+
 for 3-13 at m/z 276.0700, consistent with a molecular formula of 
C9H19NNaO3S2, with all the spectroscopic data collected matching the 
literature.
178
 
 
 
Scheme 38 - Synthesis of 3-13 by thiol-disulfide exchange.
178
  (a) 
Cysteamine.HCl, MeOH, Et3N; (b) Boc2O, MeOH, 48%. 
 
Boc deprotection of 3-13 and subsequent coupling with 1,5-dimethyl citrate 
2-21 to produce 3-15 
 
Having isolated compound 3-13, it was possible to continue the synthesis 
towards intermediate 3-15.  First, the Boc protecting group was cleaved 
with trifluoroacetic acid to produce 3-14.
178
  Without further purification, 
3-14 was coupled to 1,5-dimethyl citrate 2-21 using HATU and DIPEA in 
DMF to produce 3-15 in 46% yield (Scheme 39).  Compound 3-15 was 
characterised using 
1
H and 
13
C NMR spectroscopy, infra-red spectroscopy 
and ESI mass spectrometry.  Formation of 3-15 was supported by 
13
C 
NMR spectroscopy, with a characteristic resonance at 171.7 ppm for the 
amide functional group present in the spectrum.  Furthermore, ESI-MS 
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analysis gave a molecular ion peak [M+Na]
+
 for 3-15 at m/z 378.0647, 
consistent with a molecular formula of C12H21NNaO7S2. 
 
 
Scheme 39 - Synthesis of compound 3-15.  (a) TFA, CH2Cl2; (b) HATU, 
DMF, DIPEA, 46% 
 
Formation of the carbamate functional group to produce compound 3-16 
 
The conditions used for the formation of 2-22 (Chapter 2) were employed 
towards the synthesis of 3-16, from 3-15 and ciprofloxacin methyl ester 2-
15.  Compound 3-15 was treated with N,N’-disuccinimidyl carbonate and 
DIPEA in DMF, followed by the addition of ciprofloxacin methyl ester 2-15 
(Scheme 40).  Under these conditions, compound 3-16 was isolated in 37% 
yield.  The formation of 3-16 was supported by 
13
C NMR spectroscopy, 
with a characteristic resonance at 154.8 ppm for the carbamate group.  
Furthermore, ESI-MS analysis gave a molecular ion peak [M+Na]
+
 for 2-
22 at m/z 749.1921, consistent with a molecular formula of 
C31H39FN4NaO11S2.  Additionally the 
1
H NMR spectrum shows two 
triplets, representing the two methylene groups at 2.80 and 2.96 ppm in α-
position to the disulfide linkage.  The triplet at 2.96 ppm is part of a 
multiplet which also contains one of the roofed doublets (2.78 and 2.93 
ppm), corresponding to the diastereotopic protons of the citrate moiety 
(Figure 32).  The observation of the roofed doublets demonstrates the 
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retention of symmetry in the citrate moiety, supporting the assignment of 
3-16. 
 
 
Scheme 40 - Carbamate formation using N,N’-disuccinimidyl carbonate to 
produce compound 3-16.  (a) DSC, DIPEA, DMF, 37%. 
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Figure 32 - 
1
H NMR spectrum of 3-16 in CDCl3.  The J-coupling splitting 
pattern is shown below.  The assignment for H-2 overlaps partially with the 
doublet for the diastereotopic protons of the citrate moiety.  *The 
assignment of H
a
 and H
b
 can be interchanged. 
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Attempted base-catalysed hydrolysis of the protected disulfide-linked 
conjugate 3-16 to target 3-8 
 
Having isolated compound 3-16, the next step was to remove the methyl 
ester protecting groups (Scheme 41).  It was expected that the citrate 
moiety would isomerise in a manner analogous to that discussed in Chapter 
2.  However, target compound 3-8 was never isolated under the reaction 
conditions investigated. 
 
 
Scheme 41 - Attempted base hydrolysis of 3-16 to target 3-8.  (a) (i) 0.1 M 
NaOH, H2O, (ii) HCl. 
 
Investigation of the base-catalysed hydrolysis reaction of 3-16 by 
1
H NMR 
spectroscopy 
 
It was first decided to examine the hydrolysis reaction of 3-16 by 
1
H NMR 
spectroscopy (400 MHz spectrometer).  Compound 3-16 was dissolved in 
CD3OD, followed by the addition of 0.01% NaOD (40% in D2O).  The 
reaction was monitored over time, observing a decrease in signal intensity 
of the resonances attributed to the starting compound 3-16, and an increase 
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in intensity for free ciprofloxacin 1-5 (Figure 33), with three other 
ciprofloxacin containing species also observed (1, 2 and 3),  none of which 
were attributed to ciprofloxacin methyl ester 2-15.  As Figure 33 shows, 
the hydrolysis of 3-16 proceeded slowly, with the presence of 3-16 still 
observed after 92 hours.  Furthermore, free ciprofloxacin 1-5 appeared 
within the first hour of the reaction (Figure 33), accounting for 6% of the 
reaction mixture. 
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Figure 33 - A) 
1
H NMR spectrum of the aromatic region of compound 3-
16 in CD3OD + 0.01% NaOD (40% in D2O).  The two extra resonances at 
8.54 (3) and 8.67 (2) ppm at t = 5 min are attributed to an indeterminate 
fast reaction that occurred in the time (~5 minutes) between the addition of 
NaOD and collecting the 
1
H NMR spectrum, as they were not present in 
the spectrum prior to the addition of NaOD.  B) Plot of the % ratio of 
species present in solution based on the relative integration of the 
resonances highlighted in the 
1
H NMR spectrum over time.  Species 3 was 
omitted for clarity as it remained at a ratio of 6-7% throughout. 
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The ratio of the ciprofloxacin-containing species was plotted as a function 
of time, showing a trend between the decrease in compound 3-16 and an 
increase in released free ciprofloxacin (B - Figure 33).  Two ciprofloxacin-
containing species, 1 and 2, were observed to gradually increase in % ratio 
over the first 31 hours, before decreasing as the reaction progressed (B - 
Figure 33).  This suggests that both 1 and 2 eventually decomposed to give 
free ciprofloxacin 1-5.  In addition, species 3 was observed after the first 
hour at a ratio of 6%, which did not change over the course of the reaction.  
Whilst it was not possible to identify species 1, 2 and 3 from the NMR 
data, it is conceivable that they were formed by the loss of the methyl ester 
groups from 3-16, with one of the species expected to be the required 
product 3-8.  However, the observation of the concurrent release of free 
ciprofloxacin 1-5 during the reaction indicated that the disulfide linker 
cleaved on treatment with sodium hydroxide. 
 
With the 
1
H NMR study indicating that hydrolysis of 3-16 proceeded 
slowly in methanol, reasoned in part to be due to the partial solubility of 3-
16 in the solvent, leading to dilute solutions in order to fully dissolve the 
compound.  It was therefore necessary to find conditions that would 
improve the rate of reaction.  Additionally, with the release of free 
ciprofloxacin 1-5 observed over time, it was also hoped that by increasing 
the rate of the deprotection reaction it would be possible to isolate the 
required target compound 3-8 prior to decomposition of the disulfide 
linkage.  The caveat of this would be the risk that the rate of the release of 
ciprofloxacin could also be increased. 
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Treating 3-16 with sodium hydroxide in 1,4-dioxane and water 
 
It was found through both TLC analysis and solubility screening that a 
mixture of 45 weight % 1,4-dioxane in water greatly improved both the 
solubility of 3-16 and the rate of reaction, with a complete reaction 
observed by TLC analysis within an hour, determined by the absence of 3-
16.  Therefore, compound 3-16 was mixed with 3.6 equivalents of sodium 
hydroxide in 45 % 1,4-dioxane and water (w/w).  TLC analysis showed 
that the reaction was complete after 15 minutes, as no starting compound 3-
16 remained.  When the pH was reduced to 2.15, a precipitate formed, 
which was filtered and washed with both water and chloroform (Figure 
34).  The precipitate, the aqueous residue, and the organic residue were 
analysed individually by HPLC, ESI-MS and 
1
H NMR spectroscopy.  
These three samples equated to a total of 96% mass recovery based on the 
starting compound 3-16. 
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Figure 34 - Flow chart depicting the base hydrolysis reaction of 3-16. 
 
Analysis of the organic residue 
 
The 
1
H NMR spectrum of the organic residue was complex with at least 
four ciprofloxacin-containing compounds present (Figure 35).  In addition, 
there were no resonances observed for the diastereotopic protons of the 
citrate moiety.  However, the ESI mass spectrum suggested the presence of 
the starting compound 3-16.  Furthermore, the ESI mass spectrum of the 
organic filtrate indicated that another ciprofloxacin-related species was 
present, the homodisulfide compound 3-17, with a peak observed at m/z 
919.2574, corresponding to the sodiated molecular ion [M+Na]
+
.  This 
indicated that disulfide scrambling had occurred, suggesting cleavage of 
the disulfide bond. 
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Figure 35 - 
1
H NMR spectrum of the aromatic region of the organic 
residue in CDCl3.  Four ciprofloxacin species are observed 1, 2, 3 and 4.  
The four highlighted peaks correspond to an aromatic proton (pointed out 
as ~ 8.55 ppm) on a ciprofloxacin-containing species. 
 
 
 
HPLC analysis was conducted on the organic residue, confirming that there 
were four major ciprofloxacin-containing species present in the residue 
(Figure 36).  Compounds were observed to elute at 7.7, 10.4, 11.5 and 12.5 
minutes.  These were determined to be ciprofloxacin-containing species 
based on their similar UV/Vis absorption spectra, which were obtained by 
diode array detection, each with a λmax of approximately 285 nm, 
comparable to free ciprofloxacin.  It can also be seen that, in addition, there 
are several minor species present (Figure 36). 
 
Chapter 3 
153 
 
 
Figure 36 - HPLC trace of the organic residue at 285 nm detection.  
Nothing eluted after 20 minutes (total run time = 35 min).  Conditions: 
Analytical HPLC Method A (Chapter 7). 
 
None of the species evident in the HPLC trace, either major or minor, 
corresponded to ciprofloxacin methyl ester 2-15, which elutes at 1.32 
minutes under these conditions.  It is also important to note that the starting 
compound 3-16 was not present, as it elutes at 7.2 minutes.  To identify the 
species present in the organic residue LC-MS was performed (by Karl 
Heaton).  From the LC-MS trace the first species to elute showed a 
molecular ion peak [M+H]
+
 at m/z 526.1469, consistent with a molecular 
formula of C23H29FN3O6S2, which is consistent with the formula of 
compound 3-18.  The second species to elute showed a molecular ion peak 
[M+H]
+
 at m/z 695.1828, consistent with a molecular formula of 
C30H36FN4O10S2, which is consistent with the molecular formula of 
compound 3-19.  The presence of the succinimide 3-19 indicated that 
cyclisation could have occurred in a manner analogous to that discussed in 
Chapter 2.  The third compound to elute was the homodisulfide 3-17, with 
a sodiated peak analogous to that stated above.  The fourth compound to 
elute on the LC-MS had a mass of 568.1385, the structure for which could 
not be identified. 
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Finally, it should be noted that an impurity had carried through the 
reaction, with the corresponding species eluting at 7.7 minutes (Figure 37). 
 
 
Figure 37 - Overlay of HPLC trace of the starting compound 3-16 (red) 
and the organic residue (blue), showing a possible impurity carried through 
into the organic residue at 7.7 minutes.  The window is focused for clarity.  
Conditions: Analytical HPLC Method A (Chapter 7). 
 
In conclusion, the analysis of the organic residue indicated that a mixture 
of species was present.  Some of these species could have been produced 
through disulfide scrambling.  In addition, the citrate moiety has undergone 
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cyclisation to form a succinimide, analogous to that previously discussed in 
Chapter 2.  These observations confirm that the rate of deprotection is 
similar to those of the side reactions, therefore giving rise to a mixture of 
products, none of which are the cleanly deprotected target compound 3-8.  
The next stage of the analysis was to investigate the compounds present in 
the aqueous residue to find out if 3-8 had portioned into the aqueous phase 
due to its higher hydrophilicity. 
 
Analysis of the aqueous residue 
 
The 
1
H NMR spectrum of the aqueous residue indicated that the isolated 
sample contained only one ciprofloxacin-containing species, free 
ciprofloxacin 1-5 itself, in agreement with the only observed product in the 
ESI mass spectrum.  Interestingly, the 
1
H NMR spectrum of the aqueous 
residue also demonstrated the presence of diastereotopic protons that 
indicated the presence of several citrate-related species through numerous 
roofed doublets (Figure 38).  Furthermore, the relative integrations for 
these diastereotopic protons were above what would be expected if a citrate 
was still conjugated through a linker to the ciprofloxacin moiety, 
suggesting that decomposition products of the conjugate are present in the 
aqueous residue.  Indeed, the HPLC trace of the aqueous residue indicated 
only one ciprofloxacin-containing species at 9.8 minutes (Figure 39), 
consistent with free ciprofloxacin 1-5.  On spiking the sample with 
ciprofloxacin 1-5, there was no change in the observed trace.  By 
combining these observations, it was clear that the residue isolated from 
the aqueous filtrate consisted of the decomposition products of compound 
3-16. 
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Figure 38 - 
1
H NMR spectrum of the aqueous residue in D2O, shown in the 
citrate region.  The relative integrations are compared to a known 
integration of one for an aromatic ciprofloxacin proton at 8.62 ppm.  
Several species are present, with three examples of diastereotopic coupling 
highlighted below, though it can be seen that the multiplet between 2.72-
2.83 ppm contains several more overlapping doublets. 
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Figure 39 - HPLC trace of the aqueous residue at 285 nm detection.  
Nothing eluted after 20 minutes (total run time = 35 min).  Conditions: 
Analytical HPLC Method B (Chapter 7). 
 
Analysis of the isolated precipitate 
 
Despite evidence indicating that both scrambling and decomposition of the 
disulfide linker had occurred, it was necessary to determine the 
composition of the isolated precipitate.  The ESI mass spectrum indicated 
the presence of the desired product 3-8 in the precipitate, with a [M+Na]
+
 
peak at m/z 683.1512, which is consistent with a molecular formula of 
C28H32FN4O11S2.  However, the ESI mass spectrum also indicated the 
presence of free ciprofloxacin 1-5.  The 
1
H NMR spectrum was complex, 
and no resonances were observed for the diastereotopic protons of the 
citrate moiety.  On analysis by HPLC, it was evident that there were a 
number of different species (Figure 40).  Among the compounds observed 
in the HPLC trace of the precipitate was un-reacted starting compound 3-
16 (7.2 minutes) and species also observed within the organic residue at 
10.4, 11.5 and 12.5 minutes.  Furthermore, on employing the same gradient 
used to analyse the aqueous filtrate, it was observed that one major species 
in the isolated precipitate was free ciprofloxacin 1-5, with a peak at 9.8 
minutes (Figure 41).  In light of the observation that the precipitate also 
contained free ciprofloxacin 1-5, it was deemed unlikely that the precipitate 
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contained the desired product 3-8 in sufficiently high quantities to merit 
isolation. 
 
 
Figure 40 - HPLC Trace of the isolated precipitate at 285 nm detection.  
Nothing eluted after 20 minutes (total run time = 35 min).  Conditions: 
Analytical HPLC Method A (Chapter 7). 
 
 
Figure 41 - HPLC Trace of the isolated precipitate at 285 nm detection..  
Conditions: Analytical HPLC Method B (Chapter 7). 
 
In summary, the treatment of 3-16 with sodium hydroxide for 15 minutes 
led to the decomposition of the conjugate, releasing free ciprofloxacin 1-5.  
Whilst studies have reported the use of sodium hydroxide to cleave esters 
in the presence of disulfides, such as that by Schofield et al.,
196
 it has been 
suggested by others that disulfide bonds are unstable above pH 11, with the 
addition of hydroxide across the disulfide bond, eliminating a free thiol, 
thereby resulting in cleavage of the disulfide bridge.
186, 197
  With these 
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conflicting studies, it is nevertheless important to note that a high pH used 
in this study, resulting from the use of 0.1 M sodium hydroxide, resulted in 
the decomposition and scrambling of the disulfide bond, despite using a 
maximum of 1.2 equivalents of base per ester group.  As such, alternative 
methods of ester cleavage were necessary. 
 
Attempted hydrolysis of 3-16 with potassium trimethylsilanolate 
 
Potassium trimethylsilanolate could avoid any potential hydroxide-based 
decomposition of the disulfide linkage.  There are two possible 
mechanisms for the action of the nucleophilic trimethylsilanolate ion, one 
following an SN2 attack of the alkyl group (A - Scheme 42) and the second 
involving nucleophilic attack at the ester carbonyl (B - Scheme 42).
198
  It 
has been suggested that the most likely mechanism is via the SN2 route.
198
  
In turn, this would suggest that potassium trimethylsilanolate is less likely 
to attack the disulfide bond.  Therefore compound 3-16 was dissolved in 
tetrahydrofuran and a solution of potassium trimethylsilanolate (2M in 
THF, 38 equivalents) was added.  However, on work-up and 
characterisation of the reaction after one hour, a mixture of at least three 
species was observed in the 
1
H NMR spectrum.  ESI-MS analysis of the 
mixture indicated that starting material 3-16 was present, with a molecular 
ion peak for [M+Na]
+
 at m/z 749.1931, consistent with a molecular formula 
of C31H39FN4NaO11S2.  In addition, another [M+Na]
+
 peak was observed, 
at m/z 721.1650, which was attributed to the loss of two methyl ester 
groups from compound 3-16, as the peak was consistent with a molecular 
formula of C29H35FN4NaO11S2.  On treating the crude mixture with a 
greater amount of potassium trimethylsilanolate for several days, it was 
found that the reaction would not proceed any further and so it was 
concluded that this reagent was also not suitable for a continued 
investigation. 
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Scheme 42 - Proposed mechanisms of ester hydrolysis using potassium 
trimethylsilanolate.
198
 
 
Attempted acid-catalysed hydrolysis of the protected disulfide-linked 
conjugate 3-16 to target 3-8 
 
It has been shown that methyl esters can be cleaved using acid-mediated 
hydrolysis, such as through the use of concentrated sulfuric acid.
140
  
However, under these conditions equilibrium between hydrolysis and 
formation occurs, which, when combined with the fact that such conditions 
are harsh for other functional groups in the molecule, meant that the use of 
sulfuric acid was deemed unsuitable.  Instead, compound 3-16 was treated 
with a large excess of trifluoroacetic acid (295 equivalents) (Scheme 43).  
After the mixture was stirred for 24 hours the solvent was removed in 
vacuo.  Unfortunately, the methyl esters were not removed.  However, 
perhaps more importantly, no decomposition of the compound was 
observed, with the isolated product being unchanged 3-16. 
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Scheme 43 - Attempted acid hydrolysis of 3-16 to target 3-8.  (a) TFA, 
CH2Cl2. 
 
Despite the unsuccessful acid-catalysed hydrolysis of 3-16, trifluoroacetic 
acid could be used for future deprotection reactions, where an alternative 
protecting group strategy would be targeted towards the synthesis of 3-8.  
Such a change of protecting group could see the use of tert-butyl ester 
protecting groups, for both the fluoroquinolone and citrate moieties, 
targeting a synthetic route proposed in Scheme 44.  The synthesis of a 
fluoroquinolone tert-butyl ester has been reported using norfloxacin 1-4,
199
 
which could be employed in the synthesis of 3-23, though the synthesis of 
tert-butyl ester citrates (3-20) would have to be developed. 
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Scheme 44 - Proposed future work synthesis of 3-8 via the use of tert-butyl 
ester protecting groups.  (a) Cysteamine.HCl, MeOH, Et3N; (b) Boc2O, 
MeOH; (c) TFA, CH2Cl2; (d) HATU, DMF, DIPEA; (e) DSC, DIPEA, 
DMF; (f) TFA, CH2Cl2. 
 
3.4 Summary, conclusions and future work for Chapter 3 
 
Compound 3-16 was synthesised as a methyl-protected precursor to the 
target conjugate 3-8.  The synthesis of 3-16 has provided procedures for the 
synthesis of a number of intermediates.  However, attempts to deprotect 
conjugate 3-16 to yield 3-8 proved unsuccessful, with an apparent 
instability of the disulfide linkage in the presence of hydroxide.  The 
mechanism by which compound 3-16 cleaves was not determined, though 
it is likely to be via cleavage of the disulfide linkage.  Furthermore, the 
release of free ciprofloxacin 1-5 during base hydrolysis can tentatively be 
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said to act as a ‘proof of concept’ for the release of the drug from the 
conjugate through the disulfide linkage.  However, only the isolation of 3-
8, and subsequent studies into the stability of the disulfide bond, can fully 
justify this argument. 
 
Having established that the protected conjugate 3-16 is stable in the 
presence of trifluoroacetic acid, future work could involve the development 
of an alternative protecting group strategy to allow the synthesis of 3-8 
(Scheme 44).  Based on the potential success of such a strategy to obtain 3-
8, future work could therefore involve ex vivo stability studies of 3-8 
against sulfhydryl species, such as glutathione, to determine the ability of 
3-8 to cleave under reducing conditions analogous to within the cytoplasm.  
Furthermore, future work could also include the biological evaluation of 
the Trojan horse conjugate to determine the efficacy of 3-8 against 
bacterial strains.  Such evaluation would involve growth assays and DNA 
gyrase assays analogous to Chapter 2. 
 
In addition to the development of bio-labile linkers, and the need to 
complete the synthesis of compound 3-8 as future work for this Chapter, 
linker design is just one aspect of the Trojan horse strategy.  Thus the 
understanding of design features required for siderophore-fluoroquinolone 
conjugates also needs to take into consideration the choice of siderophore, 
discussed in greater detail in Chapter 4. 
  
Chapter 4: Synthesis and 
antimicrobial activity 
testing of a salmochelin- 
inspired siderophore-
ciprofloxacin conjugate 
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4.1 Aims and overview 
 
In Trojan horse conjugates, the siderophore is a key component to be 
considered.  This Chapter discusses the use of a glucosylated-catecholate 
siderophore in the Trojan horse strategy, inspired by the stealth 
siderophores, the salmochelins.  As the salmochelins have only recently 
been discovered, the development of salmochelin-inspired conjugates is a 
new field of research.  The aim of the research presented in this Chapter is 
to explore the application of a salmochelin analogue as the siderophore 
component in a Trojan horse conjugate that incorporates ciprofloxacin as 
the drug. 
 
4.2 Introduction 
 
In the continued development of siderophore-fluoroquinolone conjugates, 
it is important to consider the role of the siderophore moiety.  The ability of 
many mammalian hosts to produce siderocalins to prevent the uptake and 
use of catecholate siderophores (Chapter 1),
71, 200
 suggests that siderocalins 
could also scavenge catecholate-antimicrobial conjugates, thereby 
preventing their uptake into the bacterial cell. 
 
Given that some bacterial species respond to the host’s production of 
siderocalin by producing stealth siderophores, such as the salmochelins 
(Chapter 1),
77, 78
 they provide interesting options for Trojan horse 
conjugates.  Producing Trojan horse conjugates inspired by stealth 
siderophores is a strategy that may allow the conjugate to evade the host’s 
immune response, whilst maintaining the iron-binding ability of the 
siderophore component. 
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Salmochelin-inspired Trojan horse conjugate 
 
The salmochelins were discovered in 2003,
77
 with the structures elucidated 
in 2004.
78
  Only one example of their incorporation into a Trojan horse 
conjugate has been documented to date.  This was published in 2015 by 
Nolan et al. who investigated a salmochelin-inspired β-lactam Trojan horse 
conjugate.
99
  This study was reported whilst the work conducted and 
presented herein was in progress.  Nolan et al. introduced glucosyl moieties 
onto the enterobactin scaffold of their conjugates via a chemoenzymatic 
approach, using two different C-glucosyltransferases, MceC and IroB to 
catalyse C-glucosylation, producing
 
4-1 and 4-2 respectively,
99
 with 
conjugate 4-1 based on salmochelin S4 1-16. 
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Nolan et al. tested their conjugates against E. coli strains that expressed 
IroN, the outer membrane receptor for salmochelin S4 1-16, and those that 
do not.  It was found that conjugates 4-1 and 4-2 were active against E. coli 
UTI89 and E. coli CFT073, which both express IroN, with 100- and 1000- 
fold enhanced activity against these two strains, respectively, compared to 
the parent drug.
99
  This enhancement in activity matched the activity of a 
comparative non-glucosylated conjugate 1-32 (Chapter 1).
98
  Additionally, 
conjugates 4-1 and 4-2 demonstrated negligible antibacterial activity 
against three E. coli strains which lacked IroN.
99
  Significantly, Nolan et al. 
also demonstrated that conjugates 4-1 and 4-2 evaded the siderocalin 
protein, with the conjugates still able to kill E. coli in the presence of a 10-
fold excess of siderocalin.
99
  Indeed the activity of their non-glucosylated 
conjugate 1-32 was reduced in the presence of siderocalin,
98
 suggesting the 
siderocalin protein scavenged and de-activated this conjugate. 
 
As Nolan et al. successfully demonstrated that the β-lactam conjugates 4-1 
and 4-2 were able to evade siderocalin binding,
99
 the use of glucosylated 
siderophores for Trojan horse conjugates, the approach outlined in this 
Chapter, has been demonstrated as viable for designing a salmochelin-
inspired siderophore-fluoroquinolone Trojan horse conjugate.  Our work 
was conducted in parallel to the study reported by Nolan et al. 
 
The chemoenzymatic glycosylation approach employed by Nolan et al., 
using MceC and IroB to recognise and perform glycosylation of the 
enterobactin motif of conjugates, potentially limits the development of 
future conjugates to those with an enterobactin scaffold.  Even though 
studies have found the residues involved in substrate binding of 
enterobactin, there is insufficient evidence to determine the exact 
specificity of substrate recognition for these enzymes.
201-203
  Conversely, 
the chemical synthesis of a glucosylated siderophore component is likely to 
be more versatile for the future development of salmochelin-inspired 
Trojan horse conjugates, as it circumvents the likely requirement of 
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substrate recognition in an enzymatic approach.  As such, the approach 
outlined in this Chapter is the chemical synthesis of a glucosylated 
siderophore mimic, which also provides a key intermediate that can be 
used towards future salmochelin-inspired Trojan horse conjugates.  
Furthermore, with no salmochelin-inspired Trojan horse conjugates 
incorporating fluoroquinolones reported at the time of writing, it is 
therefore important to explore such an approach. 
 
Conjugate Design 
 
A number of previous investigations have incorporated catecholate 
siderophore components into siderophore-fluoroquinolone conjugates.
115, 
119, 120, 123, 125, 127
  However, these conjugates do not incorporate features 
which prevent scavenging by siderocalin.
115, 119, 120, 123, 125, 127
  As Nolan et 
al. have demonstrated that a non-glycosylated catecholate-β-lactam 
conjugate (1-32) was scavenged by siderocalin,
98
 it can be hypothesised 
that that siderocalin could scavenge other catecholate siderophore-
antimicrobial Trojan horse conjugates. 
 
Taking inspiration from the salmochelin class of stealth siderophores, 
conjugate 4-3 was designed.  Two glycosylated catecholate siderophore 
components were incorporated, with a lysine linker to connect to 
ciprofloxacin 1-5 (Figure 42).  Conjugate 4-3 utilises a tetradentate 
siderophore in its design.  It was therefore important to consider the uptake 
of tetradentate siderophores, as well as the uptake mechanisms of 
salmochelin-type siderophores. 
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Figure 42 - Conjugate 4-3 and salmochelin S4 1-16.  Dark blue = 
glucosylated catecholate units; Light blue = backbone/linker; Green = 
ciprofloxacin antimicrobial; Grey = remainder of salmochelin S4 structure. 
 
Uptake of tetradentate and salmochelin-type siderophores 
 
With regards to the choice of a tetradentate siderophore in target 4-3, it is 
worth noting that the bacterial uptake of Fe(III) bound tetradentate 
siderophores has been demonstrated in E. coli, with the uptake of the linear 
dimer enterobactin hydrolysis product 1-10.
54
  Indeed for Campylobacter 
jejuni preferential binding of the tetradentate enterobactin linear dimer 1-10 
over hexadentate enterobactin 1-9 to a periplasmic binding protein was 
observed, indicating that this scavenger bacterium may have developed this 
strategy to compete with other pathogens.
204
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The uptake pathways for the salmochelins should also be highlighted.  
Since the discovery of the salmochelins, the proposed uptake mechanisms 
of salmochelin S4 1-16 in E. coli has evolved from that first suggested by 
Hantke et al. in 2005 (Figure 43).
79
  As can be seen, salmochelin S4 1-16 
was proposed to first pass through the outer membrane receptor IroN, 
followed by cleavage in the periplasm by the esterase IroE to give the 
linear trimer salmochelin S2, which would be subsequently taken into the 
cytoplasm through IroC (Figure 43).
79
  In the cytoplasm, action by the 
esterase IroD cleaves the siderophore backbone to release the iron from the 
complex. 
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Figure 43 - Early model for the uptake of salmochelin S4 and its 
hydrolysis products proposed by Hantke et al. in 2005.
79
  Ent = 
Enterobactin; DHBS = 2,3-dihydroxybenzoylserine; Glu = glucose.  Taken 
from M., Zhu, M. Valdebenito, G. Winkelmann and K. Hantke, 
Microbiology, 2005, 151, 2363-2372, with permission from the 
Microbiology Society. 
 
Later studies by Fang et al. in 2008 established that on entering the cell 
through IroN, the esterase IroE is not required for the uptake of 
salmochelin S4 1-16, as an entC iroE mutant was able to transport this 
siderophore.
205
  It was determined that salmochelin S4 did not enter the 
cytoplasm through IroC, through the use of an IroC negative strain, but in 
fact was chaperoned by the periplasmic binding protein FepB to pass into 
the cytoplasm via FepCDG, the same ABC transporters utilised by 
enterobactin 1-9 (Figure 44).
205
  Indeed, IroC was in fact found to export 
salmochelin S4 from the cell.
205, 206
  However, whilst the understanding of 
the uptake mechanisms for salmochelin S4 1-16 has developed, the study 
of the salmochelin hydrolysis products, such as the tetradentate 
salmochelin S1 1-17, remains less well investigated. 
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Figure 44 - Simplified schematic representation for salmochelin S4 1-16 
uptake, according to Fang et al.
205
  The updated proposed uptake 
mechanism by Hantke et al. for salmochelin S1 1-17 is also shown.
206
  
Blue circle/half-circle = Siderophore / Green triangle = Glucosyl Moiety / 
Red circle = Fe(III). 
 
The uptake pathways of the hydrolysis products of salmochelin S4, such as 
tetradentate salmochelin S1 1-17, are still hypothetical (Figure 44).
79
  In 
fact, the most recent proposed mechanism, also by Hantke et al. (2009), 
suggests that salmochelin S1 1-17 enters into the periplasm through the 
outer membrane receptors Cir, IroN and FepA (Figure 44),
206
 analogous to 
their first proposed mechanism for salmochelin S1 uptake (Figure 43).
79
  
The only difference is that Hantke et al. instead propose that the remainder 
of salmochelin S1 1-17 uptake proceeds through the Fep system,
206
 
accounting for the mechanism outlined by Fang et al.
205
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With the lack of complete understanding in the uptake mechanisms of the 
salmochelin hydrolysis products, it is important to highlight that 
salmochelin S1 1-17 supports bacterial growth.
79, 205, 206
  Despite the uptake 
mechanism of tetradentate salmochelin S1 1-17 being less well understood, 
it is still expected that 4-3 would allow for the uptake of the conjugate as a 
whole via the Fep system.  Therefore it should be highlighted that the 
design of a tetradentate siderophore in 4-3 allows for a shorter synthetic 
route than if the full tri-serine scaffold of salmochelin S4 1-16 was used.  
Incorporating a hydrolytically stable lysine linker provides a simpler 
synthetic route to the target molecule.  The carboxylic acid group of the 
lysine moiety provides an attachment point for the antimicrobial.  This 
strategy differs from work presented by Nolan et al. where extra 
functionality must be introduced on one catechol moiety to attach the 
antimicrobial directly, demonstrated in conjugates 4-1 and 4-2.
99
 
 
Synthetic design of compound 4-3 
 
In order to establish a synthetic route to compound 4-3, a disconnection 
approach was applied to give the individual components (Figure 45), 
which could then be coupled via sequential amide bond formation.  The 
target compound 4-3 consisted of three key components: a β-ᴅ-
glucosylated dihydroxybenzoic acid 4-4, L-lysine and ciprofloxacin 1-5.  
The synthetic route was envisaged as shown in Scheme 56, discussed in 
greater detail later in the Chapter. 
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Figure 45 - The three key components of conjugate 4-3. 
 
Synthesis of aryl-C-glycosides 
 
As Figure 45 highlights, conjugate 4-3 required an aryl-C-glycoside (4-
4) as the siderophore moiety.  The synthesis of an acetyl-protected form of 
4-4, compound 4-7 has been reported, discussed in detail later.
207, 208
  It 
should however be highlighted that a number of approaches to aryl-C-
glycoside formation are available, including direct C-C cross coupling, 
arylation and alkylation reactions.
209-212
  These approaches typically 
involve an electrophilic anomeric centre with a nucleophilic aryl ring (e.g. 
Scheme 46).  
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Aryl-C-glycoside synthesis via Lewis acid promoters and arylation 
 
The first example of the synthesis of an aryl-C-glycoside was reported by 
Hurd and Bonner in 1945, who employed a Friedel-Crafts reaction using 
aluminium chloride with tetraacetyl-α-D-glucosyl chloride and benzene 
(Scheme 45).
213
  However, the lack of stereo control makes this approach 
unsuitable towards the synthesis of 4-3. 
 
 
Scheme 45 - Friedel-Crafts approach utilised by Hurd and Bonner to form 
an aryl-C-glucoside.
213
 
 
Arylation reactions utilising organometallic aromatics have proven as 
effective methods for the synthesis of aryl-C-glycosides.
209, 211, 214
  
Grignard reagents were first reported for aryl-C-glycoside synthesis by 
Hurd and Bonner in 1945, at the same time as their investigation into the 
Friedel-Crafts approach, producing the same product as in Scheme 45.
215
  
Subsequent studies into stereoselective control saw a change of protecting 
group strategy for the hydroxyl moieties and changes in leaving groups, 
such as that by Junge et al. who produced only the α-anomer (Scheme 
46).
216, 217
  In contrast, others have solely obtained the β-anomer through 
the use of benzyl protecting groups,
218
 or through a combination of using a 
Grignard reagent on a lactone, followed by a hydride reaction with a Lewis 
acid.
219
  Beyond the use of Grignard reagents, numerous studies have 
synthesised aryl-C-glycosides through other organometallic reagents for 
arylation reactions,
209, 211, 214
 including the use of aryllithium reagents,
220, 
221
 and aryl cuprates.
222
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Scheme 46 - Grignard reaction by Junge et al., forming the α-anomer.216 
 
Aryl-C-glycoside synthesis via metal catalysed C-C cross coupling 
 
More recent syntheses of aryl-C-glycoside have involved the use of metal 
catalysts to perform C-C cross coupling reactions.  Such couplings have 
predominantly involved the Heck, Suzuki, Stille and Negishi reactions,
210, 
223-225
 though iron and cobalt catalysts were recently employed for the 
synthesis of α-anomer aryl-C-glycosides.226  In particular, the Heck 
reaction has been used extensively as a means to synthesise C-nucleosides, 
particularly as many natural C-nucleosides are antibiotics.
223, 227
  Based on 
this, Lee and Kool also employed Heck coupling to synthesise novel 
benzopyrimidines to act as analogues of DNA bases (Scheme 47).
228
  
Furthermore, Lee and Kool found the β-anomer was formed exclusively, 
and attributed this to the large tert-butyldiphenylsilyl ether protecting 
group at the 3-position, directing the reaction to occur on the least sterically 
hindered face of the glycal.
228, 229
  This finding supported many other 
similar examples of Heck coupling for aryl-C-glycosides synthesis.
228, 229
  
More recently, Liu et al. were able to selectively produce α-anomer 
products using oxidative Heck coupling of (3R)-glycals with aryl 
hydrazines (Scheme 48).
230
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Scheme 47 - Heck reaction employed by Lee and Kool to synthesise 
analogues of DNA bases.
228
 
 
 
Scheme 48 - Oxidative Heck coupling of glycals and aryl hydrazines by 
Liu et al.
230
 
 
Suzuki and Stille cross coupling reactions for the synthesis of aryl-C-
glycosides typically involve the reaction of an activated glycal with an aryl 
halide.
210, 223-225
  Among examples, Sakamaki recently employed Suzuki 
coupling to react a glycal boronate with aryl bromides, producing 2-
arylglycals (Scheme 49).
231
  In turn, subsequent steps led to the isolation of 
β-anomer aryl-C-glycosides.231  Similarly, Stille cross couplings, using 
stannylated glycals with palladium catalysts and aryl halides have also 
been previously employed for the synthesis of 2-arylglycals.
232, 233
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Scheme 49 - Suzuki cross coupling to give 2-arylglycals as intermediates 
in the synthesis of aryl-C-glycosides.
231
 
 
With the advances in aryl-C-glycoside synthesis to produce stereoselective 
products as either the α- or β- anomer as required, the synthesis of a key 
intermediate of interest in this Chapter (compound 4-7) has been reported, 
involving a Negishi C-C cross coupling reaction.
207, 208
 
 
Aryl-C-glycoside synthesis via Negishi C-C cross-coupling 
 
The Negishi coupling reaction first involved the coupling of an 
organohalide with an alkenylaluminium intermediate to produce C-C bonds 
using a palladium or nickel catalyst.
234
  Developed in 1976, Negishi was 
jointly awarded the 2010 Nobel Prize in Chemistry for this reaction 
(Scheme 50).  Subsequent studies have developed a range of nickel and 
palladium catalysts, as well as the use of other organometallic 
intermediates containing Zn and Zr.
235-237
  There are disadvantages 
however, with organozinc compounds being extremely sensitive to both 
water and oxygen, and also it being difficult to couple large or sterically 
hindered organohalides.
237, 238
 
 
 
Scheme 50 - The first reported Negishi coupling.
234
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There are a two reported examples using Negishi coupling for the synthesis 
of aryl-C-glycosides, with the first being by Ousmer et al. in 2006.
239
  They 
first formed an organozinc glycal, through deprotonation, followed by the 
addition of zinc dichloride.  Following this in situ reaction, the palladium 
catalyst and an iodoarene were added to give the coupled product in 90% 
yield (Scheme 51).
239
  Subsequent steps afforded the acetyl protected aryl-
C-glucoside as the β-anomer.239 
 
 
Scheme 51 - Negishi coupling of a glycal with an iodoarene using a 
palladium catalyst, by Ousmer et al.
239
 
 
Later, Gagné et al. reported a direct Negishi cross-coupling to synthesise 
aryl-β-C-glycosides with high stereoselectivity (20:1 β:α).207, 208  Unlike the 
approach of Ousmer et al., they formed an arylzinc compound (4-6) in situ 
by activating a benzylated-iodoarene (4-5) with zinc, lithium chloride and 
iodine in DMF at 70 °C (Scheme 52).
207, 208
  On adding the organozinc to 
acetobromo-α-D-glucose in the presence of a nickel catalyst, the aryl-C-
glucoside 4-7 was produced in high β-selectivity, due to nucleophilic 
substitution at the anomeric centre (Scheme 52).
207, 208
 
 
Chapter 4 
180 
 
 
Scheme 52 - Direct Negishi cross-coupling reported by Gagné et al. for 
aryl-C-glycoside synthesis.
207, 208
 
 
The choice of the acetyl protecting groups by Gagné et al. can help direct 
stereoselectivity of the product to the β-anomer,207, 208 due to neighbouring 
group participation (Scheme 53).
240
 
 
 
Scheme 53 - Rationalising the high β-selectivity of the Negishi reaction by 
neighbouring group participation of an acetate group.
240
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Gagné et al. also discuss two proposed variants on the mechanism of alkyl-
alkyl Negishi cross-couplings, to hypothesise the role of the nickel catalyst 
in their reaction.
207, 241, 242
  The first, by Vicic et al., proposes a reaction 
between the nickel-ligand complex and the alkyl halide to give an alkyl 
radical and intermediate complex (Scheme 54).
241
  Next, Vicic et al. 
speculated that oxidative radical addition affords a nickel(III)-dialkyl 
species, followed by fast reductive elimination to produce the cross-
coupled dialkyl species and an iodo-nickel complex, which in turn can 
undergo alkylation to restart the catalytic cycle (Scheme 54).
241
 
 
 
Scheme 54 - Proposed Negishi mechanism of alkyl-alkyl couplings by 
Vicic et al.
241
 
 
The second proposed mechanism, by Cárdenas et al., differs from that 
suggested by Vicic et al., proposing abstraction of the halide to leave an 
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alkyl radical (Scheme 55), which in turn can react in a similar manner to 
that already described.
242
  As Gagné et al. highlight, these mechanisms 
differ slightly in how the alkyl radical is produced (single electron transfer 
versus halide abstraction), though they both proceed via a one-electron 
process.
207
 
 
 
Scheme 55 - Proposed Negishi mechanism of alkyl-alkyl couplings by 
Cárdenas et al.
242
 
 
Gagné et al. continue their discussion on the potential mechanism of their 
reaction by highlighting the fact that radicals of their glucosyl unit would 
be subject to the anomeric effect.
207, 243
  In turn they point out that these 
radicals would likely form the α-organometallic intermediate, and by 
extension the α-products, assuming the transmetalation and reductive 
elimination steps remain the same as that by Vicic et al.
241
  As Gagné et al. 
point out, the fact that they obtain high β-selectivity (20:1 β:α) for their 
synthesis of aryl-C-glucosides indicates there is likely another dominating 
effect.
207
  Finally, Gagné et al. discuss the complexity of radical-metal 
addition reactions, suggesting that more sterically encumbered metals, 
resulting from the choice of ligand, choose the β-face of the glucosyl 
radical, thus resulting in the β-anomeric product.207  To help understand 
this, Gagné et al. investigated other carbohydrate moieties to determine the 
scope of their reaction.
207
  In turn they found that on using acetobromo-α-D-
mannose they obtained a ratio of β:α anomers of 1:2.9, whereas with 
acetobromo-α-D-galactoside the ratio of β:α was 10:1.
207
  Interestingly, they 
found that on changing the ligand from 4,4′,4″-tri-tert-butyl-2,2′:6′,2″-
terpyridine (
t
Bu-Terpy) to 2,6-bis(oxazolin-2-yl)-(15)N2-pyridine (PyBox), 
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the stereoselectivity of the mannosyl product increased significantly to 1:20 
β:α.207  Given that neighbouring group participation of the acetyl protecting 
group of a mannosyl moiety would be expected to selectively direct the α-
anomer, the significant difference in stereoselectivity on changing the 
ligand helps suggest that ligand choice is also key. 
 
With the mechanism of the Negishi coupling for aryl-C-glucoside synthesis 
not fully understood, it is nevertheless encouraging that high 
stereoselectivity can be achieved.  More recently, Lemaire et al. built upon 
the work of Gagné et al. by employing arylzinc reagents without the need 
for transition metal catalysts to selectively produce β-anomers in good 
yields.
244
  However, despite the avoidance of using transition metal 
catalysts, the methodology of Lemaire et al. has not been applied with the 
functionality required for compound 4-3.  As Gagné et al. have reported 
the synthesis of a key intermediate (compound 4-7),
207, 208
 required towards 
the synthesis of compound 4-3, it was thus decided to employ their 
methodology. 
 
4.3 Synthesis 
 
The full proposed synthesis of 4-3 is summarised in Scheme 56.  As 
Scheme 56 shows, the linker, the antimicrobial and the glucosylated 
siderophore, would be individually protected and coupled together by 
amide bond formation, before final global deprotection to reveal conjugate 
4-3. 
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Scheme 56 - Summary of the proposed synthesis of 4-3 from three 
commercially available starting materials. 
 
Synthesis of the lysine-linked ciprofloxacin component 4-12 
 
As Scheme 56 demonstrates, the synthesis of conjugate 4-3 involves four 
convergent synthetic routes.  Two of these routes provide access to a 
lysine-linked, benzyl-protected ciprofloxacin component, compound 4-12 
(Scheme 57), which allows for coupling to the siderophore component.  In 
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this case the ciprofloxacin antimicrobial requires protection with a benzyl 
ester, as opposed to the methyl ester utilised in other targets discussed in 
Chapters 2 and 3.  The benzyl ester protecting group was chosen to allow 
for the final global deprotection by palladium catalysed hydrogenolysis to 
yield compound 4-3. 
 
 
Scheme 57 - Synthesis of the lysine-linked, benzyl-protected ciprofloxacin 
component.  (a) NaOH, Boc2O, 1,4-dioxane, 50°C, 89%; (b) Boc2O, 
NaOH, 1,4-dioxane, H2O; (c) BnBr, Cs2CO3, DMF, 51%; (d) TFA, 
CH2Cl2, quantitative; (e) EDC.HCl, HOBt.H2O, DMF, 55%, (f) TFA, 
CH2Cl2, quantitative. 
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tert-Butyloxycarbonyl (Boc) protection of ʟ-lysine 
 
The first step required was protection of the  and  amino groups of 
lysine.
245
  This protection was necessary as the amino groups were required 
to couple later to the glucosylated-catechol moieties.  Given that the 
reaction to attach the lysine linker to the antimicrobial involves amide 
coupling, the amino groups would be free to participate in amide coupling 
if not protected. 
 
ʟ-lysine monohydrochloride was dissolved in water with sodium 
hydroxide, followed by the slow addition of di-tert-butyl dicarbonate 
(Scheme 58), according to a literature procedure.
245
  After work-up, 4-8 
was isolated in 89% yield, with data consistent to the literature.
245
  The 
formation of 4-8 was supported by 
1
H NMR spectroscopic analysis, with 
the appearance of a resonance at 1.44 ppm of relative integration eighteen, 
corresponding to the two Boc groups, evident in the spectra.  Furthermore, 
ESI-MS analysis gave a molecular ion peak [M+H]
+
 for 4-8 at m/z 
347.2117, consistent with a molecular formula of C16H31N2O6. 
 
 
Scheme 58 - Synthesis of 4-8.
245
  (a) NaOH, Boc2O, 1,4-dioxane, 50°C, 
89%. 
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Benzyl ester protection of ciprofloxacin 1-5 to produce 4-10 
 
As previously stated, it was necessary to protect the carboxylic acid of 
ciprofloxacin 1-5 to prevent unwanted side reactions and therefore retain 
the β-keto acid moiety essential for antimicrobial activity.  It was decided 
to protect ciprofloxacin 1-5 with a benzyl ester group to allow for the later 
global deprotection of all the benzyl groups of 4-25 by hydrogenolysis, 
discussed in detail later.  However, in order to protect the carboxylic acid, 
it was first necessary to protect the nucleophilic secondary amine of the 
piperazine moiety.  This amine protection was essential, to prevent reaction 
with benzyl bromide during the following protection of the carboxylic acid.  
If the amine was benzyl protected, selective deprotection would not be 
possible.  As such Boc protection was chosen for the piperazinyl amine as 
it cleaves under orthogonal conditions to the benzyl ester group, allowing 
for selective removal. 
 
Combining the methodologies of Lippur et al. and Miller et al., 
ciprofloxacin 1-5 was first treated with di-tert-butyl dicarbonate and 
sodium hydroxide in a 1:1 1,4-dioxane:water mixture.
126, 246
  The 
intermediate was then treated with benzyl bromide and caesium carbonate 
in DMF.
126, 246
  After work-up and purification by column chromatography, 
compound 4-9 was isolated in 51% yield (Scheme 59), with data consistent 
with the literature.
126, 246
  Formation of 4-9 was supported by singlet 
resonances at 5.40 ppm and 1.50 ppm evident in the 
1
H NMR spectrum, 
corresponding to the methylene and Boc protons respectively.  
Furthermore, ESI-MS analysis gave a molecular ion peak [M+H]
+
 for 4-9 
at m/z 522.2423, consistent with a molecular formula of C29H33FN3O5. 
 
Chapter 4 
188 
 
 
Scheme 59 - Synthesis of compound 4-9.
126, 246
  (a) Boc2O, NaOH, 1,4-
dioxane, H2O; (b) BnBr, Cs2CO3, DMF, 51%. 
 
Compound 4-9 was treated with trifluoroacetic acid in dichloromethane to 
reveal the piperazine ammonium salt (Scheme 60).
126, 246
  On removing the 
solvent, 4-10 was isolated in quantitative yield, supported by the absence of 
the resonance due to the Boc group protons in the 
1
H NMR spectrum, and 
ESI-MS analysis showing a [M+H]
+
 peak at 422.1878, consistent with a 
molecular formula of C24H25FN3O3. 
 
 
Scheme 60 - Synthesis of compound 4-10.
126, 246
  (a) TFA, CH2Cl2, 
quantitative. 
 
Amide coupling of the protected lysine and antimicrobial moieties 
 
Next it was necessary to couple 4-8 and 4-10 via an amide link.  It was 
decided to use the methodology reported by Milner et al. for a structurally 
related molecule.
124
  Therefore 4-8 and 4-10 were mixed with EDC.HCl, 
HOBt.H2O and DIPEA in DMF (Scheme 61).  After work up and 
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purification by column chromatography, compound 4-11 was isolated in 
55% yield.  Formation of 4-11 was supported by the presence of a peak at 
170.8 ppm in the 
13
C NMR spectrum, corresponding to the amide carbonyl, 
and ESI-MS analysis showing a [M+H]
+
 peak at 750.3873, consistent with 
a molecular formula of C40H53FN5O8. 
 
 
Scheme 61 - Synthesis of 4-11.  (a) EDC.HCl, HOBt.H2O, DMF, 55%. 
 
Compound 4-11 was then treated with trifluoroacetic acid in 
dichloromethane to remove the lysine-associated Boc protecting groups 
(Scheme 62).  On removing the solvent, 4-12 was isolated in quantitative 
yield, supported by the loss of the resonances in both the 
1
H and 
13
C NMR 
spectrum for the Boc groups, and also the ESI-MS analysis showing a 
[M+H]
+
 peak at 550.2819, consistent with a molecular formula of 
C30H37FN5O4.  The isolation of 4-12 provided the lysine linked 
antimicrobial component that formed the first key part of target 4-3. 
 
 
Scheme 62 - Synthesis of 4-12.  (a) TFA, CH2Cl2, quantitative. 
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Initial synthetic route targeting the glucosylated salmochelin-inspired 
siderophore component 4-19 
 
The work in this section was completed with the assistance of Ellis Wilde, 
a PhD student.  Ellis worked in collaboration with me to synthesise 
compound 4-15 to target 4-19 for her research. 
 
As highlighted in Scheme 56, a key intermediate in the synthesis of 
conjugate 4-3 required the benzyl-protected glucosylated siderophore 
component 4-19, which has been reported by Gagné et al.
207, 208
  It was 
decided to follow the published method to synthesise this key intermediate. 
The synthesis of 4-19 would allow for its later coupling to 4-12, forming 4-
25 in the synthesis towards compound 4-3, discussed in detail later. 
 
 
Scheme 63 - Synthesis of the Bn-protected glucosylated salmochelin-
inspired siderophore component 4-19 as reported by Gagné et al.
207, 208
  (a) 
MeOH, H2SO4, reflux, 90%; (b) K2CO3, BnBr, MeOH, 32%; (c) NaClO, 
NaOH, NaI, MeOH, 14%; (d) BnBr, NaI, K2CO3, acetone; (e) (i) Zn, LiCl, 
I2, DMF, 70°C, (ii) 
t
Bu-Terpy, Ni(COD)2, DMF, acetobromo-α-D-glucose; 
(f) Na2CO3, MeOH; (g) BnBr, Bu4NI, NaH, DMF; (h) NaOH, THF, 
MeOH. 
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Protection of 2,3-dihydroxybenzoic acid 4-13 by esterification to produce 
4-14 
 
In order to avoid the unwanted formation of a benzyl ester during the 
synthetic step to produce 4-15, it was planned to protect the carboxylic acid 
with a methyl ester.  Commercial 2,3-dihydroxybenzoic acid 4-13 was 
heated under reflux in methanol with sulfuric acid to give the methyl ester 
protected catechol 4-14 in 90% yield (Scheme 64), following the procedure 
by Gagné et al.
207
  Formation of 4-14 was supported by 
1
H NMR 
spectroscopy, with the appearance, in the spectrum, of a singlet resonance 
at 3.96 ppm of relative integration three corresponding to the methyl ester 
group.  ESI-MS analysis also gave a molecular ion peak [M+Na]
+
 for 4-14 
at m/z 191.0313, consistent with a molecular formula of C8H8NaO4. 
 
 
Scheme 64 - Synthesis of 4-14.
207
  (a) MeOH, H2SO4, reflux, 90%. 
 
Mono-benzyl ether protection of 4-14 to produce 4-15 
 
Next it was necessary to selectively protect the hydroxyl group in 3-
position of the catechol ring.  When mixed with one equivalent of benzyl 
bromide, selective protection should occur at the 3-position due to its lower 
pKa value (red - Figure 46).
45, 247
  Despite expecting the lower pKa value to 
be at the 2-position, resulting from increased resonance stabilisation of the 
hydroxyl anion with the ester functionality, the 3-position in fact has the 
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lower pKa value.
247
  A strong intramolecular hydrogen bond formed 
between the ester and the ortho hydroxyl proton is reasoned to stabilise this 
proton, increasing the pKa value for the 2-position (Figure 46).
247
  This 
observation has been supported by other studies investigating the pKa 
values of the hydroxyl protons for both 2,3-dihydroxybenzoic acid and 2,3-
dihydroxybenzaldehyde.
248-250
  In each case, the authors also reason that a 
strong hydrogen bond forms with the hydroxyl proton at the 2-position 
leading to a higher pKa value for this proton in each compound.
248-250
  The 
reason for the selective protection of one catechol moiety to produce 4-15 
is to help direct selective iodination at the C-5 position in the later 
synthesis of 4-16 (Figure 47). 
 
 
Figure 46 - Difference in pKa values for the catechol moieties.
45, 247
 
 
The importance of the free hydroxyl group in 4-15 should be noted.  The 
hydroxyl group is both ortho and para directing on the aryl ring, relative to 
itself, due to its electron donating ability (Figure 47).  Given that each 
ortho position is occupied, the free hydroxyl will therefore direct addition 
exclusively to the position para to itself.  While the benzyl ether also 
directs addition to both the ortho and para position, again due to its 
electron donating ability, it has a weaker effect than the free hydroxyl 
group.  Furthermore, the electron-withdrawing ester group is meta directing 
with respect to addition.  Combining these resonance effects of the free 
hydroxyl and ester groups allows selective electrophilic addition at the C-5 
position required in compound 4-16 (Figure 47). 
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Figure 47 - Simplified illustration of the resonance effects that favour an 
electrophilic addition in position C-5 (red). 
 
The method of Gagné et al. was used.  Compound 4-14 was mixed with 
sodium hydride, followed by the addition of benzyl bromide in a 1:1:1 ratio 
of reagents, under an inert atmosphere (Scheme 65/Run 1 - Table 1).
207, 208
  
However, the crude mixture was difficult to separate, and attempts at 
purification twice by column chromatography gave a mixture of products 
with an apparent yield of 4-15 of ~31%, against residual starting material. 
 
 
Scheme 65 - Synthesis of 4-15 as reported by Gagné et al.
207, 208
  (a) NaH, 
BnBr, THF, ~31%. 
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Run Electrophile Base Anhydrous Solvent Yield of 4-8 (%) 
1 BnBr NaH THF ~31
a
 
2 BnBr NaH THF 10
c 
3
d
 BnCl K2CO3 EtOH <3
b
 
4
d
 BnCl K2CO3 MeOH 27
c 
5
d
 BnBr K2CO3 MeOH 19
c 
6 BnBr K2CO3 MeOH 32
c 
7
d
 BnBr DIPEA MeOH 12
c 
Table 1 - Conditions used for the synthesis of 4-15.  
a
 = Approximate yield 
determined by the relative integration of the product against against 
residual starting material observed in the 
1
H NMR spectrum.  
b
 = 
Approximate yield of the product within in the crude 
1
H NMR spectrum.  
c
 
= Isolated yield.  
d
 = Reaction undertaken by Ellis Wilde. 
 
It was decided to apply more rigorous anhydrous conditions, utilising a 
Schlenk apparatus (Run 2 - Table 1), whilst maintaining a 1:1:1 ratio.  
However, despite the previous run indicating a yield of ~31%, the isolated 
yield was 10% (Scheme 65).  The formation of 4-15 was supported by 
1
H 
NMR spectroscopy, with the appearance of a singlet resonance at 5.19 ppm 
of relative integration two due to the methylene protons of the benzyl 
moiety.  ESI-MS analysis gave a molecular ion peak [M+H]
+
 at m/z 
259.0964, consistent with molecular formula of C15H15O4. 
 
It was clear that a 10% yield was too low to continue with the synthetic 
route to compound 4-19.  As such it was decided to systematically vary the 
reaction conditions and reagents in order to improve the yield of 4-15.  
Variations in the method included the use of potassium carbonate as the 
base, the  change of electrophile to benzyl chloride and the use of ethanol 
as the solvent in a nitrogen-purged vessel (Run 3 - Table 1), conditions 
successfully utilised for the formation of benzyl ethers,
251
 maintaining a 
1:1:1 ratio of reagents.  However, there was clear evidence of a partial 
trans-esterification of the methyl ester to the ethyl ester, and an apparent 
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very low yield of 4-8 of <3% by 
1
H NMR spectroscopy.  The solvent was 
changed to methanol (Run 4 - Table 1), to avoid trans-esterification, 
leading to an improved isolated yield of 27%. 
 
It was decided to return to the use of the more reactive electrophilic benzyl 
bromide, although this reagent is more prone to hydrolysis.  Unfortunately, 
the yield dropped to 19% (Run 5 - Table 1).  Under more rigorously 
anhydrous conditions, utilising a Schlenk apparatus, the yield was 
improved to 32% (Run 6 - Table 1).  The final run saw the use of DIPEA 
as the base, maintaining the 1:1:1 ratio of reagents.  Utilising the Schlenk 
apparatus, the yield was only 12% (Run 7 - Table 1).  It was clear the 
method still required optimisation. 
 
It should be noted that in each attempt, an undesired side product was also 
isolated, indicated by the presence of two methylene groups in the 
1
H NMR 
spectrum at 5.13 and 5.16 ppm, each of relative integration two.  
Furthermore, ESI-MS analysis showed a [M+H]
+
 at 349.1431, consistent 
with a molecular formula of C22H21O5.  This data matches that for a 
dibenzylated product, 4-20.
126
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Electrophilic addition of an iodonium cation to the catechol moiety 
 
Despite the low yields obtained for compound 4-15, it was possible to 
investigate the next step of the synthetic route, the iodination of 4-15 to 
generate 4-16 (Scheme 63).  The conditions used were originally reported 
by Gerdes et al., employing reagents for a disproportionation reaction, and 
were applied by Gagné et al. for the specific target.
207, 208, 252
  The iodinated 
product, 4-16, would provide the required aryl halide for the later Negishi 
coupling. 
 
Compound 4-15 was treated with sodium iodide and sodium hydroxide in 
methanol and the solution cooled to 0 °C, followed by dropwise addition of 
10-15% sodium hypochlorite solution (Scheme 66).  After work-up and 
purification by column chromatography, compound 4-16 was isolated in 
14% yield.  Formation of 4-16 was supported by the loss of an aromatic 
proton in the 
1
H NMR spectrum, as well as ESI-MS analysis indicating a 
[M+H]
+
 at 384.9932, consistent with a molecular formula of C15H14IO4. 
 
 
Scheme 66 - Iodination of 4-15 to produce 4-16.  (a) NaClO, NaOH, NaI, 
MeOH, 14%. 
 
Clearly the yield from the reaction was too low to scale up in the full 
synthetic route, and consequently an alternative procedure had to be 
developed.  Since compound 4-21 is commercially available, attempts were 
made to use it as an alternative starting material.  Initially a number of test 
reactions were performed in order to iodinate 4-21 (Scheme 67).  
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Iodination selectively occurs at the C-5 position for the same reasoning as 
with compound 4-15 (Figure 47). 
 
 
Scheme 67 - The iodination reaction to produce 4-22.  (a) Sources of ‘I+’. 
 
The iodination of 4-21 was first attempted using the conditions described 
by Gagné et al., using 1.5 equivalents of both sodium iodide and sodium 
hydroxide in methanol, followed by the addition of two equivalents of 10-
15% sodium hypochlorite solution.
207, 208
  Formation of 4-22 was supported 
by the loss of an aromatic proton in the 
1
H NMR spectrum, with the 
remaining two protons observed as doublets, each with a J value of 2.1 Hz, 
indicative of a 
4
JH-H split.  In addition, formation of 4-22 was supported by 
a molecular ion peak in the ESI mass spectrum for [M+Na]
+
 at m/z 
330.9426, consistent for a molecular formula of C9H9INaO4.  
Unfortunately, the isolated yield of 4-22 was only 4%, indicating that the 
reaction conditions required further optimisation. 
 
A series of test reactions were designed to determine suitable reaction 
conditions for the iodination of 4-21, all using one equivalent of 4-21 
(Scheme 67/Table 2).  These test reactions included modification of the 
original conditions previously explored, with changes to the relative ratios 
of the reagents (entries 1-4, Table 2).  Conditions were also explored for 
iodination using iodine and potassium hydroxide in methanol (entries 5-7, 
Table 2).
253
  Finally, entry 8 (Table 2) saw the use of triethylamine as a 
base, as a means of avoiding any potential hydrolysis of the ester by the use 
of sodium hydroxide. 
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The test reactions showed a marginal improvement in the conversion, by 
TLC and 
1
H NMR of the crude mixture, of 4-21 to 4-22 for entries 5-8.  
There was no improvement using triethylamine (entry 8 - Table 2) and so 
it was not considered further.  The most promising conditions appeared to 
be for entry 6, yet its isolated yield for 4-22 was only 17%.  It was decided 
not to purify the remaining entries given the potentially very low yields. 
 
Entry 
Reagent 
1 
Equiv. 
Reagent 
1 
Reagent 
2 
Equiv. 
Reagent 
2 
Base 
Equiv. 
Base 
1 NaI 1 NaClO 1 NaOH 1 
2 NaI 2 NaClO 2 NaOH 2 
3 NaI 5 NaClO 5 NaOH 5 
4
a 
NaI 2 NaClO 2 NaOH 2 
5 I2 1 KI 1 NaOH 1 
6 I2 1.5 KI 1.5 NaOH 2 
7 I2 3 KI 3 NaOH 4 
8 I2 1.5 KI 1.5 Et3N 2 
Table 2 - Test reaction conditions for the iodination of 4-21 to produce 4-
22.  All entries used MeOH as the solvent, except entry 4 where 
a
 = DMF. 
 
The use of iodine monochloride, with pyridine and silver nitrate in 
chloroform can result in selective iodination (Scheme 67/Scheme 68).
254
  
When these conditions were applied, 4-22 was isolated in 40% yield.  
Repetition of the reaction saw an improvement in the yield to 68%, with 
spectroscopic data of 4-22 consistent with that described earlier. 
 
With an improvement in the yield for the iodination of 4-21 to produce 4-
22 and the difficulty in obtaining higher yields for the mono-benzyl 
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protection of 4-14 to produce 4-15, it was decided to continue the synthesis 
towards 4-19 via compound 4-22. 
 
Second synthetic route targeting the glucosylated salmochelin-inspired 
siderophore component 4-19 
 
As shown in Scheme 68, the second synthetic route adapts the early steps 
of Scheme 63, with one less synthetic step than that reported by Gagné et 
al.,
207, 208
 giving six synthetic steps rather than seven to obtain 4-19.  
Following the iodination of 4-21 to produce 4-22, described above, it was 
planned to deprotect the methyl ether using boron tribromide to give 4-
23,
255
 followed by benzyl ether protection of the hydroxyl groups to yield 
compound 4-5.  This change in protecting group from the methyl ether to 
benzyl ethers was decided upon to allow for the final deprotection of 4-25 
via global hydrogenolysis, conditions known to be high yielding and 
simple to purify.
140
  Therefore, on producing 4-5, it was planned to 
continue the synthesis as reported by Gagné et al.
207, 208
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Scheme 68 - Newly developed synthetic route to compound 4-5.  The 
remaining synthesis of the glucosylated salmochelin inspired siderophore 
component 4-19 was adapted from Gagné et al.
207, 208
  (a) AgNO3, ICl, 
pyridine, CHCl3, 68%, (b) BBr3, CH2Cl2, (c) MeOH, H2SO4, reflux, 91%, 
(d) BnBr, NaI, K2CO3, DMF, 72%, (e) (i) Zn, LiCl, I2, DMF, 70 °C, (ii) 
t
Bu-Terpy, Ni(COD)2, DMF, acetobromo-α-D-glucose, 63% (f) Na2CO3, 
MeOH, reflux, (g) BnBr, Bu4NI, NaH, DMF, 74% combined (h) NaOH, 
THF, MeOH, 87%. 
 
Methyl ether deprotection utilising boron tribromide 
 
Deprotection of the methoxy group of 4-22 was carried out using boron 
tribromide in dichloromethane,
255
 to produce 4-23 in 13% yield after 
recrystallisation.  Formation of 4-23 was supported by the loss of a singlet 
with relative integration of three at 3.86 ppm in the 
1
H NMR spectrum, 
equating to the loss of the methoxy group.  In addition, a new singlet 
resonance at 5.67 ppm with a relative integration of one was observed, 
corresponding to the new hydroxyl proton.  ESI-MS analysis gave a 
molecular ion peak [M+Na]
+
 at m/z 316.9274, consistent with molecular 
formula of C9H7INaO4.  However, repetition did not allow for an 
improvement in yield from 13% and therefore the crude reaction mixture 
was analysed. 
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After quenching the reaction mixture with water, it was observed that there 
was a mixture of the required product 4-23, and the free carboxylic acid, 
which were difficult to separate.  As a result, the reaction was developed 
into a two-stage process, with the boron tribromide reaction first, followed 
by the immediate re-esterification of the crude mixture using sulfuric acid 
in methanol (Scheme 69).  Following work-up, the yield of 4-23 improved 
to 91%. 
 
 
Scheme 69 - Methyl ether removal and re-esterification to produce 4-23.  
(a) BBr3, CH2Cl2, (b) MeOH, H2SO4, reflux, 91%. 
 
Benzyl ether protection of 4-23 to produce 4-5 
 
The next stage in the synthesis was the protection of the free hydroxyl 
groups of 4-23 to give 4-5 (Scheme 70).  Using benzyl bromide, with 
sodium iodide as a Williamson’s catalyst in DMF, and using potassium 
carbonate as a base, compound 4-5 was isolated in 72% yield after 
purification, with data consistent to the literature.
207, 208
  Formation of 4-5 
was supported by the presence of two singlets at 5.11 and 5.07 ppm in the 
1
H NMR spectrum, both with a relative integration of two, corresponding 
to the methylene protons of the two benzyl groups.  In addition, a multiplet 
corresponding to the benzyl protons was observed between 7.30 and 7.46 
ppm.  The formation of 4-5 was also supported by the observation of a 
molecular ion peak at [M+Na]
+
 at m/z 497.0230 in the ESI mass spectrum, 
consistent with a molecular formula of C22H19INaO4. 
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Scheme 70 - Synthesis of 4-5.  (a) BnBr, NaI, K2CO3, DMF, 72%. 
 
Negishi coupling of acetobromo-α-D-glucose and 4-5 to produce the C-aryl 
glucoside 4-7 
 
On isolating 4-5, Negishi coupling with acetobromo-α-D-glucose to 
produce 4-7 was explored (Scheme 68 and Scheme 71).  Given the success 
of Gagné’s approach, their conditions were applied in an attempt to 
synthesise 4-7.
207, 208
  In a glove box, zinc and lithium chloride were mixed 
together and then dried further in vacuo on a Schlenk line.  To this, a 
solution of iodine and 4-5 in DMF were added, and then heated overnight 
at 70 °C, to produce 4-6 (Scheme 71).  Separately in the glove box, 
4,4’,4”-tert-butyl-2,2’:6’,2”-terpyridine and bis(1,5-
cyclooctadiene)nickel(0) were mixed together in DMF to activate the 
nickel catalyst, giving a deep blue colour, followed by the addition of 
acetobromo-α-D-glucose.  Once outside of the glove box, the solution of 4-
6 was added to the catalyst mixture.  However, on purification by column 
chromatography no product was isolated.  It was found that the products 
formed were the reduced arene 4-20, and the aldehyde 4-24, possibly as a 
result of reaction with the DMF solvent.  Formation of the reduced arene 
product 4-20 was supported by the gain of an aromatic proton in the 
1
H 
NMR spectrum, as well as the loss of the clear 
4
JH-H coupling between the 
two protons either side of the original iodide.  In the case of the aldehyde 
4-24, a 2.0 Hz 
4
JH-H coupling between the two protons either side of the 
aldehyde group was present, as well as a singlet resonance peak at 9.92 
ppm of relative integration one, characteristic of an aldehyde proton.  A 
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new peak at 190.4 ppm was present in the 
13
C NMR spectrum, 
characteristic of an aldehyde carbonyl. 
 
 
 
For the next attempt it was decided to modify the reaction by reducing the 
time activating 4-5 to produce 4-6.  Activation was carried out for one 
hour, followed by addition to the catalyst mixture.  After purification the 
aryl-C-glucoside 4-7 was isolated in 50% yield, with the side products of 4-
20 and 4-24 isolated as minor impurities.  Repetition saw the yield of 4-7 
improve to 63%, a moderate improvement on the reported literature yield 
of 56%.
207
  The formation of 4-7 was supported by ESI-MS analysis, with a 
[M+Na]
+
 peak at 701.2195, consistent with a molecular formula of 
C36H38NaO13.  The data was consistent with that reported in the 
literature.
207
 
 
 
Scheme 71 - Negishi coupling reaction of 4-5 to produce 4-7, first reported 
by Gagné et al.
207
  (a) (i) Zn, LiCl, I2, DMF, 70°C, (ii) 
t
Bu-Terpy, 
Ni(COD)2, DMF, acetobromo-α-D-glucose, 63%. 
 
It was also necessary to confirm the β-stereoselectivity in 4-12.  This could 
be achieved by analysis of the signal for the anomeric proton at 4.39 ppm 
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in the 
1
H NMR spectrum.  Typically, 
3
JH-H coupling constants between 
diaxial protons in a β-configuration have values of 7-9 Hz, whereas 
coupling between equatorial-axial protons in the α-anomer have coupling 
constant values of 2-4 Hz.
256
  In compound 4-12, the coupling constant for 
the anomeric proton was 10.1 Hz, thereby confirming that the isolated 
product was the β-anomer, with no α-anomer isolated or observed. 
 
Protecting group manipulation – deacetylation and subsequent benzylation 
of the glucosyl hydroxyl groups 
 
The next stage of the synthetic route required protecting group 
manipulation on the glucosyl moiety of 4-7.  While necessary for aiding β-
selectivity for the Negishi reaction (Scheme 53), the acetate protecting 
group is base labile,
140
 and would cleave under the hydrolysis conditions 
used to deprotect the ester to produce the carboxylic acid.  As such, the 
change in protecting groups first required the removal of the acetate groups 
then formation of benzyl ethers to give 4-17 (Scheme 72).
207, 208
 
 
The methodology reported by Gagné et al. was followed, first treating 4-7 
with sodium carbonate in methanol.
207, 208
  Once the acetate groups were 
removed, as determined by TLC analysis, the filtered mixture was 
concentrated in vacuo.  The residue was dissolved in DMF, and 
subsequently added to sodium hydride in DMF.  A solution of benzyl 
bromide and tetrabutylammonium iodide in DMF was added (Scheme 72).  
After work-up and purification by column chromatography compounds 4-
17 and 4-18 were isolated with a combined yield of 40%.  The formation of 
4-17 was supported by the presence of multiple methylene groups in both 
the 
1
H and 
13
C NMR spectra.  ESI-MS analysis showing a [M+Na]
+
 peak at 
893.3676 consistent with a molecular formula of C56H54NaO9.  This data 
was consistent with the literature.
207
  In addition, successful formation of 4-
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18 was supported by the ESI spectrum showing a [M+Na]
+
 peak at 
969.3977 for a molecule of formula C62H58NaO9. 
 
The yield of 40% was lower than required, and lower than those of the 
combined 73% of 4-17 and 4-18 reported by Gagné et al.
207, 208
  It was 
found that the first stage acetate deprotection of 4-7 proceeded poorly, with 
4-7 being sparingly soluble in methanol.  This was overcome by heating 
the reaction mixture under reflux, increasing the solubility of the starting 
material.  It was also found that the de-protected intermediate was 
sparingly soluble in DMF, and therefore transfer of the residue to the 
sodium hydride solution was problematic.  The sodium hydride reagent 
was added directly to the intermediate and the molar ratio of sodium 
hydride and benzyl bromide were both increased.  This was to ensure the 
complete deprotonation of the free hydroxyl moieties, and that there was 
sufficient benzyl bromide available.  With these modifications the yield 
was improved to a combined 74%. 
 
 
Scheme 72 - Protecting group manipulation to produce 4-17 and 4-18.
207
  
(a) Na2CO3, MeOH, reflux, (b) BnBr, Bu4NI, NaH, DMF, 74% combined. 
 
Ester hydrolysis to produce compound 4-15 
 
The isolation of both esters 4-17 and 4-18 allowed for the completion of 
the synthesis of the glucosylated catechol intermediate 4-19.  A mixture of 
4-17 and 4-18 was dissolved in tetrahydrofuran and methanol (3:1), and 
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then treated with sodium hydroxide (Scheme 73).  After work up and 
purification by column chromatography, compound 4-15 was isolated in 
87% yield.  Formation of 4-19 was supported by ESI-MS analysis, with a 
[M+Na]
+
 peak observed at 879.3516, consistent with a molecule of formula 
C55H52NaO9, matching the data reported in the literature.
207
  The NMR 
assignment of 4-19 is discussed in greater detail in Chapter 5. 
 
 
Scheme 73 - Ester hydrolysis to furnish 4-19.
207
  (a) NaOH, THF, MeOH, 
87%. 
 
The isolation of 4-19 represented an important milestone in the synthesis, 
since it allowed for the continuation of the synthesis towards 4-3.  The 
overall yield of 4-19 was increased to 18%, compared to that reported by 
Gagné et al. of 11%,
207, 208
 and the number of synthetic steps was reduced 
by one in the overall process. 
 
Completion of the synthesis of compound 4-3 
 
With the isolation of 4-19 it was possible to continue the synthesis towards 
4-3, by coupling 4-19 with 4-12 to furnish 4-25, followed by global 
hydrogenolysis to give the target compound 4-3 (Scheme 74). 
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Scheme 74 - Coupling of 4-12 and 4-19 to furnish the benzyl protected 
conjugate 4-25, followed by hydrogenolysis to yield the target conjugate 4-
3.  (a) coupling reagent, (b) Pd catalyst, H2. 
 
Coupling of 4-12 and 4-19 to give the fully benzylated conjugate 4-25 
 
The first step towards the synthesis of 4-3 was an amide coupling reaction 
between 4-12 and 4-19 to produce the fully benzylated conjugate 4-25.  
During the synthesis of the salmochelins, Gagné et al. utilised thionyl 
chloride to form the acid chloride with catalytic DMF, before the addition 
of the amine to form the amide bond.
207, 208
  These conditions were trialled, 
with 4-19 treated with thionyl chloride and DMF in dichloromethane for 3 
hours.  After isolating the acid chloride, by removing the solvent in vacuo 
on a Schlenk line, a solution of 4-12 in dichloromethane and triethylamine 
was added and the mixture stirred for 19 hours.  Purification by column 
chromatography gave compound 4-25 in 19% yield.  However, replication 
of these conditions proved problematic with low yields, and in some cases, 
as evidenced in the 
1
H NMR spectrum, partial cleavage of benzyl 
protecting groups.  This de-benzylation may have resulted from the acidic 
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conditions generated by the formation of hydrogen chloride as a by-product 
in the acid chloride formation. 
 
Therefore, other amide coupling conditions were explored.  The coupling 
reagent HATU was used due to its wide application in challenging 
coupling reactions.
257
  Compound 4-19 and HATU were dissolved in 
dichloromethane with DIPEA, before the addition of 4-12 in 
dichloromethane and DIPEA.  Despite the use of column chromatography, 
giving compound 4-25 in 35% yield, there was still unreacted HATU 
present, with the observation of the PF6
-
 counter ion in the 
19
F NMR 
spectrum, with a doublet resonance at -73.3 ppm, and a 
1
JF-P coupling 
constant of 712.4 Hz.  Whilst it was possible to remove the unreacted 
HATU via further purification, it was decided to find an alternative 
coupling reagent to avoid this impurity. 
 
A coupling reaction was carried out between 4-12 and 4-19 using 
EDC.HCl, HOBt.H2O and DIPEA in dichloromethane (Scheme 75).  After 
work up and purification by column chromatography, compound 4-25 was 
isolated in 42% yield.  The formation of 4-25 was supported by ESI-MS 
analysis, with a molecular ion peak for [M+Na]
+
 at m/z 2249.9665, 
consistent with a molecular formula of C140H137FN5NaO20. 
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Scheme 75 - Synthesis of 4-25.  (a) EDC.HCl, HOBt.H2O, DIPEA, 
CH2Cl2, 42%. 
 
Furthermore, the 
13
C NMR spectrum supported the isolation of 4-25, with 
characteristic carbonyl resonances observed at 164.5 and 164.7 ppm, 
corresponding to the two amides between the lysine and catechol moieties.  
A more detailed NMR assignment of 4-25 is discussed in Chapter 5.  With 
the amide coupling reaction indicating that 4-25 was produced, the next 
synthetic step was to proceed to 4-3 by hydrogenolysis. 
 
Hydrogenolysis of 4-25 to give the target conjugate 4-3 
 
The final stage in the synthesis of 4-3 was to remove the benzyl ether 
protecting groups on 4-25 by global hydrogenolysis using a palladium 
catalyst (Scheme 74). 
 
It had previously been demonstrated that ciprofloxacin 1-5 containing 
compounds gave low yields and poor mass recovery when deprotected by 
hydrogenolysis using palladium on charcoal.
258
  It was suggested that the 
poor mass recovery was due to adsorption of either the product or starting 
material on the catalyst surface.
258
  Indeed activated carbon has been 
shown to adsorb ciprofloxacin 1-5.
259
  Therefore, compound 4-25 was 
dissolved in toluene and ethanol and a catalytic amount of palladium black 
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was added.  The resultant suspension was stirred under H2 at 34 atm.  
However, despite adding more catalyst and leaving the reaction over a 
number of days, the deprotection failed to proceed to completion.  There 
was evidence of partial deprotection in the 
1
H NMR spectrum of the crude 
product, yet the spectrum proved complex.  An alternative catalyst Pd/C 
was used with 4-25 in toluene and ethanol, despite the risk that product 
adsorption to the charcoal support may reduce the yield of the product.  
These conditions were also not successful in completing the 
hydrogenolysis of 4-25. 
 
Other palladium catalysts were considered.  It has been suggested that 
Pearlman’s catalyst, Pd(OH)2/C is particularly effective for the removal for 
sterically inaccessible and/or multiple benzyl ethers.
240
  Therefore 
unsupported Pd(OH)2 was used with compound 4-25 in DMF under H2, 
again resulting in an inconclusive and complex crude mixture, as indicated 
by the 
1
H NMR spectrum. 
 
Finally, 20% wt. Pd(OH)2/C with 4-25 in a 1:1 mixture of methanol:ethyl 
acetate resulted in the successful isolation of 4-3 in a crude yield of 80%, 
with no obvious indication of significant product retention by the charcoal 
support.  After purification by reverse-phase preparative HPLC (Figure 
48), compound 4-3 was isolated in 45% yield (Scheme 76).  The isolation 
of 4-3 was supported by the presence of seven aromatic protons in the 
1
H 
NMR spectrum, with the loss of the benzyl protecting groups within the 
aromatic region and also the loss of the methylene signals between 4.50-
5.50 ppm.  Furthermore, ESI-MS analysis showed a [M-H]
-
 peak at 
1054.3556, consistent with a molecular formula of C49H57FN5O20. 
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Figure 48 - HPLC trace of 4-3 product at 285 nm after preparative HPLC 
purification.  Conditions: Analytical HPLC Method C (Chapter 7). 
 
 
Scheme 76 - Hydrogenolysis to produce target 4-3.  (a) Pd(OH)2/C (20% 
wt.), H2, 1:1 MeOH:EtOAc, 45%. 
 
One possible rationale for why Pd(OH)2 failed yet Pd(OH)2/C succeeded 
could be based on the function of the charcoal support.  A number of 
investigations have demonstrated that sugar moieties coordinate palladium 
nanoparticles.
260-265
  Indeed, Sarkar et al. established that palladium(II) 
nanoparticles stabilised by glucose exhibited enhanced ferromagnetic 
properties under exposure to hydrogen.
265
  Given the complex nature of the 
1
H NMR spectra obtained during the unsuccessful attempts at 
hydrogenolysis using unsupported Pd(OH)2, potential reasoning could be 
that the charcoal support is required to prevent the glucosyl moieties of the 
deprotected conjugate from coordinating to palladium.  This explanation 
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could possibly be extended further to the failure in palladium black to 
complete the hydrogenolysis of 4-25, though steric factors may also be a 
reason for incomplete removal of the benzyl groups. 
 
In summary, 4-3 was synthesised, with key intermediates 4-10 and 4-19, 
which can be used for future salmochelin-inspired Trojan horse conjugates, 
also produced.  The finding that Pearlman’s catalyst, Pd(OH)2/C, can be 
utilised for complete global deprotection of the benzyl protecting groups on 
both the glucosyl and antimicrobial moieties allows for the conditions to be 
applied to future target compounds.  The isolation of compound 4-3 
allowed for an investigation into its antimicrobial activity. 
 
4.4 Antimicrobial Testing of the Salmochelin Inspired 
Siderophore-Ciprofloxacin Conjugate 4-3 
 
Growth Assay 
 
The antimicrobial activity of 4-3 was assessed against E. coli BW25113 
wild type in two media, LB nutrient and M9 minimal, mirroring the 
conditions used in Chapter 2.  The OD650 values were also taken every 30 
minutes over 16 hours on a plate reader at drug concentrations of 0.01 µM, 
0.1 µM, 0.5 µM, 1 µM and 10 µM, with a negative control of 0 µM 
(DMSO).  As in Chapter 2, the data presented here is at the time point at 10 
hours, where bacterial growth has plateaux (Figure 49 - Figure 51 - see 
Appendix III for individual graphs). 
 
Unfortunately, the growth assay in iron-rich LB media indicates that 
conjugate 4-3 has no activity against wild type E. coli across all of the 
concentrations tested, with no suppression of growth observed (Figure 49).  
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However, suppression of wild type E. coli growth was observed for 
conjugate 4-3 in iron-poor M9 minimal media, even at the lowest drug 
concentration of 0.01 µM (Figure 50).  The disparity between the bacterial 
growth in these two media can potentially be explained by the different 
availabilities of iron in these media.  Under the iron rich conditions 
provided by the LB media, it may be that the outer membrane receptors 
required for the transport of conjugate 4-3 were not expressed, with outer 
membrane receptors generally not present when sufficient nutrient iron is 
available.
266
  In turn, under the iron deficient conditions in M9 minimal 
media, the expression of outer membrane receptors, such as IroN, may 
have allowed for the uptake of conjugate 4-3, increasing the intracellular 
concentration of the drug resulting in antimicrobial activity and therefore 
reduced bacterial growth (Figure 50). 
 
 
Figure 49 - E. coli BW25113WT growth in LB media across 
concentrations at t = 10 h for both ciprofloxacin 1-5 (blue) and conjugate 4-
3 (red).  The experiment was run in quadruplicate and the error bars show 
one standard deviation from the mean. 
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Figure 50 - E. coli BW25113WT growth in M9 minimal media across 
concentrations at t = 10 h for both ciprofloxacin 1-5 (blue) and conjugate 4-
3 (red).  The experiment was run in quadruplicate and the error bars show 
one standard deviation from the mean. 
 
To test this hypothesis, a growth assay was performed in M9 media, with a 
controlled Fe(III) concentration.  The addition of iron, using ferric chloride 
at a concentration of 0.2 µM, would provide nutrient iron for bacterial 
growth, which could in turn reduce expression of the outer membrane 
receptors required for the transport of conjugate 4-3.  As can be seen in 
Figure 51, the addition of iron resulted in no reduction in wild type E. coli 
growth across any of the concentrations, analogous to the results seen in 
LB media (Figure 49).  Indeed the addition of iron to M9 media negated 
the reduction in growth observed when there was no added iron in M9 
minimal media (Figure 50).  Based on the lack of activity observed for 
conjugate 4-3 in iron sufficient media, it can again be suggested that under 
such conditions the uptake of 4-3 is reduced or nullified, resulting in the 
observed bacterial growth across all concentrations (Figure 49 and Figure 
51).  However, as mentioned previously in Chapter 2, M9 minimal media 
best resembles the in vivo conditions of a host, where iron concentrations 
are very low.  In turn, the lack of bacterial growth observed in M9 minimal 
media (Figure 50) could again suggest that there is active uptake of 
conjugate 4-3. 
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Figure 51 - E. coli BW25113WT growth in 0.2 µM [Fe(III)] M9 media, 
across concentrations at t = 10 h for both ciprofloxacin 1-5 (blue) and 
conjugate 4-3 (red).  The experiment was run in quadruplicate and the error 
bars show one standard deviation from the mean. 
 
However, it should be noted that these growth assays do not determine 
whether the lack of conjugate activity for 4-3 in iron-sufficient media 
results from an inability of 4-3 to utilise the active transport mechanisms 
into the cell, especially as the conjugate would have to pass through both 
the outer and cytoplasmic membranes to reach the gyrase target.  The 
reduction in bacterial growth observed in M9 minimal media could suggest 
that conjugate 4-3 is utilising the active transport mechanisms, though this 
is not conclusive.  If the conjugate does not enter the cell via active 
transport, the reduction of bacterial growth observed in M9 minimal media 
could be hypothesised to result from the extracellular binding of any 
residual iron in the media by the siderophore moiety of the conjugate, 
preventing the ability of bacteria to sequester this crucial nutrient.  Indeed, 
Nolan et al. found that whilst conjugate 4-2 demonstrated no antibacterial 
activity against E. coli strains which did not express IroN (discussed 
earlier), it was able to reduce bacterial growth of these strains at a 
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concentration of 10 µM.
99
  They reasoned that this reduction in bacterial 
growth resulted from 4-2 sequestering iron in the medium, causing iron 
deprivation for the bacterial cells.
99
  This hypothesis is however difficult to 
confirm without further study, especially as it is known that wild type E. 
coli produces enterobactin,
267
 the tightest iron binding siderophore known, 
which would likely compete with the siderophore moiety of conjugate 4-3. 
 
In addition, it was important to determine if the conjugate is able to inhibit 
the drug target DNA gyrase.  It could be argued that if conjugate 4-3 is not 
actively transported into the cell, then the lack of activity observed in iron 
rich media could be as a result of disrupted binding of the ciprofloxacin 
moiety in the gyrase target site, due to steric hindrance of the siderophore 
moiety. 
 
DNA Gyrase Assay 
 
With one suggested hypothesis that the siderophore moiety is disrupting 
binding at the DNA gyrase site, it was important to determine if the 
ciprofloxacin moiety of conjugate 4-3 inhibits the supercoiling of DNA 
gyrase (Chapter 1), by performing a DNA gyrase assay. 
 
Using the same method as described in Chapter 2, it is apparent that 
conjugate 4-3 demonstrates no inhibition at concentrations up to 20 µM, 
(Figure 52).  It can therefore be argued that the siderophore moiety could 
prevent the antimicrobial from binding within the active site of DNA 
gyrase, due to steric hindrance.  This would agree with similar findings of 
siderophore hindrance of DNA gyrase binding for other siderophore-
fluoroquinolone conjugates.
121, 124, 128
  However, as discussed earlier in 
Chapter 2, the DNA gyrase assay directly delivers the compound to the 
gyrase target in vitro, and so only gives a suggestion of conjugate 
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effectiveness.  As the in vivo growth assays potentially involve the active 
transport of conjugate 4-3, it could be explained that the reduction in 
growth observed in M9 minimal media results from the increase in 
intracellular concentration of the drug, especially as expression of the 
uptake proteins would be increased under iron limited conditions.
266
  The 
apparent activity observed at 0.01 µM in the M9 minimal media growth 
assay (Figure 50) is however in contrast to the lack of activity observed up 
to 20 µM in the DNA gyrase assay (Figure 52). 
 
 
Figure 52 - DNA gyrase assay of A) ciprofloxacin 1-5 and B) conjugate 4-
3 at concentrations ranging from 20-0 µM.  0 µM = DMSO control.  + = 
positive control, with DNA gyrase present without the antimicrobial.  - = 
negative control, no DNA gyrase or antimicrobial. 
 
Despite the lack of DNA gyrase inhibition at concentrations up to 20 µM, it 
was prudent to determine if conjugate 4-3 retains any activity at higher 
concentrations.  Thus another DNA gyrase assay was performed with 
concentrations up to 100 µM.  As can be seen, the assay indicates that 
conjugate 4-3 does have inhibitory activity at these higher concentrations 
(Figure 53).  The assay suggests that conjugate 4-3 has a MIC value of 
between 20 and 30 µM, with the observation of a portion of relaxed DNA 
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gyrase at 30 µM (Figure 53).  However, complete inhibition is not 
observed until 75 µM, and thus the concentration required for 100% 
inhibition is between 50-75 µM (Figure 53).  With the ability to bind DNA 
gyrase being key for the antimicrobial activity, it is clear that while 
conjugate 4-3 demonstrates some inhibitory activity, it is much lower than 
the free ciprofloxacin 1-5 drug. 
 
 
Figure 53 - DNA gyrase assay of conjugate 4-3 at concentrations ranging 
from 100-20 µM.  + = positive control, with DNA gyrase present without 
the antimicrobial.  - = negative control, no DNA gyrase or antimicrobial. 
 
The disparity between the DNA gyrase assays and the bacterial growth 
assays should be highlighted.  The immediate reduction in bacterial growth 
in M9 media at 0.01 µM (Figure 50) could be due to the active uptake of 
4-3, as discussed.  However, as Figure 50 also shows, there is no further 
reduction in bacterial growth as the concentration of 4-3 is increased.  This 
could in turn suggest that the siderophore disrupts binding of the 
antimicrobial target site after uptake.  On the other hand, the conjugate may 
not be actively transported at all, or it could be that the concentration of 
iron was so low that it was a growth limiting factor in the uptake of the 
conjugate beyond 0.01 µM.  In this case adding higher concentrations of 
the conjugate would not lead to an increase in uptake, leading to the 
activity of the conjugate levelling off.  To support this, it would be suitable 
to determine the concentration of Fe(III) within M9 minimal media.  It 
could also be that the reduction in growth results from extracellular iron 
scavenging by the siderophore moiety of the conjugate, preventing the 
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sequestering of iron by the bacterial cells.  This would be similar to 
findings suggested by Nolan et al.
99
  As such, this could explain the 
reduction in antimicrobial activity observed for conjugate 4-3 in both LB 
and iron added media (Figure 49/Figure 51), as well as the DNA gyrase 
binding assays (Figure 52/Figure 53), compared to free ciprofloxacin 1-5.  
However, more data is required to confirm this, including iron binding and 
uptake studies to determine the iron binding ability and uptake pathway of 
the conjugate. 
 
4.5 Summary, conclusions and future work 
 
The target compound 4-3, a conjugate inspired by the salmochelin class of 
siderophores, was synthesised and characterised.  In turn, the synthesis 
involved the isolation of a number of key intermediates, including 
compounds 4-10 and 4-19, which can be used for future salmochelin-
inspired conjugates.  In addition, the NMR characterisation of these 
glucosylated compounds, discussed in detail in Chapter 5, allows for the 
understanding of the complexity of the NMR spectra to aid in the 
assignment of future glucosylated Trojan horse conjugates. 
 
The activity of 4-3 is lower than that of the parent drug, as determined by 
the DNA gyrase assay.  Furthermore, the gyrase assay indicates that the 
siderophore moiety disrupts conjugate 4-3 from binding at the target site, 
and so it is clear that the development of bio-labile linkers, targeted in 
Chapters 2 and 3, is important for the future development of salmochelin-
inspired siderophore-fluoroquinolone conjugates.  However, the synthesis 
of conjugate 4-3 was necessary as it can allow for comparison against 
future salmochelin-inspired siderophore-fluoroquinolone conjugates which 
would be designed to incorporate a bio-labile linker. 
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It is important to understand the function of the siderophore moiety further, 
and so studies must be conducted to investigate the iron uptake pathway of 
the conjugate, as well as iron binding studies to determine how well the 
siderophore moiety captures iron.  In turn, the iron binding studies would 
help determine if the siderophore moiety of conjugate 4-3 is a factor in 
causing the reduction of wild type E. coli growth in M9 minimal media, by 
determining if the siderophore moiety can compete with the siderophores 
secreted by the bacteria itself.  In addition, determination of transport 
protein expression for the salmochelins would be essential in establishing if 
conjugate 4-3 was actively transported.  Finally, screening of conjugate 4-3 
against siderocalin would determine if the glucosyl moieties prevent 
binding to the mammalian response protein, so allowing a greater 
understanding of the potential of salmochelin-inspired Trojan horse 
conjugates. 
 
  
Chapter 5: NMR 
characterisation of 
compounds 4-19 and 4-25 
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5.1 Introduction 
 
The complexity of the NMR spectra for the glucosylated compounds 
discussed in Chapter 4 needs to be considered.  The resonances from the 
spectra obtained for compounds 4-17 and 4-19 generally match the 
characterisation data reported by Gagné et al.
207
  However, there are a 
number of resonances reported which did not agree with those obtained 
within the present work.  For example, Gagné et al. report two singlets for 
two methylene CH2 groups,
207
 which in the present work appeared as two 
pairs of doublets, indicating diastereotopic protons.  Additionally, a 
number of other resonances did not match those reported, highlighted 
within this Chapter.  Furthermore, Gagné et al. do not provide an 
assignment for compounds 4-17 or 4-19, listing only the relevant 
resonances obtained for both the 
1
H and 
13
C spectra.  Whilst the provided 
data allowed for confirmation that the compounds were isolated in the 
present work, the assignment of these compounds was necessary to provide 
understanding towards the assignment of other glucosylated compounds.  
The assignments of the NMR resonances of these two glucosylated 
compounds, and those for 4-18 (for which Gagné et al. do not report any 
characterisation data), were therefore made using a combination of HMQC, 
HMBC and COSY NMR spectra to support the 
1
H and 
13
C NMR spectra. 
 
In addition, two novel compounds reported in this thesis, 4-25 and 4-3, also 
require characterisation by NMR.  This Chapter discusses the NMR 
characterisation of compound 4-19, to clarify the reported NMR data by 
Gagné et al.,
207
 as well as to provide a basis of understanding towards the 
NMR assignment of 4-25, also discussed within this Chapter. 
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5.2 NMR characterisation of Compound 4-19 
 
The successful formation of compound 4-19 was supported by NMR 
spectroscopy (700 MHz spectrometer).  Assignments were made using a 
combination of Heteronuclear Multiple-Quantum Correlation (HMQC), 
Heteronuclear Multiple-Bond Correlation (HMBC) and Correlation 
Spectroscopy (COSY) two-dimensional NMR experiments to confirm 
proton and carbon environments in the respective one-dimensional 
1
H and 
13
C NMR spectra.  For easier visualisation of 4-19 a pullout is provided at 
the back of this thesis as a reference.  Furthermore, the full 
1
H, 
13
C, 
HMQC, HMBC, COSY and DEPT spectra of compound 4-19 can be found 
in Appendix IV - Figures 139-144. 
 
Assignment of the glucosyl moiety of 4-19 
 
At the start of the assignment process of compound 4-19 it was observed 
that the anomeric proton, H18 (Figure 54), was within the expected region 
of the 
1
H NMR spectrum,
256
 with a doublet at 4.24 ppm (Figure 55).  
Furthermore, the anomeric proton (H-18) demonstrated a coupling constant 
of 9.3 Hz, which is typical of a 
3
JH-H coupling between two diaxial protons 
for the β-configuration of a carbohydrate moiety.256  On investigating the 
COSY spectrum (Figure 56), the doublet at 4.24 ppm (H-18) was observed 
to couple with a pseudo triplet at 3.43 ppm, also with a coupling constant 
of 9.3 Hz.  In turn, this pseudo triplet at 3.43 ppm was assigned as H-19, 
with the coupling constant of this resonance confirming the 
stereochemistry of the β-configuration. 
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Figure 54 - Full structure of compound 4-19. 
 
 
Figure 55 - 
1
H NMR spectrum (CDCl3) of 4-19. 
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Figure 56 - COSY spectrum (CDCl3) of 4-19. 
 
From the pseudo triplet at 3.43 ppm, the COSY spectrum allowed the 
assignments of the remaining glucosyl protons (Figure 56), summarised in 
Table 3.  It should be noted that three of these protons appear as pseudo 
triplets, and there is also some overlap between resonances, demonstrated 
in both Figure 55 and Figure 56.  The doublet of triplets for H-22 at 3.63 
ppm was expected, due to its coupling with two unique proton 
environments, H-21 (pseudo triplet at 3.74 ppm) and H-23 (doublet at 3.76 
ppm).  In turn, the assignment of H-22 confirms the previous assignments 
of the glucosyl protons, given the coupling observed between all the proton 
environments in the COSY spectrum (Figure 56/Table 3). 
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Assignment 
1
H 
Resonance 
(ppm) 
Multiplicity COSY Coupled 
1
H Resonance 
(ppm) 
Reported 
1
H 
Resonance by 
Gagné et al.
207
 
(ppm) 
18 4.24 d 3.43 (H-19) 4.25 (d) 
19 3.43 Pseudo t 3.82 (H-20)/4.24 
(H-18) 
3.44 (t) 
20 3.82 Pseudo t 3.43 (H-19)/3.74 
(H-21) 
3.70-3.86 (m) 
21 3.74 Pseudo t 3.63 (H-22)/3.82 
(H-20) 
3.70-3.86 (m) 
22 3.63 dt 3.74 (H-21)/3.76 
(H-23) 
3.51 (m) 
23 3.76 Overlap d 3.63 (H-22) 3.70-3.86 (m) 
Table 3 - 
1
H assignments of the glucosyl moiety 4-19 based on COSY 
coupling in Figure 56. 
 
Next the HMQC NMR spectrum was investigated to correlate the proton 
environments on the glucosyl moiety with their respective carbon 
environments (Figure 57).  The carbon environments of the glucosyl 
moiety are assigned as shown in Table 4. 
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Figure 57 - HMQC spectrum (CDCl3) of 4-19. 
 
Assignment 
1
H Resonance 
(ppm) 
HMQC Coupled 
13
C 
Resonance (ppm) 
18 4.24 80.5 
19 3.43 83.6 
20 3.82 86.7 
21 3.74 78.2 
22 3.63 79.3 
23 3.76 69.0 
Table 4 - 
1
H and 
13
C assignment of the glucosyl moiety of 4-19 based on 
HMQC coupling in Figure 57. 
 
To determine the proton and carbon environments of the benzyl protecting 
groups on the glucosyl moiety, the HMBC spectrum was examined.  From 
the HMBC spectrum, coupling is observed between the pseudo triplet at 
3.43 ppm (H-19) with three resonances in the 
13
C NMR spectrum; 74.9, 
80.5 and 86.3 ppm (Figure 58).  With the resonances at 80.5 and 86.7 ppm 
previously assigned as C-18 and C-20, respectively, it can be therefore 
reasoned that the resonance at 74.9 ppm corresponds to the methylene CH2 
group of C24, supported by a negative signal in the DEPT spectrum. 
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Figure 58 - HMBC spectrum (CDCl3) of 4-19. 
 
Based on this assignment for C-24, the HMQC spectrum showed coupling 
between the resonance at 74.9 ppm in the 
13
C spectrum and two doublets in 
the 
1
H NMR, at 3.84 ppm and 4.48 ppm, each with a relative integration of 
one (Figure 59).  The coupling constants for these doublets are 10.8 Hz, 
which are typical of geminal 
2
JH-H coupling.
172
  As such, these doublets 
were assigned as the two diastereotopic protons H-24
a
 and H-24
b
, as part of 
an AB system. 
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Figure 59 - HMQC spectrum (CDCl3) of 4-19. 
 
From the assignment of H-24, coupling was observed in the HMBC 
spectrum between these diastereotopic protons and a carbon resonance at 
137.4 ppm in the 
13
C NMR spectrum (Figure 60), which can thus be 
assigned as the quaternary carbon C-25. 
 
 
Figure 60 - HMBC spectrum (CDCl3) of 4-19. 
Chapter 5 
230 
 
 
The same approach described for the assignment of environments H/C-24 
and C-25 was also applied to assign the remaining benzylic proton and 
carbon resonances associated with the glucosyl moiety, summarised in 
Table 5.  Furthermore, the doublets assigned to H-29
a/b
, H-34
a/b
 and H-
39
a/b
 demonstrated a roofing effect, due to their diastereotopic nature, as 
shown in Figure 61.  Also, it can be seen in Figure 61 that two doublets 
overlap at 4.64 ppm, giving an apparent doublet.  However, on closer 
inspection it is possible to see a shoulder on the resonance at 4.63 ppm, 
which in turn explains why two different carbon resonances couple to this 
apparent doublet in the HMBC spectrum.  It should be noted that Gagné et 
al. report the resonance at 4.95 ppm in the 
1
H NMR spectrum as a doublet 
with a J value of 3.3 Hz.
207
  As Table 5 shows, this has been clarified in 
the present assignment as two doublets at 4.93 and 4.95 ppm, each with a J 
value of 11.1 Hz, and herein assigned as H-29
a/b
. 
  
Chapter 5 
231 
 
Assignment 
13
C 
Resonance 
(ppm) 
HMQC 
Coupled 
1
H 
Resonance 
(ppm) 
HMBC 
Coupled 
1
H 
Resonance 
(ppm) 
Reported 
1
H 
Resonance by 
Gagné et al.
207
 
(ppm) 
24 74.9 3.84 (d), 4.48 
(d) 
3.43 (H-19) 3.70-3.86 
(m)/4.49 (d) 
25 137.4 - 3.84/4.48 
(H-24
a/b
) 
- 
29 75.6 4.93 (d), 4.95 
(d) 
3.82 (H-20) 4.95 (d, J = 3.3 
Hz) 
30 138.5 - 4.93/4.95 
(H-29
a/b
) 
- 
34 75.1 4.64 (d), 4.87 
(d) 
3.74 (H-21) 4.56-4.67 
(m)/4.80-4.90 (m) 
35 138.0/138.1 - 4.64/4.87 
(H-34
a/b
) 
- 
39 73.4 4.53 (d), 4.64 
(d) 
3.76 (H-23) 4.56-4.67 (m) 
40 138.0/138.1 - 4.53/4.64 
(H-39
a/b
) 
- 
Table 5 - 
1
H and 
13
C assignment of the benzyl groups associated with the 
glucosyl moiety based on HMQC and HMBC coupling.  Figures 
supporting these assignments can be found in Appendix IV - Figures 145-
147.  The resonances for the carbons of C-35 and C-40 are 
indistinguishable. 
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Figure 61 - 
1
H NMR spectrum (CDCl3) of 4-19.  The J-coupling splitting 
pattern is shown below, explaining the splitting for each of the resonances.  
*The assignment of H
a
 and H
b
 can be interchanged for each region. 
 
It should be highlighted that there are a number of resonances for the 
aromatic carbons between 127.6 - 129.3 ppm in the 
13
C spectrum.  
Chapter 5 
233 
 
Likewise there are a number of protons at 6.94-6.96 ppm and 7.28-7.43 
ppm in the 
1
H NMR spectrum which cannot be individually assigned to 
their respective aromatic protons due to the complexity of the HMQC, 
HMBC and COSY spectra within these regions. 
 
Assignment of the catechol moiety of 4-19 
 
The assignment continued onto the protected catechol acid moiety of 4-19.  
Coupling was observed in the HMBC spectrum between the doublet at 4.24 
ppm for the anomeric proton (H-18), and a resonance at 136.3 ppm in the 
13
C spectrum (Figure 62), which was therefore assigned as C-5. 
 
 
Figure 62 - HMBC spectrum (CDCl3) of 4-19. 
 
Coupling was observed in the HMBC spectrum between the resonance at 
136.3 ppm (C-5) and a doublet at 7.26 ppm in the 
1
H NMR spectrum, for 
either aromatic protons H-4 or H-6 (Figure 63).  This doublet at 7.26 ppm 
(Figure 64) has a coupling constant of 1.7 Hz, indicative of a 
4
JH-H 
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coupling.  Furthermore, the COSY spectrum indicates coupling between 
the doublet at 7.26 ppm and another doublet at 7.88 ppm, also with a 
coupling constant of 1.7 Hz (Figure 65).  It should be noted that Gagné et 
al. report the resonance at 7.88 ppm as a singlet.
207
 
 
 
Figure 63 - HMBC spectrum (CDCl3) of 4-19. 
 
 
Figure 64 - 
1
H NMR spectrum (CDCl3) of 4-19. 
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Figure 65 - COSY spectrum (CDCl3) of 4-19. 
 
To confirm the assignment of the two doublets at 7.26 and 7.88 ppm as 
either H-4 or H-6, coupling was observed in the HMBC spectrum between 
the doublet at 7.88 ppm and a carbonyl resonance at 165.2 ppm, which 
corresponds to the carboxylic acid C7 (Figure 66).  Therefore it can be 
determined that proton H-6 is the doublet at 7.88 ppm, based on the 
3
JC-H 
coupling observed in the HMBC spectrum, which in turn indicates that H-4 
corresponds to the doublet at 7.26 ppm. 
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Figure 66 - HMBC spectrum (CDCl3) of 4-19. 
 
Based on their proton assignments, the carbon resonances for C-4 and C-6 
were assigned by inspection of the HMQC spectrum (Figure 67).  
Coupling was observed between, the doublet at 7.26 ppm (H-4) and a 
resonance at 117.7 ppm, whilst the doublet at 7.88 ppm (H-6)  coupled 
with a peak at 123.1 ppm.  Both these resonances were confirmed as 
tertiary CH carbons by positive signals in the DEPT spectrum and so C-4 
was assigned as 117.7 ppm and C-6 as 123.1 ppm.  It should be noted that 
the peak at 122.8 ppm shown in the HMQC spectrum (Figure 67) is not 
present in the DEPT spectrum, and thus is a quaternary carbon, which is 
assigned later. 
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Figure 67 - HMQC spectrum (CDCl3) of 4-19. 
 
To determine the quaternary carbons of C-2 and C-3, the HMBC spectrum 
was examined (Figure 68).  The spectrum shows coupling between the 
doublet at 7.88 ppm (H-6) and a resonance at 146.5 ppm, whilst the doublet 
at 7.26 ppm (H-4) also couples with the resonance at 146.5 ppm, and 
another at 151.0 ppm.  As such it can be determined that the resonance at 
146.5 ppm corresponds to C-2, with 
3
JC-H coupling to both H-4 and H-6, 
whilst the resonance at 151.0 ppm relates to C-3, with 
2
JC-H coupling to H-
4 observed. 
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Figure 68 - HMBC spectrum (CDCl3) of 4-19. 
 
From the assignments of C-2 and C-3, the assignments of both methylene 
benzyl CH2 groups are also possible.  From investigation of the HMBC 
spectrum, it is possible to see coupling between the quaternary carbons of 
C-2 and C-3 with two pairs of highly roofed doublets for each (Figure 69).  
The coupling observed between 146.5 ppm for C-2 and the two roofed 
doublets at 5.25 and 5.27 ppm indicates that these correlate to two 
diastereotopic protons, H-8
a
 and H-8
b
.  In turn, the coupling between C-3 at 
151.0 ppm and the two roofed doublets at 4.97 and 5.00 ppm indicates that 
these doublets correspond to the diastereotopic protons H-13
a
 and H-13
b
.  It 
should be highlighted that both of these methylene CH2 groups were 
reported by Gagné et al. as singlets, at 5.26 and 4.99 ppm respectively.
207
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Figure 69 - HMBC spectrum (CDCl3) of 4-19. 
 
As such, the HMQC spectrum allowed the assignment of the relevant CH2 
methylene carbons (Figure 70).  Coupling was observed between the 
doublets at 4.97 and 5.00 ppm (H-13) with a resonance at 71.2 ppm, 
thereby allowing this resonance to be assigned as C-13.  Subsequently, the 
resonance at 76.9 ppm (within the residual solvent peaks) can be assigned 
as C-8, with both resonances confirmed as methylene groups by their 
negative signals in the DEPT spectrum. 
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Figure 70 - HMQC spectrum (CDCl3) of 4-19. 
 
Investigation of the HMBC spectrum also allowed for the assignment of 
the benzyl quaternary carbons.  As Figure 71 shows, the doublets at 4.97 
and 5.00 ppm (H-13) couple with a resonance at 135.7 ppm, subsequently 
assigned as C-14, whilst the doublets at 5.25 and 5.27 ppm (H-8) couple 
with a resonance at 134.6 ppm, allowing its assignment as C-9. 
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Figure 71 - HMBC spectrum (CDCl3) of 4-19. 
 
Despite the successful assignment of nearly all the proton and carbon 
resonances for compound 4-19, except some aromatic carbon and proton 
resonances of the benzyl groups as discussed previously, there remains one 
unassigned carbon resonance at 122.8 ppm.  This resonance is not present 
in the DEPT spectrum, indicating that it is a quaternary carbon.  While this 
resonance demonstrates no observed coupling in the HMBC spectrum, it 
can be assigned as the sole remaining unassigned quaternary carbon, C-1. 
 
Summary of the assignment for compound 4-19 
 
The assignment of compound 4-19 is outlined in Table 6.  This assignment 
clarifies the 
1
H NMR resonances reported by Gagné et al.,
207
 with regards 
to a number of multiplets and singlets, which are compared in Table 6.  
The assignment of 4-19 facilitated the assignment of 4-7, 4-17 and 4-18 
and also allowed assignment of compound 4-25, discussed next in this 
Chapter. 
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Assignment 
1
H NMR (ppm) / 
(multiplicity) 
13
C NMR 
(ppm) 
Reported 
1
H Resonance by 
Gagné et al.
207
 (ppm)
 
1 - 122.8 - 
2 - 146.5 - 
3 - 151.0 - 
4 7.26 (d) 117.7 6.95-7.43 (m) 
5 - 136.3 - 
6 7.88 (d) 123.1 7.89 (s) 
7 - 165.2 - 
8 5.25 (d) / 5.27 (d) 76.9 5.26 (s) 
9 - 135.7 - 
13 4.97 (d) / 5.00 (d) 71.2 4.99 (s) 
14 - 134.6 - 
18 4.24 (d) 80.5 4.25 (d) 
19 3.43 (pseudo t) 83.6 3.44 (t) 
20 3.82 (pseudo t) 86.7 3.70-3.86 (m) 
21 3.74 (pseudo t) 78.2 3.70-3.86 (m) 
22 3.62 (dt) 79.3 3.51 (m) 
23 3.76 (overlap d) 69.0 3.70-3.86 (m) 
24 3.84 (d) / 4.48 (d) 74.9 3.70-3.86 (m) / 4.49 (d) 
25 - 137.4 - 
29 4.93 (d) / 4.95 (d) 75.6 4.95 (d, J = 3.3 Hz) 
30 - 138.5 - 
34 4.64 (d) / 4.87 (d) 75.1 4.56-4.67 (m) / 4.80-4.90 (m) 
35 - 138.0 / 138.1 - 
39 4.58 (d) / 4.64 (d) 73.4 4.56-4.67 (m) 
40 - 138.0 / 138.1 - 
Table 6 - Summary of the assignment of compound 4-19. 
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5.3 NMR characterisation of Compound 4-25 
 
The assignment of compound 4-25 was completed using NMR 
spectroscopy (400 MHz), also through the examination of a combination of 
COSY, HMBC and HMQC NMR spectra to support the 
1
H and 
13
C NMR 
spectra.  For easier visualisation of 4-25 a pullout is also provided at the 
back of this thesis as a reference.  Furthermore, the full 
1
H, 
13
C, HMQC, 
HMBC, COSY and DEPT spectra for compound 4-25 can be found in 
Appendix V - Figures 148-153. 
 
Assignment of the ciprofloxacin moiety of 4-25 
 
There are four main components of compound 4-25, the protected 
ciprofloxacin antimicrobial, the lysine linker, the protected catechols and 
the protected glucosyl moieties (Figure 72).  The starting point for the 
discussion on the assignment of 4-25 will be the protected antimicrobial 
(green - Figure 72). 
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Figure 72 - Full structure of compound 4-25.  Dark blue = protected 
glucosylated siderophore moiety.  Light blue = lysine linker moiety.  Green 
= protected antimicrobial moiety. 
 
The full NMR assignment of free ciprofloxacin in d6-DMSO is 
established,
268
 which in turn aided the full NMR assignment of compound 
4-9 (Chapter 4) in CDCl3 (not discussed).  As such, the full assignment of 
the protected antimicrobial OF 4-25 will also not be discussed, with 
supporting figures for the assignments given in the appendices where 
highlighted.  With the assignment of ciprofloxacin moieties well 
understood, the NMR assignment of the antimicrobial moiety of 4-25 is 
listed later in Table 7.  However, a few key signals should he highlighted 
which differ from usual ciprofloxacin related resonances, as well as those 
which aid confirmation that the antimicrobial and lysine linker moieties are 
coupled together.  Furthermore, it was also necessary to determine that the 
benzyl protecting group was present. 
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To start, investigation of the proton assigned as H-47 (8.51 ppm) 
demonstrated coupling in the HMBC spectrum with two carbonyl peaks in 
the 
13
C NMR, 173.0 ppm (C-49) and 165.6 ppm (C-58) (Figure 73).  In 
turn, the assignment of the methylene protons H65 were possible due to 
observed coupling in the HMBC spectrum.  Coupling was observed 
between a carbonyl at 165.5 ppm (C-58) with a singlet of relative 
integration two at 5.41 ppm in the 
1
H NMR (Figure 74).  Based on this 
assignment, C-65 was subsequently assigned as 66.3 ppm in the 
13
C NMR, 
due to coupling observed in the HMQC spectrum (Figure 75), as well as 
being supported by a negative signal in the DEPT spectrum. 
 
 
Figure 73 - HMBC spectrum (CDCl3) of 4-25. 
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Figure 74 - HMBC spectrum (CDCl3) of 4-25. 
 
 
Figure 75 - HMQC spectrum (CDCl3) of 4-25. 
 
The assignments of the piperazinyl CH2 groups are based on their expected 
proton environments, and subsequent coupling within the HMQC spectrum 
(Figure 76).  Interestingly, the protons and subsequent carbons are non- 
equivalent, likely as a result of the chirality of the lysine moiety.  These 
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proton and carbon environments usually show symmetry, demonstrated in 
the 
1
H spectrum for compound 4-9 (Chapter 4) (Figure 77), and so the 
spectra observed for 4-25, where the protons and carbons are non-
equivalent, indicates that the ciprofloxacin and lysine moieties are coupled 
together.  However, without corresponding HMBC coupling observed from 
either C-59 (assigned later) or C-53 it is not possible to directly assign 
H/C-56 or H/C-57, and so they have to be considered as interchangeable.  
Thus H/C-56 and H/C-57 are assigned as the multiplets 3.22-3.35/3.72-
4.01 ppm in the 
1
H spectrum, and as 41.9/45.6/49.9/50.2 ppm in the 
13
C 
spectrum. 
 
 
Figure 76 - HMQC spectrum (CDCl3) of 4-25. 
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Figure 77 - 
1
H NMR spectrum of 4-9 (Chapter 4) (CDCl3) showing the 
symmetry of the piperazinyl protons. 
 
It should be noted that there was no observed coupling within the spectra to 
allow the assignment of C-48.  However, based on previous understanding 
and assignments for other ciprofloxacin based compounds, such as 4-9 
(Chapter 4), C-48 was assigned as 110.1 ppm.  As such, the full assignment 
of the antimicrobial moiety is listed in Table 7.  This assignment of one 
component therefore supports the isolation of 4-25, though for 
confirmation of the isolation of 4-25 the remainder of the assignment must 
be conducted. 
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Assign. 
1
H NMR 
(ppm) / 
(multi.) 
13
C NMR 
(ppm) / 
(multi.) 
Append. V 
- Figure 
No. 
1
H NMR 
Resonance 
of 4-9 (ppm) 
13
C NMR 
Resonance of 
4-9 (ppm) 
44 1.03 (m) / 
1.29 (m) 
8.1 164/165 1.13 (m) / 
1.31 (m) 
8.1 
45 1.03 (m) / 
1.29 (m) 
8.1 164/165 1.13 (m) / 
1.31 (m) 
8.1 
46 3.33 (m) 34.5 162/163 3.42 (m) 34.5 
47 8.51 (s) 148.3 161 8.54 148.3 
48 - 110.1 - - 110.1 
49 - 173.0 157 - 172.9 
50 - 123.5 (d) 156 - 123.3 (d) 
51 8.12 (d) 113.5 (d) 154/155 8.09 (d) 113.4 (d) 
52 - 153.4 (d) - - 153.3 (d) 
53 - 144.0 (d) 158 - 144.4 (d) 
54 7.17-7.21 
(m) 
105.3 (d) 159/160 7.53 (m) 105.0 (d) 
56 3.22-3.33 
(m) / 
3.72-4.01 
(m) 
41.9 / 
45.6 / 
49.9 / 
50.2 
- 3.22 (m) / 
3.66 (m) 
50.0 
57 3.22-3.33 
(m) / 
3.72-4.01 
(m) 
41.9 / 
45.6 / 
49.9 / 
50.2 
- 3.22 (m) / 
3.66 (m) 
50.0 
58 - 165.6 - - 165.5 
65 5.41 (s) 66.3 - 5.40 (s) 66.3 
Table 7 - Summary of the assignment of the protected ciprofloxacin 
moiety of 4-25, compared to 4-9.  Figures supporting these assignments 
can be found in Appendix V - Figures 154-165. 
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Assignment of the glucosyl moiety of 4-25 
 
Analogous to compound 4-19, the assignment of the glucosyl moieties of 
4-25 could be started with the anomeric protons.  As before, it was known 
that the two doublets at 4.19 and 4.25 ppm in the 
1
H NMR spectrum 
(Figure 78) correspond to anomeric protons on the glucosyl moieties, H-
18/18’ (Figure 79).  This assignment is again supported by their typical 
3
JH-H coupling constants of the β-configuration, with 9.6 Hz and 9.2 Hz 
respectively.
256
 
 
 
Figure 78 - 
1
H NMR spectrum (CDCl3) of 4-25. 
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Figure 79 - Expansion of one benzyl protected glucosylated catechol unit 
of compound 4-25 for ease of reference visualisation. 
 
The chemical shift of the anomeric protons allowed for the continued 
assignment of compound 4-25 in a manner similar to that employed for 
compound 4-19 (Table 8), and so these will not be discussed in detail.  
However, the assignments for H/C-20/20’, H/C-21/21’ and also for H/C-
23/23’ are much harder to confirm, given the complexity of a multiplet 
observed between 3.72-3.86 ppm in the 
1
H NMR spectrum (Figure 78).  It 
could be possible to infer the likely assignments of these resonances, based 
on the assignment of 4-19 described previously.  However, the evidence for 
the exact confirmation of these resonances is insufficient, meaning the 
assignments of H/C-20/20’/21/21’/23/23’ should therefore be considered as 
interchangeable (Table 8). 
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Assignment 
1
H Resonance (ppm) 
13
C Resonance (ppm) 
18/18’ 4.19/4.25 81.0/81.1 
19/19’ 3.50 83.8/83.9 
20/20’ 3.72-3.86 78.3 / 86.6 / 86.7 
21/21’ 3.72-3.86 78.3 / 86.6 / 86.7 
22/22’ 3.62 79.3/79.3 
23/23’ 3.72-3.86 69.1 / 69.2 
Table 8 - 
1
H and 
13
C assignment of the glucosyl moiety of 4-25.  Figures 
supporting these assignments can be found in Appendix V - Figures 166-
169. 
 
Also similar to the assignment of 4-19, it was possible to assign some of 
the proton and carbon environments of the benzyl protecting groups.  It 
should be highlighted that in compound 4-25, the protons H19/19’ appear as 
an apparent quartet, which differs to the pseudo triplet for the analogous 
proton in 4-19.  From the HMBC NMR spectrum (Figure 80), a coupling 
between the apparent quartet at 3.50 ppm (H-19/19’) in the 1H NMR and 
74.8/74.8 and/or 75.1/75.1 ppm in the 
13
C NMR spectrum is seen.  
Therefore, the methylene CH2 group of C-24/24’ can be assigned as 
either/or 74.8/74.8/75.1/75.1 ppm in the 
13
C NMR spectrum, also 
reinforced by negative signals in the DEPT spectrum. 
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Figure 80 - HMBC spectrum (CDCl3) of 4-25. 
 
Using the HMQC spectrum (Figure 81), coupling was observed between  a 
multiplet at 3.82-3.86 ppm (within a greater multiplet at 3.72-3.86 ppm), 
and two overlapping doublets at 4.44 ppm, with the resonances 
75.1/75.0/74.8/74.8 ppm (C-24/24’) in the 13C spectrum.  From the 
assignment of 4-19, it is likely that resonances at 3.82-3.86 ppm and 4.44 
ppm correspond to the diastereotopic protons of the methylene CH2 groups 
H-24
a
/H-24
b
/H-24’a/H-24’b (Figure 82).  This assignment was supported 
by the COSY spectrum, where coupling was observed between the 
multiplet at 3.82-3.86 ppm and the two overlapping doublets at 4.44 ppm. 
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Figure 81 - HMQC spectrum (CDCl3) of 4-25. 
 
The assignments of the remaining methylene CH2 groups, 
29/29’/34/34’/39/39’, are more challenging, also due to the complexity of 
the multiplet between 3.72-3.86 ppm in the 
1
H NMR spectrum, as well the 
inability to confirm the exact carbon assignments for C-20/20’ and C-
21/21’.  With this multiplet at 3.72-3.86 ppm not allowing a confirmation 
of the assignment of the carbon resonances for C-20/20'/21/21’, the 
assignments of both the 
1
H and 
13
C resonances for 29/29’/34/34’/39/39’ 
can again only be indirect.  The likely assignments for these regions are 
listed in Table 9, though they must be considered interchangeable.  Despite 
the difficulty in confirming the exact assignments of the methylene CH2 
groups associated with the protected glucosyl moiety, the protons are all 
diastereotopic in nature, analogous to compound 4-19, as demonstrated in 
Figure 82. 
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Assignment 
1
H Resonance 
(ppm) 
HMQC Coupled 
13
C Resonance 
(ppm) 
HMBC Coupled 
13
C 
Resonance (ppm) 
29/29’ 4.95 75.5 / 75.5 86.6/86.7 
34/34’ 4.63 / 4.88 74.8/74.8/75.1/75.1 78.3 
39/39’ 4.56 / 4.63 73.3 / 73.4 69.1/69.2 (C-23/23’) 
Table 9 - Likely 
1
H and 
13
C assignment of the remaining benzyl groups 
associated with the glucosyl moiety for compound 4-25, inferred from the 
previous assignment of 4-19.  Figures suggesting these assignments can be 
found in Appendix V - Figures 170-176 though they must all be 
considered interchangeable. 
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Figure 82 - 
1
H NMR spectrum 3.72-3.86 ppm of 4-25.  The J-coupling 
splitting pattern is shown below, explaining the splitting for each of the 
resonances.  *The assignment of H
a
 and H
b
 can be interchanged for each 
region.  **The assignment of H-8
a
 and H-8
b
 is discussed later. 
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The assignment of the glucosyl moieties is listed later, in Table 10.  
However, the assignment of another component further supports the 
isolation of 4-25, though for full confirmation the remainder of the 
assignment must be also discussed. 
 
Assignment of the catechol moiety of 4-25 
 
The assignment of the catechol moiety could also be completed in a similar 
fashion to that described for 4-19.  It was deemed that the multiplet at 7.88 
ppm in the 
1
H NMR spectrum (Figure 83) contains two doublets, each 
with a 
4
JH-H coupling constant of 1.8 Hz, corresponding to the aromatic 
protons H-6/6’.  This would agree with the assignment for this proton 
environment in compound 4-19, discussed earlier.  Furthermore, this 
assignment also confirmed by the HMBC spectrum, with coupling 
observed to two carbonyl resonances at 164.5 and 164.7 ppm, which in turn 
correspond to the amides C-7/7’ (Figure 84).  It should be noted that 
within the multiplet at 7.88 ppm there is an amide proton, the assignment 
of which is discussed later. 
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Figure 83 - 
1
H NMR spectrum (CDCl3) of 4-25. 
 
 
Figure 84 - HMBC spectrum (CDCl3) of 4-25. 
 
Like compound 4-19, coupling was observed within the HMQC and 
HMBC spectra with H-6/6’, which allowed the assignments of C-6/6’ 
(122.1/122.1 ppm), C-2/2’ (146.2/146.5 ppm) and C-3/3’ (115.8/116.3 
ppm).  In turn the assignment of H/C-8/8’ could be made from the 
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assignments of C-2/2’.  However, the resonances for the diastereotopic 
methylene CH2 protons H-8/8’ were observed to be more complex than 
those for 4-19, with two sets of doublets in the 
1
H NMR at 5.02, 5.09 and 
5.27 ppm (Figure 85).  The assignment for these protons were determined 
by coupling observed in the HMBC spectrum between the resonances at 
146.2 and 146.5 ppm for C-2/2’ and these doublets (Figure 85).  It should 
be noted that underneath the multiplet of overlapping doublets at 5.09 ppm 
there is another proton, given this multiplet has a relative integration of 
three as opposed to two; the assignment of which is discussed later.  In 
turn, the assignment of H-8/8’ allowed for the assignment of their 
corresponding carbon resonances using the HMQC spectrum (C-8/8’ = 
76.0/76.3 ppm). 
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Figure 85 - HMBC spectrum (CDCl3) of 4-25.  The J-coupling splitting 
pattern for H-8
a
/ H-8
b
 is shown above, explaining the splitting for each of 
the resonances. 
 
Furthermore, the assignment of C-3/3’ (115.8/116.3 ppm) allowed the 
assignment of H/C-13/13’ (4.98 ppm and 71.0/71.2 ppm) also using 
HMBC/HMQC spectra.  However, unlike in compound 4-19, where the 
protons of H-13 appeared as two doublets, corresponding to diastereotopic 
protons, the resonance observed for H-13/13’ in 4-25 instead appeared as 
an apparent singlet resonance at 4.98 ppm in the 
1
H NMR (Figure 86), 
overlapping another resonance. 
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Figure 86 - HMBC spectrum (CDCl3) of 4-25. 
 
To complete the assignment of the catechol units, it was observed in the 
HMBC spectrum (Figure 87) that there is coupling between the protons at 
7.88 ppm (H-6/6’) with two resonances at 115.8 and 116.3 ppm in the 13C 
NMR spectrum.  Based on the assignment for 4-19, and the coupling 
observed in the HMQC spectrum (Figure 88), it can be inferred that the 
resonances at 115.8 and 116.3 ppm correlate to C-4/4’.  In turn, the HMQC 
spectrum thereby indicates that protons H-4/4’ lie within the multiplet 
between 7.17-7.25 ppm in the 
1
H NMR.  In this instance for compound 4-
25 the resonances observed for H-4/4’ are not as defined as in compound 4-
19, where a doublet was observed. 
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Figure 87 - HMBC spectrum (CDCl3) of 4-25. 
 
 
Figure 88 - HMQC spectrum (CDCl3) of 4-25. 
 
The assignments of both the glucosyl and catechol moieties are listed in 
Table 10.  Once again, the assignment of yet another component further 
supported the successful isolation of 4-25. It was next required to assign 
the lysine moiety to complete the NMR characterisation of 4-25. 
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Assign. 
1
H NMR (ppm) 
/ (multiplicity) 
13
C NMR 
(ppm) 
Append. V 
- Figure 
No.
 
1
H NMR 
of 4-19 
(ppm) 
13
C NMR 
of 4-19 
(ppm) 
7/7’ - 164.5 / 
164.7 
- - 165.2 
6/6’ 7.88 (m) 122.1 / 
122.1 
177 7.88 (d) 123.1 
4/4’ 7.17-7.21 (m) 115.8 / 
116.3 
- 7.26 (d) 117.7 
3/3’ - 151.4 / 
151.5 
178 - 151.0 
2/2’ - 146.2 / 
146.5 
178 - 146.5 
18/18’ 4.19 (d) / 4.25 
(d) 
81.0 / 81.1 166/168 4.24 (d) 80.5 
19/19’ 3.50 (ap. q) 83.8 / 83.9 166/168 3.43 (ps 
t) 
83.6 
20/20’ 3.72-3.86 (m) 78.3 / 86.6 / 
86.7 
167/168 3.82 (ps 
t) 
86.7 
21/21’ 3.72-3.86 (m) 78.3 / 86.6 / 
86.7 
167/168 3.74 (ps 
t) 
78.2 
22/22’ 3.63 (m) 79.3 / 79.3 167/168 3.62 (dt) 79.3 
23/23’ 3.72-3.86 (m) 69.1 / 69.2 167/168/169 3.76 (d) 69.0 
8/8’ 5.02 (d) / 5.09 
(m) / 5.27 (d) 
76.0 / 76.3 179 5.25 (d) / 
5.27 (d) 
76.9 
13/13’ 4.98 (ap. s) 71.0 / 71.2 180 4.97 (d) / 
5.00 (d) 
71.2 
24/24’ 3.72-3.86 (m) 74.8 / 74.8 / 
75.0 / 75.1 
167 3.84 (d) / 
4.48 (d) 
74.9 
29/29’ 4.56 (d) / 4.63 
(d) / 4.63 (d) / 
4.88 (d) / 4.93 
(m) 
73.3/ 73.4 / 
75.0 / 75.1 / 
75.5 / 75.5 
170 /171 
/172 / 174 / 
175 / 176 
4.93 (d) / 
4.95 (d) 
75.6 
34/34’ 4.56 (d) / 4.63 
(d) / 4.63 (d) / 
4.88 (d) / 4.93 
73.3/ 73.4 / 
75.0 / 75.1 / 
75.5 / 75.5 
170 / 171 / 
172 / 174 / 
176 
4.64 (d) / 
4.87 (d) 
75.1 
Chapter 5 
264 
 
(m) 
39/39’ 4.56 (d) / 4.63 
(d) / 4.63 (d) / 
4.88 (d) / 4.93 
(m) 
73.3/ 73.4 / 
75.0 / 75.1 / 
75.5 / 75.5 
170 /171 / 
172 /173 / 
174 
4.58 (d) / 
4.64 (d) 
73.4 
Table 10 - Summary of the assignment of the protect glucosyl and catechol 
moieties of 4-25, compared to 4-19.  Figures supporting these assignments 
can be found in Appendix V - Figures 166-180. 
 
Assignment of the lysine linker moiety of 4-25 
 
It was determined earlier that the amide carbonyls, C-7/7’, corresponded to 
the resonances 164.5 and/or 164.7 ppm in the 
13
C NMR spectrum (Figure 
84).  From these amide carbonyls, coupling was observed in the HMBC 
spectrum with a multiplet at 5.09 ppm (Figure 89).  Therefore it was 
determined that the third proton in this multiplet at 5.09 ppm corresponded 
to H-60 (Figure 90).  This assignment was supported by the HMQC 
spectrum (Figure 91).  A coupling between the multiplet at 5.09 ppm and a 
resonance of 48.7 ppm in the 
13
C NMR spectrum was observed.  This 
resonance is positive in the DEPT spectrum and so is a tertiary carbon.  As 
such, the resonance at 48.7 ppm was assigned as C-60.  Furthermore, the 
proton H-60 coupled with a resonance at 170.5 ppm in the 
13
C spectrum, 
which thus corresponded to the amide carbonyl C-59, observed in the 
HMBC spectrum (Figure 89). 
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Figure 89 - HMBC spectrum (CDCl3) of 4-25. 
 
 
Figure 90 - 
1
H NMR (CDCl3) of 4-25. 
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Figure 91 - HMQC spectrum (CDCl3) of 4-25. 
 
To assign the amide proton nearest C7, coupling was inspected with H-60 
in the COSY spectrum (Figure 92), and also within the HMBC spectrum 
with C-7 and C-60.  It was observed that these resonances coupled with a 
doublet at 8.68 ppm in the 
1
H NMR spectrum, which was therefore 
assigned as the amide.  Furthermore, the assignment of the amide nearest 
C-7 also allowed for the subsequent assignment of the other amide (nearest 
C-7’) as within the multiplet at 7.88 ppm. 
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Figure 92 - COSY spectrum (CDCl3) of 4-25. 
 
In order to assign the remainder of the lysine moiety (Figure 90), coupling 
of H-60 was examined.  It was observed within the HMBC spectrum that 
there is coupling between the multiplet at 5.09 ppm and a singlet resonance 
at 32.4 ppm in the 
13
C spectrum (Figure 93).  It was determined that the 
resonance at 32.4 ppm relates to C-61, supported by a negative signal in the 
DEPT spectrum.  Coupling in the HMQC spectrum between 32.4 ppm (C-
61) in the 
13
C spectrum and multiplets at 1.48 and 1.71 or 1.82 ppm in the 
1
H spectrum (Figure 94) indicates that these multiplets, each with a 
relative integration of one, correlate to the two diastereotopic protons H-
61
a
/H-61
b
, supported by coupling between these resonances in the COSY 
spectrum.  The two multiplets for the protons of H-61 are likely due to their 
non-equivalence resulting from the chiral centre at C-60. 
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Figure 93 - HMBC spectrum (CDCl3) of 4-25. 
 
 
Figure 94 - HMQC spectrum (CDCl3) of 4-25. 
 
Based on the above assignment for H-18, the remainder of the lysine chain 
for regions 62, 63 and 64 were possible.  Again using a combination of 
COSY, HMQC and HMBC spectra, the assignments of the lysine chain 
were made as outlined in Table 11.  Having assigned the final component, 
it was thus confirmed that 4-25 was the isolated product (Chapter 4). 
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Assignment 
1
H NMR (ppm) 
/ (multiplicity) 
13
C NMR 
(ppm) 
1
H NMR of 
4-8 (ppm)
 
13
C NMR of 
4-8 (ppm)
 
59 - 170.5 - 176.3 
60 5.09 (m) 48.7 4.30 (m) 52.9 
61 1.48 (m) / 1.71 
(m) or 1.82 (m) 
32.4 1.73 (m) / 
1.85 (m) 
31.7 
62 1.23-1.35 (m) 23.1 1.49 (m) 22.0 
63 1.23-1.35 (m) 29.2 1.49 (m) 29.0 
64 3.24 (m) 39.3 3.11 (m) 39.8 
Table 11 - Summary of the assignment of the lysine linker moiety of 4-25, 
compared to 4-8 (Chapter 4).  Figures supporting the assignments of H/C-
62, H/C-63 and H/C-64 can be found in Appendix V - Figures 181-183. 
 
Summary of the assignment of 4-25 
 
The NMR assignment of compound 4-25 is outlined in Table 7, Table 10 
and Table 11.  This assignment therefore confirmed the isolation of 
compound 4-25.  With the NMR assignment of 4-25, it should be noted 
that the assignment for a number of the quaternary carbons, were not 
possible.  These include C-1/C-1’/C-5/C-5’/C-55, and all those on the 
benzyl groups which are indistinguishable from one another, given the 
number of resonances between 135.5 and 138.7 ppm in the 
13
C spectrum 
corresponding to these carbon environments.  Furthermore, the benzyl CH 
carbons are also interchangeable, with a number of resonances between 
126.5 and 129.0 ppm present for these carbon environments.  Likewise the 
aromatic protons for the benzyl CH protons are also not assigned due to 
their indistinguishable nature. 
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5.4 Summary of Chapter 5 
 
The NMR assignments have been presented for the glucosylated 
compounds 4-19 and 4-25, outlined in Table 6, Table 7, Table 10 and 
Table 11.  These assignments validate the synthesis and isolation of both 
4-19 and 4-25.  Indeed the intermediate catechol acid 4-19 can be utilised 
to access future targets, building upon the work presented in Chapter 4.  
Therefore the characterisation of 4-19 can aid characterisation of future 
targets, in a manner analogous to that applied for the NMR characterisation 
of 4-25.  
  
Chapter 6: Summary, 
Conclusions and Future 
Work 
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6.1 Overall Summary, Conclusions and Future Work 
 
Bio-labile linkers in Trojan horse conjugates (Chapters 2 and 3) 
 
The synthesis and characterisation of conjugate 2-12, incorporating a 
carbamate linker between a citrate siderophore and the antimicrobial 
ciprofloxacin, was achieved.  During the synthesis towards conjugate 2-11, 
isomerisation of the citrate moiety was observed on treatment of 2-22 with 
hydroxide.  The mechanism was proposed, with the isolation of a 
succinimide intermediate 2-39 during the purification of 2-22, which, on 
treatment with base, selectively ring-opened to produce the single 
regioisomer 2-12.  Antimicrobial activity of 2-12 was investigated against 
both BW25113 wild type and BW25113 fecA::kan E. coli strains.  The 
conjugate is an active antimicrobial against these strains, though has lower 
activity than free ciprofloxacin.  The limited growth observed for the FecA 
negative strain when subjected to 10 µM of 2-12 indicates that FecA is not 
essential for active transport of this citrate-based conjugate.  The 
mechanism by which conjugate 2-12 enters the cell was not determined, 
but it is likely to be passive diffusion given that activity was retained in the 
FecA negative strain.  It also remains unclear if the carbamate group gives 
intracellular release of free ciprofloxacin.  Future work is required to 
establish if FecA does actively transport citrate conjugates, despite FecA 
being non-essential.  In addition, determining the stability of the carbamate 
group against a range of carboxylesterases would aid in understanding if 
the linker can cleave inside bacterial cells. 
 
The synthesis of a disulfide-linked citrate-ciprofloxacin conjugate was 
unsuccessful as the methyl ester protected precursor decomposed on 
treatment with hydroxide, releasing free ciprofloxacin.  Release of the free 
drug is a ‘proof of concept’ in the development of a bio-labile linker for 
siderophore-fluoroquinolone Trojan horse conjugates.  However, 
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successful synthesis of compound 3-8 is required to allow investigation 
into the application of a bio-labile disulfide linker to Trojan horse 
conjugate synthesis.  There is a balance to be established between 
developing an extracellular stable compound whilst retaining intracellular 
bio-lability.  Future work would involve completing the synthesis of 
conjugate 3-8 via a revised protecting group strategy, such as the use of 
tert-butyl esters, which can be removed using an acid.  Furthermore future 
work would also involve testing the ex vivo stability and in vivo 
antimicrobial activity of 3-8. 
 
Synthesis and antimicrobial activity testing of a salmochelin-inspired 
Trojan horse conjugate (Chapter 4) 
 
The synthesis and characterisation of 4-3, a salmochelin-inspired conjugate 
was completed.  The synthesis involved thirteen synthetic steps over four 
convergent routes.  Several synthetically versatile intermediates were 
produced which could be used in future salmochelin-inspired conjugate 
synthesis.  The antimicrobial activity of 4-3 was tested against wild type E. 
coli, with higher antimicrobial activity observed in iron deficient media at 
low concentrations of the conjugate, compared to free ciprofloxacin.  
However, this reduction in growth did not correlate with the activity of the 
conjugate against DNA gyrase, which demonstrated reduced inhibitory 
activity compared to free ciprofloxacin.  The gyrase assay suggests that the 
siderophore moiety is disrupting the ability of the antimicrobial to bind 
DNA gyrase.  Future work should establish the function of the siderophore 
moiety of the conjugate, both in its iron binding ability and its role in 
mediating the active uptake of the conjugate.  Additionally, the conjugate 
should be screened against siderocalin to determine if the glucosyl moieties 
prevent binding to this protein in an analogous manner to salmochelin S4.  
Finally, combining the choice of a salmochelin-based siderophore with a 
suitable bio-labile linker would tie together the two concepts explored in 
this thesis.  A design containing both features could work towards a new 
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antimicrobial with the potential to combat permeability-associated 
resistance and evade host mammalian immune responses. 
 
6.2 Concluding Remarks 
 
The conclusion that FecA is not essential for transport of citrate-based 
conjugates suggests that siderophore choice is a key factor for the 
development of actively transported Trojan horse conjugates.  Any 
development of new citrate-based conjugates, such as the production of the 
disulfide conjugate 3-8, should consider this finding.  Furthermore, the 
synthesis of a salmochelin-inspired conjugate 4-3 could also provide 
insight into the choice of siderophore in conjugate design, though further 
study is required to determine the role of the siderophore moiety in both 
iron binding and uptake.  Such conjugates are a relatively new field of 
study and so their development is essential for understanding this new class 
of Trojan horse conjugates.  The choice of a bio-labile linker between the 
siderophore and antimicrobial moieties is key for the development of future 
fluoroquinolone Trojan horse conjugates.  The reduction in antimicrobial 
activity of the carbamate-linked conjugate 2-12, compared to free 
ciprofloxacin, suggests that the linker is not sufficiently labile to allow for 
intracellular release of the drug, though this needs further investigation.  
Conversely, the premature decomposition of the disulfide-based linker 
during synthesis may suggest that such a linker could function as a bio-
labile linker.  As such, a disulfide-based linker should be explored further 
to determine if it is indeed suitable for the desired intracellular release of a 
fluoroquinolone following uptake. 
 
In addition to the continued development and synthesis of novel 
siderophore-fluoroquinolone Trojan horse conjugates, the current 
conjugates in this thesis should also be screened against a range of other 
clinically relevant bacterial strains.  This may unveil improved efficacy of 
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these conjugates for specific Gram-positive and Gram-negative bacteria 
species.  Additionally, different bacterial species may allow for better 
release of the carbamate linker if more compatible carboxylesterases are 
present.  Furthermore, screening against a larger range of bacterial strains 
would aid in the understanding of the scope for using salmochelin-based 
siderophores in Trojan horse conjugates. 
  
Chapter 7: Experimental 
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7.1 General Chemistry Procedures 
 
Mass Spectrometry 
 
High resolution positive and negative ESI mass spectrometry was 
performed on a Thermo-Finnigan LCQ Spectrometer by Karl Heaton or 
Helen Robinson.  LC-MS was performed by Karl Heaton on an Agilent 
Series 1200 LC with Bruker MicrOTOF using an analogous method to 
Analytical HPLC Method A described later. 
 
NMR 
 
1
H NMR (400 MHz), 
13
C NMR (100.6 MHz) and 
19
F NMR (376 MHz) 
spectra were acquired on a Jeol ECX400 or ECS400 spectrometer in the 
stated deuterated solvents.  
1
H NMR (700 MHz) and 
13
C NMR (175 MHz) 
were acquired on a Bruker AV700 NMR spectrometer by Pedro Aguiar.  
13
C NMR (125 MHz) was acquired on a Bruker AV500 NMR spectrometer 
by Ben Coulson.  Variable temperature NMR was performed on either a 
Jeol ECX400 or ECS400 spectrometer.  All chemical shifts (δ) are reported 
in parts per million (ppm) using the residual solvent signal as a reference.  
All J values are reported in Hertz to one decimal place.  All 
13
C NMR 
spectra are proton de-coupled.  Reference signals are as follows: 7.26 ppm 
and 77.16 ppm (CD3Cl), 3.31ppm and 49.00 ppm (CD3OD), 2.50 ppm and 
39.52 ppm (d6-DMSO).  Chemical shifts for multiplets are reported from 
the middle of the multiplet.  Multiplicity abbreviations are as follows: br. = 
br; s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; dd = 
double doublet; dt = double triplet.  All NMR assignments were aided by 
DEPT 135, HSQC, HMQC, COSY and HMBC experiments when 
required.  All spectra were processed using ACD/NMR Processor 
Academic Edition software. 
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IR 
 
IR were recorded on a Perkin Elmer FT-IR Spectrum Two spectrometer 
(ATIR) in the region 4000-400 cm
-1
. 
 
HPLC 
 
Analytical HPLC was performed on a Shimadzu HPLC system 
(Prominence) with a LC-20AD pump, SIL-20A autosampler, DGU-20AS 
degasser, CTO-20AC column oven, CBM-20A communication bus module 
and SPD-M20A diode array detector, using a SunFire C18 column (5 µm, 
4.6 x 150 mm), with the specified eluent gradient.  Preparative HPLC was 
performed on a Varian ProStar HPLC system with two 210 series pumps 
(25 mL), a 325 series UV detector, a model 701 fraction collector and 
model 410 autosampler, using a SunFire Prep C18 column (10 µm, 19 x 550 
mm), with the specified eluent gradient. 
 
Analytical HPLC Method A: 
Starting ratio is 2:3 MeCN + 0.1% Formic Acid (FA):H2O + 0.1% FA.  
Gradient raised over 10 minutes to 4:1 MeCN + 0.1% FA:H2O + 0.1% FA.  
Ratio maintained at 4:1 MeCN + 0.1% FA:H2O + 0.1% FA for 5 minutes.  
At 15 minutes - ratio raised to 95:5 MeCN + 0.1% FA:H2O + 0.1% FA.  
Ratio maintained at 95:5 MeCN + 0.1% FA:H2O + 0.1% FA for 10 
minutes.  At 25 minutes - ratio reduced to 2:3 MeCN + 0.1% Formic Acid 
(FA):H2O + 0.1% FA.  Ratio maintained at 2:3 MeCN + 0.1% Formic Acid 
(FA):H2O + 0.1% FA for 10 minutes.  Total method = 35 minutes.  Flow 
rate = 1 mL/min. 
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Analytical Method B: 
Starting ratio is 5:95 MeCN + 0.1% FA:H2O + 0.1% FA.  Gradient raised 
over 20 minutes to 1:1 MeCN + 0.1% FA:H2O + 0.1% FA.  At 20 minutes 
- ratio raised to 95:5 MeCN + 0.1% FA:H2O + 0.1% FA.  Ratio maintained 
at 95:5 MeCN + 0.1% FA:H2O + 0.1% FA for 5 minutes.  At 25 minutes - 
ratio reduced to 5:95 MeCN + 0.1% FA:H2O + 0.1% FA.  Ratio maintained 
at 5:95 MeCN + 0.1% FA:H2O + 0.1% FA for 10 minutes.  Total method = 
35 minutes.  Flow rate = 1 mL/min. 
 
Analytical Method C: 
Starting ratio is 1:4 MeCN + 0.1% Formic Acid (FA):H2O + 0.1% FA.  
Gradient raised over 10 minutes to 1:1 MeCN + 0.1% FA:H2O + 0.1% FA. 
Ratio maintained at 1:1 MeCN + 0.1% FA:H2O + 0.1% FA for 5 minutes.  
At 15 minutes - ratio raised to 95:5 MeCN + 0.1% FA:H2O + 0.1% FA.  
Ratio maintained at 95:5 MeCN + 0.1% FA:H2O + 0.1% FA for 5 minutes.  
At 20 minutes - ratio reduced to 1:4 MeCN + 0.1% Formic Acid (FA):H2O 
+ 0.1% FA.  Ratio maintained at 1:4 MeCN + 0.1% Formic Acid (FA):H2O 
+ 0.1% FA for 10 minutes.  Total method = 30 minutes.  Flow rate = 1 
mL/min. 
 
Preparative HPLC Method A: 
Starting ratio is 1:4 MeCN + 0.1% Formic Acid (FA):H2O + 0.1% FA.  
Gradient raised over 15 minutes to 1:1 MeCN + 0.1% FA:H2O + 0.1% FA. 
Ratio maintained at 1:1 MeCN + 0.1% FA:H2O + 0.1% FA for 10 minutes.  
At 25 minutes - ratio raised to 95:5 MeCN + 0.1% FA:H2O + 0.1% FA.  
Ratio maintained at 95:5 MeCN + 0.1% FA:H2O + 0.1% FA for 5 minutes.  
At 20 minutes - ratio reduced to 1:4 MeCN + 0.1% Formic Acid (FA):H2O 
+ 0.1% FA.  Ratio maintained at 1:4 MeCN + 0.1% Formic Acid (FA):H2O 
+ 0.1% FA for 10 minutes.  Total method = 40 minutes.  Flow rate = 20 
mL/min. 
Chapter 7 
280 
 
 
Melting Points 
 
Uncorrected melting points were recorded using a Stuart Scientific SMP3 
instrument and are accurate to ± 0.05 °C. 
 
Elemental Analysis 
 
Elemental analysis was collected on an Exeter CE-440 elemental analyser 
by Graeme McAllister. 
 
X-Ray Crystallography 
 
Single crystal X-ray diffraction data was collected, processed and solved 
by Natalie Pridmore. 
 
Solvents 
 
Solvents were supplied by Aldrich, Fischer Scientific and VWR.  Solvents 
were dried over 3 or 4 Å molecular sieves prior to use where appropriate.  
Deionised water was used for all synthetic procedures.  Dry solvents were 
obtained from departmental solvent stills (Prosolv MD 7 solvent 
purification system where solvents are passed through two columns of 
meolecular sieves).  For the Negishi coupling reaction Acros Organics 
DMF AcroSeal
®
 (99.8%, extra dry, over molecular sieves) was used. 
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Chemical Reagents 
 
All chemical reagents were used as supplied unless otherwise stated and 
purchased from commercial suppliers: Acros, Alfa-Aesar, Fisher Scientific, 
Fluka, Fluorochem, Sigma Aldrich, TCI Chemicals.  Chemicals were 
handled according to their toxicity.  Acetobromo-α-D-glucose was passed 
through a short silica gel column (anhydrous EtOAc) and rigorously dried 
prior to use. 
 
Moisture Sensitive Reactions 
 
Moisture sensitive reactions were carried out under a N2 or Ar atmosphere 
with flame-dried glassware when appropriate.  Reactions were carried out 
on a Schlenk apparatus where appropriate as well as in a glove box for the 
Negishi coupling reaction. 
 
Chromatography 
 
Analytical TLC used Merck silica gel 60 F254 aluminium-backed plates, 
with the specified eluent.  All plates were visualised through UV light 
using Chromato-vue Model CC-10 at 254 nm or 365 nm, or stained with 
potassium permanganate.  Column chromatography was performed with 
the specified eluent using Sigma-Aldrich high-purity grade silica gel, pore 
size 60 Å, 220-440 mesh particle size, 35-75 µm. 
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7.2 Chemical Synthesis 
 
Methyl-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylate, 2-15 
 
 
 
Thionyl chloride (4.4 mL, 7.216 g, 60.7 mmol) was added dropwise to a 
stirred solution of 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylic acid (1-5) (1.017 g, 3.07 mmol) in 
anhydrous MeOH (35 mL).  The reaction mixture was heated under reflux 
for 26 h.  The reaction was cooled to room temperature and concentrated in 
vacuo to give a yellow oil.  The oil was basified to pH 10 using 5% w/v 
aqueous K2CO3 (40 mL).  The aqueous solution was extracted with CH2Cl2 
(5 x 20 mL).  The combined organic extracts were washed with H2O (2 x 
15 mL).  The aqueous phase was then diluted with 5% w/v aqueous K2CO3 
(40 mL) and re-extracted with CH2Cl2 (5 x 20 mL).  The organic extracts 
were combined, dried over MgSO4, filtered and the solvent removed in 
vacuo to give the title compound 2-15 as an off white solid. 
Yield:  0.688 g, 1.99 mmol, 65% 
m.p.  228.2 - 229.6 °C (dec.) (lit. 227 - 228 °C dec.
121
) 
Rf  0.12 (3:1 CHCl3:MeOH) 
HRMS (ESI):  m/z calculated for C18H21FN3O3 [M+H]
+
 346.1561 found 
346.1557 (1.3 ppm error), C18H20FN3NaO3 [M+Na]
+
 368.1381 found 
368.1387 (-1.8 ppm error) 
Chapter 7 
283 
 
1
H NMR (400 MHz, CDCl3) δ (ppm):  8.53 (s, 1H, H-4), 8.00 (d, 
3
JH-F 
13.2 Hz, 1H, H-8), 7.26 (d, 
4
JH-F 7.0 Hz, 1H, H-11), 3.90 (s, 3H, H-16), 
3.46-3.41 (m, 1H, H-3), 3.26-3.24 (m, 4H, H-14), 3.12-3.10 (m, 4H, H-13), 
2.28 (br s, 1H, NH), 1.34-1.29 (m, 2H, H-1
a
/2
a
), 1.15-1.11 (m, 2H, H-1
b
/2
b
) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  173.6 (d, 
4
JC-F 2.3 Hz, C-6), 166.8 
(C-15), 153.8 (d, 
1
JC-F 248.6 Hz, C-9), 148.7 (C-4), 145.3 (d, 
2
JC-F 10.7 Hz, 
C-10), 138.3 (C-12), 123.1 (d, 
3
JC-F 6.9 Hz, C-7), 113.4 (d, 
2
JC-F 23.0 Hz, 
C-8), 110.1 (C-5), 104.9 (d, 
4
JC-F 3.1 Hz, C-11), 51.9 (C-16), 50.7 (d, 
4
JC-F 
4.6 Hz, C-13), 45.7 (C-14), 34.3 (C-3), 7.7 (C-1/2) 
19
F NMR (376 MHz, CDCl3) δ (ppm):  -123.4 (dd, 
3
JH-F 13.2 Hz, 
4
JH-F 7.0 
Hz) 
IR (ATIR) (cm
-1
):  2950.5 w (C-H), 2832.4 w (C-H), 1720.8 s (C=O), 
1616.7 s (C=C), 1255.7 s (C-N) 
Characterisation data consistent with literature.
121
 
 
2-hydroxy-4-methoxy-2-(2-methoxy-2-oxoethyl)-4-oxobutanoic acid, 2-
21 and trimethyl 2-hydroxypropane-1,2,3-tricarboxylate, 2-25 
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Citric acid 1-12 (30.242 g, 0.16 mol) was dissolved in anhydrous MeOH 
(150 mL) and conc. H2SO4 (0.6 mL, 0.11 mol).  The mixture was heated 
under reflux for 1 h.  The mixture was neutralised to pH 7 with Ca(OH)2 
and the white precipitate was filtered.  The filtrate was reduced in vacuo 
giving an oil which crystallised on standing.  The white crystaline solid 
was ground to a powder and dried under vacuum.  The powder was 
suspended in H2O (60 mL) and sonicated for 20 min.  The insoluble 
material was filtered and the filtrate acidified using conc. HCl (6 mL), 
giving a white precipitate.  The precipitate was isolated by vacuum 
filtration and dissolved in sat. aq. NaHCO3 (100 mL).  The aqueous 
solution was washed with CHCl3 (3 x 40 mL) and the aqueous layer 
acidified to pH 0 with conc. HCl (10 mL), giving a precipitate.  The 
precipitate was filtered, washed with CHCl3 (20 mL), and then dried to 
give the title compound 2-21.  The CHCl3 extracts were combined, dried 
over MgSO4, and the solvent removed in vacuo to give 2-25. 
 
Compound 2-21: 
Yield:  5.708 g, 0.026 mol, 16% 
m.p.  123.1 - 125.3 °C (lit. 118 - 123 °C 
269
) 
HRMS (ESI):  m/z calculated for C8H12NaO7 [M+Na]
+
 243.0474 found 
243.0475 (0.4 ppm error) 
1
H NMR (400 MHz, DMSO-d6) δ (ppm):  3.56 (s, 6H, H-1), 2.84 (d, 
2
JH-H 
15.2 Hz, 2H, H-3
a
), 2.73 (d, 
2
JH-H 15.2 Hz, 2H, H-3
b
) 
13
C NMR (100 MHz, DMSO-D6) δ (ppm):  175.0 (C-5), 170.6 (C-2), 72.7 
(C-4), 51.5 (C-1), 42.7 (C-3) 
IR (ATIR) (cm
-1
):  3406.7 br m (O-H), 2963.7 w (C-H), 1732.8 s (C=O), 
1714.2 s (C=O), 1438.0 m (C-O) 
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Compound 2-25: 
Yield:  1.089 g, 0.005 mol, 3% 
m.p.  78.1 - 79.2 °C (lit. 74.5 - 75.0 °C 
269
) 
HRMS (ESI):  m/z calculated for C9H14NaO7 [M+Na]
+
 257.0630 found 
257.0632 (0.7 ppm error) 
1
H NMR (400 MHz, DMSO-D6) δ (ppm):  5.75 (s, 1H, -OH), 3.65 (s, 3H, 
H-6), 3.56 (s, 6H, H-1), 2.87 (d, 
2
JH-H 15.2 Hz, 2H, H-3
a
), 2.73 (d, 
2
JH-H 
15.2 Hz, 2H, H-3
b
) 
13
C NMR (100 MHz, DMSO-D6) δ (ppm):  173.8 (C-5), 170.4 (C-2), 73.3 
(C-4), 52.2 (C-6), 51.6 (C-1), 43.1 (C-3) 
IR (ATIR) (cm
-1
):  3477.4 m (O-H), 2960.3 w (C-H), 1740.2 s (C=O), 
1718.8 s (C=O), 1436.6 m (C-O) 
Characterisation data consistent with literature.
164, 165
 
 
3-hydroxy-5-methoxy-3-(methyoxycarbonyl)-5-oxopentanoic acid, 2-23 
 
 
 
Trimethyl 2-hydroxypropane-1,2,3-tricarboxylate (2-25) (1.061 g, 4.50 
mmol) was dissolved in MeOH:H2O (1:1 50 mL).  0.1 M NaOH (21.5 mL) 
was added and the mixture stirred at room temperature for 2 h.  The 
mixture was extracted with EtOAc (3 x 40 mL).  The combined organic 
extracts were dried over MgSO4, filtered and the solvent removed in vacuo 
to yield unreacted trimethyl 2-hydroxypropane-1,2,3-tricarboxylate (2-25) 
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(0.430 g, 1.83 mmol).  The aqueous phase was concentrated in vacuo to 
~15 mL, acidified to pH 0 with 1 M HCl (4.5 mL).  The mixture was 
extracted with EtOAc (3 x 15 mL) and the combined organic extracts dried 
over MgSO4, and the solvent solvent removed in vacuo to yield an oil.  The 
oil was crystallised from hot PhMe to give the title compound 2-23 as a 
colourless solid. 
Yield:  0.160 g, 0.73 mmol, 27% 
m.p.  73.4 - 75.8 °C (lit. 80 - 81 °C 
164
) 
HRMS (ESI):  m/z calculated for C8H12NaO7 [M+Na]
+
 243.0475 found 
243.0468 (2.9 ppm error), C8H11O7 [M-H]
-
 219.0510 found 219.0514 (-1.6 
ppm error) 
1
H NMR (400 MHz, DMSO-D6) δ (ppm):  12.36 (br s, 1H, -COOH), 5.61 
(br s, 1H, -OH), 3.63 (s, 3H, H-6), 3.56 (s, 3H, H-10), 2.85 (d, 
2
JH-H 15.1 
Hz, 1H, H-3ª/7
a
), 2.80 (d, 
2
JH-H 15.6 Hz, 1H, H-3ª/7
a
), 2.72 (d, 
2
JH-H 15.1 
Hz, 1H, H-3
b
/7
b
), 2.65 (d, 
2
JH-H 15.6 Hz, 1H, H-3ª/7
a
) 
13
C NMR (100 MHz, DMSO-D6) δ (ppm):  173.2 (C-8), 171.0 (C-5), 169.8 
(C-2), 73.0 (C-4), 52.1 (C-1/6), 51.5 C-1/6), 43.1 (C-3/7), 43.0 (C-3/7) 
IR (ATIR) (cm
-1
):  3404.1 br m (O-H), 3000.4 w (C-H), 2956.1 w (C-H), 
2933.1 w (C-H), 1730.4 s (C=O), 1703.4 s (C=O), 1440.1 m (C-O) 
Characterisation data consistent with literature.
164, 165
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Methyl 7-(4-((2-((((9H-fluoren-9-
yl)methoxycarbonyl)amino)ethoxy)carbonyl)piperazin-1-yl)-1-
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate, 2-18 
 
 
 
To methyl-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylate (2-15) (0.206 g, 0.60 mmol) in anhydrous 
DMF (10 mL) were added Cs2CO3 (0.235 g, 0.72 mmol) and 
tetrabutylammonium iodide (0.270 g, 0.73 mmol).  Carbon dioxide gas was 
bubbled through the reaction mixture for 1.5 h.  N-Fmoc-2-
bromoethylamine (2-16) (0.252 g, 0.73 mmol) was dissolved in anhydrous 
DMF (3 mL) and then added dropwise over 40 min with continued 
bubbling.  The mixture was stirred for 23 h, with continuous carbon 
dioxide aspiration.  The reaction mixture was poured into H2O (30 mL) and 
extracted with EtOAc (3 x 30 mL).  The organic extracts were washed with 
H2O (2 x 30 mL) and brine (3 x 30 mL).  The combined organic extracts 
were dried over MgSO4, filtered and the solvent removed in vacuo to give 
an oil (0.277 g).  The oil was purified by column chromatography (9:1:0.5 
CHCl3:EtOAc:MeOH) and the solvent removed in vacuo to give the title 
compound 2-18 as a pale brown crystalline solid. 
Yield:  0.035 mg, 0.05 mmol, 9% 
Rf  0.23 (9:1:0.5 CHCl3:EtOAc:MeOH) 
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HRMS (ESI):  m/z calculated for C36H36FN4O7 [M+H]
+
 655.2563 found 
655.2553 (1.5 ppm error), C36H35FN4NaO7 [M+Na]
+
 677.2382 found 
677.2406 (-3.5 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  8.53 (s, 1H, H-4), 8.05 (d, 
3
JH-F 
13.0 Hz, 1H, H-8), 7.73 (d, 
3
JH-H 7.2 Hz, 2H, H-27), 7.57 (d, 
3
JH-H 7.3 Hz, 
2H, H-24), 7.38 (t, 
3
JH-H 7.3 Hz, 2H, H-26), 7.30 (t, 
3
JH-H 7.3 Hz, 2H, H-
25), 7.19 (d, 
4
JH-F 6.6 Hz, 1H, H-11), 4.37 (d, 
3
JH-H 7.3 Hz, 2H, H-21) 4.26 
- 4.20 (m, 3H, H-18/22), 3.92 (s, 3H, H-16), 3.68 (br s, 1H, H-14), 3.52 (m, 
2H, H-19), 3.31 (m, 1H, H-3), 3.15 (br s, 4H, H-13), 1.25 (m, 2H, H-1
a
/2
a
), 
1.06 (br s, 2H, H-1
b
/2
b
) 
19
F NMR (376 MHz, CDCl3) δ (ppm):  -123.7 (dd, 
3
JH-F 13.0 Hz, 
4
JH-F 7.2 
Hz) 
IR (ATIR) (cm
-1
):  3321.2 w, 2980.7 m (C-H), 1696.6 s (C=O), 1617.8 s 
(C=O), 1239.3 s (C=O) 
 
Benzyl (2-bromoethyl)carbamate, 2-17 
 
 
 
2-Bromoethylamine hydrobromide (3.005 g, 14.7 mmol) was dissolved in 
1,4-dioxane (15 mL) and treated with 1 M NaOH (30 mL).  The mixture 
was stirred and cooled in an ice bath for 15 min under an inert atmosphere.  
Benzyl chloroformate (2.1 mL, 2.498 g, 14.6 mmol) was added dropwise to 
the cooled mixture over 5 min.  The reaction mixture was stirred for a 
further 10 min, then allowed to warm to room temperature and stirring was 
continued for 22 h.  The reaction mixture was diluted with Et2O (75 mL) 
and washed with H2O (2 x 20 mL).  The organic extracts were dried over 
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MgSO4, filtered and the solvent removed in vacuo to give the title 
compound 2-17 as a colourless oil. 
Yield:  3.390 g, 13.2 mmol, 90% 
HRMS (ESI):  m/z calculated for C10H13
79
BrNO2 [M+H]
+
 258.0124 found 
258.0117 (2.9 ppm error), C10H12
79
BrNNaO2 [M+Na]
+
 279.9944 found 
279.9930 (5.0 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  7.40 - 7.32 (m, 5H, H-1/2/3), 5.12 
(s, 2H, H -5), 3.61 (q, 
3
JH-H 5.9, 2H, H-7), 3.47 (t, 
3
JH-H 5.9, 2H, H-8)
 
13
C NMR (100 MHz, CDCl3) δ (ppm):  156.5 (C-6), 136.5 (C-4), 128.8 (C-
2), 128.5 (C-1), 128.4 (C-3), 66.9 (C-5), 42.5 (C-7), 32.2 (C-8) 
IR (ATIR) (cm
-1
):  3256.1 m, 2980.7 m (C-H), 2912.5 m (C-H), 1718.3 s 
(C=O) 
Characterisation data consistent with literature.
170
 
 
Methyl 7-(4-((2-
(((benzyloxy)carbonyl)amino)ethoxy)carbonyl)piperazin-1-yl)-1-
cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinolne-3-carboxylate, 2-19 
 
 
 
Method A: 
To methyl-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylate (2-15) (0.208 g, 0.60 mmol) in anhydrous 
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DMF (10 mL) were added Cs2CO3 (0.296 g, 0.91 mmol) and 
tetrabutylammonium iodide (0.336 g, 0.91 mmol).  Carbon dioxide gas was 
bubbled through the reaction mixture for 1.17 h.  (2-Bromo-ethyl)-
carbamic acid benzyl ester (2-17) (0.234 g, 0.91 mmol) was dissolved in 
anhydrous DMF (5 mL) and then added dropwise over 20 min.  The 
mixture was stirred at room temperature for 22 h, with continuous  carbon 
dioxide aspiration.  The reaction mixture was poured into H2O (30 mL) and 
extracted with EtOAc (3 x 30 mL).  The organic extracts were washed with 
H2O (2 x 30 mL) and brine (4 x 30 mL).  The combined organic extracts 
were dried over MgSO4, filtered and the solvent removed in vacuo to give 
an oil.  The oil was purified by column chromatography (9:1:0.5 
CHCl3:EtOAc:MeOH) and the solvent removed in vacuo to leave the title 
compound 2-19 as a colourless solid. 
Yield:  0.074 g, 0.13 mmol, 22% 
 
Method B: 
Benzyl (2-hydroxyethyl)carbamate (2-29) (0.117 g, 0.60 mmol) was 
dissolved in anhydrous DMF (4 mL).  DSC (0.185 g, 0.72 mmol) and 
pyridine (9.7 μL, 0.010 g, 0.12 mmol) were added.  The reaction mixture 
was heated to 40 °C and stirred for 19 h, then the reaction mixture cooled 
to room temperature.  A mixture of methyl-1-cyclopropyl-6-fluoro-4-oxo-
7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate (2-15) (0.208 g, 
0.60 mmol) and potassium phosphate tribasic (0.256 g, 1.20 mmol) in 
anhydrous DMF (4 mL) was added.  The reaction mixture was stirred at 
room temperature for 26 h.  The reaction mixture was poured into H2O (20 
mL) and the aqueous phase extracted with EtOAc (5 x 15 mL).  The 
combined organic extracts were washed with 1 M HCl (20 mL), H2O (2 x 
20 mL) and brine (20 mL).  The organic phase was dried over MgSO4, 
filtered and the solvent removed in vacuo to leave a crude oil.  The oil was 
purified by column chromatography (7:3 CHCl3:MeCN) and the solvent 
removed in vacuo to give the title compound 2-19 as a colourless solid. 
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Yield:  0.223 g, 0.39 mmol, 65% 
m.p.  194.1 - 195.0 °C 
Rf  0.18 (9:1:0.5 CHCl3:EtOAc:MeOH) / 0.31 (7:3 CHCl3:MeCN) 
HRMS (ESI):  m/z calculated for C29H32FN4O7 [M+H]
+
 567.2250 found 
567.2241 (1.4 ppm error), C29H31FN4NaO7 [M+Na]
+
 589.2069 found 
589.2059 (1.8 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  8.51 (s, 1H, H-4), 7.99 (d, 
3
JH-F 
13.1 Hz, 1H, H-8), 7.35 - 7.31 (m. 5H, H-22/23/24/25), 7.24 (d, 
4
JH-F 7.1 
Hz, 1H, H-11), 5.09 (s, 2H, H-21), 4.21 (d, 
3
JH-H 5.1 Hz, 2H, H-18), 3.89 
(s, 3H, H-16), 3.66 (br s, 1H, H-14), 3.49 (m, 2H, H-19), 3.40 (m, 1H, H-
3), 3.18 (br s, 4H, H-13), 1.29 (m, 2H, H-1
a
/2
a
), 1.12 (br s, 2H, H-1
b
/2
b
)
 
13
C NMR (100 MHz, CDCl3) δ (ppm):  173.4 (d, 
4
JC-F 1.5 Hz, C-6), 166.7 
(s, C-15), 156.8 (s, C-20), 155.4 (s, C-17), 153.7 (d, 
1
JC-F 248.6 Hz,C-9), 
148.7 (s, C-4), 144.5 (d, 
2
JC-F 10.7 Hz, C-10), 138.2 (d, 
4
JC-F 1.5 Hz, C-12), 
136.6 (s, C-22), 128.8 (s, C-24), 128.4 (s, C-23), 128.3 (s, C-25), 123.6 (d, 
3
JC-F 6.9 Hz, C-7), 113.5 (d, 
2
JC-F 23.0 Hz, C-8), 110.2 (s, C-5), 105.2 (d, 
4
JC-F 3.1 Hz, C-11), 66.7 (s, C-21), 64.5 (s, C-18), 51.9 (s, C-16), 49.6 (d, 
4
JC-F 3.8 Hz, C-13), 43.4 (s, C-14), 40.4 (s, C-19), 34.2 (s, C-3), 7.7 (s, C-
1/2) 
19
F NMR (376 MHz, CDCl3) δ (ppm):  -123.7 (dd, 
3
JH-F 13.1 Hz, 
4
JH-F 7.1 
Hz) 
IR (ATIR) (cm
-1
):  2917.1 w (C-H), 1698.5 s (C=O), 1618.7 s (C=C), 
1432.4 m, 1238.5 s (C=O) 
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Benzyl (2-hydroxyethyl)carbamate, 2-29 
 
 
 
To a solution of ethanolamine (2.0 mL, 2.024 g, 33.1 mmol) in anhydrous 
CH2Cl2 (30 mL) at 0 °C was added a solution of benzyl chloroformate (3.7 
mL, 4.422 g, 25.9 mmol) in anhydrous CH2Cl2 (20 mL) over 30 min.  The 
reaction was stirred at 0 °C for 2 h then allowed to warm to room 
temperature and stirring continued for 18 h.  The mixture was washed with 
sat. aq. NaHCO3 (3 x 50 mL) and the aqueous phase extracted with CH2Cl2 
(3 x 50 mL).  The organic extracts were dried over MgSO4, filtered, and the 
solvent removed in vacuo to give the title compound 2-29 as a colourless 
oil. 
Yield:  4.381 g, 22.5 mmol, 87% 
HRMS (ESI):  m/z calculated for C10H14NO3 [M+H]
+
 196.0968 found 
196.0965 (1.6 ppm error), C10H13NNaO3 [M+Na]
+
 218.0788 found 
218.0788 (0.0 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  7.34 - 7.22 (m, 5H, H-1/2/3), 5.30 
(br s, 1H, -NH), 5.02 (s, 2H, H-5), 3.59 (m, 2H, H-7), 3.24 (br s, 2H, H-8), 
2.57 (br s, 1H, -OH) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  157.5 (C-5), 136.6 (C-4), 128.7 (C-
2), 128.4 (C-1), 128.3 (C-3), 66.8 (C-5), 61.9 (C-8), 43.2 (C-7) 
IR (ATIR) (cm
-1
):  3320.2 br s (O-H), 2941.0 m (C-H), 2885.4 m (C-H), 
1692.0 s (C=O) 
Characterisation data consistent with literature.
171
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2-hydroxy-N
1
,N
2
,N
3
-tris(2-hydroxyethyl)propane-1,2,3-
tricarboxamide, 2-36 
 
 
 
1,5-Dimethylcitrate (2-21) (0.110 g, 0.50 mmol) was dissolved in 
anhydrous THF (6 mL).  CDI (0.103 g, 0.63 mmol) was added and the 
mixture was stirred for 1 h at room temperature under an inert atmosphere. 
Ethanolamine (0.452 mL, 0.458 g, 7.50 mmol) was added and the mixture 
stirred for 42 h.  The solvent was removed in vacuo and the residue 
purified by column chromatography (3:1 CHCl3:MeOH) to give the title 
compound as 2-36 a colourless oil. 
Yield:  0.111 g, 0.34 mmol, 69% 
Rf  0.24 (3:1 CHCl3:MeOH) (permanganate stain) 
HRMS (ESI):  m/z calculated for C12H23N3NaO7 [M+Na]
+
 344.1428 found 
344.1412 (4.6 ppm error) 
1
H NMR (400 MHz, CD3OD) δ (ppm):  3.60 (m, 6H, H-1/8), 3.33 (m, 2H, 
H-7), 3.29 - 3.23 (m, 4H, H-2), 2.73 (d, 
2
JH-H 14.4, 2H, H-4), 2.57 (d, 
2
JH-H 
14.4, 2H, H-4) 
13
C NMR (100 MHz, CD3OD) δ (ppm):  177.4 (C-6), 173.5 (C-3), 76.6 (C-
5), 61.7 (C-1/8), 61.6 (C-1/8), 44.5 (C-2/4/7), 43.0 (C-2/4/7), 42.9 (C-
2/4/7) 
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2-hydroxy-4-((2-hydroxyethyl)amino)-2-(2-methoxy-2-oxoethyl)-4-
oxobutanoic acid, 2-37 
 
 
 
1,5-Dimethylcitrate (2-21) (0.110 g, 0.50 mmol) was dissolved in 
anhydrous THF (7 mL). CDI (0.101 g, 0.63 mmol) was added and the 
mixture was stirred for 1.5 h at room temperature. Ethanolamine (0.038 
mL, 0.038 g, 0.62 mmol) was added and the mixture stirred for 18 h. The 
solvent was removed in vacuo and the residue purified by column 
chromatography (3:1 CHCl3:MeOH) to give the title compound 2-37 as a 
colourless oil. 
Yield:  0.030 g, 0.12 mmol, 24% 
Rf  0.89 (3:1 CHCl3:MeOH) (permanganate stain) 
HRMS (ESI):  m/z calculated for C9H14NO7 [M-H]
-
 248.0776 found 
248.0781 (-2.1 ppm error) 
1
H NMR (400 MHz, CD3OD) δ (ppm): 3.69 - 3.62 (m, 7H, H-1/2/8), 3.08 - 
2.91 (m, 3H, H-4/6
a
), 2.68 (d, 
2
JH-H 18.3, 1H, H-6
b
) 
13
C NMR (100 MHz, CD3OD) δ (ppm): 181.1 (C-9), 177.6 (C-3), 172.9 
(C-7), 73.5 (C-5), 59.5 (C-1), 52.5 (C-8), 43.1 (C-2), 42.0 (C-4), 41.7 (C-6) 
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Dimethyl 3-hydroxy-3-((2-hydroxyethyl)carbamoyl)pentanedioate, 2-
29 
 
 
 
1,5-Dimethylcitrate (2-21) (0.441 g, 2.0 mmol) and HATU (0.912 g, 2.4 
mmol) were dissolved in anhydrous DMF (40 mL) at 0 °C under an inert 
atmosphere.  The mixture was stirred for 1.5 h.  Ethanolamine (0.145 mL, 
0.147 g, 2.4 mmol) and DIPEA (1.05 mL, 0.775 g, 6.0 mmol) were added.  
The mixture was allowed to warm to room temperature and stirring 
continued for 19 h.  The solvent was removed in vacuo and the residue 
purified by column chromatography (18:1 CHCl3:MeOH) to give the title 
compound 2-29 as a colourless oil. 
Yield:  0.483 g, 1.8 mmol, 92% 
Rf  0.41 (18:1 CHCl3:MeOH) (permanganate stain) 
HRMS (ESI):  m/z calculated for C10H18NO7 [M+H]
+
 264.1078 found 
264.1079 (-0.6 ppm error), C10H17NNaO7 [M+Na]
+
 286.0897 found 
286.0904 (-2.4 ppm error) 
1
H NMR (400 MHz, CD3OD) δ (ppm):  3.66 - 3.62 (m, 8H, H-1/7), 3.35 
(m, 2H, H-6), 2.93 (d, 
2
JH-H 15.2 Hz, 2H, H-3), 2.74 (d, 
2
JH-H 15.2 Hz, 2H, 
H-3) 
13
C NMR (100 MHz, CD3OD) δ (ppm):  177.0 (C-5), 172.8 (C-2), 75.5 (C-
4), 61.7 (C-7), 52.4 (C-1), 44.3 (C-6), 42.9 (C-3) 
IR (ATIR) (cm
-1
):  3382.3 br w (O-H), 2954.8 w (C-H), 1726.4 s (C=O), 
1651.8 s (C=O) 
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Dimethyl 3-((2-((4-(1-cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-
1,4-dihydroquinolin-7-yl)piperazine-1-carbonyl)oxy)ethyl)carbamoyl)-
3-hydroxypentanedioate, 2-22 
 
 
 
Dimethyl 3-hydroxy-3-((2-hydroxyethyl)carbamoyl)pentanedioate (2-29) 
(0.154 g, 0.58 mmol) was dissolved anhydrous DMF (4 mL).  DSC (0.185 
g, 0.72 mmol) and DIPEA (0.105 mL, 0.078 g, 0.60 mmol) were added.  
The reaction mixture was heated to 40 °C and stirred for 5.5 h.  The 
reaction mixture was cooled to room temperature then methyl-1-
cyclopropyl-6-fluoro-4-oxo-7-(piperzin-1-yl)-1,4-dihydroquinoline-3-
carboxylate (2-15) (0.208 g, 0.60 mmol) in DMF (4 mL) was added.  The 
reaction mixture was stirred at room temperature for 18.5 h.  The solvent 
removed in vacuo and the residue purified by column chromatography (9:1 
CHCl3:MeOH) to give the title compound 2-22 as a colourless solid. 
Yield:  0.165 g, 0.26 mmol, 45% 
m.p.  124.3 - 126.8 °C 
Rf  0.29 (9:1 CHCl3:MeOH) 
HRMS (ESI):  m/z calculated for C29H36FN4O11 [M+H]
+
 635.2359 found 
635.2372 (-2.0 ppm error), C29H35FN4NaO11 [M+Na]
+
 657.2179 found 
657.2194 (-2.4 ppm error) 
Chapter 7 
297 
 
1
H NMR (400 MHz, CDCl3) δ (ppm):  8.58 (s, 1H, H-4), 8.09 (d, 
3
JH-F 
13.1 Hz, 1H, H-8), 7.30 (d, 
4
JH-F 7.1 Hz, 1H, H-11), 4.98 (br s, 1H, -NH), 
4.25 (t, 
3
JH-H 5.4 Hz, 2H, H-18), 3.92 (s, 3H, H-16), 3.72 – 3.70 (m, 10H, 
H-14/24), 3.58 (q, 
3
JH-H 5.4 Hz, 2H, H-19), 3.44 (m, 1H, H-3), 2.91 (d, 
2
JH-
H 15.7 Hz, 2H, H-22), 2.81 (d, 
2
JH-H 15.7 Hz, 2H, H-22), 1.34 (m, 2H, H-
1
a
/2
a
), 1.15 (m, 2H, H-1
b
/2
b
) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  173.7 (C-23), 173.5 (d, 
4
JC-F 2.3 
Hz, C-6), 172.1 (C-20), 166.9 (C-15), 155.5 (C-17), 153.8 (d, 
1
JC-F 248.6 
Hz, C-9), 148.8 (C-4), 144.7 (d, 
2
JC-F 10.7 Hz, C-10), 138.3 (d, 
4
JC-F 1.5 
Hz, C-12), 123.7 (d, 
3
JC-F 1.5 Hz, H-7), 113.7 (d, 
2
JC-F 23.0 Hz, C-8), 110.3 
(C-5), 105.2 (d, 
3
JC-F 3.1 Hz, C-11), 74.3 (C-21), 64.1 (C-18), 52.0 (C-16), 
51.9 (C-24), 49.7 (C-13), 43.5 (C-14), 41.3 (C-19), 38.8 (C-22), 34.3 (C-3), 
7.8 (C-1/2) 
19
F NMR (376 MHz, CDCl3) δ (ppm):  -123.7 (dd, 
3
JH-F 13.1 Hz, 
4
JH-F 7.1 
Hz) 
IR (ATIR) (cm
-1
):  3448.1 w, 3317.4 w, 2995.1 w (C-H), 2954.9 w (C-H), 
2858.3 w (C-H), 1728.0 s (C=O), 1706.2 s (C=O). 1615.8 s (C=O), 1431.1 
s (C-H bend), 1235.5 s, 1207.1 s 
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2-(2-((2-((4-(3-carboxy-1-cyclopropul-6-fluoro-4-oxo-1,4-
dihydroquinolin-7-yl)piperazine-1-carbonyl)oxy)ethyl)amino)-2-
oxoethyl)-2-hydroxysuccinic acid, 2-12 
 
 
 
Dimethyl 3-((2-((4-(1-cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-
1,4-dihydroquinolin-7-yl)piperazine-1-carbonyl)oxy)ethyl)carbamoyl)-3-
hydroxypentanedioate (2-22) (0.100 g, 0.16 mmol) was dissolved in 0.1 M 
tetrabutylammonium hydroxide (1 M in MeOH diluted with H2O, 7 mL, 
0.70 mmol) and stirred at room temperature for 19.5 h.  The pH was 
adjusted to 1.38 by the addition of 1 M HCl (~0.6 mL).  The resultant 
precipitate was filtered, washed with H2O (30 mL) and CHCl3 (50 mL), 
and dried to give the title compound 2-12 as a cream solid. 
Yield:  0.059 g, 0.10 mmol, 64% 
m.p.  176.2 - 178.3 °C 
HRMS (ESI):  m/z calculated for C26H28FN4O11 [M-H]
- 
591.1744 found 
591.1749 (-0.7 ppm error) 
1
H NMR (400 MHz, DMSO-D6) δ (ppm):  8.68 (s, 1H, H-4), 8.10 (br t, 
3
JH-H 5.5 Hz, -NH), 7.94 (d, 
3
JH-F 13.1 Hz, 1H, H-8), 7.60 (d, 
4
JH-F 7.2 Hz, 
1H, H-11), 4.01 (t, 
3
JH-H 5.3 Hz, 2H, H-17), 3.82 (br s, 1H, H-3), 3.61 (br s, 
4H, H-14), 2.76 - 3.54 (m, 4H, H-20/23), 1.32 (m, 2H, H-1
a
/2
 a
), 1.18 (m, 
2H, H-1
b
/2
b
)
 
13
C NMR (100 MHz, DMSO-D6) δ (ppm):  177.1 (d, 
4
JC-F 7.7 Hz, C-6), 
175.7 (C-22), 172.1 (C-24), 170.5 (C-19), 166.7 (C-15), 155.1 (C-16), 
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153.6 (d, 
1
JC-F 248.6 Hz, C-9), 148.7 (C-4), 145.7 (d, 
2
JC-F 10 Hz, C-10), 
139.7 (C-7), 119.4 (C-5), 119.3 (d, 
4
JC-F 1.5 Hz, H-12), 111.4 (d, 
2
JC-F 23.8 
Hz, C-8), 107.1 (C-11), 73.0 (C-21), 64.0 (C-17), 49.3 (C-14), 43.3 (C-
20/23), 43.1 (C-13), 42.9 (C-20/23), 37.9 (C-18), 35.9 (C-3), 7.5 (C-1/2) 
19
F NMR (376 MHz, DMSO-D6) δ (ppm):  -121.7 (dd, 
3
JH-F 13.1 Hz, 
4
JH-F 
7.2 Hz) 
IR (ATIR) (cm
-1
):  3357.8 br w (O-H), 1712.9 s (C=O), 1675.8 s (C=O), 
1628.3 s (C=O), 1467.9 s (C-H bend), 1440.3 s (C-H bend), 1247.3 s 
(C=O) 
Elemental Analysis:  Calculated for [C26H29FN4O11.1.5H2O] %C 50.40, 
%H 5.21, %N 9.04, Measured for [C26H29FN4O11.1.5H2O] %C 50.68, %H 
4.93, %N 8.77 
 
Methyl 1-cyclopropyl-6-fluoro-7-(4-((2-(3-hydroxy-3-(2-methoxy-2-
oxoethyl)-2,5-dioxypyrrolidin-1-yl)ethoxy)carbonyl)piperazin-1-yl)-4-
oxo-1,4-dihydroquinoline-3-carboxylate, 2-39 
 
 
 
Isolated during the chromatographic purification of 2-22. 
Rf   0.31 (9:1 CHCl3:MeOH) / 0.10 (MeCN) 
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HRMS (ESI):  m/z calculated for C28H32FN4O10 [M+H]
+
 603.2091 found 
603.2112 (-3.5 ppm error), C28H31FN4NaO10 [M+Na]
+
 625.1916 found 
625.1934 (-2.9 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  8.52 (s, 1H, H-4), 7.94 (d, 
3
JH-F 
12.8 Hz, 1H, H-8), 7.26 (d, 
4
JH-F 7.1 Hz, 1H, H-11), 4.30 (t, 
3
JH-H 5 Hz, 2H, 
H-18), 3.88 (s, 3H, H-16), 3.83 (q, 
3
JH-H 5 Hz, 2H, H-19), 3.66 - 3.63 (m, 
7H, H-14/26), 3.44 (m, 1H, H-3), 3.19 (br s, 4H, H-13), 3.05 (d, 
2
JH-H 16.8 
Hz, 1H, H-22), 2.95 (d, 
2
JH-H 18.1 Hz, 1H, H-24), 2.95 (d, 
2
JH-H 16.8 Hz, 
1H, H-22), 2.81 (d, 
2
JH-H 18.1 Hz, 1H, H-24), 1.32 (m, 2H, H-1
a
/2
a
), 1.11 
(m, 2H, H-1
b
/2
b
)
 
13
C NMR (100 MHz, CDCl3) δ (ppm):  178.8 (C-25), 174.9 (C-23), 173.4 
(C-6), 171.1 (C-20), 166.5 (C-15), 155.4 (C-17), 153.7 (d, 
1
JC-F 248.6 Hz, 
C-9), 148.8 (C-4), 144.8 (d, 
2
JC-F 10.7 Hz, C-10), 138.3 (d, 
4
JC-F 1.5 Hz, C-
12), 123.4 (d, 
3
JC-F 1.5 Hz, C-7), 113.4 (d, 
2
JC-F 22.2 Hz, C-8), 110.0 (C-5), 
105.3 (d, 
3
JC-F 3.1 Hz, C-11), 72.3 (C-21), 62.1 (C-18), 51.9 (C-16), 51.9 
(C-26), 49.5 (C-13), 43.4 (C-14), 42.1 (C-19), 40.2 (C-22), 38.3 (C-24), 
34.4 (C-3), 7.8 (C-1/2) 
19
F NMR (376 MHz, CDCl3) δ (ppm):  -123.7 (dd, 
3
JH-F 12.9 Hz, 
4
JH-F 7.1 
Hz) 
IR (ATIR) (cm
-1
):  3365.4 br w (O-H), 2912.6 w (C-H), 1722.0 s (C=O), 
1702.1 s (C=O), 1699.6 s (C=O), 1667.3 s (C=O), 1515.6 m (C=C), 1247.1 
s (C=O) 
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Tert-butyl (2-((2-hydroxyethyl)disulfanyl)ethyl)carbamate, 3-13 
 
 
 
Cysteamine hydrochloride (10.067 g, 88.61 mmol) was dissolved in MeOH 
(70 mL) then cooled to 0 °C.  A solution of 2-hydroxyethyl disulfide (3-12) 
(11 mL, 8.723 g, 56.55 mmol) and Et3N (25 mL, 34.435 g, 340.30 mmol) 
in MeOH (50 mL) was added dropwise over 40 min.  The reaction was 
stirred at 0 °C for 15 min and then warmed to room temperature and 
stirring continued for 19h.  The mixture was cooled to 0 °C and di-tert-
butyl carbonate (29.169 g, 133.65 mmol) in MeOH (30 mL) added 
dropwise over 15 min.  The reaction mixture was stirred 0 °C for 30 min 
and then warmed to room temperature and stirring continued for 71h.  The 
solvent was removed in vacuo and the residue dissolved in EtOAc (200 
mL).  The organic phase was washed with H2O (2 x 100 mL) and brine 
(100 mL), then dried over MgSO4, filtered and the solvent removed in 
vacuo.  The residue was purified by column chromatography (1:1 
EtOAc:Petroleum Ether 40-60) to give the title compound 3-13 as a 
colourless oil. 
Yield:  6.842 g, 27.00 mmol, 48% 
Rf  0.23 (1:1 EtOAc:Petroleum Ether 40-60) (permanganate stain) 
HRMS (ESI):  m/z calculated for C9H19NNaO3S2 [M+Na]
+
 276.0699 found 
276.0700 (-0.5 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  4.95 (br s, 1H, -OH), 3.88 (t, 
3
JH-H 
5.7 Hz, 2H, H-1), 3.46 (m, 2H, H-4), 2.88 (t, 
3
JH-H 5.7 Hz, 2H, H-2), 2.80 
(t, 
3
JH-H 6.4 Hz, 2H, H-3), 1.44 (s, 9H, H-7) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  156.0 (C-5), 79.8 (C-6), 60.3 (C-
1), 41.8 (C-2), 39.4 (C-4), 38.2 (C-3), 28.5 (C-7) 
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IR (ATIR) (cm
-1
):  3323.5 br w (O-H), 2970.8 w (C-H), 2929.0 w (C-H), 
2867.4 w (C-H), 1675.8 s (C=O) 
Characterisation data consistent with literature.
178
 
 
2-((2-aminoethyl)disulfanyl)ethanol trifluoroacetic acid salt, 3-14 
 
 
 
Prepared using a literature preparation and used without purification.
178
 
 
Dimethyl 3-hydroxy-3-((2-((2-
hydroxyethyldisulfanyl)ethyl)carbamoyl)pentanedioate, 3-15 
 
 
 
2-Hydroxy-4-methoxy-2-(2-methoxy-2-oxoethyl)-4-oxobutanoic acid (2-
21) (0.910 g, 4.13 mmol) and HATU (2.034 g, 5.34 mmol) were dissolved 
in anhydrous DMF (30 mL) and stirred at 0 °C under an inert atmosphere 
for 30 min.  A solution of 2-((2-aminoethyl)disulfanyl)ethanol 
trifluoroacetic acid salt (3-14) (2.243 g, 8.39 mmol) and DIPEA (3.2 mL, 
4.313 g, 33.37 mmol) in anhydrous DMF (20 mL) was added.  The mixture 
was warmed to room temperature and stirring continued for 68 h.  The 
solvent was removed in vacuo and the residue purified by column 
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chromatography (1:1 MeCN:CHCl3) to give the title compound 3-15 as a 
colourless oil. 
Yield:  0.676 g, 1.90 mmol, 46% 
Rf  0.31 (1:1 MeCN:CHCl3) (permanganate stain) 
HRMS (ESI):  m/z calculated for C12H21NNaO7S2 [M+Na]
+
 378.0652 
found 378.0647 (1.2 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  7.34 (br s, 1H, -NH), 4.94 (s, 1H, -
OH), 3.93 (t, 
3
JH-H 5.5 Hz, 1H, -OH), 3.89 (t, 
3
JH-H 5.5 Hz, 2H, H-9), 3.72 
(s, 6H, H-1), 3.65 (q, 
3
JH-H 6.5 Hz, 2H, H-6), 2.96 (d, 
2
JH-H 16.0 Hz, 2H, H-
3
a
), 2.90 (m, 2H, H-8), 2.85 (t, 
3
JH-H 6.5 Hz, 2H, H-7), 2.80 (d, 
2
JH-H 16.0 
Hz, 2H, H-3
b
) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  173.4 (C-2), 171.7 (C-5), 74.3 (C-
4), 60.3 (C-9), 52.1 (C-1), 41.8 (C-8), 41.5 (C-3), 38.3 (C-6), 37.3 (C-7) 
IR (ATIR) (cm
-1
):  3380.2 br m (O-H), 2952.2 m (C-H), 1728.9 s (C=O), 
1656.0 s (C=O) 
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Dimethyl 3-((2-((4-(1-cyclopropyl-6-fluoro-3-(methoxycarbonyl)-4-oxo-
1,4-dihydroquinolin-7-yl)piperazine-1-
carbonyl)oxy)ethyl)disulfanyl)ethyl)carbomyl)-3-
hydroxypentanedioate, 3-16 
 
 
 
Dimethyl 3-hydroxy-3-((2-((2-
hydroxyethyldisulfanyl)ethyl)carbamoyl)pentanedioate (3-15) (0.246 g, 
0.69 mmol), DSC (0.278 g, 1.09 mmol) and DIPEA (0.19 mL, 0.141 g, 
1.09 mmol) were dissolved in anhydrous DMF (10 mL).  The mixture was 
stirred for 17 h at 40 °C.  The mixture was cooled to room temperature and 
a solution of methyl-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylate (2-15) (0.245 g, 0.71 mmol) in anhydous 
DMF (10 mL) was added.  The mixture was stirred at room temperature for 
25 h.  The solvent was removed in vacuo and the residue purified by 
column chromatography (15:1 CHCl3:MeOH) to give the title compound 3-
16 as a cream solid. 
Yield:  0.184 g, 0.25 mmol, 37% 
m.p.  136.2 - 139.4 °C 
Rf  0.24 (15:1 CHCl3:MeOH) 
HRMS (ESI):  m/z calculated for C31H40FN4O11S2 [M+H]
+
 727.2114 found 
727.2098 (2.2 ppm error), C31H39FN4NaO11S2 [M+Na]
+
 749.1933 found 
749.1921 (1.6 ppm error) 
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1
H NMR (400 MHz, CDCl3) δ (ppm):  8.50 (s, 1H, H-4), 7.97 (d, 
3
JH-F 
13.1 Hz, 1H, H-8), 7.35 (m, 1H, -NH), 7.26 (d, 
4
JH-F 7.3 Hz, 1H, H-11), 
4.97 (br s, 1H, -OH), 4.38 (t, 
3
JH-H 6.4 Hz, 2H, H-18), 3.89 (s, 3H, H-16), 
3.72 (m, 10H, H-14/26), 3.61 (q, 
3
JH-H 6.4 Hz, 2H, H-21), 3.44 (m, 1H, H-
3), 3.22 (m, 4H, H-13), 2.96 (t, 
3
JH-H 6.4 Hz, 2H, H-19), 2.93 (d, 
2
JH-H 15.8 
Hz, 2H, H-24
a
), 2.84 (t, 
3
JH-H 6.4 Hz, 2H, H-20), 2.78 (d, 
2
JH-H 15.8 Hz, 
2H, H-24
b
), 1.32 (m, 2H, H-1
a
/2
a
), 1.14 (m, 2H, H-1
b
/2
b
) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  173.2 (C-25), 172.9 (C-6), 166.2 
(C-15), 154.8 (C-17), 153.3 (d, 
1
JC-F 248.3 Hz, C-9), 148.4 (C-4), 144.2 (d, 
2
JC-F 10.5 Hz, C-10), 138.9 (C-12), 123.3 (d, 
3
JC-F 6.7 Hz, C-7), 109.9 (C-
5), 105.1 (d, 
3
JC-F 2.9 Hz, C-11), 74.2 (C-23), 63.4 (C-18), 52.0 (C-26), 
52.0 (C-16), 49.8 (C-13), 43.6 (C-14), 41.6 (C-24), 38.1 (C-21), 37.6 (C-
20), 37.4 (C-19), 34.5 (C-3), 8.1 (C-1/2) 
19
F NMR (376 MHz, CDCl3) δ (ppm):  -123.7 (dd, 
3
JH-F 13.1 Hz, 
4
JH-F 7.3 
Hz) 
IR (ATIR) (cm
-1
):  3378.9 br w (O-H), 2951.0 w (C-H), 1720.0 s (C=O). 
1703.7 s (C=O), 1617.8 s (C=C) 
Elemental Analysis:  Calculated for [C31H39FN4O11S2] %C 51.23, %H 
5.41, %N 7.71, Measured for [C31H39FN4O11S2] %C 50.77, %H 5.37, %N 
7.55 
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(S)-2,6-bis((tert-butoxycarbonyl)amino)hexanoic acid, 4-8 
 
 
 
ʟ-lysine monohydrochloride (1.253 g, 6.9 mmol) and NaOH (0.556 g, 13.9 
mmol) were dissolved in H2O (13 mL) and the mixture heated to 50 °C. A 
solution of di-tert-butyl dicarbonate (4 mL, 3.800 g, 17.4 mmol) in 
anhydrous 1,4-dioxane (25 mL) was added dropwise over 30 min and 
stirring was continued for 18 h. The reaction mixture was concentrated to 
~6 mL in vacuo, diluted with H2O (20 mL) and washed with cyclohexane 
(3 x 25 mL). The pH of the aqueous layer was reduced to ~3 through 
addition of 1 M HCl (6 mL). The resulting precipitate was dissolved in 
EtOAc (25 mL) and the aqueous layer extracted with EtOAc (3 x 25 mL) 
and the combined organic extracts dried over MgSO4.  The solvent was 
removed in vacuo to give the title compound 4-8 as a thick colourless gel. 
Yield:  2.115 g, 6.1 mmol, 89% 
HRMS (ESI): m/z calculated for C16H31N2O6 [M+H]
+
 347.2186 found 
347.2117 (-2.6 ppm error), C16H30FN2NaO6 [M+Na]
+
 369.1987 found 
369.1996 (2.4 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm): 5.27 (d, 
2
JH-H 7.0 Hz, 1H,  H-14), 
4.68 (br s, 1H, H-13), 4.31 (br s, 1H, H-2), 3.11 (br s, 2H, H-6), 1.85 (br s, 
1H, H-3
a
), 1.73 (br s, 1H, H-3
b
), 1.51-1.47 (m, 4H, H-4/5), 1.44 (s, 18H,  
H-9/12) 
13
C NMR (100 MHz, CDCl3) δ (ppm): 176.3 (C-1), 156.7 (C-7/10), 156.1 
(C-7/10), 79.8 (C-8/11), 79.2 (C-8/11), 52.9 (C-2), 39.8 (C-6), 31.7 (C-3), 
29.0 (C-5), 28.0 (C-9/12), 28.0 (C-9/12), 22.0 (C-4) 
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IR (ATIR) (cm
-1
):  3334.4 br m (O-H), 2977.7 m (C-H), 2933.0 m (C-H), 
1687.6 s (C=O) 
Characterisation data consistent with literature.
245
 
 
Benzyl 7-(4-(tert-butoxycarbonyl)piperazin-1-yl)-1-cyclopropyl-6-
fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate, 4-9 
 
 
 
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-
carboxylic acid (1-5) (2.008 g, 6.06 mol) was suspended in 1,4-
dioxane:H2O (1:1, 40 mL) and 1 M NaOH (10 mL) was added.  The 
mixture was stirred for 1 h.  Di-tert-butyl dicarbonate (2.030 g, 9.30 mmol) 
was added and stirring continued for 19.5 h.  The reaction mixture was 
concentrated in vacuo to ~¼ volume and acetone (50 mL) added to give a 
precipitate (2.308 g).  The precipitate (2.010 g) and Cs2CO3 (2.429 g, 7.45 
mmol) were suspended in DMF (50 mL) and stirred at room temperature 
for 1 h.  BnBr (1.5 mL, 2.157 g, 12.61 mmol) was added and stirring 
continued for 23 h.  The solvent was removed in vacuo and the residue 
dissolved in CHCl3 (150 mL).  The organic phase was washed with H2O (2 
x 100 mL) and brine (100 mL).  The organic phase was dried over MgSO4, 
and the solvent removed in vacuo to give a solid.  The solid was suspended 
in Et2O (100 mL), filtered and washed with Et2O, and then purified by 
column chromatography (1:1 EtOAc:CHCl3) to give the title compound 4-9 
as a colourless solid. 
Yield:  1.383 g, 2.65 mmol, 51% 
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m.p.  195.3 - 197.8 °C (lit. 191 - 193 °C 
126
) 
Rf  0.41 (1:1 EtOAc:CHCl3) 
HRMS (ESI): m/z calculated for C29H33FN3O5 [M+H]
+
 522.2399 found 
522.2423 (-4.7 ppm error), C29H32FN3NaO5 [M+Na]
+
 544.2218 found 
544.2232 (-2.4 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  8.54 (s, 1H, H-4), 8.09 (d, 
3
JH-F 
13.5 Hz, 1H, H-8), 7.53 (m, 2H, H-11/20), 7.26-7.40 (m, 4H, H-18/19), 
5.40 (s, 2H, H-16), 3.66 (m, 4H, H-13), 3.41 (m, 1H, H-3), 3.22 (m, 4H, H-
14), 1.50 (s, 9H, H-23), 1.31 (m, 2H, H-1
a
/2
a
), 1.13 (m, 2H, H-1
b
/2
b
) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  172.9 (C-6), 165.5 (C-15), 154.6 
(C-21), 153.3 (d, 
1
JC-F 248.3 Hz, C-9), 148.3 (C-4), 144.4 (d, 
2
JC-F 10.5 Hz, 
C-10), 137.9 (C-12/17), 136.4 (C-12/17), 128.5 (C-18/19/20), 127.9 (C-
18/19/20), 127.9 (C-18/19/20), 123.3 (d, 
3
JC-F 6.7 Hz, C-7), 113.4 (d, 
2
JC-F 
23.0 Hz, C-8), 110.1 (C-5), 105.0 (d, 
3
JC-F 2.9 Hz, C-11), 80.2 (C-22), 66.3 
(C-16), 49.9 (C-13/14). 49.8 (C-13/14), 34.5 (C-3), 28.4 (C-23), 8.1 (C-
1/2) 
19
F NMR (376 MHz, CDCl3) δ (ppm):  -123.6 (dd, 
3
JH-F 13.5 Hz, 
4
JH-F 6.5 
Hz) 
IR (ATIR) (cm
-1
):  2979.9 m (C-H), 1698.4 s (C=O), 1623.0 s (C=O), 
1588.9 m (C=C) 
Characterisation data consistent with literature.
126
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Benzyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylate trifluoroacetic acid salt, 4-10 
 
 
 
Benzyl 7-(4-(tert-butoxycarbonyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-
4-oxo-1,4-dihydroquinoline-3-carboxylate (4-9) (1.239 g, 2.38 mmol) was 
dissolved in CH2Cl2 (50 mL).  Trifluoroacetic acid (5 mL) was added and 
the mixture stirred at room temperature for 17 h.  The reaction was 
concentrated in vacuo.  The residue was dissolved in EtOH (10 x 20 mL) 
and the solvent removed in vacuo to remove residual trifluoroacetic acid 
and give the title compound 4-10 as a cream solid. 
Yield:  1.270 g, 2.38 mmol, 100% 
m.p.  229.1 - 231.3 °C (lit. 250 -255 °C dec. for HCl salt 
126
) 
HRMS (ESI): m/z calculated for C24H25FN3O3 [M+H]
+
 422.1874 found 
422.1878 (-0.8 ppm error), C24H24FN3NaO3 [M+H]
+
 444.1694 found 
444.1713 (-4.2 ppm error) 
1
H NMR (400 MHz, DMSO-d6) δ (ppm):  9.20 (br s, 2H, -NH2), 8.47 (s, 
1H, H-4), 7.78 (d, 
3
JH-F 13.5 Hz, 1H, H-8), 7.31-7.50 (m, 6H, H-
11/18/19/20), 5.27 (s, 2H, H-16), 3.66 (m, 1H, H-3), 3.45 (m, 6H, H-
13/14), 3.34 (m, 2H, H-13/14), 1.24 (m, 2H, H-1
a
/2
a
), 1.09 (m, 2H, H-
1
b
/2
b
) 
13
C NMR (100 MHz, DMSO-d6) δ (ppm):  171.6 (d, 
4
JC-F 1.9 Hz, C-6), 
164.6 (C-15), 152.5 (d, 
1
JC-F 246.3 Hz, C-9), 148.6 (C-4), 142.8 (d, 
2
JC-F 
10.5 Hz, C-10), 138.0 (C-12/17), 136.6 (C-12/17), 128.4 (C-18/19/20), 
127.8 (C-18/19/20), 127.6 (C-18/19/20), 122.6 (d, 
3
JC-F 6.7 Hz, C-7), 111.8 
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(d, 
2
JC-F 22.0 Hz, C-8), 108.9 (C-5), 106.8 (d, 
3
JC-F 2.9 Hz, C-11), 65.3 (C-
16), 46.6 (d, 
4
JC-F 3.8 Hz, C-13), 42.7 (C-14), 34.9 (C-3), 7.6 (C-1/2) 
19
F NMR (376 MHz, DMSO-d6) δ (ppm):  -73.6 (s), -124.5 (dd, 
3
JH-F 13.5 
Hz, 
4
JH-F 7.9 Hz) 
IR (ATIR) (cm
-1
):  3488.6 br w, 2968.8 m (C-H), 2843.3 m (C-H), 2742.9 
m (C-H), 2544.1 m, 1708.4 s (C=O), 1688.3 s (C=O), 1613.7 s (C=C) 
Characterisation data consistent with literature.
126
 
 
(S)-benzyl 7-(4-(2,6-bis((tert-
butoxycarbonyl)amino)hexanoyl)piperazin-1-yl)-1-cyclopropyl-6-
fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate, 4-11 
 
 
 
Benzyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylate trifluoroacetic acid salt (4-10) (0.376 g, 
0.70 mmol), (S)-2,6-bis((tert-butoxycarbonyl)amino)hexanoic acid (4-8) 
(0.246 g, 0.71 mmol), HOBt.H2O (0.096 g, 0.71 mmol), EDC.HCl (0.138 
g, 0.72 mmol) and DIPEA (0.185 mL, 0.138 g, 1.06 mmol) were dissolved 
in anhydrous DMF (25 mL).  The mixture was stirred at room temperature 
for 18.5 h.  The reaction mixture was concentrated in vacuo, the residue 
taken up in H2O (80 mL) and extracted with CH2Cl2 (3 x 100 mL).  The 
combined organic extracts were washed with H2O (80 mL), 0.05 M HCl 
(80 mL), 0.05 M NaHCO3 (80 mL), brine (80 mL) and H2O (80 mL).  The 
organic phased was dried over MgSO4, and the solvent removed in vacuo 
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and the residue purified by column chromatography (20:1 CHCl3:MeOH) 
to give the title compound 4-11 as a colourless solid. 
Yield:  0.290 g, 0.386 mmol, 55% 
m.p.  103.1 - 105.4 °C 
Rf  0.19 (20:1 CHCl3:MeOH) 
HRMS (ESI): m/z calculated for C40H53FN5O8 [M+H]
+
 750.3873 found 
750.3873 (-0.0 ppm error), C40H52FN5NaO8 [M+H]
+
 772.3692 found 
752.3690 (0.2 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  8.55 (s, 1H, H-4), 8.10 (d, 
3
JH-F 
12.9 Hz, 1H, H-8), 7.53 (m, 2H, H-11/32), 7.29-7.40 (m, 4H, H-30/31), 
5.43 (d, 
3
JH-H 9.2 Hz, -NH), 5.40 (s, 2H, H-28), 4.63 (m, 2H, H-17/-NH), 
3.73 (m. 4H, H-13), 3.42 (m. 1H. H-3), 3.09-3.30 (m. 6H, H-14/21), 1.74 
(m, 1H, H-18
a
), 1.55 (m, 3H, H-18
b
/20), 1.43 (m, 20H, H-19/24/27), 1.33 
(m, 2H, H-1
a
/2
a
), 1.13 (m, 2H, H-1
b
/2
b
) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  172.9 (d, 
4
JC-F 1.9 Hz, C-6), 170.8 
(C-16), 165.5 (C-15), 156.0 (C-22/25), 155.6 (C-22/25), 153.3 (d, 
1
JC-F 
248.3 Hz, C-9), 148.4 (C-4), 143.8 (d, 
2
JC-F 10.5 Hz, C-10), 137.9 (C-
12/29), 136.4 (C-12/29), 128.5 (C-30/31/32), 127.9 (C-30/31/32), 127.9 
(C-30/31/32), 123.6 (d, 
3
JC-F 6.7 Hz, C-7), 113.5 (d, 
2
JC-F 23.0 Hz, C-8), 
110.2 (C-5), 105.2 (d, 
3
JC-F 2.9 Hz, C-11), 79.8 (C-22/25), 79.1 (C-22/25), 
66.4 (C-28), 50.3 (C-13), 49.7 (C-17), 45.4 (C-14), 41.8 (C-19), 40.1 (C-
21), 34.5 (C-3), 33.2 (C-18), 29.5 (C-20), 28.4 (C-24/27), 28.3 (C-24/27), 
22.3 (C-18), 8.1 (C-1/2) 
19
F NMR (376 MHz, CDCl3) δ (ppm):  -123.8 (dd, 
3
JH-F 12.9 Hz, 
4
JH-F 7.2 
Hz) 
IR (ATIR) (cm
-1
):  3321.1 br w, 2975.2 m (C-H), 1693.8 s (C=O), 1620.7 s 
(C=O) 
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(S)-benzyl 1-cyclopropyl-7-(4-(2,6-diaminohexanoyl)piperazin-1-yl)-6-
fluoro-oxo-1,4-dihydroquinoline-3-carboxylate trifluoroacetic acid salt, 
4-12 
 
 
 
(S)-Benzyl 7-(4-(2,6-bis((tert-butoxycarbonyl)amino)hexanoyl)piperazin-
1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (4-
11) (0.502 g, 0.67 mmol) was dissolved in CH2Cl2 (50 mL).  
Trifluoroacetic acid (2 mL) was added and the mixture stirred at room 
temperature for 16 h.  The solvent was removed in vacuo.  The residue was 
dissolved in EtOH (20 x 20 mL) and the solvent removed in vacuo to 
remove residual trifluoroacetic acid and give the title compound 4-12 as a 
cream solid. 
Yield:  0.520 g, 0.67 mmol, 100% 
m.p.  68.1 - 71.1 °C (dec.), 97.4 - 99.7 °C 
HRMS (ESI): m/z calculated for C30H37FN5O4 [M+H]
+
 550.2824 found 
550.2819 (1.0 ppm error), C30H36FN5NaO4 [M+H]
+
 572.2644 found 
552.2632 (0.2 ppm error) 
1
H NMR (400 MHz, CD3OD) δ (ppm):  8.54 (s, 1H, H-4), 7.67 (d, 
3
JH-F 
12.8 Hz, 1H, H-8), 7.44 (m, 2H, H-11/29), 7.34 (m, 4H, H-24/25), 5.27 (s, 
2H, H-22), 4.58 (m, 1H, H-17), 3.94 (m, 1H, H-14), 3.72 (m, 3H, H-14), 
3.54 (m, 1H, H-13), 3.35 (m, 2H, H-13), 3.20 (m, 1H, H-13), 3.00 (m, 2H, 
H-21), 1.93 (m, 2H, H-18), 1.77 (m, 2H, H-19/20), 1.58 (m, 2H, H-19/20), 
1.26 (m, 2H, H-1
a
/2
a
), 1.06 (m, 2H, H-1
b
/2
b
) 
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13
C NMR (100 MHz, CD3OD) δ (ppm):  175.2 (C-6), 168.9 (C-16), 165.7 
(C-15), 154.7 (d, 
1
JC-F 248.3 Hz, C-9), 150.2 (C-4), 145.7 (d, 
2
JC-F 10.5 Hz, 
C-10), 139.7 (d, 
4
JC-F 1.9 Hz, C-12), 137.9 (C-23), 129.8 (C-24/25/26), 
129.4 (C-24/25/26), 129.4 (C-24/25/26), 121.1 (C-7), 113.2 (d, 
2
JC-F 24.0 
Hz, C-8), 109.8 (C-5), 107.5 (d, 
3
JC-F 1.9 Hz, C-11), 67.3 (C-22), 51.6 (C-
17), 51.2 (d, 
4
JC-F 3.8 Hz, C-13), 50.7 (d, 
4
JC-F 2.9 Hz, C-13), 46.6 (C-14), 
43.4 (C-14), 40.4 (C-21), 36.5 (C-3), 31.6 (C-18), 28.3 (C-20), 22.7 (C-19), 
8.7 (C-1/2) 
19
F NMR (376 MHz, CD3OD) δ (ppm):  -76.7 (s), -124.4 (m) 
IR (ATIR) (cm
-1
):  3414.7 w (N-H), 2950.4 m (C-H), 1672.5 s (C=O), 
1621.7 s (C=O), 1478.7 s (C-H bend) 
 
Methyl 2,3-dihydroxybenzoate, 4-14 
 
 
 
2,3-Dihydroxybenzoic acid (4-13) (2.008 g, 13.03 mmol) was dissolved in 
MeOH (17 mL) and conc. H2SO4 (0.7 mL) was added.  The mixture was 
heated under reflux for 23 h, then cooled to room temperature and 
concentrated in vacuo.  The residue was dissolved in EtOAc (70 mL) 
washed with sat. aq. NaHCO3 (3 x 30 mL) and brine (2 x 30 mL). The 
organic phase was dried over MgSO4, filtered and the solvent removed in 
vacuo to give the title compound 4-14 a pale yellow solid. 
Yield:  1.981 g, 11.78 mmol, 90% 
m.p.  79.6 - 81.2 °C (lit. 77 - 80 °C 
270
) 
Rf  0.19 (1:9 EtOAc:Petroleum Ether 40-60) 
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HRMS (ESI): m/z calculated for C8H8NaO4 [M+Na]+ 191.0315 found 
191.0313 (1.0 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm): 10.92 (s, 1H, -OH), 7.37 (dd, 3JH-H 
8.1 Hz, 
4
JH-H 1.5 Hz, 1H, H-6), 7.12 (m, 1H, H-4), 6.80 (t, 
3
JH-H 8.1 Hz, 
1H, H-5), 5.74 (s, 1H, -OH), 3.96 (s, 3H, H-8) 
13
C NMR (100 MHz, CDCl3) δ (ppm): 171.2 (C-7), 149.2 (C-2), 145.3 (C-
3), 120.8 (C-6), 120.0 (C-5), 119.4 (C-4), 112.5 (C-1), 52.3 (C-8) 
IR (ATIR) (cm
-1
):  3453.8 br s (O-H), 2956.5 w (C-H), 1668.3 s (C=O) 
Characterisation data consistent with literature.
207, 208, 270
 
 
Methyl 3-(benzyloxy)-2-hydroxybenzoate, 4-15 
 
 
 
Methyl 2,3-dihydroxybenzoate (4-14) (0.495 g, 2.94 mmol) was dissolved 
in MeOH (20 mL) with K2CO3 (0.407 g, 2.94 mmol).  BnBr (0.35 mL, 
0.503 g, 2.94 mmol) was added and the reaction mixture heated under 
reflux for 19.5 h under an inert atmosphere.  The reaction mixture was 
cooled to room temperature and concentrated in vacuo.  The residue was 
taken up in EtOAc (60 mL) and washed with H2O (40 mL) and brine (2 x 
40 mL).  The organic layer was dried over MgSO4, and the solvent 
removed in vacuo to give an oily residue  The residue was purified by 
column chromatography (1:9 EtOAc:Petroleum Ether 40-60) to give the 
title compound 4-15 as a colourless solid. 
Yield:  0.245 g, 0.95 mmol, 32% 
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m.p.  63.3 - 65.1 °C (lit. 69.5 - 70.5 °C 
271
) 
Rf  0.31 (1:9 EtOAc:Petroleum Ether 40-60) 
HRMS (ESI): m/z calculated for C15H15O4 [M+H]
+
 259.0965 found 
259.0964 (0.3 ppm error), C15H14NaO4 [M+Na]
+ 
281.0784 found 281.0784 
(0.1 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  11.05 (s, 1H, -OH), 7.48 – 7.29 (m, 
6H, H-4/11/12/13), 7.06 (dd, 
3
JH-H 8.1 Hz, 
4
JH-H 1.1 Hz, 1H, H-6), 6.76 (t, 
3
JH-H 8.1 Hz, 1H, H-5), 5.18 (s, 2H, H-9), 3.96 (s, 3H, H-1) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  170.9 (C-2), 152.8 (C-8), 147.5 (C-
7), 136.9 (C-10), 128.7 (C-12), 128.1 (C-13), 127.5 (C-11), 121.9 (C-4), 
119.8 (C-5), 118.5 (C-6), 113.0 (C-3), 71.4 (C-9), 52.5 (C-1) 
IR (ATIR) (cm
-1
):  3057.8 w (C-H), 3028.5 m (C-H), 2948.8 m (C-H), 
2873.9 w (C-H), 1728.0 s (C=O) 
Characterisation data consistent with literature.
207, 208
 
 
Methyl 2,3-bis(benzyloxy)benzoate, 4-20 
 
 
 
Isolated during the synthesis of 4-15. 
HRMS (ESI): m/z calculated for C22H21O5 [M+H]
+
 349.1434 found 
349.1431 (1.0 ppm error), C22H20NaO5 [M+Na]
+
 371.1254 found 371.1250 
(1.0 ppm error) 
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1
H NMR (400 MHz, CDCl3) δ (ppm):  7.33-7.48 (m, 11H, H-
6/11/12/13/16/17/18), 7.16 (dd, 
3
JH-H 7.9 Hz, 
4
JH-H 1.1 Hz, 1H, H-6), 7.10 
(t, 
3
JH-H 7.9 Hz, 1H, H-5), 5.16 (s, 2H, H-9/14), 5.13 (s, 2H, H-9/14), 3.86 
(s, 3H, H-8) 
Characterisation data consistent with literature.
270
 
 
Methyl 3-(benzyloxyl)-2-hydroxy-5-iodobenzoate, 4-16 
 
 
 
Methyl 3-benzyloxy)-2-hydroxybenzoate (4-15) (0.100 g, 0.39 mmol) was 
dissolved in MeOH (2 mL).  NaI (0.087 g, 0.58 mmol) and NaOH (0.023 g, 
0.58 mmol) were added and the solution cooled to 0 °C.  NaClO (10-15%, 
0.48 mL) was added dropwise and the reaction mixture allowed to warm to 
room temperature and stirred for 18 h.  The mixture was quenched with 
Na2S2O3 (10%, 3 mL) and adjusted to pH 7 with 1 M HCl.  The aqueous 
phase was extracted with Et2O (20 mL) and the combined organic phase 
dried over MgSO4, and concentrated in vacuo.  The residue was purified by 
column chromatography (1:9 EtOAc:Petroleum Ether 40-60) to give the 
title compound 4-16 as a pale yellow solid. 
Yield:  0.021 g, 0.05 mmol, 14% 
m.p.  138.1 - 139.2 °C 
Rf  0.28 (1:9 EtOAc:Petroleum Ether 40-60) 
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HRMS (ESI): m/z calculated for C15H14IO4 [M+H]
+
 384.9931 found 
384.9932 (-0.3 ppm error), C15H13INaO4 [M+Na]
+ 
406.9751 found 
406.9753 (-0.5 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm): 11.01 (s, 1H, -OH), 7.79 (d, 
4
JH-H 
1.8 Hz, 1H, H-6), 7.32-7.47 (m, 5H, H-4/11/12/13), 5.13 (s, 2H, H-9), 3.96 
(s, 3H, H-8) 
Characterisation data consistent with literature.
208
 
 
Methyl 2-hydroxy-5-iodo-3-methoxybenzoate, 4-22 
 
 
 
Iodine monochloride (0.825 mL, 2.673 g, 1.65 mmol) was dissolved in 
CHCl3 (25 mL) then added dropwise over 30 min. to a solution of AgNO3 
(2.816 g, 1.66 mmol) in CHCl3 (30 mL) and pyridine (20 mL).  The 
mixture was stirred for 1 h at room temperature, then a solution of methyl-
3-methoxysalicylate (4-21) (1.999 g, 1.10 mmol) in CHCl3 (25 mL) was 
added dropwise over 30 min, and stirring was continued for 22 h.  The 
mixture was diluted with Et2O (100 mL), the insoluble material filtered off 
and washed with a mixture of CHCl3:Et2O (1:1, 200 mL).  The combined 
filtrates were concentrated in vacuo, giving a solid-residue which was 
dissolved in CHCl3 (200 mL) and washed with 0.1 M hydrochloric acid 
(100 mL), sat. aq. Na2S2O3 (2 x 100 mL) and H2O (100 mL).  The organic 
layer was dried over MgSO4, and concentrated in vacuo.  The residual solid 
was recrystallised with hot EtOH and co-crystallised with a minimal 
amount of H2O to induce precipitation. The resulting precipitate was 
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filtered and washed with cold H2O to give the title compound 4-22 as a 
pale yellow solid. 
Yield:  2.286 g, 0.74 mmol, 68% 
m.p.  112.4 - 114.3 °C 
Rf  0.20 (10% EtOAc in Petroleum Ether 40-60) 
HRMS (ESI):  m/z calculated for C9H10IO4 [M+H]
+
 308.9618 found 
308.9619 (-0.1 ppm error), C9H9INaO4 [M+Na]
+
 330.9438 found 330.9426 
(3.6 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  10.98 (s, 1H, -OH), 7.74 (d, 
4
JH-H 
2.1 Hz, 1H, H-4/6), 7.23 (d, 
4
JH-H 2.1 Hz, 1H, H-4/6), 3.95 (s, 3H, H-8), 
3.88 (s, 3H, H-9) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  169.5 (C-7), 152.0 (C-2/3), 149.3 
(C-2/3), 129.5 (C-4/6), 124.9 (C-4/6), 114.1 (C-1), 79.2 (C-5), 56.4 (C-9), 
52.6 (C-8) 
IR (ATIR) (cm
-1
):  3087.2 w (C-H), 2982.5 w (C-H), 2942.1 w (C-H), 
1672.6 m (C=O) 
 
Methyl 2,3-dihydroxy-5-iodobenzoate, 4-23 
 
 
 
Methyl 2-hydroxy-5-iodo-3-methoxybenzoate (4-22) (4.052 g, 13.15 
mmol) was dissolved in CH2Cl2 (10 mL).  BBr3 (1 M in CH2Cl2, 22 mL, 22 
mmol) was added and the mixture stirred at room temperature for 17.5 h.  
Ice cold H2O (25 mL) was slowly added and the mixture stirred for a 
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further 1 h.  The reaction was concentrated in vacuo.  MeOH was added 
then removed in vacuo (3 x 100 mL).  The residue was dissolved in MeOH 
(100 mL) and conc. H2SO4 (4 mL), and heated under reflux for 18.5 h.  The 
reaction was concentrated in vacuo, the residue dissolved in EtOAc (300 
mL) and washed with sat. aq. NaHCO3 (3 x 150 mL) and brine (2 x 150 
mL).  The organic layer was dried over over MgSO4, the solvent removed 
in vacuo to give the title compound 4-23 as a pale brown solid. 
Yield:  3.512 g, 11.94 mmol, 91% 
m.p.  136.1 - 137.6 °C 
Rf  0.14 (1:9 EtOAc:Petroleum Ether 40-60) 
HRMS (ESI):  m/z calculated for C8H8IO4 [M+H]
+
 294.9462 found 
294.9457 (1.7 ppm error), C9H7INaO4 [M+Na]
+
 316.9281 found 316.9274 
(2.2 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  10.89 (s, 1H, -OH), 7.70 (d, 
4
JH-H 
2.3 Hz, 1H, H-4/6), 7.40 (d, 
4
JH-H 2.3 Hz, 1H, H-4/6), 5.67 (br s, 1H, -OH), 
3.97 (s, 3H, H-8) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  169.6 (C-7), 148.9 (C-2/3), 146.0 
(C-2/3), 129.2 (C-4/6), 128.3 (C-4/6), 114.1 (C-1), 80.1 (C-5), 52.8 (C-8) 
IR (ATIR) (cm
-1
):  3448.7 br s (O-H), 3088.0 m (C-H), 2956.5 m (C-H), 
1663.5 s (C=O) 
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Methyl 2,3-bis(benzyloxy)-5-iodobenzoate, 4-5 
 
 
 
A mixture of methyl 2,3-dihydroxy-5-iodobenzoate (4-23) (1.499 g, 5.09 
mmol), NaI (0.057 g, 0.38 mmol) and K2CO3 (3.110 g, 22.50 mmol) were 
suspended in anhydrous DMF (30 mL).  BnBr (3.9 mL, 5.608 g, 32.79 
mmol) was added and the mixture stirred at room temperature for 19 h.  
The reaction was concentrated in vacuo and the residue partitioned 
between EtOAc (100 mL) and H2O (60 mL).  The layers were separated 
and the aqueous phase extracted with EtOAc (2 x 100 mL).  The combined 
organic extracts were dried over MgSO4, filtered and the solvent removed 
in vacuo to give a solid residue which was purified by column 
chromatography (1:9 EtOAc:Petroleum Ether 40-60) to give the title 
compound 4-5 as a colourless solid. 
Yield:  1.730 g, 3.65 mmol, 72% 
m.p.  101.9 - 102.8 °C (lit. 105 - 106 °C 
207
) 
Rf  0.26 (1:9 EtOAc:Petroleum Ether 40-60) 
HRMS (ESI):  m/z calculated for C22H19INaO4 [M+Na]
+
 497.0220 found 
497.0230 (-2.0 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  7.70 (d, 
4
JH-H 1.8 Hz, 1H, H-4/6), 
7.30-7.46 (m, 11H, H-4/6/10/11/12/15/16/17), 5.11 (s, 2H, H-8/13), 5.07 
(s, 2H, H-8/13), 3.85 (s, 3H, H-18) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  165.2 (C-7), 153.5 (C-2/3), 148.2 
(C-2/3), 137.0 (C-5/9/14), 135.8 (C-5/9/14), 131.5 (C-5/9/14), 128.7 (C-
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4/6/10/11/12/15/16/17), 128.6 (C-4/6/10/11/12/15/16/17), 128.4 (C-
4/6/10/11/12/15/16/17), 128.3 (C-4/6/10/11/12/15/16/17), 128.1 (C-
4/6/10/11/12/15/16/17), 127.6 (C-4/6/10/11/12/15/16/17), 126.5 (C-
1/4/6/10/11/12/15/16/17), 86.3 (C-5), 75.1 (C-8/13), 71.5 (C-8/13), 52.4 
(C-18) 
IR (ATIR) (cm
-1
):  3027.9 w (C-H), 1716.7 s (C=O) 
Characterisation data consistent with literature.
207
 
 
Methyl 2,3-bis(benzyloxy)-5-formylbenzoate, 4-24 
 
 
 
By-product isolated during the synthesis of 4-7. 
HRMS (ESI): m/z calculated for C23H20NaO5 [M+Na]
+
 399.1203 found 
399.1189 (3.5 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  9.92 (s, 1H, H-19), 7.89 (d, 
4
JH-H 
2.0 Hz, 1H, H-4/6), 7.68 (d, 
4
JH-H 2.0 Hz, 1H, H-4/6), 7.31-7.48 (m, 10H, 
H-11/12/13/16/17/18), 5.22 (s, 2H, H-9/14), 5.20 (s, 2H, H-9/14), 3.89 (s, 
3H, H-8) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  Crude spectrum indicated 190.4 
(C-19) 
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(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3,4-bis(benzyloxy)-5-
(methoxycarbonyl)phenyl)tetrahdyro-2H-3,4,5-triyl triacetate, 4-7 
 
 
 
Part 1: 
To a flame dried Schlenk flask in a glove box was added Zn (0.186 g, 2.84 
mmol,) and LiCl (0.077 g, 1.82 mmol).  The flask was taken from the glove 
box and heated at 70 °C for 1.75 h in vacuo.  A solution of I2 (0.029 g, 0.11 
mmol) and methyl 2,3-bis(benzyloxy)-5-iodobenzoate (4-5) (0.775 g, 1.63 
mmol) in anhydrous DMF (3.3 mL) was added to the flask via syringe. The 
resultant mixture was stirred at 70 °C for 1 h under an inert atmosphere to 
give 4-6 (~0.5 M concentration in DMF). 
 
Part 2: 
To a flame dried Schlenk flask in a glove box was added 4,4’,4”-tri-tert-
butyl-2,2’:6’2”-terpyridine (0.066 g, 0.17 mmol), bis(1,5-
cyclooctadiene)nickel(0) (0.032 g, 0.12 mmol) and anhydrous DMF (2 
mL).  The mixture was stirred for 15 min and then acetobromo-α-D-
glucose (0.402 g, 0.98 mmol) was added. The flask was taken from the 
glove box and the solution of 4-6 (~0.5 M in DMF, 3.2 mL) was added via 
syringe, and the mixture stirred at room temperate under an inert 
atmosphere for 19 h. 
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Work-Up/Purification: 
The reaction mixture was concentrated in vacuo and the residue purified by 
silica gel chromatography (1:1 EtOAc:Petroleum Ether 40-60) to give the 
title compound 4-7 as a colourless solid. 
Yield:  0.420 g, 0.62 mmol, 63% 
m.p.  124.1 - 126.6 °C (lit. 128 - 129 °C 
207
) 
Rf  0.36 (1:1 EtOAc:Petroleum Ether 40-60) 
HRMS (ESI):  m/z calculated for C36H38NaO13 [M+Na]
+
 701.2205 found 
701.2195 (1.4 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  7.48-7.29 (m, 11H, H-
4/10/11/12/15/16/17), 7.22 (d, 
4
JH-H 2.3 Hz, 1H, H-6), 5.34 (t, 
3
JH-H 9.6 Hz, 
1H, H-20), 5.24 (t, 
3
JH-H 9.6 Hz, 1H, H-21), 5.16-5.08 (m, 5H, H-8/13/19), 
4.39 (d, 
3
JH-H 10.1 Hz, 1H, H-18), 4.30 (dd, 
2
JH-H 12.4 Hz, 
3
JH-H 5.0 Hz, 1H, 
H-23
a
), 4.18 (dd, 
2
JH-H 12.4 Hz, 
3
JH-H 2.3 Hz, 1H, H-23
b
), 3.86 (m, 1H, H-
22), 3.84 (s, 3H, H-32), 2.11 (s, 3H, H-25/27/29/31), 2.08 (s, 3H, H-
25/27/29/31), 2.02 (s, 3H, H-25/27/29/31), 1.83 (s, 3H, H-25/27/29/31) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  170.6 (C-24/26/28/30), 170.2 (C-
24/26/28/30), 169.5 (C-24/26/28/30), 168.9 (C-24/26/28/30), 166.2 (C-7), 
153.1 (C-3), 148.5 (C-2), 137.1 (C-9/14), 136.2 (C-9/14), 132.0 (C-5), 
128.5 (C-10/11/12/15/16/17), 128.2 (C-10/11/12/15/16/17), 128.1 (C-
10/11/12/15/16/17), 127.9 (C-10/11/12/15/16/17), 127.6 (C-
10/11/12/15/16/17), 126.2 (C-1), 122.1 (C-4), 115.7 (C-6), 79.4 (C-18), 
76.2 (C-22), 75.5 (C-8/13), 74.0 (C-20), 72.2 (C-19), 71.3 (C-8/13), 68.5 
(C-23), 62.3 (C-23), 52.1 (C-32), 20.7 (C-25/27/29/31), 20.6 (C-
25/27/29/31), 20.3 (C-25/27/29/31) 
IR (ATIR) (cm
-1
):  2950.3 w (C-H), 1739.6 s (C=O), 1713.9 s (C=O) 
Characterisation data consistent with literature.
207
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Methyl 2,3-bis(benzyloxy)-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxyl)-
6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)benzoate, 2-17 and 
benzyl 2,3-bis(benzyloxy)-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxyl)-6-
((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)benzoate, 2-18 
 
 
 
(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3,4-bis(benzyloxy)-5-
(methoxycarbonyl)phenyl)tetrahdyro-2H-3,4,5-triyl triacetate (4-7) (0.777 
g, 1.14 mmol) and Na2CO3 (0.607 g, 5.73 mmol) were suspended in 
anhydrous MeOH (50 mL).  The mixture was heated under reflux for 18 h.  
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The cooled mixture was filtered and the residue washed with MeOH (3 x 
20 mL).  The reaction mixture was concentrated in vacuo to give a solid 
residue.  To the solid was added NaH (60% dispersion in oil, 0.314 g, 7.85 
mmol) and anhydrous DMF (15 mL).  The mixture was stirred at 0 °C for 
15 min.  A solution of tetrabutylammonium iodide (0.047 g, 0.13 mmol) 
and BnBr (1.8 mL, 1.250 g, 7.3 mmol) in anhydrous DMF (5 mL) was 
added over 5 min.  The reaction was stirred at 0 °C for 5 min  then at room 
temperature for 19 h.  To the reaction mixture was added H2O (20 mL) and 
extracted with EtOAc (5 x 50 mL).  The combined organic extracts were 
dried over MgSO4, and the solvent removed in vacuo to give an oily 
residue which was purified by column chromatography (2:8 
EtOAc:Petroleum Ether 40-60) to give the title compounds 4-17 and 4-18 
as two colourless solids (combined yield 74%). 
 
Compound 4-17: 
Yield:  0.476 g, 0.55 mmol, 48% 
Rf  0.16 (2:8 EtOAc:Petroleum Ether 40-60) 
HRMS (ESI):  m/z calculated for C56H54NaO9 [M+Na]
+
 893.3660 found 
893.3676 (-1.8 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  7.51 (d, 
4
JH-H 1.5 Hz, 1H, H-6), 
7.31-7.46 (m, 24H, H-Ar), 7.21 (m, 5H, H-Ar), 6.95 (m, 2H, H-Ar), 5.12 
(s, 2H, H-8), 5.00 (s, 2H, H-13), 4.87-4.97 (m, 3H, H-24/29/39), 4.58-4.68 
(m, 3H, H-23/24/29), 4.46 (d, 
3
JH-H 9.9 Hz, 1H, H-23), 4.22 (d, 
3
JH-H 9.2 
Hz, 1H, H-18), 3.86 (s, 3H, H-44), 3.76-3.82 (m, 5H, H-20/21/24/34), 3.61 
(m, 1H, H-22), 3.44 (t, 
3
JH-H 9.2 Hz, 1H, H-19) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  166.4 (C-7), 152.7 (C-3), 148.0 (C-
2), 138.6 (C-5/9/14/25/30/35/40), 138.3 (C-5/9/14/25/30/35/40), 138.1 (C-
5/9/14/25/30/35/40), 137.4 (C-5/9/14/25/30/35/40), 136.4 (C-
5/9/14/25/30/35/40), 135.1 (C-5/9/14/25/30/35/40), 128.7 (C-Ar), 128.5 
(C- Ar), 128.4 (C- Ar), 128.4 (C- Ar), 128.3 (C- Ar), 128.3 (C- Ar), 128.1 
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(C- Ar), 128.0 (C- Ar), 128.0 (C- Ar), 127.8 (C- Ar), 127.7 (C- Ar), 127.6 
(C- Ar), 127.6 (C- Ar), 127.6 (C- Ar), 126.4 (C- Ar), 121.9 (C-6), 116.7 
(C-4), 86.7 (C-20), 84.0 (C-19), 80.9 (C-18), 79.3 (C-22), 78.2 (C-21), 75.7 
(C-8/13/23/24/29/34/39), 75.6 (C-8/13/23/24/29/34/39), 75.2 (C-
8/13/23/24/29/34/39), 75.0 (C-8/13/23/24/29/34/39), 73.4 (C-
8/13/23/24/29/34/39), 71.2 (C-8/13/23/24/29/34/39), 69.0 (C-
8/13/23/24/29/34/39) 
Ar = 10/11/12/15/16/17/26/27/28/31/32/33/36/37/38/41/42/43 
Characterisation data consistent with literature.
207
 
 
Compound 4-18: 
Yield:  0.287 g, 0.30 mmol, 26% 
Rf  0.20 (2:8 EtOAc:Petroleum Ether 40-60) 
HRMS (ESI):  m/z calculated for C62H58NaO9 [M+Na]
+
 969.3973 found 
969.3977 (-0.4 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  7.52 (d, 
4
JH-H 1.7 Hz, 1H, H-6), 
7.29-7.43 (m, 27H, H-Ar), 7.14-7.29 (m, 9H, H-4/Ar), 6.95 (m, 2H, H-Ar), 
5.36 (d, 
1
JH-H 12.4 Hz, 1H, H-44
a
), 5.32 (d, 
1
JH-H 12.4 Hz, 1H, H-44
b
), 5.10 
(d, 
1
JH-H 10.1 Hz, 1H, H-8
a
), 5.08 (d, 
1
JH-H 10.1 Hz, 1H, H-8
b
), 5.00 (s, 2H, 
H-13), 4.88-4.97 (m, 3H, H-24/29/39), 4.66 (d, 
1
JH-H 11.4 H, 2H, H-
23/24/29), 4.59 (d, 
1
JH-H 12.4 H, 1H, H-23/24/29), 4.45 (
1
JH-H 10.5 H, 1H, 
H-23), 4.23 (d, 
3
JH-H 9.2 Hz, 1H, H-18), 3.77-3.83 (m, 5H, H-20/21/24/34), 
3.62 (m, 1H, H-22), 3.46 (t, 
3
JH-H 9.4 Hz, H-19), 3.61 (m, 1H, H-22), 3.44 
(t, 
3
JH-H 9.2 Hz, 1H, H-19) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  165.9 (C-7), 152.5 (C-3), 148.0 (C-
2), 138.6 (C-5/9/14/25/30/35/40/45), 138.2 (C-5/9/14/25/30/35/40/45), 
138.1 (C-5/9/14/25/30/35/40/45), 137.4 (C-5/9/14/25/30/35/40/45), 137.2 
(C-5/9/14/25/30/35/40/45), 136.3 (C-5/9/14/25/30/35/40/45), 135.9 (C-
5/9/14/25/30/35/40/45), 135.1 (C-5/9/14/25/30/35/40/45), 128.7 (C-Ar), 
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128.5 (C-Ar), 128.4 (C- Ar), 128.4 (C- Ar), 128.4 (C- Ar), 128.3 (C- Ar), 
128.2 (C- Ar), 128.2 (C- Ar), 128.1 (C- Ar), 128.1 (C- Ar), 128.0 (C- Ar), 
127.9 (C- Ar), 127.8 (C- Ar), 127.8 (C- Ar), 127.7 (C- Ar), 127.6 (C- Ar), 
127.6 (C- Ar), 127.6 (C- Ar), 126.4 (C- Ar), 122.0 (C-6), 116.5 (C-4), 86.6 
(C-20), 83.9 (C-19), 80.9 (C-18), 79.3 (C-22), 78.2 (C-21), 75.6 (C-
8/13/23/24/29/34/39/44), 75.6 (C-8/13/23/24/29/34/39/44), 75.1 (C-
8/13/23/24/29/34/39/44), 75.0 (C-8/13/23/24/29/34/39/44),  73.4 (C-
8/13/23/24/29/34/39/44), 71.0 (C-8/13/23/24/29/34/39/44), 68.9 (C-
8/13/23/24/29/34/39/44) ), 67.0 (C-8/13/23/24/29/34/39/44) 
Ar = 10/11/12/15/16/17/26/27/28/31/32/33/36/37/38/41/42/43/46/47/48 
 
2,3-bis(benzyloxy)-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-
((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)benzoic acid, 4-19 
 
 
 
A mixture of methyl 2,3-bis(benzyloxy)-5-((2S,3S,4R,5R,6R)-3,4,5-
tris(benzyloxyl)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)benzoate, 
(4-17) and benzyl 2,3-bis(benzyloxy)-5-((2S,3S,4R,5R,6R)-3,4,5-
tris(benzyloxyl)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)benzoate, 
(4-18) (0.190 g) were dissolved in THF:MeOH (3:1, 20 mL).  5 M NaOH 
(5 mL) was added and the mixture stirred at room temperature for 14 h.  
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The mixture was acidified to pH 2.79 with 6 M HCl (~2 mL) and extracted 
with CH2Cl2 (5 x 30 mL).  The combined organic extracts were dried over 
MgSO4, and the solvent removed in vacuo to give an oily residue which 
was purified by column chromatography (30:1 CHCl3:MeOH) to give the 
title compound 4-19 as a colourless solid. 
Yield:  0.150 g, 0.17 mmol, 87% 
m.p.  93.3 - 95.8 °C (lit. 94 - 96 °C 
207
) 
Rf  0.44 (30:1 CHCl3:MeOH) 
HRMS (ESI):  m/z calculated for C55H52NaO9 [M+Na]
+
 879.3504 found 
879.3516 (-1.4 ppm error) 
1
H NMR (700 MHz, CDCl3) δ (ppm):  11.27 (br s, 1H, -OH), 7.88 (d, 
4
JH-H 
1.7 Hz, 1H, H-6), 7.28-7.43 (m, 23H, H-Ar), 7.26 (d, 
4
JH-H 1.7 Hz, 1H, H-
4), 7.21 (m, 5H, H- Ar), 6.95 (m, 2H, H- Ar), 5.27 (d, 
1
JH-H 10.3 Hz, 1H, 
H-8
a
), 5.25 (d, 
1
JH-H 10.3 Hz, 1H, H-8
b
), 5.00 (d, 
1
JH-H 11.0 Hz, 1H, H-13
a
), 
4.97 (d, 
1
JH-H 11.0 Hz, 1H, H-13
b
), 4.95 (d, 
1
JH-H 11.1 Hz, 1H, H-29
a
), 4.93 
(d, 
1
JH-H 11.1 Hz, 1H, H-29
b
), 4.87 (d, 
1
JH-H 10.8 Hz, 1H, H-34
a
), 4.64 (d, 
1
JH-H 10.8 Hz, 1H, H-34
b
), 4.64 (d, 
1
JH-H 12.5 Hz, 1H, H-39
a
), 4.58 (d, 
1
JH-H 
12.5 Hz, 1H, H-39
b
), 4.48 (d, 
1
JH-H 10.8 Hz, 1H, H-24
a
), 4.24 (d, 
3
JH-H 9.3 
Hz, 1H, H-18), 3.84 (d, 
1
JH-H 10.8 Hz, 1H, H-24
b
), 3.82 (t, 
3
JH-H 9.2 Hz, 
1H, H-20), 3.76 (d, 
3
JH-H 3.2 Hz, 2H, H-23), 3.74 (t, 
3
JH-H 9.3 Hz, 1H, H-
21), 3.62 (dt, 
3
JH-H 9.3, 
3
JH-H 3.2 Hz, 1H, H-22), 3.43 (t, 
3
JH-H 9.3 Hz, 1H, 
H-19) 
13
C NMR (100 MHz, CDCl3) δ (ppm):  165.2 (C-7), 151.0 (C-3), 146.5 (C-
2), 138.5 (C-30), 138.1 (C-35/40), 138.0 (C-35/40), 137.7 (C-25), 136.3 
(C-5), 135.7 (C-9), 134.6 (C-14), 129.3 (C- Ar), 129.2 (C- Ar), 128.7 (C- 
Ar), 128.7 (C- Ar), 128.5 (C- Ar), 128.4 (C- Ar), 128.4 (C- Ar), 128.2 (C- 
Ar), 128.1 (C- Ar), 128.0 (C- Ar), 127.8 (C- Ar), 127.7 (C- Ar), 127.7 (C- 
Ar), 127.6 (C- Ar), 127.6 (C- Ar), 127.6 (C- Ar), 123.1 (C-6), 122.8 (C-1), 
117.7 (C-4), 86.7 (C-20), 83.6 (C-19), 80.5 (C-18), 79.3 (C-22), 78.2 (C-
21), 76.9 (C-8), 75.6 (C-29), 75.1 (C-34), 74.9 (C-24), 73.4 (C-39), 71.2 
(C-13), 69.0 (C-23) 
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IR (ATIR) (cm
-1
):  3063.1 w (C-H), 3031.1 w (C-H), 2863.7 w (C-H), 
1697.9 m (C=O), 1605.8 w (C=O) 
Ar = 10/11/12/15/16/17/26/27/28/31/32/33/36/37/38/41/42/43 
Characterisation data consistent with literature.
207
 
 
Benzyl 7-(4-((S)-2,6-bis(2,3-bis(benzyloxy)-5-((2S,3S,4R,5R,6R)-3,4,5-
tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-
yl)benzamido)hexanoyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-
1,4-dihydroquinoline-3-carboxylate, 4-25 
 
 
 
Method A: 
2,3-bis(benzyloxy)-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-
((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)benzoic acid (2-19) (0.023 
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g, 0.03 mmol) was dissolved in anhydrous CH2Cl2 (2 mL) and anhydrous 
DMF (0.02 mL).  Thionyl chloride (0.05 mL) was added and the mixture 
stirred at room temperature for 3 h.  The mixture was concentrated in 
vacuo then dried for 2 h.  The residue was dissolved in anhydrous CH2Cl2 
(5 mL) a solution of (S)-benzyl 1-cyclopropyl-7-(4-(2,6-
diaminohexanoyl)piperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinolne-3-
carboxylate trifluoroacetic acid salt (4-12) (0.011 g, 0.01 mmol) and Et3N 
(0.05 mL) in anhydrous CH2Cl2 (1 mL) was added at 0 °C.  The mixture 
was warmed to room temperature and stirred for 19 h.  The reaction was 
concentrated in vacuo to give an oily residue which was purified by 
column chromatography (3:2 CHCl3:EtOAc) to give the title compound 4-
25 as a colourless solid. 
Yield:  0.006 g, 0.003 mmol, 19% 
 
Method B: 
A mixture of (S)-benzyl 1-cyclopropyl-7-(4-(2,6-
diaminohexanoyl)piperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinolne-3-
carboxylate trifluoroacetic acid salt (4-12) (0.228 g, 0.29 mmol), 2,3-
bis(benzyloxy)-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-
((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)benzoic acid (2-19) (0.552 
g, 0.64 mmol), HOBt.H2O (0.122 g, 0.90 mmol), EDC.HCl (0.141 g, 0.73 
mmol) and DIPEA (1.5 mL, 2.022 g, 15.6 mmol) were dissolved in 
anhydrous CH2Cl2 (40 mL).  The mixture was stirred at room temperature 
for 19 h.  The reaction was concentrated in vacuo.  The residue was 
dissolved in EtOAc (200 mL) and washed with 0.1 M HCl (100 mL), 0.1 
M NaHCO3 (100 mL), brine (100 mL) and H2O (100 mL).  The organic 
layer was dried over MgSO4, and the solvent removed in vacuo to give a 
solid residue which was purified by column chromatography (4:1 to 3:2 
CHCl3:MeCN) to give the title compound 4-25 as a colourless solid. 
Yield:  0.275 g, 0.12 mmol, 42% 
Rf  0.28  (3:2 CHCl3:MeCN) 
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HRMS (ESI):  m/z calculated for C140H137FN5NaO20 [M+Na]
+ 
2249.9733 
found 2249.9665 (3.0 ppm error) 
1
H NMR (400 MHz, CDCl3) δ (ppm):  8.68 (d, 
3
JH-H 7.8 Hz, 1H, -NH), 
8.51 (s, 1H, H-47), 8.12 (d, 
3
JH-F 12.8 Hz, 1H, H-51), 7.88 (m, 3H, H-6/6’/-
NH), 7.53 (m, 2H, H-51/Ar), 7.28-7.42 (m, 46H, H-51/Ar), 7.17-7.25 (m, 
16H, H-Ar), 6.96 (m, 4H, H-Ar), 5.41 (s, 2H, H-64), 5.27 (d, 
1
JH-H 10.5 Hz, 
1H, H-8/8’), 5.09 (m, 3H, H-8/8’/60), 5.02 (d, 1JH-H 10.5 Hz, 1H, H-8/8’), 
4.98 (s, 4H, H-39/39’), 4.93 (m, 4H, H-29/29’/34/34’/39/39’), 4.88 (d, 1JH-
H 10.5 Hz, 2H, H-29/29’/34/34’/39/39’), 4.63 (d, 
1
JH-H 10.5 Hz, 2H, H-
29/29’/34/34’/39/39’), 4.63 (d, 1JH-H 12.6 Hz, 2H, H-29/29’/34/34’/39/39’), 
4.56 (d, 
1
JH-H 12.6 Hz, 2H, H-29/29’/34/34’/39/39’) 4.44 (d, 
1
JH-H 10.5 Hz, 
1H, H-24/24’), 4.44 (d, 1JH-H 10.5 Hz, 1H, H-24/24’), 4.26 (d, 
3
JH-H 9.6 Hz, 
1H, H-18/18’), 4.19 (d, 3JH-H 9.2 Hz, 1H, H-18/18’), 3.90-4.01 (m, 3H, H-
56/57), 3.72-3.86 (m, 13H, H-20/20’/21/21’/24/24’/56/57), 3.62 (m, 2H, H-
22/22’), 3.50 (m, 4H, H-19/19’), 3.31 (m, 3H, H-46/56/57), 3.24 (m, 4H, 
H-56/57/64), 1.82 (m, 1H, H-61), 1.71 (m, 1H, H-61), 1.48 (m, 1H, H-62), 
1.23-1.35 (m, 7H, H-44/45/62/63), 1.03 (m, 2H, H-44/45) 
Ar = 10/10’/11/11’/12/12’/15/15’/16/16’/17/17’/26/26’/27/27’/28/28’/31 
/31’/32/32’/33/33’/36/36’/37/37’/41/41’/42/42’/43/43’ 
13
C NMR (125 MHz, CDCl3) δ (ppm):  173.0 (C-49), 170.5 (C-59), 165.6 
(C-58), 164.7 (C-7/7’), 164.5 (C-7/7’), 153.4 (d, 1JC-F 249.3 Hz, C-52), 
151.5 (C-3/3’), 151.4 (C-3/3’), 148.3 (C-47), 146.5 (C-2/2’), 146.2 (C-
2/2’), 144.0 (d, 2JC-F 11.0 Hz, C-53), 138.7 (C-Ara), 138.6 (C-Ara), 138.2 
(C-Ara), 138.2 (C-Ara), 138.1 (C-Ara), 138.1 (C-Ara), 137.9 (C-Ara), 137.7 
(C-Ara), 137.6 (C-Ara), 136.4 (C-Ara), 136.2 (C-Ara), 136.2 (C-Ara), 136.1 
(C-Ara), 136.1 (C-Ara), 135.6 (C-Ara), 135.5 (C-Ara), 129.0 (C-Arb), 128.8 
(C-Arb), 128.7 (C-Arb), 128.6 (C-Arb), 128.4 (C-Arb), 128.4 (C-Arb), 128.4 
(C-Arb), 128.4 (C-Arb), 128.3 (C-Arb), 128.2 (C-Arb), 128.2 (C-Arb), 128.2 
(C-Arb), 128.1 (C-Arb), 128.1 (C-Arb), 128.1 (C-Arb), 127.9 (C-Arb), 127.9 
(C-Arb), 127.9 (C-Arb), 127.8 (C-Arb), 127.8 (C-Arb), 127.7 (C-Arb), 127.7 
(C-Arb), 127.6 (C-Arb), 127.6 (C-Arb), 127.6 (C-Arb), 127.5 (C-Arb), 127.5 
(C-Arb), 127.1 (C-Arb), 126.5 (C-Arb), 123.5 (d, 
3
JC-F 6.4 Hz, C-50), 122.1 
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(C-6/6’), 122.1 (C-6/6’), 116.3 (C-4/4’), 115.8 (C-4/4’), 113.5 (d, 3JC-F 22.9 
Hz, C-51), 110.1 (C-48), 105.3 (d, 
3
JC-F 1.8 Hz, C-54), 86.7 (C-
20/20’/21/21’), 86.6 (C-20/20’/21/21’), 83.9 (C-19/19’), 83.8 (C-19/19’), 
81.1 (C-18/18’), 81.0 (C-18/18’), 79.3 (C-22/22’), 79.3 (C-22/22’), 78.3 
(C-20/20’/21/21’), 76.3 (C-8/8’), 76.0 (C-8/8’), 75.5 (C-
29/29’/34/34’/39/39’), 75.5 (C-29/29’/34/34’/39/39’), 75.1 (C-
29/29’/34/34’/39/39’), 75.0 (C-29/29’/34/34’/39/39’), 74.8 (C-24/24’), 74.8 
(C-24/24’), 73.4 (C-29/29’/34/34’/39/39’), 73.3 (C-29/29’/34/34’/39/39’), 
71.2 (C-13/13’), 71.0 (C-13/13’), 69.2 (C-23/23’), 69.1 (C-23/23’), 66.3 
(C-48), 50.2 (C-56/57), 49.9 (C-56/57), 48.7 (C-60), 45.6 (C-56/57), 41.9 
(C-56/57), 39.3 (C-64), 34.5 (C-46), 32.4 (C-61), 29.2 (C-62), 23.1 (C-62), 
8.1 (C-44/45) 
Ara = 1/1’/5/5’/9/9’/14/14’/25/25’/30/30’/35/35’/40/40’/66 
Arb = 10/10’/11/11’/12/12’/15/15’/16/16’/17/17’/26/26’/27/27’/28/28’/31/ 
31/31’/32/32’/33/33’/36/36’/37/37’/38/38’/41/41’/42/42’/43/43’/67/68/69 
19
F NMR (376 MHz, CDCl3) δ (ppm):  -123.6 (m) 
IR (ATIR) (cm
-1
):  3030.3 w (C-H), 2862.9 w (C-H), 1728.8 m (C=O), 
1690.6 m (C=O), 1644.0 s (C=O), 1621.1 s (C=O) 
Elemental Analysis:  Calculated for [C140H136FN5O20.0.35CHCl3] %C 
74.28, %H 6.06, %N 3.09, Measured for [C140H136FN5O20.0.35CHCl3] %C 
74.28, %H 6.08, %N 3.07 
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7-(4-((S)-2,6-bis(2,3-dihydroxy-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)benzamido)hexanoyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-
1,4-dihydroquinoline-3-carboxylic acid, 4-3 
 
 
 
Benzyl 7-(4-((S)-2,6-bis(2,3-bis(benzyloxy)-5-((2S,3S,4R,5R,6R)-3,4,5-
tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-
yl)benzamido)hexanoyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylate (4-25) (0.125 g, 0.06 mmol) was dissolved 
in MeOH:EtOAc (1:1, 50 mL).  Pd(OH)2/C (20 wt. %, 0.192 g) was added 
and the mixture purged with N2.  The mixture was stirred under H2 for 17 
h, then filtered and washed with MeOH (50 mL).  The filtrate was 
concentrated in vacuo to give a residue.  The residue was taken up in 
MeOH (50 mL) and filtered again.  The solvent was removed in vacuo to 
leave a solid residue which was purified by reverse phase preparative 
HPLC to give the title compound 4-3 as a white solid. 
Preparative HPLC:  Preparative HPLC Method A.  Compound elutes at 
9.24 minutes. 
Analytical HPLC:  Analytical HPLC Method C.  Compound elutes at 9.53 
minutes. 
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Yield:  0.027 g, 0.03 mmol 45% 
m.p.  225.3 - 228.2 °C (dec.) 
HRMS (ESI):  m/z calculated for C49H58FN5NaO20 [M+Na]
+
 1078.3551 
found 1078.3557 (-0.5 ppm error), C49H57FN5O20 [M-H]
-
 1054.3586 found 
1054.3556 (2.8 ppm error) 
1
H NMR (700 MHz, DMSO-D6) δ (ppm):  8.66 (s, 1H, H-4), 7.93 (d, 
3
JH-F 
13.2 Hz, 1H, H-8), 7.56 (d, 
4
JH-F 6.6 Hz, 1H), 7.43 (br. s, 1H, H-
24/26/37/39), 7.25 (br. s, 1H, H-24/26/37/39), 6.91 (br. s, 1H, H-
24/26/37/39), 6.87 (br. s, 1H, H-24/26/37/39), 4.96-5.01 (m, 2H, H-
13/14/17/29/30/31/32/33/34/42/43/44/45/46/47), 3.80-3.87 (m, 8H, H-
13/14/17/29/30/31/32/33/34/42/43/44/45/46/47), 3.66-3.68 (m, 5H, H-
13/14/17/29/30/31/32/33/34/42/43/44/45/46/47), 3.15-3.31 (m, 14H, H-
13/14/17/29/30/31/32/33/34/42/43/44/45/46/47), 1.77-1.83 (m, 2H, H-18), 
1.58 (m, 2H, H-20), 1.41 (m, 2H, H-19), 1.28 (m, 2H, H-1
a
/2
a
), 1.15 (m, 
2H, H-1
b
/2
b
) 
13
C NMR (175 MHz, DMSO-D6) δ (ppm):  176.4 (C-6), 169.8 (C-
16/22/35), 169.7 (C-16/22/35), 168.6 (C-16/22/35), 165.9 (C-15), 152.9 (d, 
1
JC-F 250.0 Hz, C-9), 149.2 (C-27/28/40/41), 148.1 (C-27/28/40/41), 145.6 
(C-27/28/40/41), 144.8 (C-10), 139.2 (C-7), 118.9 (C-12/24/26/37/39), 
118.4 (C-12/24/26/37/39), 116.9 (C-24/26/37/39), 114.7 (C-24/26/37/39), 
114.0 (C-24/26/37/39), 111.0 (d, 
2
JC-F 24.1 Hz, H-8), 106.8 (C-11), 81.6 
(C-29/30/31/32/33), 81.6 (C-29/30/31/32/33), 81.3 (C-29/30/31/32/33), 
81.2 (C-29/30/31/32/33), 78.4 (C-29/30/31/32/33), 78.4 (C-
29/30/31/32/33), 74.1 (C-29/30/31/32/33), 74.1 (C-29/30/31/32/33), 70.5 
(C-29/30/31/32/33), 70.4 (C-29/30/31/32/33), 61.4 (C-34/47), 49.6 (C-
13/14/17), 49.3 (C-13/14/17), 48.9 (C-13/14/17), 44.8 (C-13/14), 38.8 (C-
21), 35.9 (C3), 31.0 (C-18), 28.8 (C-20), 22.9 (C-19), 7.6 (C-1/2), 7.6 (C-
1/2) 
19
F NMR (376 MHz, DMSO-D6) δ (ppm):  -121.6 (m) 
IR (ATIR) (cm
-1
):  3330.6 br s (O-H), 2951.8 w (C-H), 1704.9 w (C=O), 
1625.5 s (C=O), 1445.8 s, 1332.0 m, 1257.9 s (C-O) 
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Elemental Analysis:  Calculated for [C49H58FN5O20.2.3H2O.9.4CH2O2] 
%C 45.84, %H 5.36, %N 4.58, Measured for 
[C49H58FN5O20.2.3H2O.9.4CH2O2] %C 45.30, %H 4.80, %N 5.15 
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7.3 1H NMR study into the base hydrolysis of 3-16 
 
Compound 3-16 (2.7 mg) was dissolved in CD3OD (1 mL) and EtOH (0.1 
mL).  0.7 mL of the solution was added to an NMR tube and a 
1
H NMR 
spectrum collected (400MHz spectrometer - Figure 95).  NaOD (40% in 
D2O, 7 µL) was added and a spectrum 
1
H NMR collected at time points: 1, 
2, 4, 22, 31, 52, 92 and 168 h.  The % ratio of species observed is listed in 
Table 12 and plotted in Chapter 3. 
 
 
Figure 95 - 
1
H NMR spectrum of the aromatic region of compound 3-16 in 
CD3OD, prior to the addition of NaOD. 
 
Time (h) Compound 
3-16 
Ciprofloxacin 
1-5 
1 (8.55 
ppm) 
2 (8.65 
ppm) 
3 (8.52 
ppm) 
0 100 0 0 0 0 
1 76 6 0 12 6 
2 72 6 0 16 6 
4 63 6 6 19 6 
22 33 27 13 20 7 
31 26 27 20 20 7 
52 20 40 20 13 7 
92 14 65 14 0 7 
168 0 86 7 0 7 
Table 12 - Ciprofloxacin containing species (%).  As a reference to 
determine the % ratios between the species in the spectrum by their relative 
integration, the NMR solvent was spiked with EtOH as a standard.  
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7.4 Biological Studies 
 
Bacterial Strains 
 
Two bacterial strains were used: E. coli BW25113 Wild Type and 
BW25113 FecA::kan.
60, 272
 
 
Media 
 
All solutions and media were prepared using MilliQ deionised H2O and 
sterilised by autoclave prior to use.  The antibiotic kanamycin was also 
added where required.  LB media was prepared using 10 g tryptone, 5 g of 
yeast extract and 10 g NaCl per litre.  M9 minimal media was prepared 
using 6 g Na2HPO4, 3 g KH2PO4, 1 g NH4Cl and 0.5 g NaCl per litre and 
adjusted to pH 7.  After autoclaving, the solution was supplemented with 
sterilised solutions of 20% w/v glucose, 1 M MgSO4 and 1 M CaCl. 
 
Growth Assays 
 
O/D650 measurements 
 
Optical densities were recorded to 3 decimal places using a Jenway 6305 
spectrophotometer in plastic cuvettes with a 1 cm path length, and are 
accurate to ±0.0005.  These values were used to normalise the OD650 of 
each culture prior to use in each growth assay. 
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Plate reader 
 
The plate reader used was a BMG LabTech FLUOstar Omega plate reader.  
The OD650 was measured every 30 minutes for 16 hours.  The plate was 
shaken at 200 RPM between each measurement to maintain aerobic 
bacterial growth.  Blank wells were measured for their optical densities and 
subtracted from the sample wells to normalise the OD650 measurements 
used for data analysis. 
 
Growth assay 
 
Cultures of the selected strain were inoculated into 5 mL of media and 
shaken at 37 °C overnight.  The OD650 of each were normalised prior to use 
in the assay.  To a 96 well plate was added (Figure 96): sterile H2O (200 
µL) in all perimeter wells; media (198 µL) in blank wells; media (193 µL) 
into remaining wells; specific concentrations of antimicrobial into each 
well (2 µL); normalised bacterial culture into each well (5 µL); DMSO into 
0 µM row/DMSO row (2 µL); H2O into blank wells (2 µL).  The plate was 
placed into the plate reader and the experiment run as described above. 
 
Figure 96 - 96 well plate layout. 
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DNA Gyrase Assay 
 
Agarose gel electrophoresis 
 
TAE running buffer was prepared using 750 mL of H2O, 48.4 g/L of Tris, 
22.8 mL of glacial acetic acid, 200 mL of 29.2 g/L EDTA.  The solution 
was made up to 1 L using H2O.  To produce a working concentration of 
TAE buffer the solution was diluted by 1 in 10 in H2O.  The agarose gels 
used were prepared using 1% w/v agarose in 1 x TAE buffer. 
 
Stop buffer 
 
To terminate the assay a combination of 24:1 solution of 
chloroform/isoamyl alcohol and stop buffer were used.  The stop buffer 
was prepared using 40% w/v sucrose, 12.11 g/L Tris·HCl (pH 7.5), 0.29 
g/L EDTA and 0.5 mg/mL of bromophenol blue. 
 
DNA gyrase assay buffer 
 
A pre-prepared kit from Inspiralis contained the DNA gyrase assay buffer.  
The buffer contained 3.92 g/L Tris·HCl (pH 7.5), 1.79 g/L KCl, 0.38 g/L 
MgCl2, 0.3 g/L dithiothreitol, 0.26 g/L spermidine, 0.5 g/L ATP, 6.5% 
(w/v) glycerol and 0.1 mg/mL BSA. 
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DNA Gyrase Assay 
 
Stock solutions of ciprofloxacin and the conjugates were prepared in 0.1 M 
acetic acid and DMSO, respectively.  The antimicrobial compounds were 
combined with relaxed pBR322 DNA, DNA gyrase and assay buffer in 
H2O at fixed proportions (Table 13).  The solutions were incubated at 37 
°C for 30 minutes.  The assay was stopped with the addition of 30 µL of 
24:1 CHCl3:isoamyl alcohol and 30 µL stop buffer.  A portion of 20 µL 
was loaded into a 1% agarose gel.  The gel was subjected to electrophoresis 
for 80 minutes at 80 volts.  The gel was then stained using ethidium 
bromide for 20 minutes and photographed using a gel doc. 
 
Antimicrobial 
Concentration (µM) 
[Solution conc. Used] 
Vol. of 
Anti. (µL) 
Diluted 
Gyrase 
(µL) 
Assay 
Buffer 
(µL) 
pBR322 
(µL) 
H2O 
(µL) 
Positive Control 0 2 6 0.5 21.5 
Negative Control 0 0 6 0.5 23.5 
100 [300 µM] 10 2 6 0.5 11.5 
75 [300 µM] 7.5 2 6 0.5 14 
50 [300 µM] 5 2 6 0.5 16.5 
40 [300 µM] 4 2 6 0.5 17.5 
30 [300 µM] 3 2 6 0.5 18.5 
20 [600 µM] 1 2 6 0.5 20.5 
10 [300 µM] 1 2 6 0.5 20.5 
5 [150 µM] 1 2 6 0.5 20.5 
1 [30 µM] 1 2 6 0.5 20.5 
0.5 [15 µM] 1 2 6 0.5 20.5 
0 [0 µM] 1 (DMSO) 2 6 0.5 20.5 
Table 13 - Volumes of solutions added to each sample for the DNA gyrase 
assay.
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Appendix I. Crystal Data for Compound 2-39 
 
 
 
Table: Crystal data and structure refinement for akdk1401a (2-39).  
Identification code  akdk1401a  
Empirical formula  C28H31FN4O10  
Formula weight  602.57  
Temperature/K  110.05(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  10.3489(3)  
b/Å  11.1094(4)  
c/Å  12.6060(4)  
α/°  76.067(3)  
β/°  73.907(3)  
γ/°  76.812(3)  
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Volume/Å
3
  1331.14(9)  
Z  2  
ρcalcmg/mm
3
  1.503  
m/mm
-1
  0.120  
F(000)  632.0  
Crystal size/mm
3
  0.2282 × 0.1592 × 0.0624  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection  5.972 to 64.252°  
Index ranges  -15 ≤ h ≤ 14, -15 ≤ k ≤ 15, -17 ≤ l ≤ 17  
Reflections collected  12410  
Independent reflections  8324 [Rint = 0.0195, Rsigma = 0.0431]  
Data/restraints/parameters  8324/9/427  
Goodness-of-fit on F
2
  1.119  
Final R indexes [I>=2σ (I)]  R1 = 0.0631, wR2 = 0.1478  
Final R indexes [all data]  R1 = 0.0849, wR2 = 0.1597  
Largest diff. peak/hole / e Å
-3
  0.44/-0.41  
 
Structure solved by Natalie Pridmore.  
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Appendix II. Individual Growth Assay Plots for Compound 2-12 
 
 
Figure 97 - E. coli BW25113WT growth in LB media with drug 
concentrations of 0 µM for both ciprofloxacin 1-5 and conjugate 2-12.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
 
 
Figure 98 - E. coli BW25113WT growth in LB media with drug 
concentrations of 0.01 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
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Figure 99 - E. coli BW25113WT growth in LB media with drug 
concentrations of 0.1 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
 
 
Figure 100 - E. coli BW25113WT growth in LB media with drug 
concentrations of 0.5 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
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Figure 101 - E. coli BW25113WT growth in LB media with drug 
concentrations of 1 µM for both ciprofloxacin 1-5 and conjugate 2-12.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
 
 
Figure 102 - E. coli BW25113WT growth in LB media with drug 
concentrations of 10 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
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Figure 103 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 0 µM for both ciprofloxacin 1-5 and conjugate 2-12.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
 
 
Figure 104 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 0.01 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate for 2-12 and triplicate for 
ciprofloxacin, and the error bars show one standard deviation from the 
mean. 
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Figure 105 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 0.1 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
 
 
Figure 106 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 0.5 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
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Figure 107 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 1 µM for both ciprofloxacin 1-5 and conjugate 2-12.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
 
 
Figure 108 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 10 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
 349 
 
 
 
Figure 109 - E. coli BW25113 FecA::kan growth in LB media with drug 
concentrations of 0 µM for both ciprofloxacin 1-5 and conjugate 2-12.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
 
 
Figure 110 - E. coli BW25113 FecA::kan growth in LB media with drug 
concentrations of 0.01 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
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Figure 111 - E. coli BW25113 FecA::kan growth in LB media with drug 
concentrations of 0.1 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
 
 
Figure 112 - E. coli BW25113 FecA::kan growth in LB media with drug 
concentrations of 0.5 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
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Figure 113 - E. coli BW25113 FecA::kan growth in LB media with drug 
concentrations of 1 µM for both ciprofloxacin 1-5 and conjugate 2-12.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
 
 
Figure 114 - E. coli BW25113 FecA::kan growth in LB media with drug 
concentrations of 10 µM for both ciprofloxacin 1-5 and conjugate 2-12.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
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Figure 115 - E. coli BW25113 FecA::kan growth in M9 minimal media 
with drug concentrations of 0 µM for both ciprofloxacin 1-5 and conjugate 
2-12.  The experiment was run in quadruplicate for 2-12 and triplicate for 
ciprofloxacin, and the error bars show one standard deviation from the 
mean. 
 
 
Figure 116 - E. coli BW25113 FecA::kan growth in M9 minimal media 
with drug concentrations of 0.01 µM for both ciprofloxacin 1-5 and 
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conjugate 2-12.  The experiment was run in quadruplicate and the error 
bars show one standard deviation from the mean. 
 
 
Figure 117 - E. coli BW25113 FecA::kan growth in M9 minimal media 
with drug concentrations of 0.1 µM for both ciprofloxacin 1-5 and 
conjugate 2-12.  The experiment was run in quadruplicate and the error 
bars show one standard deviation from the mean. 
 
 
Figure 118 - E. coli BW25113 FecA::kan growth in M9 minimal media 
with drug concentrations of 0.5 µM for both ciprofloxacin 1-5 and 
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conjugate 2-12.  The experiment was run in quadruplicate and the error 
bars show one standard deviation from the mean. 
 
 
Figure 119 - E. coli BW25113 FecA::kan growth in M9 minimal media 
with drug concentrations of 1 µM for both ciprofloxacin 1-5 and conjugate 
2-12.  The experiment was run in quadruplicate and the error bars show 
one standard deviation from the mean. 
 
 
Figure 120 - E. coli BW25113 FecA::kan growth in M9 minimal media 
with drug concentrations of 10 µM for both ciprofloxacin 1-5 and 
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conjugate 2-12.  The experiment was run in quadruplicate and the error 
bars show one standard deviation from the mean. 
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Appendix III. Individual Growth Assay Plots for Compound 4-3 
 
 
Figure 121 - E. coli BW25113WT growth in LB media with drug 
concentrations of 0 µM for both ciprofloxacin 1-5 and conjugate 4-3.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
 
 
Figure 122 - E. coli BW25113WT growth in LB media with drug 
concentrations of 0.01 µM for both ciprofloxacin 1-5 and conjugate 4-3.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
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Figure 123 - E. coli BW25113WT growth in LB media with drug 
concentrations of 0.1 µM for both ciprofloxacin 1-5 and conjugate 4-3.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
 
 
Figure 124 - E. coli BW25113WT growth in LB media with drug 
concentrations of 0.5 µM for both ciprofloxacin 1-5 and conjugate 4-3.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
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Figure 125 - E. coli BW25113WT growth in LB media with drug 
concentrations of 1 µM for both ciprofloxacin 1-5 and conjugate 4-3.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
 
 
Figure 126 - E. coli BW25113WT growth in LB media with drug 
concentrations of 10 µM for both ciprofloxacin 1-5 and conjugate 4-3.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
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Figure 127 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 0 µM for both ciprofloxacin 1-5 and conjugate 4-3.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
 
 
Figure 128 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 0.01 µM for both ciprofloxacin 1-5 and conjugate 4-3.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
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Figure 129 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 0.1 µM for both ciprofloxacin 1-5 and conjugate 4-3.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
 
 
Figure 130 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 0.5 µM for both ciprofloxacin 1-5 and conjugate 4-3.  
The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
 
 361 
 
 
Figure 131 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 1 µM for both ciprofloxacin 1-5 and conjugate 4-3.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
 
 
Figure 132 - E. coli BW25113WT growth in M9 minimal media with drug 
concentrations of 10 µM for both ciprofloxacin 1-5 and conjugate 4-3.  The 
experiment was run in quadruplicate and the error bars show one standard 
deviation from the mean. 
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Figure 133 - E. coli BW25113WT growth in 0.2 µM [Fe(III)] M9 media 
with drug concentrations of 0 µM for both ciprofloxacin 1-5 and conjugate 
4-3.  The experiment was run in quadruplicate and the error bars show one 
standard deviation from the mean. 
 
 
Figure 134 - E. coli BW25113WT growth in 0.2 µM [Fe(III)] M9 minimal 
media with drug concentrations of 0.01 µM for both ciprofloxacin 1-5 and 
conjugate 4-3.  The experiment was run in quadruplicate and the error bars 
show one standard deviation from the mean. 
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Figure 135 - E. coli BW25113WT growth in 0.2 µM [Fe(III)] M9 minimal 
media with drug concentrations of 0.1 µM for both ciprofloxacin 1-5 and 
conjugate 4-3.  The experiment was run in quadruplicate and the error bars 
show one standard deviation from the mean. 
 
 
Figure 136 - E. coli BW25113WT growth in 0.2 µM [Fe(III)] M9 minimal 
media with drug concentrations of 0.5 µM for both ciprofloxacin 1-5 and 
conjugate 4-3.  The experiment was run in quadruplicate and the error bars 
show one standard deviation from the mean. 
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Figure 137 - E. coli BW25113WT growth in 0.2 µM [Fe(III)] M9 minimal 
media with drug concentrations of 1 µM for both ciprofloxacin 1-5 and 
conjugate 4-3.  The experiment was run in quadruplicate and the error bars 
show one standard deviation from the mean. 
 
 
Figure 138 - E. coli BW25113WT growth in 0.2 µM [Fe(III)] M9 minimal 
media with drug concentrations of 10 µM for both ciprofloxacin 1-5 and 
conjugate 4-3.  The experiment was run in quadruplicate and the error bars 
show one standard deviation from the mean. 
 365 
 
Appendix IV. Supporting spectra for compound 4-19 
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Figure 139 - Full 
13
C spectrum (CDCl3) of 4-19. 
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Figure 140 - Full 
1
H spectrum (CDCl3) of 4-19. 
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Figure 141 - Full HMBC spectrum (CDCl3) of 4-19. 
 
 369 
 
 
Figure 142 - Full HMQC spectrum (CDCl3) of 4-19. 
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Figure 143 - Full COSY spectrum (CDCl3) of 4-19. 
 371 
 
 
Figure 144 - Full DEPT spectrum (CDCl3) of 4-19.
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Figure 145 - HMBC spectrum (CDCl3) of 4-19. 
 
 
Figure 146 - HMQC spectrum (CDCl3) of 4-19. 
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Figure 147 - HMBC spectrum (CDCl3) of 4-19. 
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Appendix V. Supporting spectra for compound 4-25 
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Figure 148 - Full 
1
H spectrum (CDCl3) of 4-25. 
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Figure 149 - Full 
13
C spectrum (CDCl3) of 4-25. 
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Figure 150 - Full HMBC spectrum (CDCl3) of 4-25. 
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Figure 151 - Full HMQC spectrum (CDCl3) of 4-25. 
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Figure 152 - Full COSY spectrum (CDCl3) of 4-25. 
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Figure 153 - Full DEPT spectrum (CDCl3) of 4-25. 
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Figure 154 - HMBC spectrum (CDCl3) of 4-25. 
 
 
Figure 155 - HMQC spectrum (CDCl3) of 4-25. 
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Figure 156 - HMBC spectrum (CDCl3) of 4-25. 
 
 
Figure 157 - HMBC spectrum (CDCl3) of 4-25. 
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Figure 158 - HMBC spectrum (CDCl3) of 4-25. 
 
 
Figure 159 - HMBC spectrum (CDCl3) of 4-25. 
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Figure 160 - HMQC spectrum (CDCl3) of 4-25. 
 
 
Figure 161 - HMQC spectrum (CDCl3) of 4-25. 
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Figure 162 - HMBC spectrum (CDCl3) of 4-25. 
 
 
Figure 163 - HMQC spectrum (CDCl3) of 4-25. 
 
 386 
 
 
Figure 164 - COSY spectrum (CDCl3) of 4-25. 
 
 
Figure 165 - HMQC spectrum (CDCl3) of 4-25. 
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Figure 166 - COSY spectrum (CDCl3) of 4-25. 
 
 
Figure 167 - COSY spectrum (CDCl3) of 4-25. 
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Figure 168 - HMQC spectrum (CDCl3) of 4-25. 
 
 
Figure 169 - HMQC spectrum (CDCl3) of 4-25. 
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Figure 170 - HMBC spectrum (CDCl3) of 4-25. 
 
 
Figure 171 - COSY spectrum (CDCl3) of 4-25. 
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Figure 172 - HMQC spectrum (CDCl3) of 4-25. 
 
 
Figure 173 - HMBC spectrum (CDCl3) of 4-25. 
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Figure 174 - HMQC spectrum (CDCl3) of 4-25. 
 
 
Figure 175 - HMBC spectrum (CDCl3) of 4-25. 
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Figure 176 - HMQC spectrum (CDCl3) of 4-25. 
 
 
Figure 177 - HMQC spectrum (CDCl3) of 4-25. 
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Figure 178 - HMBC spectrum (CDCl3) of 4-25. 
 
 
Figure 179 - HMQC spectrum (CDCl3) of 4-25. 
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Figure 180 - HMQC spectrum (CDCl3) of 4-25. 
 
 
Figure 181 - HMBC spectrum (CDCl3) of 4-25. 
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Figure 182 - COSY spectrum (CDCl3) of 4-25. 
 
 
Figure 183 - HMQC spectrum (CDCl3) of 4-25. 
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Abbreviations 
 
° degrees 
°C degrees Celcius 
µ (prefix) micro 
13
C carbon 
19
F fluorine 
1
H proton 
Å Angstrom 
ABC ATP-binding cassette 
Ar aromatic 
atm atmosphere 
aq aqueous 
B. subtilis Bacillus subtilis 
BnBr benzyl bromide 
Boc tert-butyloxycarbonyl 
Boc2O di-tert-butyl dicarbonate 
Ca(OH)2 calcium hydroxide 
CBz carboxybenzyl 
CD3OD deuterated methanol 
CDCl3 deuterated chloroform 
CDI 1,1'-carbonyldiimdazole 
CH2Cl2 dichlormethane 
CHCl3 chloroform 
CO2 carbon dioxide 
COMT catechol O-methyl transferase 
Cs2CO3 caesium carbonate 
d6-DMSO deuterated dimethyl sulfoxide 
DCC dicyclohexylcarbodiimide 
DDQ dichlorodicyanoquinone 
DEPT Distortionless Enhancement by Polarisation Transfer 
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DIPEA N-N'-diisopropylethylamine 
DMF N-N-dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DSC N-N'-disuccinimidyl carbonate 
E. coli Escherichia coli 
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
ESI electrospray ionisation 
Et3N triethylamine 
EtOAc ethyl acetate 
EtOH ethanol 
Fmoc fluorenylmethyloxycarbonyl 
g grame 
h hour 
H2 hydrogen 
H2O water 
H2SO4 sulfuric acid 
HATU 
 
1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
HCl hydrochloric acid 
HMBC Heteronuclear Multiple-Bond Correlation 
HMQC Heteronuclear Multiple-Quantum Correlation 
HOBt hydroxybenzotriazole 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
HSQC Heteronuclear Single Quantum Correlation  
K Kelvin 
K2CO3 potassium carbonate 
L litre 
LB lysogeny broth 
LC liquid chromatography 
M Molar 
m metre 
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m (prefix) milli 
m/z mass/charge 
MDR multi-drug resistant 
MeOH methanol 
MIC minimum inhibitory concentration 
MS mass spectrometry 
n (prefix) nano 
NaHCO3 sodium hydrogen carbonate 
NaOH sodium hydroxide 
Ni(COD)2 bis(1,5-cyclooctadiene)nickel(0) 
nm nanometer 
NMR nuclear magnetic resonance 
OD650 optical densitry at 650 nm 
P. aeruginosa Pseudomonas aeruginosa 
P. putida Pseudomonas putida 
ppm parts per million 
Qnr quinolone resistance proteins 
RPM revolutions per minute 
s second 
S. aureus Staphylococcus aureus 
S. pnemoniae Staphylococcus pnemoniae 
t time 
TBAH tetrabutylammonium hydroxide 
TBAI tetrabutylammonium iodide 
t
Bu-Terpy 4,4’,4”-tert-butyl-2,2’:6’,2”-terpyridine  
TFA trifluoroacetic acid 
THF tetrahydrofuran 
UV/Vis ultra-violet-visible 
wt. weight 
λmax wavelength of maximum absorbance 
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